WO2005030761A1 - Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof - Google Patents

Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof Download PDF

Info

Publication number
WO2005030761A1
WO2005030761A1 PCT/GB2004/004112 GB2004004112W WO2005030761A1 WO 2005030761 A1 WO2005030761 A1 WO 2005030761A1 GB 2004004112 W GB2004004112 W GB 2004004112W WO 2005030761 A1 WO2005030761 A1 WO 2005030761A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzimidazol
alkyl
amino
methyl
butyl
Prior art date
Application number
PCT/GB2004/004112
Other languages
French (fr)
Inventor
Ziping Liu
Claire Milburn
Daniel PAGÉ
Maxime Tremblay
Christopher Walpole
Hua Yang
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to US10/572,826 priority Critical patent/US20070072853A1/en
Priority to EP04768655A priority patent/EP1673369A1/en
Priority to JP2006527485A priority patent/JP2007506718A/en
Publication of WO2005030761A1 publication Critical patent/WO2005030761A1/en
Priority to PCT/SE2005/001399 priority patent/WO2006033627A1/en
Priority to JP2007533434A priority patent/JP2008514594A/en
Priority to KR1020077006690A priority patent/KR20070057856A/en
Priority to AU2005287429A priority patent/AU2005287429A1/en
Priority to PCT/SE2005/001405 priority patent/WO2006033633A1/en
Priority to EP05784958A priority patent/EP1797070A1/en
Priority to PCT/SE2005/001400 priority patent/WO2006033628A1/en
Priority to JP2007533429A priority patent/JP2008514589A/en
Priority to JP2007533430A priority patent/JP2008514590A/en
Priority to CN200580031827.8A priority patent/CN101023075A/en
Priority to CA002582512A priority patent/CA2582512A1/en
Priority to BRPI0515876-1A priority patent/BRPI0515876A/en
Priority to EP05784565A priority patent/EP1797074A4/en
Priority to PCT/SE2005/001401 priority patent/WO2006033629A1/en
Priority to EP05786524A priority patent/EP1794150A1/en
Priority to CN200580032338.4A priority patent/CN101027292A/en
Priority to CN200580031826.3A priority patent/CN101052637A/en
Priority to PCT/SE2005/001404 priority patent/WO2006033632A1/en
Priority to EP05786401A priority patent/EP1797076A1/en
Priority to JP2007533435A priority patent/JP2008514595A/en
Priority to JP2007533431A priority patent/JP2008514591A/en
Priority to EP05784659A priority patent/EP1797075A1/en
Priority to CN200580032329.5A priority patent/CN101027291A/en
Priority to MX2007003121A priority patent/MX2007003121A/en
Priority to TW094133160A priority patent/TW200616970A/en
Priority to UY29129A priority patent/UY29129A1/en
Priority to TW094133189A priority patent/TW200626583A/en
Priority to TW094133158A priority patent/TW200614991A/en
Priority to UY29132A priority patent/UY29132A1/en
Priority to TW094133156A priority patent/TW200626582A/en
Priority to UY29133A priority patent/UY29133A1/en
Priority to TW094133192A priority patent/TW200626577A/en
Priority to UY29135A priority patent/UY29135A1/en
Priority to ARP050104024A priority patent/AR053096A1/en
Priority to ARP050104023A priority patent/AR051448A1/en
Priority to ARP050104026A priority patent/AR051449A1/en
Priority to IL182021A priority patent/IL182021A0/en
Priority to NO20072090A priority patent/NO20072090L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention is related to therapeutic compounds, pharmaceutical compositions containing these compounds, manufacturing processes thereof and uses thereof. Particularly, the present invention is related to compounds that may be effective in treating pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiavascular disorders.
  • CBi receptor e.g., CBi receptor, CB receptor
  • CB 2 receptors e.g., a cannabinoid receptor, CBi receptor, CB receptor
  • CBi receptors are located predominately in the central nervous system
  • CB 2 receptors are located primarily in the periphery and are primarily restricted to the cells and tissues derived from the immune system.
  • CB) receptor agonists such as ⁇ 9 -tetrahydrocannabinol ( ⁇ '-THC) and anadamide
  • CNS side-effects e.g., psychoactive side effects, the abuse potential, drug dependence and tolerance, etc.
  • CB agonists acting at peripheral sites or with limited CNS exposure can manage pain in humans or animals with much improved overall in vivo profile. Therefore, there is a need for new CBj receptor ligands such as agonists that may be useful in managing pain or treating other related symptoms or diseases with reduced or minimal undesirable CNS side-effects.
  • the present invention provides CBi receptor ligands which may be useful in treating pain and/or other related symptoms or diseases.
  • CB]/CB 2 receptors means CBi and/or CB 2 receptors.
  • C m . n or "C m- n group” used alone or as a prefix, refers to any group having m to n carbon atoms.
  • hydrocarbon used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms.
  • hydrocarbon radical or “hydrocarbyl” used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon.
  • alkyl used alone or as a suffix or prefix, refers to monovalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms. Unless otherwise specified, "alkyl” general includes both saturated alkyl and unsaturated alkyl.
  • alkylene used alone or as a suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.
  • alkenyl used alone or as a suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms.
  • alkynyl used alone or as a suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond and comprising at least 2 up to about 12 carbon atoms.
  • cycloalkyl used alone or as a suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms.
  • Cycloalkyl includes both monocyclic and multicyclic hydrocarbon structures. Multicyclic hydrocarbon structure includes non-fused, fused and bridged rings.
  • cycloalkenyl used alone or as a suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms.
  • Cycloalkenyl includes both monocyclic and multicyclic hydrocarbon structures. Multicyclic hydrocarbon structure includes non-fused, fused and bridged rings.
  • cycloalkynyl used alone or as a suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon triple bond and comprising about 7 up to about 12 carbon atoms.
  • Cycloalkenyl includes both monocyclic and multicyclic hydrocarbon structures. Multicyclic hydrocarbon structure includes non-fused, fused and bridged rings.
  • aryl used alone or as a suffix or prefix, refers to a hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms, wherein the radical is located on a carbon of the aromatic ring.
  • non-aromatic group or “non-aromatic” used alone, as a suffix or as prefix, refers to a chemical group or radical that does not contain a ring having aromatic character (e.g., 4n + 2 delocalized electrons).
  • arylene used alone or as a suffix or prefix, refers to a divalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms, which serves to link two structures together.
  • heterocycle used alone or as a suffix or prefix, refers to a ring- containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s).
  • Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring.
  • the rings may be fused or unfused.
  • Fused rings generally refer to at least two rings share two atoms therebetween.
  • Heterocycle may have aromatic character or may not have aromatic character.
  • heteroalkyl used alone or as a suffix or prefix, refers to a radical formed as a result of replacing one or more carbon atom of an alkyl with one or more heteroatoms selected from N, O, P and S.
  • heteromatic used alone or as a suffix or prefix, refers to a ring- containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring- containing structure or molecule has an aromatic character (e.g., 4n + 2 delocalized electrons).
  • heterocyclic group refers to a radical formed as a result of replacing one or more carbon atom of an alkyl with one or more heteroatoms selected from N, O, P and S.
  • heteromatic used alone or as a suffix or prefix, refers to a ring- containing structure or molecule having one or more multivalent heteroatom
  • heterocyclo used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.
  • heterocyclyl used alone or as a suffix or prefix, refers a radical derived from a heterocycle by removing at least one hydrogen from a carbon of a ring of the heterocycle.
  • heterocyclylene used alone or as a suffix or prefix, refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom, which serves to links two structures together.
  • heteroaryl used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character, wherein the radical of the heterocyclyl is located on a carbon of an aromatic ring of the heterocyclyl.
  • a heteroaryl may contain both aromatic and non-aromatic rings therein. These rings may be fused or otherwised linked together.
  • heteroarylcoalkyl used alone or as a suffix or prefix, refers to a heterocyclyl that does not have aromatic character.
  • heteroarylene used alone or as a suffix or prefix, refers to a heterocyclylene having aromatic character.
  • heterocycloalkylene used alone or as a suffix or prefix, refers to a heterocyclylene that does not have aromatic character.
  • the term "six-membered” used as prefix refers to a group having a ring that contains six ring atoms.
  • the term “five-membered” used as prefix refers to a group having a ring that contains five ring atoms.
  • a five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.
  • Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl.
  • a six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.
  • Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
  • substituted used as a prefix refers to a structure, molecule or group, wherein one or more hydrogens are replaced with one or more C ⁇ - ⁇ 2 hydrocarbon groups, or one or more chemical groups containing one or more heteroatoms selected from N, O, S, F, Cl, Br, I, and P.
  • substituted phenyl may refer to nitrophenyl, pyridylphenyl, methoxyphenyl, chlorophenyl, aminophenyl, etc., wherein the nitro, pyridyl, methoxy, chloro, and amino groups may replace any suitable hydrogen on the phenyl ring.
  • substituted used as a suffix of a first structure, molecule or group, followed by one or more names of chemical groups refers to a second structure, molecule or group, which is a result of replacing one or more hydrogens of the first structure, molecule or group with the one or more named chemical groups.
  • a "phenyl substituted by nitro” refers to nitrophenyl.
  • optionally substituted refers to both groups, structures, or molecules that are substituted and those that are not substituted.
  • Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5- dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, mo ⁇ holine, thiomo ⁇ holine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-lH-azepine ho opipe
  • heterocycle includes aromatic heterocycles, for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3- thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4- triazole, 1,3,4-thiadiazole, and 1,3,4- oxadiazole.
  • aromatic heterocycles for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, is
  • heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxathiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine, 1,2- benzisoxazole, benzothiophene, benzoxazo
  • heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings.
  • bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.
  • Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1 ,2,3,6-tetrahydro- pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3- dihydropyranyl, tetrahydropyranyl, 1 ,4-dihydropyridinyl, 1,
  • heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyI, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1 ,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl.
  • heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4- benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3- dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridin
  • heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings.
  • bridged heterocyclyls include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.
  • alkoxy used alone or as a suffix or prefix, refers to radicals of the general formula -O-R, wherein -R is selected from a hydrocarbon radical.
  • Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.
  • aryloxy used alone or as a suffix or prefix, refers to radicals of the general formula -O-Ar, wherein -Ar is an aryl.
  • heteroaryloxy used alone or as a suffix or prefix, refers to radicals of the general formula -O-Ar', wherein -Ar' is a heteroaryl.
  • amine or “amino” used alone or as a suffix or prefix, refers to radicals of the general formula -NRR', wherein R and R' are independently selected from hydrogen or a hydrocarbon radical.
  • "Acyl” used alone, as a prefix or suffix, means -C( 0)-R, wherein -R is an optionally substituted hydrocarbyl, hydrogen, amino or alkoxy.
  • Acyl groups include, for example, acetyl, propionyl, be zoyl, phenyl acetyl, carboethoxy, and dimethylcarbamoyl.
  • Halogen includes fluorine, chlorine, bromine and iodine.
  • Halogenated used as a prefix of a group, means one or more hydrogens on the group is replaced with one or more halogens.
  • RT or “rt” means room temperature.
  • a first ring group being “fused” with a second ring group means the first ring and the second ring share at least two atoms therebetween.
  • Link means covalently linked or bonded.
  • “Saturated carbon” means a carbon atom in a structure, molecule or group wherein all the bonds connected to this carbon atom are single bond. In other words, there is no double or triple bonds connected to this carbon atom and this carbon atom generally adopts an sp 3 atomic orbital hybridization.
  • “Unsaturated carbon” means a carbon atom in a structure, molecule or group wherein at least one bond connected to this carbon atom is not a single bond. In other words, there is at least one double or triple bond connected to this carbon atom and this carbon atom generally adopts a sp or sp' atomic orbital hybridization.
  • an embodiment of the invention provides a compound of Formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:
  • R" is selected from C ⁇ . ⁇ 0 alkyl, C 2- ⁇ oalkenyl, C 2 . ⁇ oalkynyl, C 3- ⁇ ocycloalkyl, C 3 .
  • 6 heterocycloalkyl used in defining R 2 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR 5 R 6 ; wherein R 5 , R 6 and R 7 are independently selected from -H, C ⁇ -6 alkyl, C 2 - 6 alkenyl, C 2-6 alkynyl, and a divalent C ⁇ .
  • R 6 group that together with another divalent R 5 , R 6 or R 7 forms a portion of a ring;
  • Ar is selected from C ⁇ -ioaryl and C 3-8 heteroaryl;
  • n is selected from 0, 1 , 2 and 3;
  • each of R 3 is independently selected from -H, nitro, halogen, Ci.ioalkyl, C 2 . ⁇ 0 alkenyl, C . ⁇ 0 alkynyl, Cs.iocycloalkyl, C 3 .
  • R S Rj 9 -o ⁇ - R S ⁇ R - I9; ° ⁇ and * l o each of R 8 and R 9 is independently selected from -H, Ci.ioalkyl, C 2-) oalkenyl, C 2- ⁇ oalkynyl, Cs-iocycloalkyl, C3- ⁇ 0 cycloalkyl-C ⁇ -6 alkyl, C 3 . 6 heterocyclyl, C ⁇ -ioaryl, C 3-6 heterocylcyl-C ⁇ .
  • R 6 group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR 5 R 6 ; and R 4 is selected from -H, Ci.ioalkyl, C 2 . ⁇ oalkenyl, C 2 . ⁇ oalkynyl, C 3 . ⁇ 0 cycloalkyl,
  • Another embodiment of the invention provides a compound of Formula I, wherein R 1 is selected from C,. 6 alkyl, C 2 . 6 alkenyl, C 2 .
  • R 1 6 heterocyclyl, C 3 .] 0 cycloalkyl, and C 4- 6 cycloalkenyl used in defining R 1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and -NR 5 R 6 ;
  • R " is selected from Cj. 6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl- C ⁇ -4 alkyl, C . 6 cycloalkenyl-C M alkyl, C 3 . 6 heterocycloalkyl-C). 4 alkyl, C 4 .
  • R 6 heterocycloalkyl-C ⁇ -4 alkyl, C -6 cycloalkenyl, C 3-5 heteroaryl, R 5 R 6 N-, and phenyl used in defining R ⁇ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; wherein R 5 and R are independently selected from -H, C ⁇ .
  • Ar is selected from phenyl and C 3-5 heteroaryl; n is selected from 0, 1 and 2; each of R 3 is independently selected from -H, nitro, halogen, Cj -6 alkyl, C 2 .
  • C 3-6 heterocycloalkyl optionally subsitituted with one or more groups selected from C ⁇ -6 alkyl, hydroxy, halogen and each of R 8 and R 9 is independently selected from -H, C ⁇ -6 alkyl, C 2 - 6 alkenyl, C 3 . 6 cycloalkyl, C 3 - 6 heterocyclyl and C 3 - ⁇ heterocylcyl-C ⁇ . 6 alkyl, wherein said C]. 6 alkyl, C 2 . 6 alkenyl, C 3-6 cycloalkyl, C 3 . 6 cycloalkyl-C ⁇ .
  • Cs- ⁇ heterocyclyl and C 3 - 6 heterocylcyl-Ci -6 alkyl are optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR 10 R ⁇ ; and R 4 , R 10 and R ⁇ are independently selected from -H and C]- 3 alkyl.
  • a further embodiment of the invention provides a compound of Formula I, wherein R 1 is selected from C h alky!, C ⁇ .
  • alkyl-C( 0)-0-C ⁇ -3 alkyl, C 2-6 alkenyl, phenyl-C alkyl, C 3-i 0 cycloalkyl-C ⁇ -4 alkyl, C . 6 cycloalkenyl-C). alkyl, C 3 . 6 heterocylcoalkyl-C ⁇ . 4 alkyl, C ⁇ -ioaryl, C3. ⁇ ocycloalkyl, and C -6cycloalkenyl, wherein said Cuealkyl, C 2-6 alkenyl, phenyl-C ⁇ -4 alkyl, C 3 - ⁇ ocycloalkyl-C ⁇ - alkyl, C 3-6 heterocylcoalkyl-C ⁇ .
  • R 1 alkyl, C 6 . ⁇ oaryl, C 3- ⁇ ocycloalkyl, and C4- 6 cycloalkenyl used in defining R 1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and amino;
  • R 2 is selected from C ⁇ -6 alkyl, C 2 . 6 alkenyl, C 3-6 cycloalkyl and C 3 . 6 cycloalkyI- C ⁇ -4 alkyl, wherein said C ⁇ -6 alkyl, C 2-6 alkenyl, C 3 . 6 cycloalkyl and C 3-6 cycloalkyl-
  • R ⁇ 4 alkyl used in defining R ⁇ is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;
  • Ar is selected from phenyl and C 3 .
  • 5 heteroaryl and n is selected from 0, 1 and 2; each of R 3 is independently selected from -H, halogen, nitro, C ⁇ -3 alkyl, C 3-
  • each of R 8 and R 9 is independently selected from -H, C ⁇ _ 6 alkyl, mo ⁇ holinyl- C ⁇ -3 alkyl, pyrroIidinyl-Ci. 3 alkyl, and piperidinyl-C ⁇ . 3 alkyl, wherein said C].
  • mo ⁇ holinyl- C 1-3 alkyl, and piperidinyl-C ⁇ - 3 alkyl are optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR 5 R 6 ; and R 4 , R 5 and R 6 are independently selected from -H and C ⁇ -3 alkyl.
  • R 1 is selected from cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl,cyclohexylethyl, cyclopentylethyl, bicyclo[2.2.1]hept-5-en-2- ylmethyl, 4,4-difluorocyclohexylmethyl, tetrahydropyranylmethyl, tetrahydropyranylethyl, tetrahydrofuranyl ethyl, 1 -piperidinylethyl, and N-methyl-2- piperidinylmethyl;
  • R" is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2- propyl, 2-hydroxyl-propyl, trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl
  • each of R 8 and R 9 is independently selected from -H, C ⁇ . 3 alkyl, morpholinylmethyl, pyrrolidinyl-methyl, and piperidinyl-methyl, wherein said C ⁇ -3 alkyl, mo ⁇ holinylmethyl, pyrrolidinyl-methyl, and piperidinyl-methyl are optionally substituted by one or more groups selected from hydroxy, amino and dimethylamino.
  • the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric fo ⁇ ns, or as a racemic mixture.
  • the present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I.
  • the optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter. It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes.
  • the present invention includes any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the compounds of the Formula I. It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the Formula I. Within the scope of the invention are also salts of the compounds of the Formula I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion.
  • a sufficiently basic compound for example an alkyl amine
  • a suitable acid for example, HCl or acetic acid
  • a corresponding alkali metal such as sodium, potassium, or lithium
  • an alkaline earth metal such as a calcium
  • a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.
  • a suitably acidic proton such as a carboxylic acid or a phenol
  • an alkali metal or alkaline earth metal hydroxide or alkoxide such as the ethoxide or methoxide
  • a suitably basic organic amine such as choline or meglumine
  • the compound of Formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or ?-toluenesulphonate.
  • an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or ?-toluenesulphonate.
  • the compounds of the invention exhibit selective activity as agonist of the CBi receptors and are useful in therapy, especially for relief of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive. Additionally, compounds of the present invention are useful in other disease states in which dysfunction of CBi receptors is present or implicated. Furthermore, the compounds of the invention may be used to treat cancer, multiple sclerosis, Parkinson's disease, cancer, Huntingdon's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and cardiavascular disorders.
  • Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.
  • Compounds of the invention are useful in disease states where degeneration or dysfunction of cannabinoid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).
  • PET positron emission tomography
  • Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following miocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.
  • stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various
  • Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care.
  • Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.
  • any of the compounds according to the Formula I above for the manufacture of a medicament for the treatment of any of the conditions discussed above.
  • a further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such treatment.
  • the invention provides a compound of Formula I, or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
  • the present invention provides the use of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
  • the term "therapy" also includes
  • the term “prophylaxis” unless there are specific indications to the contrary.
  • the term “therapeutic” and “therapeutically” should be contrued accordingly.
  • the term “therapy” within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition.
  • This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.
  • the compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.
  • the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
  • the route of administration may be oral, intravenous or intramuscular.
  • the dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient.
  • inert, pharmaceutically acceptable carriers can be either solid and liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture in then poured into convenient sized moulds and allowed to cool and solidify.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it.
  • cachets are included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
  • Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition.
  • a therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and inte ⁇ reted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.
  • any compound of Formula I as defined above for the manufacture of a medicament is also within the scope of the invention.
  • any compound of Formula I for the manufacture of a medicament for the therapy of pain is also provided.
  • any compound according to Formula 1 for the manufacture of a medicament for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.
  • a further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Fo ⁇ nula I above, is administered to a patient in need of such therapy.
  • a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
  • a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain.
  • a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above.
  • the present invention provides a method of preparing the compounds of the present invention.
  • the invention provides a process for preparing a compound of Formula I,
  • R 2 is selected from Ci.ioalkyl, C 2 - ⁇ 0 alkenyl, C 2- ⁇ oalkynyl, C 3 . ⁇ ocycloalkyl, C 3 .
  • R 2 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR 5 R 6 ; wherein R 5 , R 6 and R 7 are independently selected from -H, Ci. 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, and a divalent C].
  • Ar is selected from C 6 - ⁇ oaryl and C 3 . 8 heteroaryl
  • n is selected from 0, 1, 2 and 3
  • each of R 3 is independently selected from -H, nitro, halogen, Ci.ioalkyl, C 2 . l oalkenyl, C 2 . ⁇ 0 alkynyl, C 3 . ⁇ 0 cycloalkyl, C 3 . ⁇ ocycloalkyI-C ⁇ -6alkyl, C 4-8 cycloalkenyl- C ⁇ . 6 alkyl, C 3 . ⁇ heterocycloalkyl-C ⁇ . 6 alkyl, Cs- ⁇ heterocycloalkyl and
  • aanndd R L o optionally subsitituted with one or more groups selected from C ⁇ . 6 alkyl, hydroxy, halogen, amino,
  • each of R 8 and R 9 is independently selected from -H, Cj.ioalkyl, C 2 . ⁇ oalkenyl, C 2 . ⁇ oalkynyl, C 3 - ⁇ ocycloalkyl, C 3 . ⁇ 0 cycloalkyl-C
  • Ci-ioalkyl C 2 . ⁇ oalkenyI, C 2 - ⁇ oalkynyl, Cs.iocycloalkyl, C 3 .] 0 cycloalkyl- Ci- ⁇ alkyl, C 3 . 6 heterocyclyl, C ⁇ -ioaryl, C 3 . ⁇ heterocylcyl-C ⁇ .
  • C ⁇ -ioaryl-Ci- ⁇ alkyl, or divalent C ⁇ -6 group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR 5 R 6 ; and R 4 is selected from -H, Ci.ioalkyl, C 2 . ⁇ oalkenyl, C 2- ⁇ oalkynyl, C 3 .
  • the present invention also provides a method of preparing a compound of Formula I, X is selected from Cl, Br, F and OH;
  • R 1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and amino;
  • R 2 is selected from C]. 6 alkyl, C 2 . ⁇ alkenyl, C 3 . 6 cycloalkyl and C 3 . 6 cycloalkyl- Ci ⁇ alkyl, wherein said C ⁇ . 6 alkyl, C 2 . 6 alkenyl, C 3 . 6 cycloalkyl and C 3 . 6 cycloalkyl-
  • C M alkyl used in defining R" is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;
  • Ar is selected from phenyl and C3_5heteroaryl and n is selected from 0, 1 and 2; each of R 3 is independently selected from -H, nitro, halogen, C ⁇ _ 3 alkyl, C 3 .
  • C 3 . 6 heterocycloalkyl contain at least one nitrogen ring atom and the radical of C 3 . 6 heterocycloalkyl is located on the at least one nitrogen ring atom
  • each of R 8 and R 9 is independently selected from -H, C ⁇ . 6 alkyl, mo ⁇ holinyl- C ⁇ . 3 alkyl, and wherein said C ⁇ . 6 alkyl, mo ⁇ holinyl- C ⁇ . 3 alkyl, and are optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR 5 R 6 ; and R 4 , R 5 and R 6 are independently selected from -H and C ⁇ . 3 alkyl.
  • R 1 , R 2 , R 3 and R 4 are as defined in the specifications Ar is phenylene or py ⁇ dinylene
  • R ⁇ R 2 R 3 , and R 4 are as defined in the specifications Ar is phenylene or py ⁇ dinylene Scheme 5
  • R ⁇ R 2 , R 3 and R 4 are as defined in the specifications Ar is phenylene or py ⁇ dinylene
  • R 1 , R 2 , R 4 and Ar are as defined in the specifications, R 10 and R" are optionally substituted C1-6alkyl, Y and Z are halogen or -OH Scheme 8
  • R 1 , R 2 , R 4 , R ⁇ and Ar are as defined in the specifications
  • Condition B or solvent, e g DMF heat, 100-300°C R R 2 , R 4 , R ⁇ R 9 and Ar are as defined in the specifications Scheme 10
  • R 1 , R 2 , R 3 , R 4 , and Ar are as defined in the specifications.
  • hCBi and hCB? receptor binding Human CB] receptor from Receptor Biology (hCBi) or human CB 2 receptor from BioSignal (hCB 2 ) membranes are thawed at 37 °C, passed 3 times through a 25- gauge blunt-end needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5 mM EDTA, 5 mM MgCl 2 , and 0.5 mg/mL BSA fatty acid free, pH 7.4) and aliquots containing the appropriate amount of protein are distributed in 96-well plates.
  • cannabinoid binding buffer 50 mM Tris, 2.5 mM EDTA, 5 mM MgCl 2 , and 0.5 mg/mL BSA fatty acid free, pH 7.4
  • the IC 50 of the compounds of the invention at hCB) and hCB 2 are evaluated from 10-point dose-response curves done with 3 H-CP55,940 at 20000 to 25000 dpm per well (0.17- 0.21 nM) in a final volume of 300 ⁇ l.
  • the total and non-specific binding are determined in the absence and presence of 0.2 ⁇ M of HU210 respectively.
  • the plates are vortexed and incubated for 60 minutes at room temperature, filtered through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Tomtec or Packard harvester using 3 L of wash buffer (50 mM Tris, 5 mM MgCl?, 0.5 mg BSA pH 7.0). The filters are dried for 1 hour at 55 °C.
  • the radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 ⁇ l/well of MS-20 scintillation liquid.
  • hCB GTP ⁇ S binding Human CBi receptor from Receptor Biology (hCBi) or human CB 2 receptor membranes (BioSignal) are thawed at 37 °C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTP ⁇ S binding buffer (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 M MgCl 2 , pH 7.4, 0.1% BSA).
  • GTP ⁇ S binding buffer 50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 M MgCl 2 , pH 7.4, 0.1% BSA).
  • the EC so and Em a of the compounds of the invention are evaluated from 10-point dose- response curves done in 300 ⁇ l with the appropriate amount of membrane protein and 100000-130000 dpm of GTPg 35 S per well (0.11 -0.14 nM).
  • the basal and maximal stimulated binding is determined in absence and presence of 1 ⁇ M (hCB?) or 10 ⁇ M (hCBi) Win 55,212-2 respectively.
  • the membranes are pre-incubated for 5 minutes with 56.25 ⁇ M (hCB2) or 112.5 ⁇ M (hCBi) GDP prior to distribution in plates (15 ⁇ M (hCB 2 ) or 30 ⁇ M (hCBi) GDP final).
  • the plates are vortexed and incubated for 60 minutes at room temperature, filtered on Unifilters GF/B (presoaked in water) with the Tomtec or Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM MgCl 2 , 50 mM NaCl, pH 7.0). The filters are dried for 1 hour at 55 °C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 ⁇ l/well of MS-20 scintillation liquid.
  • wash buffer 50 mM Tris, 5 mM MgCl 2 , 50 mM NaCl, pH 7.0.
  • the filters are dried for 1 hour at 55 °C.
  • the radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 ⁇ l/well of MS-20 scintillation liquid.
  • Antagonist reversal studies are done in the same way except that (a) an agonist dose-response curve is done in the presence of a constant concentration of antagonist, or (b) an antagonist dose-response curve is done in the presence of a constant concentration of agonist.
  • the Ki towards human CB] receptors for most compounds of the invention is measured to be in the range of 0.7-7170 nM.
  • the Ki towards human CB receptors for most compounds of the invention is measured to be in the range of about 0.3-5800 nM.
  • the EC 50 towards human CBi receptors for most compounds of the invention is measured to be in the range of about 0.8-2810 nM.
  • the E max towards human CB] receptors for most compounds of the invention is measured to be in the range of about 22.3-140%.
  • the Ki towards human CB] receptors for most compounds of the invention is measured to be in the range of 0.7-50 nM.
  • the Ki towards human CB 2 receptors for most compounds of the invention is measured to be in the range of about 0.3-25 nM.
  • the EC 50 towards human CBi receptors for most compounds of the invention is measured to be in the range of about 0.8-100 nM.
  • the E max towards human CBi receptors for most compounds of the invention is measured to be in the range of about 60-125%.
  • Step A N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]thiophene-2- sulfonamide
  • N- ⁇ 3-Amino-4-[(cyclohexylmethyl)amino]phenyl ⁇ thiophene-2-sulfonamide (55 mg, 0.150 mmol) (for preparation, see the following steps B, C and D) was dissolved in 3 L of 1,2-dichloroethane containing TEA (0.030 L, 0.225 mmol). Trimethylacetyl chloride (0.020 mL, 0.165 mmol) was added dropwise and the solution was stirred at rt for lh. Glacial AcOH (1 mL) and a few drops of concentrated HCl were added and the solution was stirred at 80°C overnight. The solvent was evaporated.
  • the crude product was dissolved in EtOAc and washed with 2M NaOH aqueous solution, brine and dried over anhydrous MgS0 4 .
  • the product was purified by reversed-phase HPLC using 20-80% CH 3 CN/H 2 0 and then lyophilized affording the title compound as the corresponding TFA salt.
  • Step C N- ⁇ 4-[(Cyclohexylmethyl)amino]-3-nitrophenyl ⁇ thiophene-2- sulfonamide
  • N-(4-Fluoro-3-nitrophenyl)thiophene-2-sulfonamide 73 mg, 0.241 mmol
  • cyclohexylmethyl amine 0.040 mL, 0.289 mmol
  • EtOH EtOH containing TEA
  • TEA 0.050 mL, 0.361 mmol
  • the solvent was evaporated.
  • the crude product was dissolved in EtOAc and washed with 5% KHS0 4 solution, saturated ⁇ aHC0 3 solution, brine and dried over anhydrous MgS0 4 .
  • the crude product was purified by flash chromatography using 2:1 / hexanes:EtOAc on silica gel.
  • Step D N- ⁇ 3-Amino-4-[(cycIohexyImethyI)amino]phenyl ⁇ thiophene-2- sulfonamide
  • Step A N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yI]-N- methylthiophene-2-sulfonamide
  • Step B N-(4-Fluoro-3-nitrophenyI)-N-methyIthiophene-2-sulfonamide
  • Step C N- ⁇ 4-[(Cyclohexylmethyl)amino]-3-nitrophenyl ⁇ -N-methylthiophene-2- sulfonamide
  • Step D N- ⁇ 3-Amino-4-[(cyclohexylmethyI)amino]phenyl ⁇ -N-methylthiophene-2- sulfonamide
  • Step E N- ⁇ 3-Amino-4-[(cyclohexylmethyl)amino]phenyl ⁇ -N- methylbenzenesulfonamide
  • N-[4-(Benzylamino)-3-nitrophenyl]-N-methylbenzenesulfonamide (95 mg, 0.239 mmol) was dissolved in 15 mL of EtOAc containing a catalytic amount of 10% Pd C. The solution was shaken in a Parr hydrogenation apparatus under H 2 atmosphere (40 psi) at rt for 4h. The solution was filtered through Celite and the solvent was evaporated. The product was used directly for Step A without further purification. Yield: 88 mg (99%); MS (ESI) (M+H) + 367.97.
  • Step A N-[2-te/-t-Butyl-l-(cycIohexylmethyI)-lH-benzimidazoI-5-yl]-N,3,5- trimethylisoxazole-4-sulfonamide
  • Methyl chloro formate (13.2 mL, 170.2 mmol) was added dropwise to a cold (0°C) dichloromethane (200 mL) solution of 4-fluoro-3-nitro aniline (24.15 g, 154.7 mmol) and DIPEA (35 mL, 201 mmol). The reaction mixture was stirred at rt overnight. The solution was then diluted with 200 mL of dichloromethane and washed with 2M HCl, brine and dried over anhydrous MgS0 4 . The solvent was concentrated and the product was directly used for next step without further purification.
  • Step D Methyl ⁇ 3-amino-4-[(cycIohexylmethyl)amino]phenyl ⁇ carbamate
  • Step E Methyl [2-tert-butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5- yljcarbamate
  • Methyl ⁇ 3-amino-4-[(cyclohexylmethyl)amino]phenyl ⁇ carbamate 950 mg, 3.43 mmol
  • DMAP 100 mg, 0.858 mmol
  • Trimethylacetyl chloride (0.460 mL, 3.77 mmol) was added dropwise and the solution was stirred at rt for lh. The solvent was concentrated. The residue was divided in two portions and each of them was dissolved in 3 L of glacial AcOH in a sealed tube. The solutions were heated at 150°C using a Personal Chemistry Smith Synthesizer microwave instrument for three intervals of 30 min (3 X 30 min).
  • Step A N-[2-tert-butyI-l-(cyclohexylmethyI)-lH-benzimidazol-5-yllbenzene sulfonamide
  • Step B N- ⁇ 4-[(cyclohexyImethyI)amino]-3 ⁇ nitrophenyI ⁇ benzenesulfonamide
  • Step C N- ⁇ 3-amino-4-[(cyclohexylmethyI)amino]phenyl ⁇ benzenes lfonamide
  • N- ⁇ 4-[(cyclohexylmethyl)amino]-3-nitrophenyl ⁇ benzenesulfonamide (3.75 g, 9.63 mmol) was hydrogenated in ethyl acetate (200 L) catalyzed by 10% Pd/C (0.5 g) at 30-40 psi H 2 in Parr shaker for 20 h at room temperature. After filtration through Celite and concentration, 4.0 g (100%) of a light yellow solid was obtained as the title compound, which was used for Step A without further purification.
  • Step A N-[2-(l,l-dimethylethyl)-l-[(tetrahydro-2H-pyran-4-yl)methyl]-lH- benzimidazol-5-yl]-benzenesulfonamide
  • Step B N-[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyI]amino]phenyI]- benzenesulfonamide
  • Step C N-[3-amino-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]- benzenesulfonamide
  • Step A N-[2-(l,l-dimethylethyl)-l-[(tetrahydro-2-furanyl)methyl]-lH- benzimidazol-5-yl]-benzenesulfonamide
  • Step B N-[3-nitro-4-[[(tetrahydro-2-furanyl)methyl]amino]phenyl]- benzenesulfonamide
  • Step C N-[3-amino-4-[[(tetrahydro-2-furanyl)methyl]amino]phenyl]- benzenesulfonatnide
  • Step A N-[l-(cycIobutylmethyI)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yI]- benzenesulfonamide
  • Step A N-[l-(cyclopropylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]- benzenesulfonamide
  • Step A N-(4- ⁇ [[2-tert-butyI-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl ⁇ phenyl) acetamide
  • Methyl chloroformate (13.2 mL, 170.2 mmol) was added dropwise to a cold (0°C) dichloromethane (200 mL) solution of 4-fluoro-3 -nitro aniline (24.15 g, 154.7 mmol) and DIPEA (35 mL, 201 mmol). The reaction mixture was stirred at rt overnight. The solution was then diluted with 200 mL of dichloromethane and washed with 2M HCl, brine and dried over anhydrous MgS0 . The solvent was concentrated and the product was directly used for next step without further purification.
  • Step D Methyl ⁇ 3-amino-4-[(cyclohexylmethyl)amino]phenyl ⁇ carbamate
  • Methyl ⁇ 4-[(cyclohexylmethyl)amino]-3-nitrophenyl ⁇ carbamate (1.05 g, 3.42 mmol) was dissolved in 30 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H 2 atmosphere (40 psi) at rt overnight. The solution was filtered through Celite and the solvent was evaporated. The product was directly used for the next step without further purification. Yield: 950 mg (99%); MS (ESI) (M+H) + 277.9.
  • Step E Methyl [2-te/Y-butyl-l-(cy ohexylmethyl)-lH-benzimidazol-5- yljcarbamate
  • Methyl ⁇ 3-amino-4-[(cyclohexylmethyl)amino]phenyl)carbamate (950 mg, 3.43 mmol) and DMAP (100 mg, 0.858 mmol) were dissolved in 25 mL of dichloromethane. Trimethylacetyl chloride (0.460 mL, 3.77 mmol) was added dropwise and the solution was stirred at rt for lh. The solvent was concentrated. The residue was divided in two portions and each of them dissolved in 3 mL of glacial AcOH in a sealed tube. The solutions were heated at 150°C using a Personal Chemistry Smith Synthesizer microwave instrument for three intervals of 30 min (3 X 30 min). The two tubes were combined and the solvent was evaporated.
  • Step F 2-te/*t-Butyl-l-(cyclohexyImethyl)-N-methyl-lH r -benzimidazol-5-amine
  • N-[2-te7-t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methyl-4- nitrobenzenesulfonamide (375mg, 0.774 mmol) was dissolved in 20 mL of EtOH containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H 2 atmosphere (40 psi) at rt for 3h. The solution was filtered through celite and the solvent was concentrated.
  • Step A N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyI)-lH-benzimidazol-5-yl]-N- methyl-4-(4-morpholinyl)-benzenesulfonamide
  • Step D N- ⁇ 3-amino-4-[(cycIohexylmethyI)amino]phenyl ⁇ acetamide
  • Step E N-[l-(cycIohexylmethyl)-2-(l,l-dimethylethyI)-lH-benzimidazol-5- yl]acetamide
  • Step F N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazoI-5-yl]-N- methyl-acetamide
  • Step G N-l -(Cyclohexylmethyl)-2-(l , 1 -dimethylethyl)-N-methyI-LH- benzimidazol-5-amine
  • N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]acetamide (540.6 mg, 1.58 mmol) was dissolved in 20 mL of EtO ⁇ -2N ⁇ Cl (3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for 30 min. After concentration and dried in vacumn, 603.5 mg (100%) of a white solid was obtained as the title product.
  • Step H 4-Bromo-N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH- benzimidazol-5-yl]-N-methyl-benzenesulfonamide
  • the product was purified by MPLC using Hexanes/EtOAc (1 :1) on silica to give 529.6 mg (74%) of a white solid as the title product. A small amount of the title product was converted to the corresponding TFA salt.
  • Step A N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5- yl]-N-methyIbenzenesulfonamide
  • Step B N-Methyl-N- ⁇ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyI ⁇ benzenesulfonamide
  • Step C N- ⁇ 3-Amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl ⁇ -N- methylbenzenesulfonamide
  • Step A N-[2-te/*t-Butyl-l-(tetrahydro-2H-pyran-2-ylmethyI)-lH-benzimidazol-5- yl]-N-methylbenzenesulfonamide
  • Step B N-Methyl-N- ⁇ 3-nitro-4-[(tetrahydro-2H-pyran-2- yImethyl)amino]phenyl ⁇ benzenesulfonamide
  • Step C N- ⁇ 3-Amino-4-[(tetrahydro-2H-pyran-2-yImethyl)amino]phenyl ⁇ -N- methylbenzenesulfonamide
  • Step A N-[2-te7-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]-N,l,2-trimethyl-lH-imidazole-5-sulfonamide
  • Step B Methyl ⁇ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl ⁇ carbamate
  • Methyl (4-fluoro-3-nitrophenyl)carbamate (2.0g, 9.32 mmol) and 4-aminomethyl tetrahydropyran (1.28g, 1 1.2 mmol) were stirred in 50 mL of EtOH containing TEA (2.0 mL, 14.0 mmol) at 75°C for 48h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous 5% KHSO 4 , saturated aqueous
  • Step C Methyl ⁇ 3-amino-4-[(tetrahydro-2H-pyran-4- ylmethyI)amino]phenyl ⁇ carbamate
  • Methyl ⁇ 3 -nitro-4- [(tetrahydro-2H-pyran-4-y lmethy l)am ino]pheny 1 ⁇ carbamate (2.53 g, 8.18 mmol) was dissolved in 50 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under H 2 atmosphere (40 psi) using a Parr hydrogenation apparatus overnight at rt. The solution was filtered through celite and the solvent was evaporated. Yield: 2.29 g (99%).
  • Step D Methyl [2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazoI-5-yl]carbamate
  • Methyl ⁇ 3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl ⁇ carbamate (2.29 g, 8.20 mmol) and DMAP (0.20 g, 1.64 mmol) were dissolved in 75 mL of DCM.
  • Trimethylacetyl chloride (1.10 mL, 9.02 mmol) was added dropwise and the solution was stirred at rt for 2h. The solution was washed with aqueous Na ⁇ C ⁇ 3 solution, brine and dried over anhydrous MgS0 4 . The residue was dissolved in 25 mL of AcOH and was heated at 125°C for lh using a Personal Chemistry microwaves apparatus.
  • Step E 2-tert-Butyl-N-methyI-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-amine
  • Step A N-[2-tert-Butyl-l-(cycIopentyImethyI)-lH-benzimidazol-5-yI]-N- methylbenzenesulfonamide
  • N- ⁇ 3-Amino-4-[(cyclopentylmethyl)amino]phenyl ⁇ -N-methylbenzenesulfonamide (see following Steps B and C for preparation) (50 mg, 0.139 mmol) and trimethylacetyl chloride (0.019 mL, 0.153 mmol) were stirred in 2 mL of DCM containing a catalytic amount of DMAP at rt for lh. The solvent was evaporated. The product was dissolved in 2 mL of AcOH and was stirred at 150°C for 40 min using a Personal Chemistry microwaves instrument. The solvent was evaporated.
  • Step B N- ⁇ 4-[(CyclopentyImethyl)amino]-3-nitrophenyl ⁇ -N- methylbenzenesulfonamide
  • N-(4-Fluoro-3-nitrophenyl)-N-methylbenzenesulfonamide (for preparation see Example 3, Steps B and C) (50 mg, 0.161 mmol) and cyclopentylmethylamine (0.062 L of a lg / 3 mL solution, 0.209 mmol) were stirred in 2 mL of EtOH containing TEA (0.025 mL, 0.241 mmol) at 75°C for 5h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% aqueous KHS0 4 solution, aqueous ⁇ aHC ⁇ 3 solution, brine and dried over anhydrous MgS0 4 .
  • Step C N- ⁇ 3-Amino-4-[(cyclopentylmethyl)amino]phenyl ⁇ -N- methylbenzenesulfonamide
  • Step A N-[2-tert-Butyl-l-(cyclobutylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
  • Step B N- ⁇ 4-[(Cyclobutylmethyl)amino]-3-nitrophenyl ⁇ -N- methylbenzenesulfonamide
  • Step D using N-(4-fluoro-3- nitrophenyl)-N-methylbenzenesulfonamide (for preparation see Example 3, Steps B and C) (50 mg, 0.161 mmol), cyclobutylmethylamine (0.040 mL of a 5.3M solution/MeOH, 0.209 mmol) in 2 mL of EtOH containing TEA (0.025 mL, 0.242 mmol).
  • the crude product was purified by silica gel flash chromatography using 3:1 / hexanes:EtOAc as eluent. Yield: 61 g (99%).
  • Step C N- ⁇ 3-Amino-4-[(cyclobutylmethyl)amino]phenyl ⁇ -N- methylbenzenesulfonamide
  • Step A N-[2-te/T-Butyl-l-(2-cycIohexylethyl)-lH-benzimidazol-5-yI]-N- methylbenzenesulfonamide
  • Step B N- ⁇ 4-[(2-CyclohexylethyI)amino]-3-nitrophenyl ⁇ -N- methylbenzenesulfona ide
  • Step C N- ⁇ 3-Amino-4-[(2-cycIohexylethyl)amino]phenyl ⁇ -N- methylbenzenesulfonamide
  • Step A N-[l-(l-Benzylpyrrolidin-3-yl)-2-tert-butyl-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
  • Step B N- ⁇ 4-[(l-Benzylpyrrolidin-3-yl)amino]-3-nitrophenyl ⁇ -N- methylbenzenesulfonamide
  • Step A N- ⁇ 2-tert-Butyl-l-[(4,4-difluorocyclohexyl)methyl]-lH-benzimidazol-5- yl ⁇ -N-methylbenzenesulfonamide
  • Step B tert-Butyl [(4,4-difluorocyclohexyl)methyl]carbamate
  • Step D N-(4- ⁇ [(4,4-Difluorocyclohexyl)methyl]amino ⁇ -3-nitrophenyl)-N- methylbenzenesulfonamide
  • Step E N-(3-Amino-4- ⁇ [(4,4-difluorocyclohexyl)methyl]amino ⁇ phenyI)-N- methylbenzenesulfonamide
  • Step A N-[2-te/-t-Butyl-l-(pyridin-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
  • Step B N-Methyl-N- ⁇ 3-nitro-4-[(pyridin-4- yImethyl)amino]phenyl ⁇ benzenesuIfonamide
  • N-(4-Fluoro-3-nitrophenyl)-N-methylbenzenesulfonamide (for preparation see Example 3, Steps B and C) (105 mg, 0.338 mmol) and 4-(aminomethyl)pyridine (0.070 mL, 0.676 mmol) were stirred in 3 mL of CH 3 C ⁇ at rt for 24h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHC0 solution, brine and dried over anhydrous MgS0 . The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Yield: 102 mg (76%).
  • Step C N- ⁇ 3-Amino-4-[(pyridin-4-ylmethyl)amino]phenyl ⁇ -N- methylbenzenesulfonamide
  • the residue was dissolved in acetic acid (10 mL) and heated for 12 h at 90 °C. Upon evaporation of the solvent, the residue was diluted with EtOAc (100 mL), washed with 2 NNaOH(10 mL), saturated NaCl (2x10 mL) and dried over anhydrous sodium sulphate. After filtration and concentration, the crude product was purified by MPLC using Hex/EtOAc (1 :1) on silica gel to give 71.4 mg (79%) of a white solid as the title compound.
  • Step A N-methyl-N-[2-(l-methyl-l-pyridin-2-ylethyl)-l-(tetrahydro-2H-pyran- 4-ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide
  • Step D N- ⁇ 3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyI)amino]phenyl ⁇ -N- methylacetamide
  • N-methyl-N- ⁇ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl ⁇ acetamide was hydrogenated in ethyl acetate (200 mL) catalyzed by 10% Pd/C (0.2 g) at 30-40 psi ⁇ 2 in Parr shaker for 18 h at room temperature. After filtration through celite and concentration, 6.0 g (100%) of a purple solid was obtained as HCl salt, which was used in the next step without purification.
  • Step E N-methyl-N-[2-(pyridin-2-ylmethyl)-l-(tetrahydro-2H-pyran-4- ylmethyI)-lH-benzimidazol-5-yI]acetamide
  • Step F N-methyl-N-[2-(l-methyl-l-pyridin-2-ylethyl)-l-(tetrahydro-2H-pyran- 4-ylmethyI)-lH-benzimidazoI-5-yI]acetamide
  • Step G N-methyI-2-(l-methyl-l-pyridin-2-ylethyI)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-amine
  • N-methyl-N-[2-(l -methyl-1 -pyridin-2-ylethyl)-l -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]acetamide (214.0 mg, 0.526 mmol) was dissolved in 5 L of EtOH-2NHCl (3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for lh. After concentration and dried in vacuo, 331 mg (100%) of a grey white solid was obtained as the title product.
  • Step A N-[2-tert-butyl-l- ⁇ (tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5 yl]-N-ethyIbenzenesulfonamide
  • Step C N-ethyl-N- ⁇ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyI)amino]phenyl ⁇ acetamide
  • Step D N- ⁇ 3-amino-4-[(tetrahydro-2H-pyran-4-yImethyI)arnino]phenyI ⁇ -N- ethylacetamide
  • Step E N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]-N-ethylacetamide
  • Step F 2-te/"t-butyl-N-ethyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH- benzimidazol-5-amine
  • Step B N-ethyI-N-[2-(l-hydroxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl] acetamide
  • Step C N-ethyl-N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyI)-lH-benzimidazol-5-yl]acetamide
  • Step D N-ethyl-2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-amine
  • Step A N-(5- ⁇ [[2-tert-Butyl-l-(cyclohexylmethyl)-lif-benzimidazol-5- yI](methyI)amino]suIfonyl ⁇ pyridin-2-yl)acetamide
  • Step B N-(3-Bromo-5- ⁇ [[2-tert-butyl-l-(cyclohexyImethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl ⁇ pyridin-2-yl)acetamide
  • the product was dissolved in 2 mL of DCE containing a catalytic amount of DMAP.
  • Acetyl chloride (0.055 L, 0.785 mmol) was added and the solution was heated at 120°C for 30 min using a Personal Chemistry microwaves instrument. The solution was washed with saturated aqueous NaHC0 3 solution, brine and dried over anhydrous MgS0 .
  • the crude product was purified by silica gel flash chromatography using 1 :1 / hexanes:EtOAc as eluent. Yield: 16 mg (18%); MS (ESI) (M+H) + : 578.28.
  • Step A N-(3- ⁇ [[2-tert-Butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl ⁇ phenyl)acetamide
  • Step B N-[2-tert-Butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5-yl]-N-methyl-3- nitrobenzenesulfonamide
  • N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methyl-3- nitrobenzenesulfonamide 72 mg, 0.149 mmol was dissolved in 15 mL of EtO ⁇ containing a catalytic amount of 10% Pd/C. The solution was shaken under ⁇ 2 atmosphere (45 psi) using a Parr hydrogenation apparatus at rt for 6h. The solution was filtered through celite and the solvent was evaporated. The crude product was purified by silica gel flash chromatography using 1:1 / hexanes:EtOAc as eluent.
  • the product was dissolved in 5 mL of DMF at 0°C and NaH (60% dispersion in oil) (7 mg, 0.185 mmol) was added followed by iodomethane (0.012 mL, 0.185 mmol). The solution was stirred at rt for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHC0 3 solution, brine and dried over anhydrous MgS0 4 . The solvent was evaporated. The product was purified by reversed-phase HPLC using 10- 60% CH 3 CN/H O and lyophilized affording the title compound as the corresponding TFA salt.
  • Step A N-(4- ⁇ [[2-te/t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyl ⁇ phenyl)-2,2-dimethylpropanamide
  • Step B N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH-benzimidazoI-5- yl]-N-methyl-4-nitrobenzenesulfonamide
  • Step C 4-Amino-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl]-N-methylbenzenesulfonamide
  • Step A N-(4- ⁇ [[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yI](methyl)amino]sulfonyl ⁇ phenyl)-2-hydroxyacetamide
  • Step B 2-[(4- ⁇ [[2-te/t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyl ⁇ henyl)amino]-2-oxoethyl acetate
  • Step A N , -(4- ⁇ [[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]suIfonyl ⁇ phenyI)-N 2 ⁇ /V 2 -dimethylglycinamide
  • Step B 2-Bromo-N-(4- ⁇ [[2-tert-butyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH- benzimidazol-5-yl](methyl)amino)sulfonyl ⁇ phenyI)acetamide
  • Step A N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5- yl]-6-[(2-hydroxyethyl)amino]-N-methyIpyridine-3-sulfonamide
  • the product was dissolved in a 5:1 / EtO ⁇ :AcO ⁇ mixture (40 mL) containing a catalytic amount of 10% Pd/C and was shaken under H 2 atmosphere (50 psi) using a Parr hydrogenation apparatus at rt for 24h. The solution was filtered through celite and the solvent was evaporated. The product was purified by reversed- phase HPLC using 10-60% CH 3 C ⁇ /H 2 0 and lyophilized affording the title compound as the corresponding TFA salt.
  • Step B 5-Bromo-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-yImethyI)-lH- benzimidazol-5-yl]-6-chloro-N-methylpyridine-3-sulfonamide
  • Step A N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]-6-(formylamino)-N-methylpyridine-3-sulfonamide
  • Step B 5-Bromo-N-[2-te;-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH- benzimidazol-5-yl]-6-(formylamino)-N-methylpyridine-3-sulfonamide
  • the product was dissolved in 25 mL of EtO ⁇ containing a catalytic amount of 10% Pd/C. The solution was shaken under ⁇ atmosphere (40 psi) using a Parr hydrogenation apparatus at rt overnight. The solution was filtered through celite and the solvent was evaporated. The residue was dissolved in 10 mL of 1:1 / DCE:pyridine and acetyl chloride (0.070 mL, 0.990 mmol) was added dropwise. The solution was stirred at rt for 3h. The solvent was evaporated. The product was dissolved in EtOAc and washed with saturated aqueous NaHC ⁇ 3 solution, brine and dried over anhydrous MgS0 .
  • Step A N-[4-( ⁇ [2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH- benzimidazoI-5-yl]amino ⁇ sulfonyI)phenyl]acetamide
  • Step B N- ⁇ 3-Nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl ⁇ acetamide
  • N-(4-Fluoro-3-nitrophenyl)acetamide 500 mg, 2.52 mmol
  • 4-aminomethyl tetrahydropyran 350 mg, 3.02 mmol
  • the solvent was concentrated.
  • the residue was dissolved in EtOAc and washed with aqueous 5% K ⁇ SO4, saturated aqueous ⁇ aHCOs solution, brine and dried over anhydrous MgS0 4 .
  • the crude product was purified by silica gel flash chromatography using EtOAc as eluent.
  • N- ⁇ 3- ⁇ itro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl ⁇ acetamide (605mg, 2.06 mmol) was dissolved in 50 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under ⁇ 2 atmosphere (40 psi) using a Parr hydrogenation apparatus overnight at rt. The solution was filtered through celite and the solvent was evaporated.
  • Step D N-[2-t ⁇ rt-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol- 5-yl] acetamide
  • N- ⁇ 3-Amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl ⁇ acetamide (315 mg, 1.20 mmol) and DMAP (30 mg, 0.240 mmol) were dissolved in 20 mL of DCM.
  • Trimethylacetyl chloride (0.160 mL, 1.32 mmol) was added dropwise and the solution was stirred at rt for 2h. The solution was washed with aqueous ⁇ a ⁇ CU 3 solution, brine and dried over anhydrous MgS0 4 . The residue was dissolved in 3 L of AcOH and was heated at 125°C for lh using a Personal Chemistry microwave apparatus. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHC ⁇ 3 solution, brine and dried over anhydrous MgS0 4 . The crude product was purified by silica gel flash chromatography using 1 :1 / hexanes : acetone as eluent.
  • N-[2-te/-t-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]acetamide (135 mg, 0.409 mmol) was dissolved in 4 mL of 1 :1 / EtO ⁇ :2M HCl. The solution was heated at 120°C for 30 min using a Personal Chemistry microwave apparatus. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 2M ⁇ aOH solution, brine and dried over anhydrous MgS0 . The solvent was evaporated.
  • Step A N-[4-( ⁇ [2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzin idazol-5- yl]amino ⁇ sulfonyl)phenyI]acetamide
  • N-(4-Fluoro-3-nitrophenyl)acetamide 500 mg, 2.52 mmol
  • cyclohexanemethylamine 0.525 mL, 3.78 mmol
  • the solvent was concentrated.
  • the residue was dissolved in EtOAc and washed with aqueous 5% KHSO4, saturated aqueous ⁇ aHC ⁇ 3 solution, brine and dried over anhydrous MgS ⁇ 4. The solvent was evaporated.
  • N- ⁇ 4-[(Cyclohexylmethyl)amino]-3-nitrophenyl ⁇ acetamide 730 mg, 2.51 mmol was dissolved in 40 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under H 2 atmosphere (45 psi) using a Parr hydrogenation apparatus overnight at rt. The solution was filtered through celite and the solvent was evaporated.
  • N- ⁇ 3-Amino-4-[(cyclohexylmethyl)amino]phenyl ⁇ acetamide (367 mg, 1.40 mmol) and DMAP (34 mg, 0.280 mmol) were dissolved in 10 mL of DCM.
  • Trimethylacetyl chloride (0.190 L, 1.54 mmol) was added dropwise and the solution was stirred at rt for lh. The solvent was evaporated. The product was dissolved in 4 mL of AcOH and was stirred at 150°C for 45 min. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous ⁇ aHC0 3 solution, brine and dried over anhydrous MgS0 4 .
  • Step E 2-tert-Butj r l-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- amine
  • N-[2-terf-Butyl-l -(cyclohexylmethyl)-lH-benzimidazol-5-yl]acetamide (260 mg, 0.794 mmol) was dissolved in 4 mL of 1:1 / EtO ⁇ :2M HCl mixture. The solution was stirred at 170°C using a Personal Chemistry microwaves instrument for 30 min. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous ⁇ aHC0 3 solution, brine and dried over anhydrous MgSU 4 . The solvent was evaporated.
  • Step A N-(4- ⁇ [[2-tert-Butyl-l-(2-piperidin-l-ylethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl ⁇ phenyl)acetamide
  • Step C Methyl ⁇ 3-amino-4-[(2-piperidin-l-ylethyI)amino]phenyl ⁇ carbamate
  • Step D Methyl [2-tert-butyl-l-(2-piperidin-l-ylethyl)-lH-benzimidazol-5- yl]carbamate
  • Methyl ⁇ 3-amino-4-[(2-piperidin-l-ylethyl)amino]phenyl)carbamate 55 mg, 0.188 mmol
  • trimethylacetyl chloride 0.025 mL, 0.207 mmol
  • the solution was washed with saturated aqueous NaHC ⁇ 3 solution, brine and dried over anhydrous MgS ⁇ 4.
  • the solvent was evaporated.
  • the residue was dissolved in 2 mL of AcOH and stirred at 150°C in a Personal Chemistry microwaves instrument for 40 min. The solvent was evaporated.
  • Step E 2-tert-Butyl-N-methyl-l-(2-piperidin-l-ylethyl)-lH-benzimidazol-5- amine
  • Methyl [2-tert-butyl-l -(2-piperidin-l -ylethyl)-lH-benzimidazol-5-yl]carbamate (27 mg, 0.0753 mmol) was dissolved in 5 mL of T ⁇ F at 0°C.
  • IM ⁇ Cl/ether (0.115 mL, 0.113 mmol) was added and the solution was stirred at 0°C for 15 min.
  • LiAlFL (15 mg, 0.377 mmol) was added and the solution was stirred at rt for 24h. The reaction was quenched at 0°C by the addition of MeOH (0.5 mL) and water (0.5 mL).
  • Step A N-(4- ⁇ [[2-te;T-Butyl-l-(l,4-dioxan-2-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl ⁇ phenyl)acetamide
  • Step B Methyl ⁇ 4-[(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl ⁇ carbamate
  • Step C Methyl ⁇ 3-amino-4-[(l,4-dioxan-2-yImethyl)amino]phenyl ⁇ carbamate
  • Step D Methyl [2-tert-butyI-l-(l,4-dioxan-2-ylmethyl)-lH-benzimidazol-5- yl]carbamate
  • Step A N-(4- ⁇ [ ⁇ 2-te/T-ButyI-l-[(l-methyIpiperidin-2-yI)methyl]-lH- benzimidazol-5-yl ⁇ (methyl)amino]sulfonyl ⁇ phenyl)acetamide
  • Step B tert-Butyl 2-[( ⁇ 4-[(methoxycarbonyl)amino]-2- nitrophenyl ⁇ amino)methyl]piperidine-l-carboxyIate
  • Step D Methyl (3-amino-4- ⁇ [(l-methylpiperidin-2- yl)methyl]amino ⁇ phenyl)carbamate
  • Step E Methyl ⁇ 2-tert-butyl-l-[(l-methylpiperidin-2-yl)methyl]-lH- benzimidazol-5-yl ⁇ carbamate
  • Step A N-(4- ⁇ [(2-tert-Butyl-l- ⁇ [(2i?)-l-methylpiperidin-2-yl]methyI ⁇ -lH- benzimidazol-5-yl)(methyI)amino]sulfonyl ⁇ phenyI)acetamide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R1, R2, R3, R4, n and Ar are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Description

BENZIMIDAZOLE DERIVATIVES. COMPOSITIONS CONTAINING THEM. PREPARATION THEREOF AND USES THEREOF
BACKGROUND OF THE INVENTION
1. Field of the invention The invention is related to therapeutic compounds, pharmaceutical compositions containing these compounds, manufacturing processes thereof and uses thereof. Particularly, the present invention is related to compounds that may be effective in treating pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiavascular disorders.
2. Discussion of Relevant Technology Pain management has been an important field of study for many years. It has been well known that cannabinoid receptor (e.g., CBi receptor, CB receptor) ligands including agonists, antagonists and inverse agonists produce relief of pain in a variety of animal models by interacting with CB] and/or CB2 receptors. Generally, CBi receptors are located predominately in the central nervous system, whereas CB2 receptors are located primarily in the periphery and are primarily restricted to the cells and tissues derived from the immune system. While CB) receptor agonists, such as Δ9-tetrahydrocannabinol (Δ'-THC) and anadamide, are useful in anti-nociception models in animals, they tend to exert undesired CNS side-effects, e.g., psychoactive side effects, the abuse potential, drug dependence and tolerance, etc. These undesired side effects are known to be mediated by the CB] receptors located in CNS. There are lines of evidence, however, suggesting that CB) agonists acting at peripheral sites or with limited CNS exposure can manage pain in humans or animals with much improved overall in vivo profile. Therefore, there is a need for new CBj receptor ligands such as agonists that may be useful in managing pain or treating other related symptoms or diseases with reduced or minimal undesirable CNS side-effects.
DESCRIPTION OF THE EMBODIMENTS The present invention provides CBi receptor ligands which may be useful in treating pain and/or other related symptoms or diseases.
Unless specified otherwise within this specification, the nomenclature used in this specification generally follows the examples and rules stated in Nomenclature of Organic Chemistiγ, Sections A, B, C, D, E, F. and H, Pergamon Press, Oxford, 1979, which is incoφorated by references herein for its exemplary chemical structure names and rules on naming chemical structures. "CB]/CB2 receptors" means CBi and/or CB2 receptors. The term "Cm.n" or "Cm-n group" used alone or as a prefix, refers to any group having m to n carbon atoms. The term "hydrocarbon" used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms. The term "hydrocarbon radical" or "hydrocarbyl" used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon. The term "alkyl" used alone or as a suffix or prefix, refers to monovalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms. Unless otherwise specified, "alkyl" general includes both saturated alkyl and unsaturated alkyl. The term "alkylene" used alone or as a suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together. The term "alkenyl" used alone or as a suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms. The term "alkynyl" used alone or as a suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond and comprising at least 2 up to about 12 carbon atoms. The term "cycloalkyl," used alone or as a suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms. "Cycloalkyl" includes both monocyclic and multicyclic hydrocarbon structures. Multicyclic hydrocarbon structure includes non-fused, fused and bridged rings. The term "cycloalkenyl" used alone or as a suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms. "Cycloalkenyl" includes both monocyclic and multicyclic hydrocarbon structures. Multicyclic hydrocarbon structure includes non-fused, fused and bridged rings. The term "cycloalkynyl" used alone or as a suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon triple bond and comprising about 7 up to about 12 carbon atoms. "Cycloalkenyl" includes both monocyclic and multicyclic hydrocarbon structures. Multicyclic hydrocarbon structure includes non-fused, fused and bridged rings. The term "aryl" used alone or as a suffix or prefix, refers to a hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms, wherein the radical is located on a carbon of the aromatic ring. The term "non-aromatic group" or "non-aromatic" used alone, as a suffix or as prefix, refers to a chemical group or radical that does not contain a ring having aromatic character (e.g., 4n + 2 delocalized electrons). The term "arylene" used alone or as a suffix or prefix, refers to a divalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (e.g., 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms, which serves to link two structures together. The term "heterocycle" used alone or as a suffix or prefix, refers to a ring- containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween. Heterocycle may have aromatic character or may not have aromatic character. The teπn "heteroalkyl" used alone or as a suffix or prefix, refers to a radical formed as a result of replacing one or more carbon atom of an alkyl with one or more heteroatoms selected from N, O, P and S. The term "heteroaromatic" used alone or as a suffix or prefix, refers to a ring- containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring- containing structure or molecule has an aromatic character (e.g., 4n + 2 delocalized electrons). The term "heterocyclic group," "heterocyclic moiety," "heterocyclic," or
"heterocyclo" used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom. The term "heterocyclyl" used alone or as a suffix or prefix, refers a radical derived from a heterocycle by removing at least one hydrogen from a carbon of a ring of the heterocycle. The term "heterocyclylene" used alone or as a suffix or prefix, refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom, which serves to links two structures together. The term "heteroaryl" used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character, wherein the radical of the heterocyclyl is located on a carbon of an aromatic ring of the heterocyclyl. A heteroaryl may contain both aromatic and non-aromatic rings therein. These rings may be fused or otherwised linked together. The term "heterocylcoalkyl" used alone or as a suffix or prefix, refers to a heterocyclyl that does not have aromatic character. The term "heteroarylene" used alone or as a suffix or prefix, refers to a heterocyclylene having aromatic character. The term "heterocycloalkylene" used alone or as a suffix or prefix, refers to a heterocyclylene that does not have aromatic character. The term "six-membered" used as prefix refers to a group having a ring that contains six ring atoms. The term "five-membered" used as prefix refers to a group having a ring that contains five ring atoms. A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S. Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl. A six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S. Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl. The term "substituted" used as a prefix refers to a structure, molecule or group, wherein one or more hydrogens are replaced with one or more Cι-ι2hydrocarbon groups, or one or more chemical groups containing one or more heteroatoms selected from N, O, S, F, Cl, Br, I, and P. Exemplar}' chemical groups containing one or more heteroatoms include heterocyclyl, -N0 , -OR, -Cl, -Br, -I, -F, -CF3, -C(=0)R, -C(=0)OH, -NH2, -SH, -NHR, -NR2, -SR, -S03H. -S02R, -S(=0)R, - CN, -OH, -C(=0)OR, -C(=0)NR2ι -NRC(=0)R, oxo (=0), imino (=NR), thio (=S), and oximino (=N-OR), wherein each "R" is a Cι-ι2hydrocarbyl. For example, substituted phenyl may refer to nitrophenyl, pyridylphenyl, methoxyphenyl, chlorophenyl, aminophenyl, etc., wherein the nitro, pyridyl, methoxy, chloro, and amino groups may replace any suitable hydrogen on the phenyl ring. The term "substituted" used as a suffix of a first structure, molecule or group, followed by one or more names of chemical groups refers to a second structure, molecule or group, which is a result of replacing one or more hydrogens of the first structure, molecule or group with the one or more named chemical groups. For example, a "phenyl substituted by nitro" refers to nitrophenyl. The term "optionally substituted" refers to both groups, structures, or molecules that are substituted and those that are not substituted. Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5- dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, moφholine, thiomoφholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-lH-azepine ho opiperazine, 1,3-dioxepane, 4,7- dihydro-l,3-dioxepin, and hexamethylene oxide. In addition, heterocycle includes aromatic heterocycles, for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3- thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4- triazole, 1,3,4-thiadiazole, and 1,3,4- oxadiazole. Additionally, heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxathiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine, 1,2- benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, thioxanthine, carbazole, carboline, acridine, pyrolizidine, and quinolizidine. In addition to the polycyclic heterocycles described above, heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane. Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1 ,2,3,6-tetrahydro- pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3- dihydropyranyl, tetrahydropyranyl, 1 ,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-lH-azepinyl, homopiperazinyl, 1,3- dioxepanyl, 4,7-dihydro-l,3-dioxepinyl, and hexamethylene oxidyl. In addition, heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyI, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1 ,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl. Additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4- benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3- dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, 1 ,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl. In addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocyclyls include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl. The term "alkoxy" used alone or as a suffix or prefix, refers to radicals of the general formula -O-R, wherein -R is selected from a hydrocarbon radical. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy. The term "aryloxy" used alone or as a suffix or prefix, refers to radicals of the general formula -O-Ar, wherein -Ar is an aryl. The term "heteroaryloxy" used alone or as a suffix or prefix, refers to radicals of the general formula -O-Ar', wherein -Ar' is a heteroaryl. The term "amine" or "amino" used alone or as a suffix or prefix, refers to radicals of the general formula -NRR', wherein R and R' are independently selected from hydrogen or a hydrocarbon radical. "Acyl" used alone, as a prefix or suffix, means -C(=0)-R, wherein -R is an optionally substituted hydrocarbyl, hydrogen, amino or alkoxy. Acyl groups include, for example, acetyl, propionyl, be zoyl, phenyl acetyl, carboethoxy, and dimethylcarbamoyl. Halogen includes fluorine, chlorine, bromine and iodine. "Halogenated," used as a prefix of a group, means one or more hydrogens on the group is replaced with one or more halogens. "RT" or "rt" means room temperature. A first ring group being "fused" with a second ring group means the first ring and the second ring share at least two atoms therebetween. "Link," "linked," or "linking," unless otherwise specified, means covalently linked or bonded. When a first group, structure, or atom is "directly connected" to a second group, structure or atom, at least one atom of the first group, structure or atom forms a chemical bond with at least one atom of the second group, structure or atom. "Saturated carbon" means a carbon atom in a structure, molecule or group wherein all the bonds connected to this carbon atom are single bond. In other words, there is no double or triple bonds connected to this carbon atom and this carbon atom generally adopts an sp3 atomic orbital hybridization. "Unsaturated carbon" means a carbon atom in a structure, molecule or group wherein at least one bond connected to this carbon atom is not a single bond. In other words, there is at least one double or triple bond connected to this carbon atom and this carbon atom generally adopts a sp or sp' atomic orbital hybridization.
In one aspect, an embodiment of the invention provides a compound of Formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:
Figure imgf000009_0001
I wherein R1 is selected from Ci.ioalkyl, C -ιoalkenyl, C -ι0alkynyl, R5-C(=0)-0- C ealkyl, R5R6N-C1-6alkyl, R50-C1-6 alkyl, R5C(=0)N(-R6)-C,-6alkyl, R5R°NS(=0)2- C,-6alkyl, R5CS(=0)2N(-R6)-C1^alkyl, R5R6NC(=0)N(-R7)-C,.6alkyl, R5R6NS(=0)2N(R7)-C1-6alkyl, C6-,oaryl-C,-6aIkyl, C6-ι0aryl-C(=O)-C1.6alkyl, C3- ιocycloalkyl-Cι-6alkyl, C -scycloalkenyl-Cι-όalkyl, C3-6heterocyclyl-Cι-6alkyl, C3-
6 heterocyclyl-C(=0)-C,.6alkyl, CMOhydrocarbylamino, R5R6N-, R50-, R5C(=0)N(- R6)-, R5RδNS(=0)2-; R5CS(=0)2N(-R6)-, R5R6NC(=0)N(-R7)-, R5R6NS(=0)2N(R7)-, C6.i0aryl, C6-ι0aryl-C(=O)-, C3-ιocycloalkyl, C4-8cycloalkenyl, C3-6heterocyclyl and C3. 6heterocyclyl-C(=0)-; wherein said Cι.]0alkyl, C -ι0alkenyl, C2-ι0alkynyl, C<5-ι0aryl- Cι-6alkyl, C6-ιoaryl-C(=0)-Cι.6alkyl, Cs.iocycloalkyl-Ci-ealkyl, C4-8cycloalkenyl- C]-6alkyl, C3.6heterocyclyl-C).6alkyl, C3.6heterocyclyl-C(=0)-C].6alkyl, Cj. lohydrocarbylamino, Cό-ioaryl,
Figure imgf000010_0001
C3-ιocycloalkyl, C4-8cycloalkenyl, C3. 6heterocyclyl or C3-όheterocyclyl-C(=0)- used in defining R1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and -NR5R6; R" is selected from Cι.ι0alkyl, C2-ιoalkenyl, C2.ιoalkynyl, C3-ιocycloalkyl, C3. i0cycloalkyl-Ci-6alkyl, C4-8cycloalkenyl-Cι-6alkyl, C3-6heterocycloalkyl-Cι.6alkyl, C4- 8cycloalkenyl, R5R6N-, C3.5heteroar}'l, Ce-ioaryl and C3-6heterocycloalkyl, wherein said Ci.ioalkyl, C -ιoalkenyl, C2-ι0alkynyl, C3.8cycloalkyl, C3.8cycloalkyl-Cι.6alk}4, C4.8cycloalkenyl-Cι-6alkyl, C3.6heterocycloalkyl-Cι-6alkyl, C4-8cycloalkenyl, C3- 5heteroaryl, Cδ-ioaryl or C3.6heterocycloalkyl used in defining R2 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR5R6; wherein R5, R6 and R7 are independently selected from -H, Cι-6alkyl, C2-6alkenyl, C2-6alkynyl, and a divalent Cι.6group that together with another divalent R5, R6 or R7 forms a portion of a ring; Ar is selected from Cό-ioaryl and C3-8heteroaryl; n is selected from 0, 1 , 2 and 3; each of R3 is independently selected from -H, nitro, halogen, Ci.ioalkyl, C2. ι0alkenyl, C .ι0alkynyl, Cs.iocycloalkyl, C3.|0cycloalkyl-Cι.6alkyl, C4-8cycloalkenyl- Cι-6alkyl, C3.6heterocycloalkyl-C].6alkyl, C3-6heterocycloalkyl,
Figure imgf000011_0001
R •fi' R"V
Figure imgf000011_0002
Figure imgf000011_0003
R ° K H ' RN R9t°κ H °!-N HA
Figure imgf000011_0005
Figure imgf000011_0006
Figure imgf000011_0004
-
Figure imgf000011_0007
optionally subsitituted with one or more groups selected from C).6alkyl, hydroxy, halogen, amino and Ci-βalkoxy,
Figure imgf000012_0001
Q o
H RS Rj9 -oΛ - RS όR-I9; ° Λ and * l o each of R8 and R9 is independently selected from -H, Ci.ioalkyl, C2-)oalkenyl, C2-ιoalkynyl, Cs-iocycloalkyl, C3-ι0cycloalkyl-Cι-6alkyl, C3.6heterocyclyl, Cό-ioaryl, C3-6heterocylcyl-Cι.6alkyl, C6-ι0aryl-Cι-6alkyl, and a divalent C]-6group that together with another divalent group selected from R and R forms a portion of a ring, wherein said Ci.ioalkyl, C2-ι0alkenyl, C2-ιoaIkynyl, C3.|0cycloalkyl, C3-ι0cycloalkyl- Cι-6alkyl, C3.6heterocyclyl, Cβ-ioaryl, C3-6heterocylcyl-Cι-6alkyl, Ce-ioaryl-Ci.ealkyl, or divalent Cι.6group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR5R6; and R4 is selected from -H, Ci.ioalkyl, C2.ιoalkenyl, C2.ιoalkynyl, C3.ι0cycloalkyl,
Cs-iocycIoalkyl-Ci.galkyl, and C4-8cycloalkenyl-Cι.6alkyl.
Another embodiment of the invention provides a compound of Formula I, wherein R1 is selected from C,.6alkyl,
Figure imgf000012_0002
C2.6alkenyl, C2.
6alkynyl, phenyl-C alkyl, C3.ιocycloalkyl-C alkyl, C^cycloalkenyl-C alkyl, C3. όheterocyclyl-CMalkyl, C6-ιoaryl, C3-6heterocyclyl, C3.ιocycloalkyl, and C4- ecycloalkenyl, wherein said
Figure imgf000013_0001
C2.6alkenyl, C2- 6alkynyl, phenyl-C alkyl, Cs.iocycloalkyl-C al yl, C4.6cycloalkenyl-Cι-4alkyl, C6- ι0aryl, C3-6heterocyclyl-Cι-4alkyl, C3.6heterocyclyl, C3.]0cycloalkyl, and C4- 6cycloalkenyl used in defining R1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and -NR5R6; R" is selected from Cj.6alkyl, C2-6alkenyl, C3-6cycloalkyl, C3-6cycloalkyl- Cι-4alkyl, C .6cycloalkenyl-CMalkyl, C3.6heterocycloalkyl-C).4alkyl, C4. όcycloalkenyl, Cs-sheteroaryl, R R°N-, and phenyl, wherein said Cι.6alkyl, C2. 6alkenyl, C3.6cycloalkyl, Qj-όcycloalkyl-C alkyl, C -6cycloalkenyl-Cι-4alkyl, C3.6heterocycloalkyl-Cι-4alkyl, C -6cycloalkenyl, C3-5heteroaryl, R5R6N-, and phenyl used in defining R~ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; wherein R5 and R are independently selected from -H, Cι.6alkyl, C2-6alkenyl, and a divalent Cι-6alkylene that together with another divalent R5 or R6 and optionally a heteroatom forms a portion of a ring; Ar is selected from phenyl and C3-5heteroaryl; n is selected from 0, 1 and 2; each of R3 is independently selected from -H, nitro, halogen, Cj-6alkyl, C2.
6alkenyl, C3-6cycloalkyl, Cs-eheterocycloalkyl-C alkyl,
Figure imgf000013_0002
and, C3-6heterocycloalkyl optionally subsitituted with one or more groups selected from Cι-6alkyl, hydroxy, halogen and
Figure imgf000014_0001
each of R8 and R9 is independently selected from -H, Cι-6alkyl, C2-6alkenyl, C3.6cycloalkyl,
Figure imgf000014_0002
C3-6heterocyclyl and C3-όheterocylcyl-Cι. 6alkyl, wherein said C].6alkyl, C2.6alkenyl, C3-6cycloalkyl, C3.6cycloalkyl-Cι.6alkyl, Cs-όheterocyclyl and C3-6heterocylcyl-Ci-6alkyl are optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR10Rπ; and R4, R10 and Rπ are independently selected from -H and C]-3alkyl. A further embodiment of the invention provides a compound of Formula I, wherein R1 is selected from Chalky!, Cι.3alkyl-C(=0)-0-Cι-3alkyl, C2-6alkenyl, phenyl-C alkyl, C3-i 0cycloalkyl-Cι-4alkyl, C .6cycloalkenyl-C). alkyl, C3.6heterocylcoalkyl-Cι.4alkyl, Cδ-ioaryl, C3.ιocycloalkyl, and C -6cycloalkenyl, wherein said Cuealkyl, C2-6alkenyl, phenyl-Cι-4alkyl, C3-ιocycloalkyl-Cι- alkyl,
Figure imgf000014_0003
C3-6heterocylcoalkyl-Cι. alkyl, C6.ιoaryl, C3-ιocycloalkyl, and C4-6cycloalkenyl used in defining R1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and amino; R2 is selected from Cι-6alkyl, C2.6alkenyl, C3-6cycloalkyl and C3.6cycloalkyI- Cι-4alkyl, wherein said Cι-6alkyl, C2-6alkenyl, C3.6cycloalkyl and C3-6cycloalkyl-
C].4alkyl used in defining R~ is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; Ar is selected from phenyl and C3.5 heteroaryl and n is selected from 0, 1 and 2; each of R3 is independently selected from -H, halogen, nitro, Cι-3alkyl, C3-
6heterocycloalkyl,
Figure imgf000015_0001
optionally subsitituted with one or
more
Figure imgf000015_0002
; wherein said C3-6heterocycloalkyl contain at least one nitrogen ring atom and the radical of C3.6heterocycloalkyl is located on at least one nitrogen ring atom, and wherein each of R8 and R9 is independently selected from -H, Cι_6alkyl, moφholinyl- Cι-3alkyl, pyrroIidinyl-Ci.3alkyl, and piperidinyl-Cι.3alkyl, wherein said C].6alkyl, moφholinyl- C1-3alkyl,
Figure imgf000015_0003
and piperidinyl-Cι-3alkyl are optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR5R6; and R4, R5 and R6 are independently selected from -H and Cι-3alkyl.
An even further embodiment of the invention provides a compound of Formula I, wherein R1 is selected from cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl,cyclohexylethyl, cyclopentylethyl, bicyclo[2.2.1]hept-5-en-2- ylmethyl, 4,4-difluorocyclohexylmethyl, tetrahydropyranylmethyl, tetrahydropyranylethyl, tetrahydrofuranyl ethyl, 1 -piperidinylethyl, and N-methyl-2- piperidinylmethyl; R" is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2- propyl, 2-hydroxyl-propyl, trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, 1- methyl-propyl, 1,1-dimethyl-propyl, l,l-dimethyl-3-buten-l-yl, ethyl, and 2-propyl; Ar is selected from phenyl, pyridyl, pyrimidyl, thiazolyl, thienyl, isoxazolyl, imidazolyl, and pyrazolyl; n is selected from 0, 1 and 2; each of R3 is independently selected from -H, Cι_3alkyl, 4-morpholinyl, 1-
piperidinyl, 1-piperazinyl,
Figure imgf000015_0004
; and wherein 4-moφholinyl, 1-piperidinyl, and 1 -piperazinyl are optionally substituted with one or more methyl; and wherein each of R8 and R9 is independently selected from -H, Cι.3alkyl, morpholinylmethyl, pyrrolidinyl-methyl, and piperidinyl-methyl, wherein said Cι-3alkyl, moφholinylmethyl, pyrrolidinyl-methyl, and piperidinyl-methyl are optionally substituted by one or more groups selected from hydroxy, amino and dimethylamino.
It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric foπns, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter. It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present invention includes any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the compounds of the Formula I. It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the Formula I. Within the scope of the invention are also salts of the compounds of the Formula I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion. It may also be possible to make a corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques. In one embodiment, the compound of Formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or ?-toluenesulphonate. We have now found that the compounds of the invention have activity as pharmaceuticals, in particular as modulators or ligands such as agonists, partial agonists, inverse agonist or antagonists of CBi receptors. More particularly, the compounds of the invention exhibit selective activity as agonist of the CBi receptors and are useful in therapy, especially for relief of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive. Additionally, compounds of the present invention are useful in other disease states in which dysfunction of CBi receptors is present or implicated. Furthermore, the compounds of the invention may be used to treat cancer, multiple sclerosis, Parkinson's disease, cancer, Huntingdon's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and cardiavascular disorders. Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents. Compounds of the invention are useful in disease states where degeneration or dysfunction of cannabinoid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET). Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following miocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension. Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids. Also within the scope of the invention is the use of any of the compounds according to the Formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above. A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Formula I above, is administered to a patient in need of such treatment. Thus, the invention provides a compound of Formula I, or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy. In a further aspect, the present invention provides the use of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy. In the context of the present specification, the term "therapy" also includes
"prophylaxis" unless there are specific indications to the contrary. The term "therapeutic" and "therapeutically" should be contrued accordingly. The term "therapy" within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders. The compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain. In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints. In one embodiment of the invention, the route of administration may be oral, intravenous or intramuscular. The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient. For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid and liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material. hi powders, the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture in then poured into convenient sized moulds and allowed to cool and solidify. Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like. The term composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration. Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art. Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition. A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and inteφreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art. Within the scope of the invention is the use of any compound of Formula I as defined above for the manufacture of a medicament. Also within the scope of the invention is the use of any compound of Formula I for the manufacture of a medicament for the therapy of pain. Additionally provided is the use of any compound according to Formula 1 for the manufacture of a medicament for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain. A further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the Foπnula I above, is administered to a patient in need of such therapy. Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier. Particularly, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain. Further, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above. In a further aspect, the present invention provides a method of preparing the compounds of the present invention. In one embodiment, the invention provides a process for preparing a compound of Formula I,
Figure imgf000021_0001
I comprising the step of reacting a compound of Fonnula II,
Figure imgf000021_0002
II with a compound of R'COX, in the presence of a base, such as an alkylamine, and optionally a coupling reagent, such as HATU, EDC, followed by treatment with an acid, such as HCl, acetic acid wherein X is selected from Cl, Br, F and OH; R1 is selected from Ci.ioalkyl, C2-ι0alkenyl, C2-ι0alkynyl, R5-C(=0)-0- Cι.6alkyl, R5R6N-Cι-6alkyl, R50-C,.6 alkyl, R5C(=0)N(-R°)-C,-6alkyl, R5R6NS(=0)2- C,.6alkyl, R5CS(=0)2N(-R6)-C,.6alkyl, R5R6NC(=0)N(-R7)-C,.6alkyl, R5R6NS(=0)2N(R7)-Ci.6alkyl, C6.ι0aryl-Cι.6alkyl, C6-ι0aryl-C(=O)-Cι.6alkyl, C3. ]0cycloalkyl-Cι.6alkyl, C4-8cycloalkenyl-Cι-6alkyl, C3.6heteiOcyclyl-Cι.6alkyl, C3. 6heterocyclyl-C(=0)-Ci-6alkyl, C,-I0hydrocarbylamino, R5R6N-, R50-, R5C(=0)N(- R6)-, R5R6NS(=0)2-, R5CS(=0)2N(-R6)-, R5R6NC(=0)N(-R7)-, R5R°NS(=0)2N(R7)-, Ce-ioaryl, C6-ιoaryl-C(=0)-, C3.ιocycloalkyl, C4.8cycloalkenyl, C3.6heterocyclyl and C3.
Figure imgf000022_0001
wherein said Ci.ioalkyl, C2.]0alkenyl, C2-ιoalkynyl, C6-ιoaryl- Cι-6alkyl, C6.ιoaryl-C(=0)-Cι.6alkyl,
Figure imgf000022_0002
C4-8cycloalkenyl- Cι-6alkyl, C3.6heterocyclyl-Cι.6alkyl, C3.6heterocyclyl-C(=0)-Ci.6alkyl, Cj. lohydrocarbylamino, Ce-ioaryl,
Figure imgf000022_0003
C3.ι0cycloalkyl, C4-scycloalkenyl, 03. 6heterocyclyl or C3.6heterocyclyl-C(=0)- used in defining R1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and -NR5R6; R2 is selected from Ci.ioalkyl, C2-ι0alkenyl, C2-ιoalkynyl, C3.ιocycloalkyl, C3. ιocycloalkyl-Cι-6alkyl, C -scycloalkenyl-Cι.6alkyl, C3-6heterocycloalkyl-Cι.6alkyI, C4. 8cycloalkenyl, R5R6N-, C3.5heteroaryl, C6.ιoaryl and C3.6heterocycloalkyl, wherein said Ci.ioalkyl, C2-ι0alkenyl, C .ιoalkynyl, C3.8cycloalkyl, C3-8cycloalkyl-Cι-6alkyl, C4.8cycIoalkenyI-C].6alkyl, C3.6heterocycloalkyl-Cι.6alkyl, C4.8cycloalkenyl, C3. sheteroaryl, C6.ioaryI or C3-6heterocycloalkyl used in defining R2 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR5R6; wherein R5, R6 and R7 are independently selected from -H, Ci.6alkyl, C2. 6alkenyl, C2.6alkynyl, and a divalent C].6group that together with another divalent R=, R6 or R7 forms a portion of a ring; Ar is selected from C6-ιoaryl and C3.8heteroaryl; n is selected from 0, 1, 2 and 3; each of R3 is independently selected from -H, nitro, halogen, Ci.ioalkyl, C2. loalkenyl, C2.ι0alkynyl, C3.ι0cycloalkyl, C3.ιocycloalkyI-Cι-6alkyl, C4-8cycloalkenyl- Cι.6alkyl, C3.όheterocycloalkyl-Cι.6alkyl, Cs-δheterocycloalkyl and
Figure imgf000023_0001
UB HΛ RN R9IH HΛ • OR9;κ H '
-°V R«ΛoΛ R
Figure imgf000023_0002
Figure imgf000023_0003
aanndd R L o optionally subsitituted with one or more groups selected from Cι.6alkyl, hydroxy, halogen, amino,
Figure imgf000023_0004
. T?
Figure imgf000024_0001
Q o O R,t°A R RJ9 -° Λ • RN Oi R 9; ° Λ and « £ o 0 A each of R8 and R9 is independently selected from -H, Cj.ioalkyl, C2.ιoalkenyl, C2.ιoalkynyl, C3-ιocycloalkyl, C3.ι0cycloalkyl-C|.6alkyl, Cs.δheterocyclyl, C6-ιoaryl, C3.6heterocylcyl-Ci.6alkyl, Ce-ioaryl-Ci-όalkyl, and a divalent C].6group that together with another divalent group selected from R8 and R9 forms a portion of a ring, wherein said Ci-ioalkyl, C2.ιoalkenyI, C2-ιoalkynyl, Cs.iocycloalkyl, C3.]0cycloalkyl- Ci-βalkyl, C3.6heterocyclyl, Cβ-ioaryl, C3.όheterocylcyl-Cι.6aIkyl, Cβ-ioaryl-Ci-όalkyl, or divalent Cι-6group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR5R6; and R4 is selected from -H, Ci.ioalkyl, C2.ιoalkenyl, C2-ιoalkynyl, C3.|0cycloalkyl,
C3-ιocycloalkyl-C).6alkyl, and C4.8cycloalkenyl-Cι.6alkyl.
The present invention also provides a method of preparing a compound of Formula I, X is selected from Cl, Br, F and OH;
2 R1 is selected from d^alkyl, Ct.6alkyl-C(=0)-0-Ci aIkyl, C2-6alkenyl, phenyl-C alkyl, C3-ιocycloalkyl-Cι.4alkyl, C^cycloalkenyl-C alkyl, Cb-ιoaryl, C3. όheterocyclyl, C3-6heterocyclyl-Cι- alkyl, C3.ιocycloalkyl, and C4.6cycloalkenyl, wherein said C].6alkyl, Cι.6alkyl-C(=0)-0-Cι-4alkyl, C2-6alkenyl, phenyl-Cι. alkyl, Cs-iocycloalkyl-C alkyl, C .6cycloalkenyl-Cι.4alkyl, Cβ-ioaryl, C3.6heterocyclyl-C).
4alkyl, C3-6heterocyclyl, C3.ι0cycloalkyl, and C4.bcycloalkenyl used in defining R1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and amino; R2 is selected from C].6alkyl, C2.όalkenyl, C3.6cycloalkyl and C3.6cycloalkyl- Ci^alkyl, wherein said Cι.6alkyl, C2.6alkenyl, C3.6cycloalkyl and C3.6cycloalkyl-
CMalkyl used in defining R" is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; Ar is selected from phenyl and C3_5heteroaryl and n is selected from 0, 1 and 2; each of R3 is independently selected from -H, nitro, halogen, Cι_3alkyl, C3.
6heterocycloalkyl-C i^alkyl,
Figure imgf000025_0001
optionally
substituted with one or more Cι.6alkyl, hydroxy, halogen, and
Figure imgf000026_0001
wherein said C3.6heterocycloalkyl contain at least one nitrogen ring atom and the radical of C3.6heterocycloalkyl is located on the at least one nitrogen ring atom, and wherein each of R8 and R9 is independently selected from -H, Cι.6alkyl, moφholinyl- Cι.3alkyl,
Figure imgf000026_0003
and
Figure imgf000026_0002
wherein said Cι.6alkyl, moφholinyl- Cι.3alkyl,
Figure imgf000026_0004
and
Figure imgf000026_0005
are optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR5R6; and R4, R5 and R6 are independently selected from -H and Cι.3alkyl.
Compounds of the present invention may also be prepared according to the synthetic routes as depicted in Schemes 1-10.
Scheme 1. F
Figure imgf000027_0001
base, e g Et3N X = halogen solvent e g EtOH 50-150°C
Figure imgf000027_0002
step 1 can be skipped solvent, e g CH,CI2 if « = H when Y=OH base, e g DIPEA solvent, e g DMF coupling reagent, e g HATU 3) solvent, e g AcOH acid, e g AcOH microwave oven heating, 100-190°C n, Ar, R1 , R2, R3 and R4 are as defined in the specifications
Scheme 2.
Figure imgf000027_0003
base e DIPEA solvent, e g DMF coupling reagent, e g HATU 3) solvent, e g AcOH acid, e g AcOH microwave oven heating, 100-190°C n, Ar, R', R2 and R3 are as defined in the specifications Scheme 3
1) reduction e g H2, Pd 1) Ac,0
HN^^^NO- solvent, e g EtOAc _— . ». ,3-N 2) R1NH2 2) RjCOY base, e g Na2C03 YΎXN°- when Y=CI XXH R' solvent e g EtOH base e g DMAP heating, 50-150°C solvent, e g CH2CI2 R3 = H when Y=OH NaH, THF base, e g DMAP " R3I solvent e g DMF Acid, 1 e HCl coupling reagent e g HATU R3 = Me, Et solvent, e THF 3) solvent e g AcOH acid, e g AcOH microwave oven heating, 100-190°C
I HN (R ■\)n,-Ar »,N XX when Y=CI base e g DMAP XH solvent, e g CH2CI2
R1, R2, R3 and R4 are as defined in the specifications Ar is phenylene or pyπdinylene
Scheme 4
H
Figure imgf000028_0001
ATU
Figure imgf000028_0002
3) solvent e g AcOH acid, e g AcOH microwave oven heating, 100-190°C
R\ R2 R3, and R4 are as defined in the specifications Ar is phenylene or pyπdinylene Scheme 5
Figure imgf000029_0001
base e g Py solvent, e g CH2CI2 (R3)„ArSO,Y when Y=OH when Y=CI base, e g DMAP solvent, e g DMF base, e g DMAP coupling reagent e g HATU solvent, e g CH2CI2
Figure imgf000029_0002
R\ R2, R3 and R4 are as defined in the specifications Ar is phenylene or pyπdinylene
Scheme 6
Figure imgf000029_0003
base, e g DIPEA solvent, e g DMF coupling reagent, e g HATU 3) solvent, e g AcOH acid, e g AcOH microwave oven heating, 100-190°C n, Ar, R\ R2, R3 and R4 are as defined in the specifications Scheme 7
02N-Ar j δ XXH
Figure imgf000030_0002
R1, R2, R4 and Ar are as defined in the specifications, R10 and R" are optionally substituted C1-6alkyl, Y and Z are halogen or -OH Scheme 8
Figure imgf000030_0003
R1, R2, R4, Rβ and Ar are as defined in the specifications
Scheme 9
Figure imgf000030_0004
Condition B or solvent, e g DMF heat, 100-300°C R R2, R4, Rβ R9 and Ar are as defined in the specifications Scheme 10
Figure imgf000031_0001
R1, R2, R3, R4, and Ar are as defined in the specifications.
Biological Evaluation hCBi and hCB? receptor binding Human CB] receptor from Receptor Biology (hCBi) or human CB2 receptor from BioSignal (hCB2) membranes are thawed at 37 °C, passed 3 times through a 25- gauge blunt-end needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5 mM EDTA, 5 mM MgCl2, and 0.5 mg/mL BSA fatty acid free, pH 7.4) and aliquots containing the appropriate amount of protein are distributed in 96-well plates. The IC50 of the compounds of the invention at hCB) and hCB2 are evaluated from 10-point dose-response curves done with 3H-CP55,940 at 20000 to 25000 dpm per well (0.17- 0.21 nM) in a final volume of 300 μl. The total and non-specific binding are determined in the absence and presence of 0.2 μM of HU210 respectively. The plates are vortexed and incubated for 60 minutes at room temperature, filtered through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Tomtec or Packard harvester using 3 L of wash buffer (50 mM Tris, 5 mM MgCl?, 0.5 mg BSA pH 7.0). The filters are dried for 1 hour at 55 °C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl/well of MS-20 scintillation liquid.
hCB, and hCB. GTPγS binding Human CBi receptor from Receptor Biology (hCBi) or human CB2 receptor membranes (BioSignal) are thawed at 37 °C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTPγS binding buffer (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 M MgCl2, pH 7.4, 0.1% BSA). The EC so and Ema of the compounds of the invention are evaluated from 10-point dose- response curves done in 300μl with the appropriate amount of membrane protein and 100000-130000 dpm of GTPg35S per well (0.11 -0.14 nM). The basal and maximal stimulated binding is determined in absence and presence of 1 μM (hCB?) or 10 μM (hCBi) Win 55,212-2 respectively. The membranes are pre-incubated for 5 minutes with 56.25 μM (hCB2) or 112.5 μM (hCBi) GDP prior to distribution in plates (15 μM (hCB2) or 30 μM (hCBi) GDP final). The plates are vortexed and incubated for 60 minutes at room temperature, filtered on Unifilters GF/B (presoaked in water) with the Tomtec or Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM MgCl2, 50 mM NaCl, pH 7.0). The filters are dried for 1 hour at 55 °C. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl/well of MS-20 scintillation liquid. Antagonist reversal studies are done in the same way except that (a) an agonist dose-response curve is done in the presence of a constant concentration of antagonist, or (b) an antagonist dose-response curve is done in the presence of a constant concentration of agonist. Based on the above assays, the dissociation constant (Ki) for a particular compound of the invention towards a particular receptor is determined using the following equation: Ki = IC50/(l+[rad]/Kd), Wherein IC50 is the concentration of the compound of the invention at which
50% displacement has been observed; [rad] is a standard or reference radioactive ligand concentration at that moment; and Kd is the dissociation constant of the radioactive ligand towards the particular receptor. Using the above-mentioned assays, the Ki towards human CB] receptors for most compounds of the invention is measured to be in the range of 0.7-7170 nM. The Ki towards human CB receptors for most compounds of the invention is measured to be in the range of about 0.3-5800 nM. The EC50 towards human CBi receptors for most compounds of the invention is measured to be in the range of about 0.8-2810 nM. The Emax towards human CB] receptors for most compounds of the invention is measured to be in the range of about 22.3-140%. In one embodiment, the Ki towards human CB] receptors for most compounds of the invention is measured to be in the range of 0.7-50 nM. The Ki towards human CB2 receptors for most compounds of the invention is measured to be in the range of about 0.3-25 nM. The EC50 towards human CBi receptors for most compounds of the invention is measured to be in the range of about 0.8-100 nM. The Emax towards human CBi receptors for most compounds of the invention is measured to be in the range of about 60-125%.
EXAMPLES
The invention will further be described in more detail by the following Examples which describe methods whereby compounds of the present invention may be prepared, purified, analyzed and biologically tested, and which are not to be construed as limiting the invention.
Example 1
N-[2-te/*t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazoI-5-yl]thiophene-2- sulfonamide
Figure imgf000033_0001
Step A. N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]thiophene-2- sulfonamide
Figure imgf000033_0002
N-{3-Amino-4-[(cyclohexylmethyl)amino]phenyl}thiophene-2-sulfonamide (55 mg, 0.150 mmol) (for preparation, see the following steps B, C and D) was dissolved in 3 L of 1,2-dichloroethane containing TEA (0.030 L, 0.225 mmol). Trimethylacetyl chloride (0.020 mL, 0.165 mmol) was added dropwise and the solution was stirred at rt for lh. Glacial AcOH (1 mL) and a few drops of concentrated HCl were added and the solution was stirred at 80°C overnight. The solvent was evaporated. The crude product was dissolved in EtOAc and washed with 2M NaOH aqueous solution, brine and dried over anhydrous MgS04. The product was purified by reversed-phase HPLC using 20-80% CH3CN/H20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 10 mg (15%); Η NMR (400 MHz, METHANOL-D4) δ 1.19 (m, 5 H), 1.57 (m, 1 H), 1.59 (m, 1 H), 1.61 (s, 9 H), 1.66 (m, 1 H), 1.73 (m, 2 H), 2.05 (m, 1 H), 4.37 (d, J-7.62 Hz, 2 H), 7.02 (dd, J=4.98, 3.81 Hz, 1 H), 7.25 (dd, J=8.98, 2.15 Hz, 1 H), 7.52 (dd, J=3.71, 1.37 Hz, 1 H), 7.66 (d, J=2.15 Hz, 1 H), 7.69 (dd, J=5.08, 1.37 Hz, 1 H), 7.76 (d, J=8.9S Hz, 1 H); MS (ESI) (M+H)+ 432.1; Anal. Calcd for C22H29N302S2 + 1.4 TFA + 0.6 H20: C, 49.48; H, 5.29; N, 6.98. Found: C, 49.47; H, 5.36; N, 6.83.
Step B. N-(4-Fluoro-3-nitrophenyl)thiophene-2-sulfonamide
Figure imgf000034_0001
4-Fluoro-3-nitroaniline (1.00 g, 6.41 mmol) and 2-thiophenesulfonyI chloride (1.75 g, 9.62 mmol) were stirred in dichloromethane (150 L) containing DMAP (1.17g, 9.62 mmol) at rt for 24 h. The solution was washed with 5% KHS0 aqueous solution, saturated ΝaHC03 aqueous solution, brine and dried over anhydrous MgS0 . The crude product was purified by flash chromatography with dichloromethane as eluent on silica gel to afford the title product. Yield: 425 mg (22%); Η NMR (400 MHz, CHLOROFORM-D) δ 6.90 (m, IH), 7.08 (dd, J= 5.08, 3.91 Hz, IH), 7.26 (t, J = 10.35 Hz, IH), 7.49 (m, IH), 7.56 (dd, J = 3.71, 1.37 Hz, IH), 7.63 (dd, J = 5.08, 1.37 Hz, IH), 7.78 (dd, J = 6.35, 2.83Hz, IH).
Step C. N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl}thiophene-2- sulfonamide
Figure imgf000035_0001
N-(4-Fluoro-3-nitrophenyl)thiophene-2-sulfonamide (73 mg, 0.241 mmol) and cyclohexylmethyl amine (0.040 mL, 0.289 mmol) were stirred in 3 mL of EtOH containing TEA (0.050 mL, 0.361 mmol) at 75°C for 6h. The solvent was evaporated. The crude product was dissolved in EtOAc and washed with 5% KHS04 solution, saturated ΝaHC03 solution, brine and dried over anhydrous MgS04. The crude product was purified by flash chromatography using 2:1 / hexanes:EtOAc on silica gel. Yield: 60 mg (63%); Η NMR (400 MHz, CHLOROFORM-D) δ 1.03 (m, 2H), 1.26 (m, 3H), 1.61 (m, 2H), 1.76 (m, 2H), 1.82 (m, 4H), 3.13 (dd, J = 6.64, 5.47Hz, 2H), 6.46 (m, IH), 6.82 (d, J = 9.18Hz, IH), 7.05 (dd, J = 4.98, 3.81Hz, IH), 7.40 (dd, J = 9.18, 2.54Hz, IH), 7.47 (dd, J = 3.71, 1.37Hz, IH), 7.59 (dd, J = 5.08, 1.37Hz, IH), 7.73 (d, J = 2.73Hz, IH), 8.17 (m, IH).
Step D. N-{3-Amino-4-[(cycIohexyImethyI)amino]phenyl}thiophene-2- sulfonamide
Figure imgf000035_0002
N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl}thiophene-2-sulfonamide (60 mg, 0.152 mmol) was dissolved in 5 mL of DMF under nitrogen. Tin (II) chloride dihydrate (170 mg, 0.760 mmol) was added and the solution stirred at rt for 6h. More tin(II) chloride dihydrate (170 mg, 0.760 mmol) was added and the solution stirred at rt overnight. The reaction mixture was quenched by addition of saturated ΝaHC03 solution at 0°C. The solution was then extracted (2X) with EtOAc and washed with brine and dried over anhydrous MgS04. The product was used directly for Step A without further purification. Yield: 55 mg (99%); MS (ESI) (M+H)+ 366.14. Example 2
N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methylthiophene-
2-suIfonamide
Figure imgf000036_0001
Step A. N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yI]-N- methylthiophene-2-sulfonamide
Figure imgf000036_0002
Following the procedure for Step A in Example 1 , using N-{3-amino-4- [(cyclohexylmethyl) amino]phenyl} -N-methylthiophene-2-sulfonamide (1 15 mg, 0.303 mmol) (for preparation, see the following steps B, C and D) and trimethylacetyl chloride (0.041 mL, 0.333 mmol) in 3mL of DCE. The product was purified by reversed-phase HPLC using 20-80% CH3CΝ H20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 65 mg (38%); Η NMR (400 MHz, METHANOL-D4) δ 1.22 (m, 5 H), 1.61 (m, 2 H), 1.64 (s, 9 H), 1.67 (m, 1 H), 1.74 (m, 2 H), 2.08 (m, 1 H), 3.29 (s, 3 H), 4.43 (d, J=7.62 Hz, 2 H), 7.15 (dd, J=5.08, 3.71 Hz, 1 H), 7.33 (dd, J=8.98, 1.95 Hz, 1 H), 7.40 (dd, J=3.71, 1.37 Hz, 1 H), 7.55 (d, J=1.56 Hz, 1 H), 7.81 (dd, J=5.08, 1.37 Hz, 1 H), 7.85 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 446.1; Anal. Calcd for C23H3|N302S2 + 1.5 TFA + 0.1 H20: C, 50.49; H, 5.33; N, 6.79. Found: C, 50.55; H, 5.39; N, 6.76.
Step B. N-(4-Fluoro-3-nitrophenyI)-N-methyIthiophene-2-sulfonamide
Figure imgf000036_0003
A solution of N-(4-fluoro-3-nitrophenyl)thiophene-2-sulfonamide (100 mg, 0.331 mmol) in MDF (1 mL) was added to a cold (0°C) stirring DMF solution (2 mL) of ΝaH (60% dispersion in oil) (20 mg, 0.496 mmol) under nitrogen. The solution was stirred at 0°C for 20 min. Methyl iodide (0.060 mL, 0.993 mmol) was added dropwise and the solution stirred at rt for 3h. The reaction mixture was quenched at 0°C by the slow addition of saturated ΝH CI solution. The solvent was evaporated in vacuo. The crude product was dissolved in EtOAc and washed with saturated NaHC03 aqueous solution, brine and dried over anhydrous MgS0 . The product was purified by flash chromatography with dichloromethane as eluent on silica gel to afford the title product. Yield: 78 mg (74%); Η NMR (400 MHz, CHLOROFORM- D) δ 3.22 (s, 3H), 7.10 (dd, J = 4.98, 3.81Hz, IH), 7.26 (dd, J= 3.91, 1.37Hz, IH), 7.56 ( , IH), 7.63 (dd, J = 5.08, 1.37Hz, IH), 7.69 (dd, J = 6.44, 2.73Hz, IH).
Step C. N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl}-N-methylthiophene-2- sulfonamide
Figure imgf000037_0001
Following the procedure for Step C in Example 1, using N-(4-Fluoro-3-nitrophenyl)- N-methylthiophene-2-suIfonamide (3) (100 mg, 0.316 mmol), methylcyclohexylamine (0.050 mL, 0.379 mmol) and TEA (0.050mL, 0.474mmol) in 3mL of EtOH. The product was used directly for the next step without any column chromatography purification. Yield: 130 mg (99%); Η ΝMR (400 MHz, CHLOROFORM-D) δ 0.98 (m, IH). 1.04 (m, IH), 1.20 (m, IH), 1.66 (m, 2H), 1.75 (m, 2H), 1.81 (d, J = 12.50Hz, 2H), 3.12 (m, 2H), 3.16 (s, 3H), 6.80 (d, J = 9.37Hz, IH), 7.09 (dd, J = 4.98, 3.81Hz, IH), 7.37 (dd, J = 3.81 , 1.27Hz, IH), 7.42 (dd, J = 9.28, 2.64Hz, IH), 7.59 (dd, J = 4.98, 1.27Hz, IH), 7.65 (d, J = 2.54Hz, IH), 8.20 (m, IH).
Step D. N-{3-Amino-4-[(cyclohexylmethyI)amino]phenyl}-N-methylthiophene-2- sulfonamide
Figure imgf000038_0001
Following the procedure for Step D in Example 1, using N-{4- [(cyclohexylmethyl)amino]-3-nitrophenyl}-N-methylthiophene-2-sulfonamide (125 mg, 0.305 mmol) and tin(II) chloride dihydrate (2X345 mg, 2X1.52 mmol). The product was used directly for Step A without further purification. Yield: 115 mg (99%); MS (ESI) (M+H)+ 379.97.
Example 3 N-(l-Benzyl-2-tert-butyl-lH-benzimidazol-5-yI)-N-methylbenzenesulfonamide
Figure imgf000038_0002
Step A. N-(l-Benzyl-2-tert-butyl-lH-benzimidazol-5-yl)-N- methylbenzenesulfonamide
Figure imgf000038_0003
Following the procedure for Step A in Example 1, using N-{3-amino-4~ [(cyclohexylmethyl)amino]phenyl} -N-methylbenzenesulfonamide (88mg, 0.239mmol), trimethylacetyl chloride (0.032mL, 0.262mmol) and DMAP (7.0mg, 0.060mmol) in 5 mL of dichloromethane. The product was purified by reversed- phase HPLC using 20-80% CH3CΝ/H20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 38 mg (29%); Η NMR (400 MHz, METHANOL-D4) δ 1.62 (s, 9 H), 3.21 (s, 3 H), 5.93 (s, 2 H), 7.09 (m, 2 H), 7.12 (dd, J=8.98, 2.15 Hz, 1 H), 7.32 (m, 4 H), 7.48 (m, 4 H), 7.57 (dd, J=1.95, 0.59 Hz, 1 H), 7.62 (m, 1 H); MS (ESI) (M+H)+ 434.1 ; Anal. Calcd for C25H27N302S + 1.4 TFA + 0.2 H20: C, 55.95; H, 4.86; N, 7.04. Found: C, 55.90; H, 4.85; N, 7.06.
Step B. N-(4-Fluoro-3-nitrophenyl)benzenesulfonamide
Figure imgf000039_0001
4-Fluoro-3-nitroaniline (2.00 g, 12.8 mmol) was dissolved in 50 mL of pyridine containing a catalytic amount of DMAP. Benzenesulfonyl chloride (1.96 L, 15.36 mmol) was added and the solution was stirred at rt for 3h. The solvent was evaporated. The crude product was dissolved in EtOAc and washed with 5% KHS0 solution, saturated NaHC03 solution, brine and dried over anhydrous MgS0 . The product was purified by flash chromatography using 2:1 / hexanes:EtOAc on silica gel. Yield: 3.40 g (90%); Η NMR (400 MHz, CHLOROFORM-D) δ 7.09 (m, IH), 7.18 (dd, J= 9.96, 8.98 Hz, IH), 7.40 (m, IH), 7.48 (m, 2H). 7.58 (m, IH), 7.71 (dd, J = 6.25, 2.73Hz, IH), 7.76 (m, 2H).
Step C. N-(4-Fluoro-3-nitrophenyI)-N-methyIbenzenesulfonamide
Figure imgf000039_0002
Following the procedure for Step B in Example 2, using N-(4-fluoro-3- nitrophenyl)benzenesulfonamide (1.00 g, 3.38 mmol), ΝaH (60% dispersion in oil) (160 mg, 4.06 mmol) and methyl iodide (0.315 mL, 5.07 mmol) in 25 mL of DMF. The product was purified by flash chromatography using dichloromethane as eluent on silica gel. Yield: 815 mg (78%); Η ΝMR (400 MHz, CHLOROFORM-D) δ 3.19 (s, 3H), 7.28 (m, IH), 7.51 (m, IH), 7.54 (m, 2H), 7.57 (m, IH), 7.65 (m, 2H).
Step D. N-[4-(BenzyIamino)-3-nitrophenyl]-N-methyIbenzenesulfonamide
Figure imgf000040_0001
Following the procedure for Step C in Example 1 , using N-(4-fluoro-3-nitrophenyl)- N-methylbenzene sulfonamide (71 mg, 0.229 mmol, benzylamine (0.030 mL, 0.275 mmol) and TEA (0.050mL, 0.344mmol) in 3mL of EtOH. The product was used directly for the next step without further purification. Yield: 99 mg (99%); Η ΝMR (400 MHz, CHLOROFORM-D) δ 3.12 (s, 3H), 4.56 (d, J = 5.47Hz, 2H), 6.81 (d, J = 9.18Hz, IH), 7.34 (m, 3H), 7.40 (m, 3H), 7.49 (m, 2H), 7.57 ( , IH), 7.60 (m, IH), 7.64 (dd, J = 4.30, 1.95Hz, IH), 8.47 (m, IH).
Step E. N-{3-Amino-4-[(cyclohexylmethyl)amino]phenyl}-N- methylbenzenesulfonamide
Figure imgf000040_0002
N-[4-(Benzylamino)-3-nitrophenyl]-N-methylbenzenesulfonamide (95 mg, 0.239 mmol) was dissolved in 15 mL of EtOAc containing a catalytic amount of 10% Pd C. The solution was shaken in a Parr hydrogenation apparatus under H2 atmosphere (40 psi) at rt for 4h. The solution was filtered through Celite and the solvent was evaporated. The product was used directly for Step A without further purification. Yield: 88 mg (99%); MS (ESI) (M+H)+ 367.97.
Example 4
N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N,3,5- trimethylisoxazole-4-sulfonamide
Figure imgf000041_0001
Step A. N-[2-te/-t-Butyl-l-(cycIohexylmethyI)-lH-benzimidazoI-5-yl]-N,3,5- trimethylisoxazole-4-sulfonamide
Figure imgf000041_0002
2-tert-Butyl-l-(cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (35 mg, 0.117 mmol) (for preparation, see the following steps B, C, D, E and F) and 3,5- dimethylisoxazole-4-sulfonyl chloride (0.030 mg, 0.140 mmol) were stirred in 3 mL of dichloromethane containing a catalytic amount of DMAP overnight at rt. The solvent was evaporated. The product was purified by reversed-phase ΗPLC using 20- 80% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 49 mg (73%); Η NMR (400 MHz, METHANOL-D4) δ 1.21 (m, 5 H), 1.58 (m, 2 H), 1.65 (s, 10 H), 1.74 (m, 2 H), 1.88 (s, 3 H), 2.08 (m, 1 H), 2.33 (s, 3 H), 3.31 (s, 3 H), 4.46 (d, J=7.81 Hz, 2 H), 7.47 (dd, J=8.98, 1.95 Hz, 1 H), 7.68 (d, J=1.76 Hz, 1 H), 7.91 (d, .1=8.98 Hz, 1 H); MS (ESI) (M+H)+ 459.2; Anal. Calcd for C24H34N403S + 1.6 TFA + 0.2 H20: C, 50.68; H, 5.63; N, 8.69. Found: C, 50.70; H, 5.65; N, 8.81.
Step B. Methyl (4-fluoro-3-nitrophenyl)carbamate
Figure imgf000041_0003
Methyl chloro formate (13.2 mL, 170.2 mmol) was added dropwise to a cold (0°C) dichloromethane (200 mL) solution of 4-fluoro-3-nitro aniline (24.15 g, 154.7 mmol) and DIPEA (35 mL, 201 mmol). The reaction mixture was stirred at rt overnight. The solution was then diluted with 200 mL of dichloromethane and washed with 2M HCl, brine and dried over anhydrous MgS04. The solvent was concentrated and the product was directly used for next step without further purification. Yield: 35.5 g (99%); Η NMR (400 MHz, CHLOROFORM-D) δ 3.81 (s, 3 H), 7.02 (s, 1 H), 7.23 (m, 1 H), 7.72 (d, J=8.59 Hz, 1 H), 8.17 (dd, J=6.35, 2.64 Hz, 1 H).
Step C. Methyl {4-[(cyclohexylmethyl)amino]-3-nitrophenyI}carbamate
Figure imgf000042_0001
Methyl (4-fluoro-3-nitrophenyl)carbamate (1.00 g, 4.67 mmol) and cyclohexylmethyl amine (0.730 L, 5.60 mmol) were stirred in EtOH (20 L) containing TEA (1.0 mL, 7.00 mmol) at 75°C for 24h. The solvent was concentrated. The residue was dissolved in EtOAc and washed with 5% KHS04 solution, saturated NaHC03 solution, brine and dried over anhydrous MgS04. The crude product was purified by flash chromatography using 4:l/hex:EtOAc on silica gel. Yield: 1.05 g (73%); Η NMR (400 MHz, CHLOROFORM-D) δl.04 (ddd, J = 24.02, 12.1 1, 2.93Hz, 2H), 1.25 (m, 3H), 1.69 ( , 2H), 1.76 (m, IH), 1.79 (m, IH), 1.83 (m, IH), 1.86 (m, IH), 3.14 (dd, J = 6.44, 5.66Hz, 2H), 3.78 (s, 3H), 6.46 (m, IH), 6.84 (d, J = 9.37 Hz, IH), 7.63 (m, IH), 8.05 (d, J = 2.54 Hz, IH), 8.09 (m, IH).
Step D. Methyl {3-amino-4-[(cycIohexylmethyl)amino]phenyl}carbamate
Figure imgf000042_0002
Methyl {4-[(cyclohexylmethyl)amino]-3-nitrophenyl}carbamate (1.05 g, 3.42 mmol) was dissolved in 30 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H2 atmosphere (40 psi) at rt overnight. The solution was filtered through Celite and the solvent was evaporated. The product was directly used for the next step without further purification. Yield: 950 mg (99%). MS (ESI) (M+H)+ 277.9.
Step E. Methyl [2-tert-butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5- yljcarbamate
Figure imgf000043_0001
Methyl {3-amino-4-[(cyclohexylmethyl)amino]phenyl}carbamate (950 mg, 3.43 mmol) and DMAP (100 mg, 0.858 mmol) were dissolved in 25 mL of dichloromethane. Trimethylacetyl chloride (0.460 mL, 3.77 mmol) was added dropwise and the solution was stirred at rt for lh. The solvent was concentrated. The residue was divided in two portions and each of them was dissolved in 3 L of glacial AcOH in a sealed tube. The solutions were heated at 150°C using a Personal Chemistry Smith Synthesizer microwave instrument for three intervals of 30 min (3 X 30 min). The contents of the two tubes were combined and the solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated NaHC03 solution, brine and dried over anhydrous MgS04. The crude product was purified by flash chromatography using 3:l/dichloromethane:diethyl ether. Yield: 656 mg (56%); Η NMR (400 MHz, CHLOROFORM-D) δ 1.08 (m, 2H), 1.18 (m, 3H), 1.54 (s, 9H), 1.65 (m, IH), 1.69 (m, 2H), 1.73 (dd, J = 5.96, 3.22 Hz, 2H), 2.02 (m, IH), 3.78 (s, 3H), 4.10 (d, J = 7.42 Hz, 2H), 6.64 (m, IH), 7.25 (d, J = 8.79 Hz, IH), 7.39 (m, IH), 7.59 (d, J = 1.76 Hz, IH).
Step F. 2-tert-Butyl-l-(cyclohexyImethyI)-N-methyl-lH-benzimidazol-5-amine
Figure imgf000044_0001
Methyl [2-tert-butyl-l -(cyclohexylmethyl)- lH-benzimidazol-5-yl]carbamate (650 mg, 1.89 mmol) was dissolved in 20 mL of TΗF at 0°C under nitrogen. IM ΗCl/ether (2.65 mL, 2.65 mmol) was added dropwise and the solution was stirred at 0°C for 15min. LiAlΗ4 (360 mg, 9.45 mmol) was then slowly added and the solution was stirred at rt overnight. The reaction mixture was quenched at 0°C by addition of MeOH (5 L) followed by water (10 mL). The solution was diluted with EtOAc and washed with saturated NaHC03 solution, brine and dried over anhydrous MgS04. The solvent was evaporated and the product was used directly for Step A without further purification. Yield: 544 mg (96%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm l .08 (s, 2 H) 1.17 (m, 3 H) 1.54 (s, 9 H) 1.64 (m, 2 H) 1.67 (m, 2 H) 1.72 (m, 2 H) 2.02 (m, 1 H) 2.87 (s, 3 H) 4.06 (d, J=7.62 Hz, 2 H) 6.60 (dd, J=8.69, 2.25 Hz, 1 H) 7.00 (d, J=1.76 Hz, 1 H) 7.12 (d, J=8.59 Hz, 1 H).
Example 5
N-[2-tert-Butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5-yl]-N,l,2-trimethyl-lH- imidazole-4-sulfonamide
Figure imgf000044_0002
Following the procedure for Step A in Example 4, using 2-tert-butyl-l- (cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (19) (36 mg, 0.120 mmol), l ,2-dimethyl-lH-imidazole-4-sulfonyl chloride (30 mg, 0.144 mmol) and DMAP (catalytic) in 3 mL of dichloromethane. The product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 47 mg (69%); Η NMR (400 MHz, METHANOL-D4) δl.22 (m, 5 H), 1.62 (m, 2 H), 1.64 (s, 9 H), 1.67 (m, 1 H), 1.75 (m, 2 H), 2.09 (m, 1 H), 2.34 (s, 3 H), 3.28 (s, 3 H), 3.61 (s, 3 H), 4.43 (d, J=7.62 Hz, 2 H), 7.43 (dd, J=8.98, 2.15 Hz, 1 H), 7.51 (s, 1 H), 7.66 (d, J=1.95 Hz, 1 H), 7.82 (d, J=9.18 Hz, 1 H); MS (ESI) (M+H)+ 458.2; Anal. Calcd for C24H35N502S + 1.7 TFA + 0.1 H20: C, 50.38; H, 5.69; N, 10.72. Found: C, 50.39; H, 5.73; N, 10.73.
Example 6
N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N,l,3,5-tetramethyl- lH-pyrazole-4-sulfonamide
Figure imgf000045_0001
Following the procedure for Step A in Example 4, using 2-tert-butyl-l-
(cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (19) (36 mg, 0.120 mmol), l,3,5-trimethyl-lH-pyrazole-4-sulfonyl chloride (30 mg, 0.144 mmol) and DMAP
(catalytic) in 3mL of dichloromethane. The product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 49 mg (70%); Η NMR (400 MHz, METHANOL-D4) δ 1.20 (m, 5 H), 1.56 (m, 2 H), 1.65 (s, 9 H), 1.67 (m, 1 H), 1.74 (m, 2 H), 1.80 (s, 3 H), 2.08 (m, 1 H), 2.16 (s, 3 H), 3.21 (s, 3 H), 3.69 (s, 3 H), 4.44 (d, J=7.81 Hz, 2 H), 7.38 (dd, J=9.08, 2.05 Hz, 1 H), 7.62 (d, J=1.56 Hz, 1 H), 7.84 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 472.2; Anal. Calcd for C25H37N502S + 1.2 TFA + 0.4 H20: C, 53.45; H, 6.38; N, 11.37. Found: C, 53.50; H, 6.38; N, 1 1.29.
Example 7
N-[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]benzene sulfonamide
Figure imgf000046_0001
Step A. N-[2-tert-butyI-l-(cyclohexylmethyI)-lH-benzimidazol-5-yllbenzene sulfonamide
Figure imgf000046_0002
DMAP (44.0 mg, 0.36 mmol) and then trimethylacetyl chloride ( 199.0 mg, 1.65 mmol) at 0 °C was added into a solution of N-{3-amino-4-
[(cyclohexylmethyl)amino]phenyl} benzene sulfonamide (540.1 mg, 1.5 mmol) (for preparation, see the following steps B and C) in dichloromethane (40 mL). The mixture was stirred for 5 h at room temperature. After evaporation of the solvent, the residue was dissolved in 1,2-dichloroethane (5x5 mL) in five Teflon-capped test tubes. The vessels were irradiated by microwave for 2h at 170 °C. The combined reaction mixture diluted with EtOAc (100 mL), washed with 2Ν NaOH(10 mL), sat. NaCl (10 mL) and dried over Na2S0 . After filtration and evaporation, the residue was purified by MPLC (hex/EtOAc 1 :1 on silica gel) to give 568.2 mg (89%) of a white solid as the title compound. Part of the product was converted to TFA salt. 'HNMR (400 MHz, CD3OD): δ 1.18 (m, 5 H), 1.55 (m, 2 H), 1.59 (s, 9 H), 1.65 (m, 1 H), 1.71 ( , 2 H), 2.03 (m, 1 H), 4.34 (d, J=7.42 Hz, 2 H), 7.20 (d, J=9.18 Hz, 1 H), 7.44 (m, 2 H), 7.53 (m, 1 H), 7.58 (s, 1 H), 7.70 (d, J=8.79 Hz, 1 H), 7.76 (d, J=7.42 Hz, 2 H). MS (ESI) (M+H)+ = 426.1. Anal. Calcd for C24H3ιN3O2S+1.10 TFA+0.10 H20: C, 56.92; H, 5.89; N, 7.60. Found: C, 56.95; H, 5.92; N, 7.56.
Step B: N-{4-[(cyclohexyImethyI)amino]-3~nitrophenyI}benzenesulfonamide
Figure imgf000047_0001
Cyclohexylmethylamine (3.48 mL, 3.03 g, 26.7 mmol ) was added to a mixture of N- (4-fluoro-3-nitrophenyl)benzenesulfonamide (3.60 g, 12.1 mmol) in 60 mL of EtOH- H 0 (1:1 V/V) at room temperature. The reaction mixture was heated for 48 h at 60 °C, and allowed to cool to room temperature and concentrated to a small volume, and then extracted with EtOAc. The crude product was purified by MPLC using Hex EtOAc (4:1) on silica gel to give 3.75 g (79%) of an orang-red solid as the title compound. 'HΝMR (400 MHz, CD3C1): δ 1.05 (m, 2 H), 1.24 (m, 3 H), 1.72 (m, 6 H), 3.12 (dd, J=6.64, 5.47 Hz, 2 H), 6.23 (s, 1 H), 6.79 (d, J=9.18 Hz, 1 H), 7.36 (dd, J=9.08, 2.64 Hz, 1 H), 7.48 (m, 2 H), 7.58 (m, 1 H), 7.63 (d, J=2.54 Hz, 1 H), 7.72 (m, 2 H), 8.14 (s, 1 H).
Step C: N-{3-amino-4-[(cyclohexylmethyI)amino]phenyl}benzenes lfonamide
Figure imgf000047_0002
N-{4-[(cyclohexylmethyl)amino]-3-nitrophenyl}benzenesulfonamide (3.75 g, 9.63 mmol) was hydrogenated in ethyl acetate (200 L) catalyzed by 10% Pd/C (0.5 g) at 30-40 psi H2 in Parr shaker for 20 h at room temperature. After filtration through Celite and concentration, 4.0 g (100%) of a light yellow solid was obtained as the title compound, which was used for Step A without further purification. 'HΝMR (400 MHz, CD3C1): δ 0.88 (m, 1 H), 0.99 (m, 2 H), 1.23 (m, 3 H), 1.56 (m, 1 H), 1.75 (m, 4 H), 2.86 (d,J=6.64 Hz, 2 H), 3.33 (s broad, 3 H), 6.30 (s broad, 1 H), 6.33 (dd, J=8.30, 2.44 Hz, 1 H), 6.41 (m, 1 H), 6.56 (d, J=2.34 Hz, 1 H), 7.41 (m, 2 H) 7.52 (m, 1 H), 7.70 (m, 2 H). MS (ESI) (M-H)+: 359.89. Example 8 N-[l-(cycIohexylmethyl)-2-ethyl-lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000048_0001
DMAP (15.0 mg, 0.12 mmol) and then propionyll chloride (50.9 mg, 0.55 mmol) was added into a solution of N-{3-amino-4-[(cyclohexylmethyl)amino]phenyl}benzene sulfonamide (180.3 mg, 0.5 mmol) in dichloromethane (15 mL) at 0 °C. The mixture was stirred for 5 h at room temperature. After evaporation of the solvent, the residue was dissolved in acetic acid (10 mL) and then heated for 20 h at 80°C. Upon concentration, the residue diluted with EtOAc (100 mL), washed with 2Ν NaOH(10 mL), sat. NaCl (10 mL) and dried over Na2S04. The crude product was purified by MPLC (hexane/EtOAc 1:9 on silica gel) to give 157.7 mg (79%) of a white solid as the title compound. Part of the product was converted to TFA salt. 'HNMR (400 MHz, CD3OD): δ 1.12 (m, 2 H), 1.21 (m, 3 H), 1.48 (t, J=7.62 Hz, 3 H), 1.60 (m, 2 H), 1.68 ( , 1 H), 1.73 (m, 2 H), 1.90 (m, 1 H), 3.18 (q, J=7.49 Hz, 2 H), 4.19 (d, J=7.62 Hz, 2 H), 7.24 (m, 1 H), 7.47 (m, 2 H), 7.56 (m, 2 H), 7.71 (d, J=8.98 Hz, 1 H), 7.79 (m, 2 H). MS (ESI) (M+H)+ = 398.1.
Example 9 N-[l-(cycIohexylmethyI)-2-isopropyI-lH-benzimidazol-5-yl]benzene sulfonamide
Figure imgf000048_0002
Following the procedure for Step A in Example 7, using N-{3-amino-4- [(cyclohexylmethyl)amino]phenyl} benzene sulfonamide (182.1 mg, 0.5 mmol), DMAP (15.0 mg, 0.12 mmol) and isobutyryl chloride (50.2 mg, 0.56 mmol) CH2C12 (15 mL). The crude product was purified by MPLC (Hex/EtOAc 1 :1). Yield: 178.4 mg (86%). 'HNMR (400 MHz, CD3OD): δ 1.17 (m, 5 H), 1.47 (d, J=6.83 Hz, 6 H), 1.60 (m, 2 H), 1.72 (m, 3 H), 1.88 (m, 1 H), 3.62 (m, 1 H), 4.25 (d, J=7.62 Hz, 2 H), 7.25 (dd, J=8.88, 2.05 Hz, 1 H), 7.48 (m, 2 H), 7.57 (m, 2 H), 7.73 (d, J=8.98 Hz, 1 H), 7.80 (m, 2 H). MS (ESD (M+H)+ = 412.1.
Example 10
N-[l-(cyclohexylmethyl)-2-(l-methylcyclopropyl)-lH-benzimidazol-5- yI]benzenesulfonamide
Figure imgf000049_0001
Diisopropylethylamine (104.7 mg, 0.81 mmol) was added into a solution of N-(3- amino-4-[(cyclohexylmethyl)amino]phenyl} benzene sulfonamide (195.6 mg, 0.543 mmol), and 1-methylcyclopropanecarboxylic acid (59.8 mg, 0.6 mmol) in DMF (5 mL) at 0 °C. Stirring for 20 min. HATU (246.4 mg, 0.65 mmol) was added. The reaction mixture was stirred for 24 h at room temperature, diluted with water (100 L), and extracted with EtOAc (2x50 mL). The combined organic phases were washed with ΝaCl (20 mL) and dried with anhydrous sodium sulphate. After filtration and concentration, the residue was dissolved in acetic acid (10 mL) and heated for 20 h at 80 °C. Upon evaporation of the solvent, 93.7 mg of the acetate salt was lyophilized, and the rest was diluted with EtOAc (100 mL), washed with 2Ν
NaOH(10 mL), sat. NaCl (2x10 mL) and dried over anhydrous sodium sulphate. After filtration and evaporation, 144.9 mg of the free amine as the title compound was obtained. Total yield: 99%. 'HNMR (400 MHz, CD3OD): δ 0.89 (m, 2 H), 1.10 (m, 4 H), 1.21 (m, 3 H), 1.45 (s, 3 H), 1.55 (d, 2 H), 1.69 (m, 3H), 2.08 (m, 1 H), 4.13 (d, J=7.62 Hz, 2 H), 7.01 (dd, J=8.79, 1.95 Hz, 1 H,) 7.25 (d, J=l .95 Hz, 1 H), 7.35 (d, J=8.79 Hz, 1 H), 7.40 (t, J=7.62 Hz, 2 H), 7.50 (t, .1=7.42 Hz, 1 H), 7.68 (d, J=7.42 Hz, 2 H). MS (ESI) (M+H)+ = 424.1. Anal. Calcd for C24H29N3O2S+0.4 AcOH+0.10 H20: C, 65.92; H, 6.98; N, 9.45. Found: C, 66.01 ; H, 6.89; N, 9.09. Example 11
N-[l-(cyclohexylmethyl)-2-(l,l-dimethylpropyl)-lH-benzimidazol-5-yl]- benzenesulfonamide
Figure imgf000050_0001
Following the procedure in Example 10, using N-{3-amino-4- [(cyclohexylmethyl)amino]phenyl}benzene sulfonamide (180.3 mg, 0.50 mmol), 2,2- dimethylbutyric acid (63.9 mg, 0.55 mmol), diisopropylethylamine (96.6 mg, 0.75 mmol) and HATU (228.1 mg, 0.60 mmol) in DMF (5 mL) and then in acetic acid (10 mL), the crude product was purified by reversed HPLC using 30-80% CH3CΝ/H20 to give 39.9 mg (14%) of a white solid as the title compound. 'HNMR (400 MHz, CD3OD): δ 0.81 (t, J=7.52 Hz, 3 H), 1.20 (m, 5 H), 1.58 (m, 2 H), 1.62 (s, 6 H), 1.68 (m, 1 H), 1.75 (m, 2 H), 1.97 (q, J=7.62 Hz, 2 H), 2.03 (m, 1 H), 4.37 (d, J=7.62 Hz, 2 H), 7.23 (dd, J=8.98, 1.95 Hz, 1 H), 7.47 (m, 2 H), 7.56 (m, 1 H), 7.59 (m, 1 H), 7.73 (d, J=8.98 Hz, 1 H), 7.80 (m, 2 H). MS (ESI) (M+H)+ = 440.2. Anal. Calcd for C25H33N3O2S+I .O TFA+0.60 H20: C, 57.45; H, 6.29; N, 7.44. Found: C, 57.49; H, 6.39; N, 7.35.
Example 12 N-[l-(cyclohexyImethyI)-2-(l,l-dimethyl-3-butenyl)-lH-benzimidazol-5-yl]- benzenesulfonamide
Figure imgf000050_0002
Following the procedure in Example 10, using N-{3-amino-4- [(cyclohexylmethyl)amino]phenyl}benzene sulfonamide (180.3 mg, 0.50 mmol), 2,2- dimethyl-4-pentenoic acid (70.5 mg, 0.55 mmol), diisopropylethylamine (96.6 mg, 0.75 mmol) and HATU (228.1 mg, 0.60 mmol) ) in DMF (5 mL) and then in acetic acid (10 mL), the crude product was purified by by reversed HPLC using 30-80%
CH3CN/H20 to give 38.2 mg (14%) of a white solid as the title compound. 'HNMR (400MHz, CD3OD): δ 1.19 ( , 5 H), 1.59 (m, 2 H), 1.65 (s, 6 H), 1.68 (m, 1 H,) 1.74 (m, 2 H), 2.04 (m, 1 H), 2.67 (d, J=7.42 Hz, 2 H), 4.40 (d, J=7.62 Hz, 2 H), 5.03 (s, 1 H), 5.07 (m, 1 H), 5.60 (m, 1 H), 7.23 (dd, J=8.98, 2.15 Hz, 1 H), 7.47 (m, 2 H), 7.56 (m, 1 H), 7.59 (d, J=1.56 Hz, 1 H), 7.74 (d, J=8.98 Hz, 1 H), 7.80 (m, 2 H). MS (ESI) (M+H)+ = 452.2. Anal. Calcd for C26H33N3O2S+I.2 TFA: C, 57.97; H, 5.86; N, 7.14. Found: C, 58.00; H, 5.74; N, 7.06.
Example 13
N-[l-(cyclohexylmethyl)-2-(l-methyl-4-piperidinyl)-LftT-benzimidazol-5-yl]- benzenesulfonamide
Figure imgf000051_0001
Following the procedure in Example 10: using N-{3-amino-4-
[(cyclohexylmethyl)amino]phenyl) benzene sulfonamide (180.3 mg, 0.50 mmol), 1- methylpiperidine 4-carboxylic acid hydrochloride (98.8 mg, 0.55 mmol), diisopropylethylamine (161.6 mg, 1.25 mmol) and HATU (228.1 mg, 0.60 mmol) in DMF (5 mL) and then in acetic acid (10 mL), the crude product was purified by
MPLC using CH2Cl2/MeOH (10:1) on silica gel to give 213.2 mg (91%) of a colorless syrup as the title compound. Part of the product was converted to TFA salt. 1HΝMR (400 MHz, CD3OD): δ 1.08 (m, 2 H), 1.18 (m, 3 H), 1.52 (m, 2 H), 1.68 (m, 3 H), 1.79 (m, 1 H), 2.15 (m, 4 H), 2.91 (s, 3 H), 3.18 (m, 2 H), 3.35 (m, 1 H), 3.62 (d, J=13.28 Hz, 2 H), 4.08 (d, J=7.81 Hz, 2 H), 7.04 (dd, J=8.79, 1.95 Hz, 1 H), 7.40 (m, 4 H), 7.50 (m, 1 H), 7.69 (m, 2 H). MS (ESI) (M+H)+ = 467.2. Anal. Calcd for C26H34N4O2S+I.5 TFA+0.9 H20: C, 53.27; H, 5.75; N, 8.57. Found: C, 53.32; H, 5.5.69; N, 8.55. Example 14
N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]-N-methyl- benzenesulfonamide
Figure imgf000052_0001
ΝaH (54.0 mg, 60%, 1.34 mmol) was added to a solution of of N-[2-tert-butyl-l- (cyclohexylmethyl)-lH-benzimidazol-5-yl]benzene sulfonamide (258.5 mg, 0.607 mmol) in TΗF (15 mL) at 0 °C. After stirring for lh, Mel (259.8 mg, 1.83 mmol) was added. The mixture was stirred overnight at room temperature, quenched with sat. ΝaΗC03 (5 mL). The two phases were separated. The aqueous was extracted with EtOAc (3x20 ml). The combined organic phases were washed with NaHC03 (2x10 mL) and dried with Na2S04. After concentration, the residue was purified by MPLC using hex/EtOAc (1:1) on silica gel to give 216.5 mg (81%) of the title product, and converted to TFA salt as a white solid. 'HNMR (400 MHz, CD3OD): δ 1.20 (m, 5 H), 1.60 (m, 2 H), 1.64 (s, 9 H), 1.67 (m, 1 H), 1.75 (m, 2 H), 2.07 (m, 1 H), 3.24 (s, 3 H), 4.42 (d, J=7.62 Hz, 2 H), 7.26 (dd, J=8.98, 2.15 Hz, 1 H), 7.50 (m, 5 H), 7.65 ( , 1 H), 7.81 (d, J=9.18 Hz, 1 H). MS (ESI) (M+H)+ = 440.2. Anal. Calcd for C25H33N3O2S+1.20 TFA: C, 57.09; H, 5.98; N, 7.29. Found: C, 57.07; H, 6.01 ; N, 7.25.
Example 15
N-[l-(cyclohexylmethyl)-2-ethyl-lH-benzimidazol-5-yl]-N-methyl-benzene sulfonamide
Figure imgf000052_0002
Following the procedure in Example 14, using N-[l-(cyclohex lmethyl)-2-ethyl-lH- benzimidazol-5-yl]benzenesulfonamide (91.3 mg, 0.23 mmol), sodium hydride (28.2 mg, 60%, 0.71 mmol) and iodomethane (97.9 mg, 0.69 mmol) in TΗF(10 mL). Yield: 69.7 mg (74%); white solid for TFA salt. 'HΝMR (400 MHz, CD3OD): δ 1.20 (m, 5 H), 1.51 (t, J=7.52 Hz, 3 H), 1.65 (m, 2 H), 1.70 (m, 1 H), 1.76 (m, 2 H), 1.95 (m, 1 H), 3.22 (q, J=7.ό2 Hz, 2 H), 3.27 (s, 3 H), 4.26 (d, J=7.62 Hz, 2 H), 7.29 (dd, J=8.88, 2.05 Hz, 1 H), 7.50 (d, J=1.95 Hz, 1 H), 7.54 (m, 4 H), 7.67 (m, 1 H), 7.80 (d, J=8.98 Hz, 1 H). MS (ESI) (M+H)+ = 412.1
Example 16
N-[l-(cyclohexylmethyI)-2-isopropyl-lH-benzimidazol-5-yl]-N-methyl-benzene sulfonamide
Figure imgf000053_0001
Following the procedure in Example 14, using N-[l -(cyclohexylmethyl)-2-isoproyl- lH-benzimidazol-5-yl]benzenesulfonamide (81.8 mg, 0.199 mmol), sodium hydride (24.0 mg, 60%, 0.596 mmol) and iodomethane (84.7 mg, 0.597 mmol) in TΗF (15 mL). Yield: 80.1 mg (95%); The title compound was converted to white solid as a TFA salt. 'ΗΝMR (400 MHz, CD3OD): δ 1.20 (m, 5 H), 1.51 (d, J=6.83 Hz, 6 H), 1.64 (m, 2 H), 1.69 (m, 1 H), 1.76 (m, 2 H), 1.93 (m, 1 H), 3.27 (s, 3 H), 3.67 (m, 1 H), 4.31 (d, J=7.62 Hz, 2 H), 7.28 (m, 1 H), 7.54 (m, 5 H), 7.68 (m, 1 H), 7.81 (d, J=8.98 Hz, 1 H). MS (ESI) (M+H)+ = 426.1.
Example 17
N-[l-(cyclohexyImethyl)-2-(l-methylcy opropyI)-lH-benzimidazoI-5-yI]-N- methyl-benzenesulfonamide
Figure imgf000054_0001
Following the procedure in Example 14, using N-[l -(cyclohexylmethyl)-2-(l- methylcyclopropyl)-lH-benzimidazol-5-yl]benzenesulfonamide (144.9 mg, 0.342 mmol), sodium hydride (30.0 mg, 60%, 0.752 mmol) and iodomethane (145.7 mg, 1.03 mmol) in TΗF (15 mL). Yield: 72.3 mg (48%); compound was converted to a white solid as a TFA salt. 1HΝMR (400 MHz, CD3OD): δ 1.19 (m, 4 H), 1.26 (m, 3 H), 1.34 (m, 2 H), 1.59 (s, 3 H), 1.71 (m, 5 H), 2.19 (m, 1 H), 3.26 (s, 3 H), 4.38 (d, J=7.81 Hz, 2 H), 7.29 (dd, J=9.08, 2.05 Hz, 1 H), 7.50 (m, 1 H), 7.52 (m, 1 H) 7.55 (m, 3 H), 7.67 (m, 1 H), 7.83 (d, J=8.98 Hz, 1 H). MS (ESI) (M+H)+ = 438.2. Anal. Calcd for C25H3ιΝ302S+1.2 TFA+0.10 H20: C, 57.11; H, 5.67; N, 7.29. Found: C, 57.19; H, 5.74; N, 7.22.
Example 18 and 19
Example 18: N-[l-(cyclohexyImethyI)-2-(l-methyI-4-piperidinyI)-lH- benzimidazol-5-yI]-N-methyl- benzenesulfonamide
Figure imgf000054_0002
Example 19: 4-[l-(cyclohexylmethyl)-5-[methyl(phenylsulfonyl)amino]-lH- benzimidazol-2-yl]-l,l-dimethyl- piperidinium
Figure imgf000055_0001
Following the procedure in Example 14: using N-[l -(cyclohexylmethyl)-2-( 1-methyl- 4-piperidinyl)-lH-benzimidazol-5-yl]- benzenesulfonamide (97.3 mg, 0.209 mmol), sodium hydride (18.4 mg, 60%, 0.459 mmol) and iodomethane/TΗF (1.0 M, 250 uL, 0.25 mmol) in TΗF (15 mL), the crude product was purified by reversed ΗPLC using 15-60% CΗ3CΝ/Η20 to give the title compounds A and B as following:
1) Compound A: N-[l-(cyclohexylmeth}'l)-2-(l-methyl-4-piperidinyl)-lH- benzimidazol-5-yl]-N-methyl- benzenesulfonamide. Yield: 36.8 mg (30%) The compound was converted to TFA salt as a white solid. 'HNMR (400 MHz, CD3OD): δ 1.10 (m, 2 H), 1.18 (m, 3 H), 1.55 (m, 2 H), 1.69 (m, 3 H), 1.81 (m, 1 H), 2.15 (m, 2 H), 2.38 (m, 2 H), 3.23 (s, 6 H), 3.46 (m, 1 H), 3.57 (m, 2 H), 3.66 (m, 2 H), 4.14 (d, J=7.62 Hz, 2 H), 7.13 (m, 1 H), 7.43 (m, 3 H), 7.51 (m, 2 H), 7.72 (m, 2 H). (M+H)+ = 481.2. Anal. Calcd for C27H36N402S+3.2 TFA+0.5 H20: C, 46.94; H, 4.74; N, 6.56. Found: C, 46.97; H, 4.76; N, 6.51.
2) Compound B: 4-[l-(cyclohexylmethyl)-5-[methyl(phenylsulfonyl)amino]-lH- benzimidazol-2-yl]- 1,1 -dimethyl- piperidinium. Yield: 41.1 mg (32%). TFA salt, white solid,. 'ΗNMR (400 MHz, CD3OD): δ 1.14 (m, 2 H), 1.23 (m, 3 H), 1.59 (m, 2 H), 1.72 (m, 3 H), 1.86 (m, 1 H), 2.18 (m, 2 H), 2.43 (m, 2 H), 3.25 (s, 3 H), 3.26 (s, 6 H,) 3.46 (m, 1 H,) 3.58 (m, 2 H), 3.69 (m, 2 H), 4.18 (d, J=7.62 Hz, 2 H), 7.11 (dd, J=8.79, 1.95 Hz, 1 H), 7.35 (d, J=1.95 Hz, 1 H), 7.50 (m, 1 H), 7.55 (m, 4 H), 7.66 (m, 1 H). MS (ESI) (M+H)+: 495.2.
Example 20 N-[2-(l,l-dimethylethyl)-l-[(tetrahydro-2H-pyran-4-yl)methyl]-lH- benzimidazol-5-yl]-benzenesuIfonamide
Figure imgf000056_0001
Step A. N-[2-(l,l-dimethylethyl)-l-[(tetrahydro-2H-pyran-4-yl)methyl]-lH- benzimidazol-5-yl]-benzenesulfonamide
Figure imgf000056_0002
Catalytic DMAP in one portion and pivaloyl chloride (0.26 mL, 1.1 eq) were added dropwise sequentially to a stirring solution of N-[3-amino-4-[[(tetrahydro-2H-pyran- 4-yl)methyl]amino] phenyl]-benzenesulfonamide (705.2 mg, 1.95 mmol) (for preparation, see Steps B and C) in CH2C12 (100 mL) at 0°C. The solution was stirred for 2 hours, then the solvent was concentrated, and the residue was re-dissolved in AcOH (2 mL). The resulting solution was heated at 150°C for 1800 s using microwave irradiation and the solvent was then concentrated. The residue was re- dissolved in EtOAc, washed with IN ΝaOH (2X) and brine and dried over anhydrous Νa2S04. Purification by MPLC using EtOAc followed by reversed-phase HPLC using 10-90% MeCN in H20 afforded the title compound as a colourless solid (16.3 mg, 2% yield); 'H NMR (400 MHz, CD3OD) δ 1.46-1.55 (m, 4 H), 1.62 (s, 9 H), 2.25-2.35 (m, 1 H), 3.30-3.34 (m, 2 H), 3.88-3.92 (m, 2 H), 4.43 (d, J=7.42 Hz, 2 H), 7.22 (dd, J=9.08, 2.05 Hz, 1 H), 7.43-7.47 (m, 2 H), 7.52-7.56 (m, 1 H), 7.60 (d, J=2.05 Hz, 1 H), 7.75-7.80 (m, 3 H); MS (ESI) (M+H)+ = 428.0.
Step B. N-[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyI]amino]phenyI]- benzenesulfonamide
Figure imgf000057_0001
4-Tetrahydropyranmethylamine (468 mg, 1.2 eq) in EtOH (0.5 mL) was added to a stirring solution of N-(4-fluoro-3-nitrophenyl)- benzenesulfonamide (1.0 g, 3.38 mmol) and triethylamine (0.47 mL, 1 eq) in EtOH:H20 4:1 (15 mL) at room temperature. The solution was heated at 60°C overnight, then cooled to room temperature. The cooled solution was poured into H20 and was extracted (3X) with EtOAc. The combined organic phases were washed with brine and dried over anhydrous Νa2S04. The crude product was purified by MPLC using 1:1 heptane:EtOAc to afford the title compound as a bright red solid (767.5 mg, 58%); 'H NMR (400 MHz, CDC13) δ 1.41-1.46 (m, 2 H), 1.65-1.75 (m, 2 H), 1.90-1.98 (m, 1 H), 3.18-3.21 (m, 2 H), 3.39-3.45 (m, 2 H), 4.00-4.04 (m, 2 H), 6.61 (s, 1 H), 6.80 (d, J=9.18 Hz, 1 H), 7.38 (dd, J=9.28, 2.64 Hz, 1 H), 7.46-7.50 (m, 2 H), 7.56-7.60 (m, 1 H), 7.69 (d, J=2.54 Hz, 1 H), 7.73-7.75 (m, 2 H), 8.10 (m, 1 H).
Step C. N-[3-amino-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]- benzenesulfonamide
Figure imgf000057_0002
Following the procedure for Step E in Example 3, using N-[3-nitro-4-[[(tetrahydro- 2H-pyran-4-yl)methyl]amino]phenyl]-benzenesulfonamide (767.5 mg, 1.96 mmol) and a catalytic amount of 10% Pd/C in EtOAc (50 mL). LC/MS analysis indicated that the compound was of sufficient purity (>95%) to be used directly for Step A. Yield: 705.2 mg, 100%; Η ΝMR (400 MHz, CDC13) δ 1.33-1.44 (m, 2 Η), 1.61-1.73 (m, 2 H), 1.81-1.88 (m, 1 H), 2.95 (d, J=6.64 Hz, 2 H), 3.37-3.43 (m, 5 H), 3.99 (dd, J=10.84, 3.42 Hz, 2 H), 6.27-6.31 (br. s., 1 H), 6.34-6.36 (m, 1 H), 6.42-6.44 (m, 1 H), 6.58 (d, J=2.34 Hz, 1 H), 7.40-7.44 (m, 2 H), 7.50-7.55 (m, 1 H), 7.70-7.74 (m, 1 H).
Example 21 N-[2-(l,l-dimethylethyl)-l-[(tetrahydro-2-furanyI)methyl]-lH-benzimidazol-5- yl]-benzenesulfonamide
Figure imgf000058_0001
Step A. N-[2-(l,l-dimethylethyl)-l-[(tetrahydro-2-furanyl)methyl]-lH- benzimidazol-5-yl]-benzenesulfonamide
Figure imgf000058_0002
Following the procedure for Step A in Example 20, using N-[3-amino-4-[[(tetrahydro-
2-furanyl)methyl]amino] phenyI]-benzenesulfonamide (597.2 mg, 1.72 mmol) (for preparation, see the following steps B and C), CH2C12 (30 mL), catalytic DMAP and pivaloyl chloride (0.23 mL, 1.1 eq), followed by AcOH (3 mL), the crude product was purified by MPLC using 4:1 EtOAc:hexanes, converted to the corresponding TFA salt and lyophilized. Yield of the title product as TFA salt: 182.3 mg (17%); 'H ΝMR (400 MHz, CD3OD) δ 1.60 (s, 9 H), 1.76-1.79 (m, 1 H), 1.89-2.04 (m, 2 H), 2.18-2.26 (m, 1 H), 3.64-3.69 (m, 1 H), 3.84-3.90 (m, 1 H), 4.28-4.34 (m, 1 H), 4.53-4.59 (m, 1 H), 4.66-4.71 (m, 1 H), 7.21 (dd, J=8.98, 1.95 Hz, 1 H), 7.43-7.47 (m, 2 H), 7.52-7.56 (m, 1 H), 7.59 (d, J=1.95 Hz, 1 H), 7.75-7.79 (m, 3 H); MS (ESI) (M+H)+ = 414.0.
Step B. N-[3-nitro-4-[[(tetrahydro-2-furanyl)methyl]amino]phenyl]- benzenesulfonamide
Figure imgf000059_0001
Following the procedure for Step Bin Example 20, using N-(4-fluoro-3-nitrophenyl)- benzenesulfonamide (1.0 g, 3.38 mmol), tetrahydrofurylamine (0.42 mL, 1.2 eq), EtOH (12 mL) and H20 (3 mL), the crude product was purified by MPLC using 1 :1 heptane:EtOAc to afford the title compound as a bright red solid (749.7 mg, 59%); Η ΝMR (400 MHz, CDC13) δ 1.62-1.73 (m, 1 H), 1.94-2.13 (m, 3 H), 3.27-3.47 (m, 2 H), 3.80-3.98 (m, 2 H), 4.15-4.22 (m, 1 H), 6.51 (s, 1 H), 6.81 (d, J=9.18 Hz, 1 H), 7.35 (dd, J=8.98, 2.54 Hz, 1 H), 7.44-7.48 (m, 2 H), 7.55-7.59 (m, 1 H), 7.63 (d, J=2.73 Hz, 1 H), 7.69-7.72 (m, 2 H), 8.18-8.20 (m, 1 H).
Step C. N-[3-amino-4-[[(tetrahydro-2-furanyl)methyl]amino]phenyl]- benzenesulfonatnide
Figure imgf000059_0002
Following the procedure for Step E in Example 3, using N-[3-nitro-4-[[(tetrahydro-2- furanyl)methyl]amino] phenyl]-benzenesulfonamide (749.7 mg, 2 mmol) and a catalytic amount of 10% Pd/C in EtOAc (50 mL), LC/MS analysis indicated that the title compound was of sufficient purity (>95%) to be used directly for the next step.
Yield: 597.2 mg, 86%; 'H ΝMR (400 MHz, CDCI3) δ 1.61 -1.70 (m, 2 H), 1.89-1.96
(m, 2 H), 2.01-2.09(m, 1 H), 2.97-3.02 (m,l H), 3.12-3.16 (m, 1 H), 3.34-3.59 (m, 3 H), 3.74-3.90 (m, 2 H), 6.28 (s, 1 H), 6.33 (dd, J=8.20, 2.34 Hz, 1 H), 6.44 (d, J=8.40
Hz, 1 H), 6.53 (d, J=2.34 Hz, 1 H), 7.39-7.44 (m, 2 H), 7.50-7.54 (m, 1 H), 7.68-7.72
(m, 2 H).
Example 22 N-[l-(cyclobutylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]- benzenesulfonamide
Figure imgf000060_0001
Step A. N-[l-(cycIobutylmethyI)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yI]- benzenesulfonamide
Figure imgf000060_0002
Following the procedure for Step A in Example 20, using N-[3-amino-4- [(cyclobutylmethyl)amino]phenyl]-benzenesulfonamide (763.8 mg, 2.30 mmol) (for preparation, see the following steps B and C), CH2C12 ( 40 mL), catalytic DMAP and pivaloyl chloride (0.31 mL, 1.1 eq), followed by AcOH (9 mL), the crude product was purified by MPLC using 1 :1 hexanes:EtOAc, followed by reversed-phase HPLC using 20-65% MeCΝ in H 0. The compound was lyophilized to afford the title compound as its TFA salt (226.8 mg, 19%); Η ΝMR (400 MHz, CD3OD) δ 1.60 (s, 9 H), 1.81-1.93 (m, 2 H), 2.01-2.07 (m, 4 H), 2.78-2.83 (m, 1 H), 4.55 (d, J=6.44 Hz, 2 H), 7.22 (dd, J=8.98, 1.95 Hz, 1 H), 7.43-7.47 (m, 2 H), 7.52-7.56 (m, 1 H), 7.59 (dd, J=1.95, 0.59 Hz, 1 H), 7.70 (dd, J=8.98, 0.59 Hz, 1 H), 7.76-7.79 (m, 2 H); MS (ESI) (M+H)+ = 398.0.
Step B. N-[4-[(cyclobutylmethyl)amino]-3-nitrophenyl]-benzenesulfonamide
Figure imgf000060_0003
Following the procedure for Step B in Example 20, using N-(4-fluoro-3-nitrophenyl)- benzenesulfonamide (1.0 g, 3.38 mmol), cyclobutylmethylamine (345.7 mg, 1.2 eq), EtOH (12 mL) and H20 (5 mL) The crude product was purified by MPLC using 7:3 hexanes:EtOAc to afford the title compound as a bright orange solid (857.7 mg, 70%); 'H ΝMR (400 MHz, CDC13) δ 1.73-1.78 (m, 2 H), 1.88-2.00 (m, 2 H), 2.13- 2.21 (m, 2 H), 2.62-2.73 (m, 1 H), 3.27-3.30 (m, 2 H), 6.44 (s, 1 H), 6.78 (d, J=9.18 Hz, 1 H), 7.36 (dd, J=9.08, 2.44 Hz, 1 H), 7.45-7.49 (m, 2 H), 7.55-7.60 (m, 1 H), 7.66 (d, J=2.73 Hz, 1 H) 7.72-7.74 (m, 2 H), 7.93-7.98 (br s, 1 H).
Step C. N-[3-amino-4-[(cycIobutylmethyI)amino]phenyl]-benzenesulfonamide
Figure imgf000061_0001
Following the procedure for Step E in Example 3, using N-[4- [(cycIobutylmethyl)amino]-3-nitrophenyl]-benzenesulfonamide (857.7 mg, 2.37 mmol) and a catalytic amount of 10% Pd/C in EtOAc (25 mL) and shaking for 48 h, LC/MS analysis indicated that the title compound was of sufficient purity (>95%) to be used directly for the next step. Yield: 763.8 mg, 97%; Η ΝMR (400 MHz, CDC13) δ 1.68-1.78 (m, 2 H), 1.86-1.98 (m, 2 H), 2.08-2.16 (m, 2 H), 2.54-2.62 (m, 1 H), 3.04 (d, J=7.42 Hz, 2 H), 3.1 1-3.42 (brs, 2 H), 6.28-3.31 (br. s., 1 H), 6.33 (dd, J=8.40, 2.34 Hz, 1 H), 6.43 (d, J=8.40 Hz, 1 H), 6.56 (d, J=2.34 Hz, 1 H), 7.40-7.44 (m, 2 H), 7.50-7.54 (m, 1 H), 7.69-7.71 (m, 2 H).
Example 23
N-[l-(cyclopropyImethyI)-2-(l,l-dimethyIethyl)-lH-benzimidazol-5-ylJ- benzenesulfonamide
Figure imgf000061_0002
Step A. N-[l-(cyclopropylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]- benzenesulfonamide
Figure imgf000062_0001
Following the procedure for Step A in Example 20, using N-[3-amino-4- [(cyclopropylmethyl)amino]phenyl]-benzenesulfonamide (736.4 mg, 2.32 mmol) (for preparation, see the following steps B and C), CH2C12 (50 mL), catalytic DMAP and pivaloyl chloride (0.31 mL, 1.1 eq), followed by AcOH (10 mL), the crude product was purified by reversed-phase HPLC using 15-45% MeCΝ in H20. The compound was lyophilized to afford the title compound as its TFA salt (50 mg, 4.2%); Η ΝMR (400 MHz, CD3OD) δ 0.57-0.61 (m, 2 H), 0.65-0.70 (m, 2 H), 1.22-1.25 (m, 1 H),
1.62 (s, 9 H), 4.47 (d, J=6.44 Hz, 2 H), 7.23 (dd, J=9.08, 2.05 Hz, 1 H), 7.43-7.47 (m, 2 H), 7.52-7.55 (m, 1 H), 7.62 (d, J=1.95 Hz, 1 H), 7.74 (d, J=8.98 Hz, 1 H), 7.73- 7.78 (m, 2 H); MS (ESI) (M+H)+ = 384.0.
Step B. N-[4-[(cyclopropylmethyl)amino]-3-nitrophenyl]-benzenesulfonamide
Figure imgf000062_0002
Following the procedure for Step B in Example 20, using N-(4-fluoro-3-nitrophenyl)- benzenesulfonamide (1.0 g, 3.38 mmol) and cyclopropylmethylamine (0.4 L, 1.2 eq) in EtOH (12 mL) and H20 (5 mL). The crude product was purified by MPLC using 7:3 hexanes:EtOAc to afford the title compound as a bright orange solid (828.3 mg, 71%); Η ΝMR (400 MHz, CDCI3) δ 0.29-0.33 (m, 2 H), 0.63-0.67 (m, 2 H), 1.14-1.19 (m, 1 H), 3.13 (dd, J=7.03, 4.88 Hz, 2 H), 6.42 (s, 1 H), 6.76 (d, J=9.37 Hz, 1 H), 7.36 (dd, J=9.18, 2.54 Hz, 1 H), 7.45-7.49 ( , 2 H), 7.56-7.59 (m, 1 H), 7.67 (d, J=2.54 Hz, 1 H), 7.71-7.74 ( , 2 H), 8.07-8.13 (m, 1 H). Step C. N-[3-amino-4-[(cyclopropylmethyl)amino]phenyl]-benzenesulfonamide
Figure imgf000063_0001
Following the procedure for Step E in Example 3, using N-[4- [(cyclopropylmethyl)amino]-3-nitrophenyl]-benzenesulfonamide (828.3 mg, 2.38 mmol), a catalytic amount of 10% Pd/C in EtOAc (30 mL). LC/MS analysis indicated that the title compound was of sufficient purity (>95%) to be used directly for the next step. Yield: 736.4 mg, 100%; Η ΝMR (400 MHz, CDC13) δ 0.20-0.24 (m, 2 H), 0.53-0.58 (m, 2 H), 1.08-1.12 (m, 1 H), 2.87 (d, J=7.03 Hz, 2 H), 3.28-3.48 (br. s., 2 H), 6.27-6.31 (br. s., 1 H), 6.31-6.34 (m, 1 H), 6.39-6.41 (m, 1 H), 6.57 (d, J=2.34 Hz, 1 H), 7.40-7.44 (m, 2 H), 7.49-7.54 ( , 1 H), 7.69-7.71 (m, 2 H).
Example 24
N-(4-{[[2-te/T-butyl-l-(cyclohexylmethyl)-lH-benzimidazoI-5- yl](methyI)amino]sulfonyl}phenyl) acetamide
Figure imgf000063_0002
Step A. N-(4-{[[2-tert-butyI-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl) acetamide
Figure imgf000063_0003
2-tert-Butyl-l-(cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (40 mg, 0.133 mmol) (for preparation, see the following steps B, C, D, E and F) and 4- acetamidobenzene sulfonyl chloride (37 mg, 0.160 mmol) were stirred in 3 mL of dichloromethane containing a catalytic amount of DMAP overnight at rt. The solvent was evaporated. The product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 63 mg (78%); 'H NMR (400 MHz, METHANOL-D ) δ 1.21 (m, 5 H), 1.61 (m, 3 H), 1.64 (s, 9 H), 1.67 (m, 1 H), 1.75 (m, 2 H), 2.07 (m, 1 H), 2.1 1 (s, 3 H), 3.22 (s, 3 H), 4.42 (d, J=7.62 Hz, 2 H), 7.29 (dd, J=9.08, 2.05 Hz, 1 H), 7.42 (d, J=8.98 Hz, 2 H), 7.50 (d, J=l .56 Hz, 1 H), 7.68 (d, J=8.98 Hz. 2 H), 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 497.2; Anal. Calcd for C27H36N403S + 1.4 TFA + 0.4 H20: C, 53.94; H, 5.80; N, 8.44. Found: C, 53.98; H. 5.79; N, 8.50.
Step B. Methyl (4-fluoro-3-nitrophenyI)carbamate
Figure imgf000064_0001
Methyl chloroformate (13.2 mL, 170.2 mmol) was added dropwise to a cold (0°C) dichloromethane (200 mL) solution of 4-fluoro-3 -nitro aniline (24.15 g, 154.7 mmol) and DIPEA (35 mL, 201 mmol). The reaction mixture was stirred at rt overnight. The solution was then diluted with 200 mL of dichloromethane and washed with 2M HCl, brine and dried over anhydrous MgS0 . The solvent was concentrated and the product was directly used for next step without further purification. Yield: 35.5 g (99%); Η NMR (400 MHz, CHLOROFORM-D) δ 3.81 (s, 3 H), 7.02 (s, 1 H), 7.23 (m, 1 H), 7.72 (d, J=8.59 Hz, 1 H), 8.17 (dd, J=6.35, 2.64 Hz, 1 H).
Step C. Methyl {4-[(cyclohexylmethyl)amino]-3-nitrophenyl}carbamate
Figure imgf000064_0002
Methyl (4-fluoro-3-nitrophenyl)carbamate (1.00 g, 4.67 mmol) and cyclohexylmethyl amine (0.730 mL, 5.60 mmol) were stirred in EtOH (20 mL) containing TEA (1.0 mL, 7.00 mmol) at 75°C for 24h. The solvent was concentrated. The residue was dissolved in EtOAc and washed with 5% KHS0 solution, saturated NaHC03 solution, brine and dried over anhydrous MgS04. The crude product was purified by flash chromatography using 4:l/hex:EtOAc on silica gel. Yield: 1.05 g (73%); Η NMR (400 MHz, CHLOROFORM-D) δl.04 (ddd, J = 24.02, 12.11, 2.93Hz, 2H), 1.25 (m, 3H), 1.69 (m, 2H), 1.76 (m, IH), 1.79 (m, IH), 1.83 (m, IH), 1.86 (m, IH), 3.14 (dd, J = 6.44, 5.66Hz, 2H), 3.78 (s, 3H), 6.46 (m, IH), 6.84 (d, J = 9.37 Hz, IH), 7.63 (m, IH), 8.05 (d, J = 2.54 Hz, IH), 8.09 (m, IH).
Step D. Methyl {3-amino-4-[(cyclohexylmethyl)amino]phenyl}carbamate
Figure imgf000065_0001
Methyl {4-[(cyclohexylmethyl)amino]-3-nitrophenyl}carbamate (1.05 g, 3.42 mmol) was dissolved in 30 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H2 atmosphere (40 psi) at rt overnight. The solution was filtered through Celite and the solvent was evaporated. The product was directly used for the next step without further purification. Yield: 950 mg (99%); MS (ESI) (M+H)+ 277.9.
Step E. Methyl [2-te/Y-butyl-l-(cy ohexylmethyl)-lH-benzimidazol-5- yljcarbamate
Figure imgf000065_0002
Methyl {3-amino-4-[(cyclohexylmethyl)amino]phenyl)carbamate (950 mg, 3.43 mmol) and DMAP (100 mg, 0.858 mmol) were dissolved in 25 mL of dichloromethane. Trimethylacetyl chloride (0.460 mL, 3.77 mmol) was added dropwise and the solution was stirred at rt for lh. The solvent was concentrated. The residue was divided in two portions and each of them dissolved in 3 mL of glacial AcOH in a sealed tube. The solutions were heated at 150°C using a Personal Chemistry Smith Synthesizer microwave instrument for three intervals of 30 min (3 X 30 min). The two tubes were combined and the solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated NaHC03 solution, brine and dried over anhydrous MgS04. The crude product was purified by flash chromatography using 3:l/dichloromethane:diethyl ether. Yield: 656 mg (56%); Η NMR (400 MHz, CHLOROFORM-D) δ 1.08 (m, 2H), 1.18 (m, 3H), 1.54 (s, 9H), 1.65 (m, IH), 1.69 (m, 2H), 1.73 (dd, J = 5.96, 3.22 Hz, 2H), 2.02 (m, IH), 3.78 (s, 3H), 4.10 (d, J = 7.42 Hz, 2H), 6.64 (m, IH), 7.25 (d, J = 8.79 Hz, IH), 7.39 (m, IH), 7.59 (d, J = 1.76 Hz, IH).
Step F. 2-te/*t-Butyl-l-(cyclohexyImethyl)-N-methyl-lHr-benzimidazol-5-amine
Figure imgf000066_0001
Methyl [2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]carbamate (650 mg, 1.89 mmol) was dissolved in 20 mL of TΗF at 0°C under nitrogen. IM ΗCl/ether (2.65 mL, 2.65 mmol) was added dropwise and the solution stirred at 0°C for 15min. LiAlΗ (360 mg, 9.45 mmol) was then slowly added and the solution was stirred at rt overnight. The reaction mixture was quenched at 0°C by addition of MeOH (5 mL) followed by water (10 mL). The solution was diluted with EtOAc and washed with saturated ΝaHCθ3 solution, brine and dried over anhydrous MgS04. The solvent was evaporated and the product was used directly for Step A without further purification. Yield: 544 mg (96%). Η NMR (400 MHz, CHLOROFORM-D) δ 1.08 (s, 2 H) 1.17 (m, 3 H) 1.54 (s, 9 H) 1.64 (m, 2 H) 1.67 (m, 2 H) 1.72 (m, 2 H) 2.02 (m, 1 H) 2.87 (s, 3 H) 4.06 (d, J=7.62 Hz, 2 H) 6.60 (dd, J=8.69, 2.25 Hz, 1 H) 7.00 (d, J=l .76 Hz, H) 7.12 (d, J=8.59 Hz, 1 H).
Example 25 N-[2-tert-ButyI-l-(cycIohexylmethyl)-lH-benzimidazol-5-yl]-N-methyl-6- morpholin-4-ylpyridine-3-sulfonamide
Figure imgf000067_0001
Following the procedure for Step A in Example 24, using 2-fert-btyl-l- (cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (39 mg, 0.130 mmol), 6- morpholino-3-pyridinesulfonyl chloride (41 mg, 0.156 mmol) and DMAP (catalytic) in 2 L of DCM. The product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 11 mg (13%); 'H MR (400 MHz, METHANOL-D4) δ 1.21 (m, 5 H), 1.61 (m, 2 H), 1.64 (s, 9 H), 1.67 (m, 1 H), 1.75 (m, 2 H), 2.08 (s, 1 H), 3.23 (s, 3 H), 3.60 (m, 4 H), 3.71 (m, 4 H), 4.42 (d, J=7.62 Hz, 2 H), 6.77 (d, J=8.59 Hz, 1 H), 7.34 (dd, J=8.98, 1.95 Hz, 1 H), 7.57 (m, 2 H), 7.83 (d, J=8.98 Hz, 1 H), 8.08 (d, j=1.95 Hz, 1 H); MS (ESI) (M+H)+ 526.0; Anal. Calcd for C28H39N503S + 1.7 TFA + 0.5 H20: C, 51.77; H, 5.77; N, 9.61. Found: C, 51.76; H, 5.75; N, 9.69.
Example 26
Λf-[2-te/-t-Butyl-l-(cycIohexylmethyl)-lH-benzimidazol-5-yl]-N-methyl-4- nitrobenzenesulfonamide
Figure imgf000068_0001
Following the procedure for Step A in Example 24, using 2-te/-t-btyl-l- (cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (253 mg, 0.845 mmol), 4- nitrobenzenesulfonyl chloride (245 mg, 1.10 mmol) and DMAP (catalytic) in 20mL of DCM. The solution was washed with saturated ΝaΗC03 aqueous solution, brine and dried over anhydrous MgS04. The crude product was purified by flash chromatography on silica gel using 2:1 / hexanes:EtOAc as eluent to afford the title product. Yield: 380 mg (93%); 'H NMR (400 MHz, CHLOROFORM-D) δ 1.09 (m, 2 H) 1.21 (m, 3 H) 1.54 (s, 9 H) 1.64 (m, 1 H) 1.67 (m, 1 H) 1.71 (m, 1 H) 1.76 (m, 2 H) 2.03 (m, 1 H) 3.27 (s, 3 H) 4.12 (d, J=7.23 Hz, 2 H) 7.18 (m, J=8.98 Hz, 2 H) 7.30 (d, J=8.98 Hz, 1 H) 7.77 (d, J=9.18 Hz, 2 H) 8.30 (d, J=9.18 Hz, 2 H).
Example 27
4-Amino-N-[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-Λ'r- methylbenzenesulfonamide
Figure imgf000068_0002
N-[2-te7-t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methyl-4- nitrobenzenesulfonamide (375mg, 0.774 mmol) was dissolved in 20 mL of EtOH containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H2 atmosphere (40 psi) at rt for 3h. The solution was filtered through celite and the solvent was concentrated. Yield: 332 mg (94%); Η ΝMR (400 MHz, METHAΝOL-D4) δ 1.22 m, 6 H) 1.60 (m, 1 H) 1.64 (s, 9 H) 1.67 (m, 1 H) 1.75 (m, 2 H) 2.08 (m, 1 H) 3.17 (s, 3 H) 4.42 (d, J=7.42 Hz, 2 H) 6.56 (d, J=8.79 Hz, 2 H) 7.14 (d, J=8.79 Hz, 2 H) 7.32 (dd, J=8.98, 1.95 Hz, 1 H) 7.49 (d, J=1.95 Hz, 1 H) 7.81 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 455.0; Anal. Calcd for C25H3 N402S + 1.5 TFA + 0.4 H20: C, 53.14; H, 5.78; N, 8.85. Found: C, 53.10; H, 5.67; N, 8.92.
Example 28
N-(4-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazoI-5- yl](methyl)amino]sulfonyl}phenyl)propanamide
Figure imgf000069_0001
4-Amino-N-[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide (50 mg, 0.110 mmol) and propionyl chloride (0.012 mL, 0.143 mmol) were stirred in 3 mL of DCM containing a catalytic amount of DMAP at rt for 12h. The solvent was concentrated and the crude product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 68mg (99%); Η NMR (400 MHz, METHANOL-D4) δ 1.16 (t, J=7.62 Hz, 3 H) 1.21 (m, 5 H) 1.60 (m, 2 H) 1.64 (s, 9 H) 1.67 (m, 1 H) 1.75 (m, 2 H) 2.07 (m, 1 H) 2.38 (q, J=7.62 Hz, 2 H) 3.22 (s, 3 H) 4.42 (d, J=7.62 Hz, 2 H) 7.29 (dd, J=9.08, 2.05 Hz, 1 H) 7.42 (d, J=S.98 Hz, 2 H) 7.49 (d, J=1.76 Hz, 1 H) 7.69 (d, J=8.98 Hz, 2 H) 7.81 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 51 1.2; Anal. Calcd for C28H38N403S + 1.5 TFA + 0.2 H20: C, 54.33; H, 5.87; N, 8.18. Found: C, 54.32; H, 5.84; N, 8.25.
Example 29
N-(4-{[[2-te/T-Butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5- yl](methyI)amino]sulfonyl}phenyl)-2-methylpropanamide
Figure imgf000070_0001
Following the procedure for Example 28, using 4-amino-N-[2-tert-butyl-l- (cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methylbenzenesulfonamide (50 mg, 0.1 10 mmol), isobutyryl chloride (0.015 mL, 0.143 mmol) and a catalytic amount of DMAP in 3mL of DCM. Yield: 73mg (99%); Η ΝMR (400 MHz, METHAΝOL-D4) δ 1.15 (d, J=6.83 Hz, 6 H) 1.21 (m, 5 H) 1.62 (m, 2 H) 1.64 (s, 9 H) 1.67 (m, 1 H) 1.75 (m, 2 H) 2.08 (m, 1 H) 2.61 (dt, J=13.82, 6.86 Hz, 1 H) 3.23 (s, 3 H) 4.42 (d, J=7.62 Hz, 2 H) 7.29 (dd, J=8.98, 1.95 Hz, 1 H) 7.42 (d, J=8.98 Hz, 2 H) 7.50 (d, J=1.95 Hz, 1 H) 7.71 (d, J=8.98 Hz, 2 H) 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 525.3; Anal. Calcd for C29H40N4O3S + 1.7 TFA + 0.3 H20: C, 53.75; H, 5.89; N, 7.74. Found: C, 53.75; H, 5.87; N, 7.73.
Example 30 N-(4-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lHr-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide
Figure imgf000070_0002
Following the procedure for Example 28, using 4-amino-N-[2-tert-butyl-l- (cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methylbenzenesulfonamide (50 mg, 0.1 10 mmol), trimethylacetyl chloride (0.018 mL, 0.143 mmol) and a catalytic amount of DMAP in 3mL of DCM. Yield: 76mg (99%); Η ΝMR (400 MHz, METHAΝOL-D4) δ 1.21 (m, 5 H) 1.26 (s, 9 H) 1.62 (m, 2 H) 1.64 (s, 9 H) 1.67 (m, H) 1.75 (m, 2 H) 2.07 (m, 1 H) 3.23 (s, 3 H) 4.42 (d, J=7.62 Hz, 2 H) 7.29 (dd, J=9.08, 2.05 Hz, 1 H) 7.42 (d, J=8.98 Hz, 2 H) 7.49 (d, J=l .76 Hz, 1 H) 7.73 (d, J=8.98 Hz, 2 H) 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 539.2; Anal. Calcd for C30H42N4O3S + 1.4 TFA + 0.5 H20: C, 55.69; H, 6.33; N, 7.92. Found: C, 55.70; H, 6.31; N, 7.92.
Example 31
N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-4-(ethylamino)-N- methylbenzenesulfonamide
Figure imgf000071_0001
4-Amino-N-[2-te/'t-butyl-l -(cyclohexylmethyl)- lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide (55 mg, 0.121 mmol), cesium carbonate (78 mg, 0.242 mmol) and ethyl iodide (0.011 mL, 0.133mmol) were dissolved in 1 mL of DMF in a sealed tube flushed with nitrogen. The solution was heated at 125°C in a Personal Chemistry SmithSynthesizer microwave instrument for 10 min. Another 0.133 mmol (0.01 1 mL) of ethyl iodide was added and the solution was heated for another 10 min. This procedure was then repeated 3 more times. The solvent was then concentrated. The residue was dissolved in EtOAc and washed with saturated ΝaΗCθ3 aqueous solution, brine and dried over anhydrous MgS04. . The solvent was concentrated and the crude product was purified by reversed-phase HPLC using 20-80% CH3CN/H 0 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 39 mg (54%); Η NMR (400 MHz, METHANOL-D4) δ 1.19 (t, J=7.23 Hz, 3 H) 1.23 (m, 5 H) 1.62 (m, 2 H) 1.64 (s, 9 H) 1.67 (m, 1 H) 1.75 (m, 2 H) 2.08 (m, 1 H) 3.10 (q, J=7.23 Hz, 2 H) 3.17 (s, 3 H) 4.43 (d, J=7.62 Hz, 2 H) 6.52 (d, J=8.98 Hz, 2 H) 7.18 (d, J=8.98 Hz, 2 H) 7.32 (dd, J=8.98, 1.95 Hz, 1 H) 7.51 (d, J=2.15 Hz, 1 H) 7.81 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 483.3; Anal. Calcd for C27H3SN402S + 1.8 TFA: C, 53.43; H, 5.83; N, 8.14. Found: C, 53.51; H, 5.81 ; N, 8.13.
Example 32 N-[2-te/*t-ButyI-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-4-(formyIamino)-N- methylbenzenesulfonamide
Figure imgf000072_0001
4-Amino-N-[2-te7-t-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-Λ/- methylbenzenesulfonamide (45 mg, 0.099 mmol), was heated in 1 mL of formic acid in a sealed tube at 125°C for 15 min using a Personal Chemistry SmithSynthesizer microwave instrument. The solvent was concentrated and the product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η 0 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 61 mg (99%); Η NMR (400 MHz, METHANOL-D4) δ 1.21 (m, 5 H), 1.62 (m, 2 H), 1.64 (s, 9 H), 1.67 (m, 1 H), 1.75 (m, 2 H), 2.08 (m, 1 H), 3.23 (s, 3 H), 4.42 (d, J=7.62 Hz, 2 H), 7.29 (dd, J=8.98, 1.95 Hz, 1 H), 7.45 (d, J=8.98 Hz, 2 H), 7.50 (d, J=l .76 Hz, 1 H), 7.70 (d, J=8.79 Hz, 2 H), 7.82 (d, J=8.98 Hz, 1 H), 8.31 (s, 1 H); MS (ESI) (M+H)+ 483.0; Anal. Calcd for C2bH34N403S + 1.4 TFA + 0.5 H20: C, 53.11; H, 5.63; N, 8.60. Found: C, 53.02; H, 5.62; N, 8.71.
Example 33
N-(4-{[[2-tert-Butyl-l-(cyclohexyImethyI)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2-pyrrolidin-l-ylacetamide
Figure imgf000073_0001
STEP A: N-(4-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2-pyrrolidin-l-ylacetamide
Figure imgf000073_0002
2-Bromo-N-(4-{[[2-te7-t-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide (42 mg, 0.0730 mmol) and pyrrolidine (0.030 mL, 0.365 mmol) were dissolved in 1 mL of DMF in a sealed tube. The solution was heated at 125°C in a Personal Chemistry SmithSynthesizer microwave instrument for 15 min. The solvent was concentrated. The residue was dissolved in EtOAc and was washed with saturated ΝaHC03 aqueous solution, brine and dried over anhydrous MgS04. The solvent was concentrated and the crude product was purified by reversed-phase HPLC using 20-80% CH3CN/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 51 mg (88%); Η NMR (400 MHz, METHANOL-D4) δ 1.24 (m, 5 H) 1.63 (m, 2 H) 1.67 (s, 11 H) 1.70 (m, 1 H) 1.78 (m, 2 H) 2.09 (m, 2 H) 2.17 (m, 2 H) 3.19 (m, 1 H) 3.27 (s, 3 H) 3.78 (m, 1 H) 4.27 (s, 2 H) 4.44 (d, J=7.62 Hz, 2 H) 7.28 (dd, J=8.98, 1.95 Hz, 1 H) 7.53 (d, J=8.98 Hz, 2 H) 7.59 (d, J=1.76 Hz, 1 H) 7.77 (d, J=8.98 Hz, 2 H) 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 566.2; Anal. Calcd for C31H43N5O3S + 2.7 TFA + 0.4 H20: C, 49.63; H, 5.32; N, 7.95. Found: C, 49.63; H, 5.33; N, 7.93. STEP B: 2-Bromo-N-(4-{[[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl] (methyl)amino] sulfonyl}phenyl)acetamide
Figure imgf000074_0001
4-Amino-N-[2-te7-t-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide (155 mg, 0.341 mmol) was dissolved in 5 mL of DCM containing a catalytic amount of DMAP. Bromoacetyl chloride (0.035 mL, 0.409 mmol) was added and the solution was stirred at rt for 3h. The solution was washed with saturated ΝaΗCθ3 aqueous solution, brine and dried over anhydrous MgS04. The crude product was purified by flash chromatography on silica gel using 50-75% EtOAc in hexanes as eluent to afford the title product. Yield: 175 mg (89%); Η NMR (400 MHz, CHLOROFORM-D) δ 1.09 (m, IH) 1.12 (m, IH) 1.15 (m, IH) 1.19 (d J=8.59 Hz, 2H) 1.54 (s, 9H) 1.65 (m, IH) 1.68 (m, IH) 1.72 (m, IH) 1.75 ( , 2H) 2.04 (m, IH) 3.21 (d, J=1.17 Hz, 3H) 4.04 (s, IH) 4.12 (m, 2H) 4.22 (s, IH) 7.20 (m, IH) 7.23 (m, IH) 7.28 (m, IH) 7.57 (m, 2H) 7.66 (t, J=8.49 Hz, 2H) 8.44 (d, J=8.40 Hz, IH).
Example 34
N1-(4-{[[2-te/t-ButyI-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-N2^V2-dimethylglycinamide
Figure imgf000074_0002
Following the procedure for Example 33, using 2-bromo-N-(4-{[[2-te7-t-butyl-l- (cyclohexylmethyl)-lH-benzimidazol-5-yl](methyl)amino]sulfonyl) phenyl) acetamide (40 mg, 0.0695 mmol), dimethylamine hydrochloride (0.030 mg, 0.348 mmol) and DIPEA (0.060 mL, 0.348 mmol) in 1 mL of DMF. Yield: 35 mg (77%); Η NMR (400 MHz, METHANOL-D4) δ 1.24 (m, 5 H) 1.64 (m, 2 H) 1.67 (s, 9 H) 1.70 (m, 1 H) 1.78 (m, 2 H) 2.10 (m, 1 H) 3.00 (s, 6 H) 3.27 (s, 3 H) 4.18 (s, 2 H) 4.45 (d, J=7.62 Hz, 2 H) 7.29 (dd, J=8.98, 1.95 Hz, 1 H) 7.54 (d, J=8.98 Hz, 2 H) 7.60 (d, J=1.76 Hz, 1 H) 7.77 (d, J=8.98 Hz, 2 H) 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 540.3; Anal. Calcd for C29H4,N503S + 2.9 TFA + 0.5 H20: C, 47.53; H, 5.15; N, 7.96. Found: C, 47.57; H, 5.1 1; N, 7.99.
Example 35
N-(4-{[[2-tert-ButyI-l-(cyclohexylmethyl)-liJ-benzimidazol-5- yI)(methyI)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide
Figure imgf000075_0001
Following the procedure for Example 33, using 2-bromo-N-(4-{[[2-te7-t-butyl-l- (cyclohexylmethyl)-lH-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl) acetamide (56 mg, 0.0973 mmol) and moφholine (0.045 mL, 0.486 mmol) in 1 mL of DMF. Yield: 15mg (26%); Η ΝMR (400 MHz, METHAΝOL-D4) δ 1.24 (m, 5 H) 1.64 (m, 2 H) 1.67 (s, 9 H) 1.70 (m, 1 H) 1.78 ( , 2 H) 2.11 (m, 1 H) 3.27 (s, 3 H) 3.42 (m, 4 H) 3.96 (m, 4 H) 4.17 (s, 2 H) 4.45 (d, J=7.62 Hz, 2 H) 7.29 (dd, J=8.98, 2.15 Hz, 1 H) 7.54 (d, J=9.18 Hz, 2 H) 7.60 (d, J=1.56 Hz, 1 H) 7.77 (d, J=8.98 Hz, 2 H) 7.83 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 582.2; Anal. Calcd for C31H43N5O4S + 3.2 TFA + 0.2 H20: C, 47.27; H, 4.94; N, 7.37. Found: C, 47.23; H, 4.92; N, 7.49.
Example 36 NN',--((44--{{[[[[22--tt<e=rt-Butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5- yI](methyl)amino]sulfonyl}phenyl)glycinamide
Figure imgf000076_0001
Following the procedure for Example 33, using 2-bromo-N-(4-{[[2-te7-t-butyl-l- (cyclohexylmethyl)-lH-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl) acetamide (37 mg, 0.0608 mmol) and ammonium hydroxide (28% aqueous) (0.5 mL, excess) in 1 mL of DMF. Yield: 28mg (74%); Η ΝMR (400 MHz, METHAΝOL- D4) δ 1.24 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.70 (m, 1 H), 1.78 (m, 2 H), 2.10 (m, 1 H), 3.27 (s, 3 H), 3.89 (s, 2 H), 4.44 (d, J=7.62 Hz, 2 H), 7.30 (dd, J=8.98, 1.95 Hz, 1 H), 7.53 (d, J=9.18 Hz, 2 H), 7.58 (d, J=1.76 Hz, 1 H), 7.76 (d, J=8.98 Hz, 2 H), 7.82 (d, J=9.18 Hz, 1 H); MS (ESI) (M+H)+ 512.0; Anal. Calcd for C27H37Ν503S + 2.6 TFA + 1.6 H20: C, 46.21; H, 5.15; N, 8.37. Found: C, 46.22; H, 5.09; N, 8.43.
Example 37
2-[(4-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yI](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyI acetate
Figure imgf000076_0002
Following the procedure for Example 33, using 2-bromo-N-(4-{[[2-te7-t-butyl-l- (cyclohexylmethyl)-lH-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl) acetamide (50 mg, 0.0869 mmol) and sodium acetate (35 mg, 0.434 mmol) in 2 mL of DMF. The product was used directly for the next step without any further purification. Yield: 48 mg (99%); MS (ESI) (M+Η)+ 555.2.
Example 38 N-(4-{[[2-te/*t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5 yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide
Figure imgf000077_0001
2-[(4-{[[2-tert-Butyl-l-(cyclohexylmetlιyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate (48 mg, 0.0869 mmol) was refluxed in 2 mL of EtOΗ containing IM LiOΗ (0.5 mL, excess) for 2h. The solvent was concentrated and the residue was dissolved in EtOAc. The organic phase was washed with saturated ΝaΗC03 aqueous solution, brine and dried over anhydrous MgS04. The solvent was concentrated and the crude product was purified by reversed-phase HPLC using 20-80% CH3CN/H20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 16 mg (29%); Η NMR (400 MHz, METHANOL-D4) δ 1.24 (m, 5 H), 1.63 (m, 2 H), 1.67 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.10 (m, 1 H), 3.27 (s, 3 H), 4.13 (s, 2 H), 4.45 (d, J=7.62 Hz, 2 H), 7.31 (dd, J=9.08, 2.05 Hz, 1 H), 7.49 (d, J=8.79 Hz, 2 H), 7.53 (d, J=1.95 Hz, 1 H), 7.83 (m, 3 H); MS (ESI) (M+H)+ 513.0.
Example 39
N-[l-(cyclohexyImethyl)-2-(l,l-dimethylethyI)-lH-benzimidazol-5-yl]-N-methyl- 4-(4-morpholinyl)-benzenesuIfonamide
Figure imgf000077_0002
Step A. N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyI)-lH-benzimidazol-5-yl]-N- methyl-4-(4-morpholinyl)-benzenesulfonamide
Figure imgf000078_0001
4-Bromo-N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]-N- methyl-benzenesulfonamide (for preparation, see the following steps B, C, D, E, F, G and Η) (80.1 mg, 0.154 mmol), moφholine (16 ul, 15.7 mg, 0.18 mmol), KOBu-t (20.2 mg, 0.21 mmol), Pd(dba)2 (12.9 mg, 0.014 mmol) and BIΝAP (1 1.5 mg, 0.018 mmol) in toluene (3 mL) were placed in a sealed tube. The mixture was heated at 170°C in a Personal Chemistry SmithSynthesizer microwave instrument for 30 min, diluted with EtOAc (50 mL), brine (2x10 mL) and dried over anhydrous Νa2S04. The solvent was concentrated and the crude product was purified by reversed-phase ΗPLC using 20-70% CΗ3CN/Η20 and then lyophilized affording the title compound as the corresponding TFA. Yield: 45.3 mg (46%); Η NMR (400 MHz, METHANOL-D4) δ 1.25 (m, 5 H), 1.63 (m, 2 H), 1.67 (s, 9 H), 1.72 (m, 1 H), 1.78 (m, 2 H), 2.11 (m, 1 H), 3.23 (s, 3-H), 3.28 (m, 4 H), 3.80 (m, 4 H), 4.45 (d, J=7.62 Hz, 2 H), 6.96 (m, 2 H), 7.33 (dd, J=9.08, 2.05 Hz, 1 H), 7.37 (m, 2 H), 7.54 (d, J=1.76 Hz, 1 H), 7.84 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 525.3.
Step B. N-(4-fluoro-3-nitrophenyl)acetamide
Figure imgf000078_0002
4-Fluoro-3-nitro-aniline (45.0 g, 0.288 mol) was added portioCnwisCe to acetic anhydride (150 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 h. The white solid was collected and dried in vacuo to give the title compound (42.0 g, 70%). Η NMR (400 MHz, CDC13): δ 2.23 (s, 3 H), 7.26 (m, 1 H), 7.50 (s broad, 1 H), 7.87 (m, 1 H), 8.23 (dd, J=6.44, 2.73 Hz, 1 H).
Step C. N-{4-[(cyclohexylmethyI)amino]-3-nitrophenyl}acetamide
Figure imgf000079_0001
Cyclohexylmethylamine (2.86 mL, 2.49 g, 22.0 mmol ) was added to a mixture of N- (4-fluoro-3-nitrophenyl)acetamide (3.96 g, 20.0 mmol) and sodium carbonate (4.66 g, 44 mmol) in EtOH (50 mL) at room temperature. The reaction mixture was heated for 48 h at 60 °C, and diluted with H20 (800 mL). The orange solid was precipitated out and collected to give the title product (6.60 g, 100%). MS (ESI) (M+H)+: 292.3.
Step D. N-{3-amino-4-[(cycIohexylmethyI)amino]phenyl}acetamide
Figure imgf000079_0002
(N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl) acetamide) was hydrogenated in ethyl acetate (300 mL) catalyzed by 10% Pd/C (0.5 g) at 20-30 psi H2 in Parr shaker for 4.5 h at room temperature. After filtration through celite and concentration, 5.08 g (97%) of a puφle solid was obtained, which was used in the next step without purification. Η ΝMR (400 MHz, CDC13): δ 1.00 (m, 2 H), 1.24 (m, 3 H), 1.59 (m, 2 H), 1.72 (m, 2 H), 1.84 (m, 2 H), 2.13 (s, 3 H), 2.91 (d, J=6.64 Hz, 2 H), 3.37 (s broad, 3 H), 6.56 (d, J=8.40 Hz, 1 H), 6.69 (dd, J=8.30, 2.25 Hz, 1 H), 6.98 (s, 1 H), 7.12 (d, J=2.34 Hz, 1 H); MS (ESI) (M+H)+: 262.3.
Step E. N-[l-(cycIohexylmethyl)-2-(l,l-dimethylethyI)-lH-benzimidazol-5- yl]acetamide
Figure imgf000079_0003
DMAP (0.15 g, 1.2 mmol) was added to a solution of N-{3-amino-4- [(cyclohexylmethyl)amino]phenyl}acetamide (1.57 g, 6.0 mmol) in dichloromethane (70 mL) at 0 °C, followed by addition of trimethylacetyl chloride (0.85 mL, 0.83 g, 6.6 mmol). The resulting mixture was stirred overnight at room temperature. After evaporation of the solvent, the residue was dissolved in dichloroethane (40 mL) and then divided to 8 sealed test tubes. The mixture was heated at 170°C in a Personal Chemistry SmithSynthesizer microwave instrument for 2 h. The combined reaction mixture was dissolved in EtOAc (200 mL), washed with 2Ν NaOH aqueous solution (2x10 mL), brine (2x10 mL) and dried over Na2S04. After filtration and evaporation, the residue was purified by MPLC using EtOAc as eluent on silica gel to give the title compound as a white solid (1.42 g, 72%). Η NMR (400 MHz, METHANOL-D4) δ 1.24 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.70 (m, 1 H), 1.77 (m, 2 H), 2.12 (m, 1 H), 2.18 (s, 3 H), 4.45 (d, J=7.62 Hz, 2 H), 7.50 (m, 1 H), 7.84 (d, J=8.98 Hz, 1 H), 8.43 (d, J=1.95 Hz, 1 H); MS (ESI) (M+H)+: 328.2.
Step F. N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazoI-5-yl]-N- methyl-acetamide
Figure imgf000080_0001
Sodium hydride (60%, 201.5 mg, 5.04 mmol) was added to a solution of N-[l- (cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]acetamide (549.8 mg, 1.68 mmol) in THF (50 mL) at 0 °C. Stirring for lh, Mel (0.31 mL, 715.4 mg, 5.04 mmol) was added. The mixture was stirred overnight at room temperature, quenched with saturated ΝaHCθ3 (5 mL), and extracted with EtOAc (3x20 mL). The combined organic phases were washed with saturated. NaHCθ3 (20 mL), brine (20 mL) and dried over Na2S0 . After filtration and concentration, the residue was purified by MPLC using EtOAc to give 580.5 mg (100%) of the title compound as a white solid. Η NMR (400 MHz, METHANOL-D4) δ 1.26 (m, 5 H), 1.67 (m, 2 H), 1.69 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 1.87 (s, 3 H), 2.14 (m, 1 H), 3.30 (s, 3 H), 4.49 (d, J=7.62 Hz, 2 H), 7.55 (d, J=8.40 Hz, 1 H), 7.71 (s, 1 H), 8.00 (d, J=8.40 Hz, 1 H); MS (ESI) (M+H)+ 342.2.
Step G. N-l -(Cyclohexylmethyl)-2-(l , 1 -dimethylethyl)-N-methyI-LH- benzimidazol-5-amine
Figure imgf000081_0001
N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]acetamide (540.6 mg, 1.58 mmol) was dissolved in 20 mL of EtOΗ-2NΗCl (3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for 30 min. After concentration and dried in vacumn, 603.5 mg (100%) of a white solid was obtained as the title product. Η ΝMR (400 MHz, METHAΝOL-D4) δ 1.26 (m, 5 H), 1.65 (m, 3 H), 1.71 (s, 9 H), 1.78 (m, 2 H), 2.1 1 (m, 1 H), 3.17 (s, 3 H), 4.53 (d, J=7.62 Hz, 2 H), 7.75 (m, 1 H), 8.03 (m, 1 H, 8.17 (m, 1 H); MS (ESI) (M+H)+ 300.1.
Step H. 4-Bromo-N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH- benzimidazol-5-yl]-N-methyl-benzenesulfonamide
Figure imgf000081_0002
N-l-(Cyclohexylmethyl)-2-(l,l-dimethylethyl)-N-methyl-lH-benzimidazol-5-amine hydrogen chloride (532.2 mg, 1.39 mmol), DMAP (679.3 mg, 5.56 mmol) and 4- bromobenzene sulfonyl chloride (426.7 mg, 1.67 mmol) in MeCΝ (50 mL) were stirred overnight at rt. The reaction mixture was quenched with saturated ΝaΗCOs (10 mL), evaporated to small volume and extracted with EtOAc (3x50 mL). The combined organic phases were washed with brine and dried over Na2S04. After evaporation of the solvent, the product was purified by MPLC using Hexanes/EtOAc (1 :1) on silica to give 529.6 mg (74%) of a white solid as the title product. A small amount of the title product was converted to the corresponding TFA salt. Η NMR (400 MHz, METHANOL-D4) δ 1.26 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.11 (m, 1 H), 3.29 (s, 3 H), 4.45 (d, J=7.62 Hz, 2 H), 7.3 l(m, 1 H), 7.45 (m, 2 H), 7.53 (d, J=1.56 Hz, 1 H), 7.72 (m, 2 H), 7.85 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 518.2.
Example 40
N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]-N-methyl- 4-(4-methyl-l-piperazinyI)-benzenesulfonamide
Figure imgf000082_0001
4-Bromo-N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]-N- methyl-benzenesulfonamide (50.1 mg, 0.093 mmol) and 1 -methylpiperazine (0.2 mL, 180 mg, 1.79 mmol) in DMF (2 mL) were placed in a sealed tube. The mixture was heated at 220°C in a Personal Chemistry SmithSynthesizer microwave instrument for 4 h. After evaporation, the residue was purified by reversed-phase ΗPLC using 15- 60% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 43.73 mg (72%); 'H NMR (400 MHz, METHANOL-D4) δ 1.25 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.11 (m, 1 H), 2.97 (s, 3 H), 3.18 (m, 4 H), 3.24 (s, 3 H), 3.60 (m, 2 H), 4.08 (m, 2 H), 4.45 (d, J=7.62 Hz, 2 H), 7.09 (m, 2 H), 7.31 (m, 1 H), 7.46 (m, 2 H), 7.59 (d, J=1.95 Hz, 1 H), 7.83 (m, 1 H); MS (ESI) (M+H)+ 538.3.
Example 41
N-I2-te7't-ButyI-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
Figure imgf000083_0001
Step A. N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5- yl]-N-methyIbenzenesulfonamide
Figure imgf000083_0002
Following the procedure for Step E in Example 4, using N-{3-amino-4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}-N-methylbenzenesulfonamide (109 mg, 0.290 mmol) (for preparation, see the following steps B and C), trimethylacetyl chloride (0.039 mL, 0.319 mmol) and DMAP (7 mg, 0.058 mmol) in 3 mL of DCM. The second step was performed in 2 mL of glacial acetic acid. The final product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 60 mg (37%); Η NMR (400 MHz, METHANOL-D4) 6 1.55 (m, 2H), 1.60 (m, 2H), 1.68 (s, 9H), 2.37 (m, IH), 3.27 (s, 3H), 3.36 (ddd, J = 11.57, 2.64Hz, 2H), 3.93 (d, J=3.52Hz, IH), 3.96 (m, IH), 4.53 (d, J=7.42Hz, 2H), 7.31 (dd, J = 8.98, 1.95Hz, IH), 7.54 (m, 5H), 7.68 (m, IH), 7.89 (d, J = 8.98Hz, IH); MS (ESI) (M+H)+ 442.3.
Step B. N-Methyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyI}benzenesulfonamide
Figure imgf000084_0001
Following the procedure for Step C in Example 1, using N-(4-fluoro-3-nitrophenyl)- N-methylbenzene sulfonamide (100 mg, 0.322 mmol), 4-aminomethyltetrahydopyran (45 mg, 0.386 mmol) and TEA (0.070 mL, 0.483 mmol) in 3 mL of EtOH. The residue was dissolved in EtOAc and washed with 5% KHS04 solution, saturated ΝaHCU3 solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using a linear gradient of 30-50% EtOAc / hexanes. Yield: 123 mg (94%); Η NMR (400 MHz, CHLOROFORM-D) δ 1.44 (m, 2H), 1.74 (m, IH), 1.77 (m, IH), 1.96 (m, IH), 3.13 (s, 3H), 3.23 (dd, J = 6.74, 5.57Hz, 2H), 3.43 (ddd, J = 11.81, 2.15, 2H), 4.40 (dd, J = 11.13, 3.91Hz, 2H), 6.84 (d, J = 9.18Hz, IH), 7.49 (m, 3H), 7.61 (m, 3H), 8.21 (m, IH).
Step C. N-{3-Amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-N- methylbenzenesulfonamide
Figure imgf000084_0002
Following the procedure for Step E in Example 3, using N-methyl-N-{3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}benzenesulfonamide (118 mg, 0.291 mmol) and a catalytic amount of 10% Pd/C in 20 mL of EtOAc. Yield: 109 mg (99%); MS (ESI) (M+Η)+ 376.16. Example 42
N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-2-ylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
Figure imgf000085_0001
Step A. N-[2-te/*t-Butyl-l-(tetrahydro-2H-pyran-2-ylmethyI)-lH-benzimidazol-5- yl]-N-methylbenzenesulfonamide
Figure imgf000085_0002
Following the procedure for Step E in Example 4, using N-{ 3-Amino-4-[(tetrahydro- 2H-pyran-2-ylmethyl)amino]phenyl}-N-methylbenzenesulfonamide (47 mg, 0.125 mmol) (for preparation, see the following steps B and C) , trimethylacetyl chloride (0.017 mL, 0.138 mmol) and DMAP (3 mg, 0.025 mmol) in 3 mL of DCM. The second step was performed in 2 mL of glacial acetic acid. The final product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 33 mg (48%); Η NMR (400 MHz, METHANOL-D4) 5 1.50 (m, 2H), 1.58 (m, 3H), 1.67 (s, 9H), 1.88 (m, IH), 1.91 (m, IH), 3.22 (ddd, J = 11.47, 2.64Hz, IH), 3.27 (s, 3H), 3.85 (m, 2H), 4.65 (m, 2H), 7.29 (dd, J = 9.08, 2.05Hz, IH), 7.51 (d, J = 1.56 Hz, IH), 7.54 (m, 3H), 7.68 (m, IH), 7.87 (d, J = 8.98Hz, IH); MS (ESI) (M+H)+ = 442.3. Anal. Calcd for C24H31N3O3S+I .5 TFA + 0.1 H20: C, 52.78; H, 5.36; N, 6.84. Found: C, 52.83; H, 5.37; N, 6.90.
Step B. N-Methyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-2- yImethyl)amino]phenyl}benzenesulfonamide
Figure imgf000086_0001
Following the procedure for Step C in Example 1, using N-(4-fluoro-3-nitrophenyl)- N-methylbenzene sulfonamide (50 mg, 0.161 mmol), 2-aminomethyltetrahydopyran hydrochloride (30 mg, 0.193 mmol) and TEA (0.056 mL, 0.403 mmol) in 3 mL of EtOH. The residue was dissolved in EtOAc and washed with 5% KHS04 solution, saturated ΝaHCθ3 solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using first DCM and then EtOAc as eluent. Yield: 58 mg (89%); Η NMR (400 MHz, CHLOROFORM-D) δ 1.46 (m, IH), 1.55 (d, J = 7.03Hz, 2H), 1.60 (m, 2H), 1.67 (m, IH), 1.91 (m, IH), 3.13 (s, 3H), 3.29 (m, IH), 3.37 (m, IH), 3.50 (ddd, J = 1 1.33, 2.93Hz, IH), 3.62 (m, IH), 4.06 (m, IH), 6.83 (d, J = 9.37Hz, IH), 7.46 (dd, J = 9.37, 2.54Hz, IH), 7.50 (m, 2H), 7.57 (m, 2H), 7.61 (m, IH), 8.33 (m, IH).
Step C. N-{3-Amino-4-[(tetrahydro-2H-pyran-2-yImethyl)amino]phenyl}-N- methylbenzenesulfonamide
Figure imgf000086_0002
Following the proce Φdure for Step E in Example 3, using N-methyl-N-{3-nitro-4- [(tetrahydro-2H-pyran-2-ylmethyl)amino]phenyl}benzenesulfonamide (55 mg, 0.136 mmol) and a catalytic amount of 10% Pd/C in 15 mL of EtOAc. Yield: 47 mg (92%); MS (ESI) (M+Η)+ 376.17.
Example 43
N-[l-(cyclohexylmethyl)-2-(l-hydroxy-l-methylethyl)-lH-benzimidazol-5-yl]- benzenesulfonamide
Figure imgf000087_0001
Diisopropylethylamine (291.4 mg, 2.25 mmol) was added into a solution ofN-{3- amino-4-[(cyclohexylmethyl)amino]phenyl} benzene sulfonamide (540.1 mg, 1.50 mmol) (for preparation, see Steps B and C in Example 7) and 2-hydroxy isobutyric acid (171.8 mg, 1.65 mmol) in DMF (15 mL) at 0 °C. Stirring for 20 min., HATU (684.4 mg, 1.80 mmol) was added. The reaction mixture was stirred for 24 h at room temperature, diluted with water (100 mL), and extracted with EtOAc (2x50 mL). The combined organic phases were washed with ΝaCl (20 mL) and dried with anhydrous sodium sulphate. After filtration and concentration, the residue was dissolved in acetic acid (5 mL) in a sealed tube. The solutions were heated at 140°C using a Personal Chemistry Smith Synthesizer microwave instrument for 30 min. LIpon evaporation of the solvent, the residue was diluted with EtOAc (100 mL), washed with 2Ν NaOH(10 mL), sat. NaCl (2x10 mL) and dried over anhydrous sodium sulphate. After filtration and evaporation, the residue was purified by MPLC (EtOAc on silica gel) to give 364.6 mg (57%) of a white solid as the title compound. Part of the product was converted to TFA salt. Η NMR (400 MHz, CD3OD): δl .17 (m, 5 H), 1.56 (m, 2 H), 1.70 (m, 3 H), 1.76 (s, 6 H), 2.09 (m, 1 H), 4.48 (d, J=7.62 Hz, 2 H), 7.23 (m, 1 H), 7.47 (m, 2 H), 7.56 (m, 2 H), 7.72 (d, J=8.98 Hz, 1 H), 7.79 (m, 2 H); MS (ESI) (M+H)+ = 428.0; Anal. Calcd for C23H29N303S+1.2TFA: C, 54.05; H, 5.39; N, 7.45. Found: C, 54.09; H, 5.50; N, 7.42.
Example 44
N-[l-(cycIohexylmethyl)-2-(l-methoxy-l-methylethyI)-lH-benzimidazoI-5-yl]-N- methyl-benzenesulfonamide
Figure imgf000088_0001
Sodium hydride (31.2 mg, 0.78 mmol) was added into a solution of N-[l- (cyclohexylmethyl)-2-(l-hydroxy-l-methylethyl)-lH-benzimidazol-5-yI]- benzenesulfonamide (111.0 mg, 0.26 mmol) (for preparation, see Example 43) in THF (10 mL) at 0 °C. Stimng for 30 min., methyl iodide (145.9 mg, 1.03 mmol) was added. The reaction mixture was stirred for 24 h at room temperature, quenched with saturated ΝaHC03 (2 mL), and extracted with EtOAc (2x50 mL). The combined organic phases were washed with NaCl (20 mL) and dried with anhydrous sodium sulphate. After filtration and concentration, the residue was purified by MPLC (Hex/EtOAc (1:1) on silica gel) to give 110.3mg (93%) of colorless syrup as the title compound, which was converted to TFA salt as a white solid. Η NMR (400 MHz, CD3OD): δ 1.21 (m,5 H), 1.62 (m, 2 H), 1.70 (m, 1 H), 1.76 (m, 2 H), 1.79 (s, 6 H), 2.13 (m, 1 H), 3.27 (s, 3 H), 3.31 (s, 3 H), 4.46 (d, J=7.62 Hz, 2 H), 7.24 (m, 1 H), 7.47 (m, 1 H), 7.55 (m, 4 H), 7.67 (m, 1 H), 7.76 (m, 1 H) ; MS (ESI) (M+H)+ = 456.0; Anal. Calcd for C25H33N3θ3S+0.8TFA+0.6H2O: C, 57.29; H, 6.33; N, 7.54. Found: C, 57.34; H, 6.31; N, 7.33.
Example 45
N-[l-(cyclohexylmethyl)-2-(l-methoxy-l-methylethyl)-lH-benzimidazol-5-yl]-- benzenesulfonamide
Figure imgf000088_0002
Following the same procedure in Example 44, using sodium hydride (25.0 mg, 0.63 mmol), N-[l-(cyclohexylmethyl)-2-(l-hydroxy-l-methylethyl)-lH-benzimidazol-5- yl]-benzenesulfonamide (89.3 mg, 0.21 mmol) (for preparation, see Example 43) and methyl iodide (27.4 mg, 0.19 mmol) in THF (10 mL). The desired title compound was purified by MPLC (Hex/EtOAc (1 :1) on silica gel) to give 34.8 mg (38%) of colorless syrup, which was converted to TFA salt as a white solid. Η NMR (400 MHz, CD3OD): δ 1.18 (m, 5 H), 1.59 (m, 2 H), 1.68 (m, 1 H), 1.74 (m, 2 H), 1.78 (s, 6 H), 2.09 (m, 1 H), 3.30 (s, 3 H), 4.42 (d, J=7.42 Hz, 2 H), 7.23 (dd, J=9.08, 2.05 Hz, 1 H), 7.47 (m, 2 H), 7.55 (m, 1 H), 7.58 (d, J=2.15 Hz, 1 H), 7.72 (d, J=9.18 Hz, 1 H), 7.80 (m, 2 H) ; MS (ESI) (M+H)+ = 442.0; Anal. Calcd for
C24H3,N3O3S+0.9TFA+0.5H2O: C, 56.01; H, 5.99; N, 7.60. Found: C, 55.97; H, 6.00; N, 7.47.
Example 46
N-[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazoI-5-yl]-N,l-dimethyl-lH- imidazole-4-sulfonamide
Figure imgf000089_0001
Following the same procedure of Step A in Example 4 using 2-te7-t-butyl- 1 -
(cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (40 mg, 0.134 mmol), 1- methyl-lΗ-imidazole-4-sulphonyI chloride (31 mg, 0.174 mmol) in 3 mL of DCM containing a catalytic amount of DMAP. The solvent was evaporated and the product was purified by reversed-phase HPLC using 20-80% CH3CΝ/H20 and lyophilized affording the title compound as the coiTesponding TFA salt. Yield: 62 mg (82%). Η NMR (400 MHz, METHANOL-D4): δ 1.22 (m, 5 H), 1.62 (s, 2 H), 1.64 (s, 9 H), 1.67 (s, 1 H), 1.75 (m, 2 H), 2.08 (m, 1 H), 3.30 (s, 3 H), 3.73 (s, 3 H), 4.43 (d, J=7.62 Hz, 2 H), 7.44 (dd, J=8.98, 2.15 Hz, 1 H), 7.60 (d, ,T=1.37 Hz, 1 H), 7.65 (d, J=1.56 Hz, 1 H), 7.74 (d, J=0.9S Hz, 1 H), 7.82 (d, J=8.59 Hz, 1 H); MS (ESI) (M+H)+ 444.0; Anal. Calcd for 3H33N5O2S + 2.0 TFA + 0.1 H20: C, 48.15; H, 5.27; N, 10.40. Found: C, 48.06; H, 5.21 ; N, 10.55. Example 47
N-(5-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}-4-methyl-l,3-thiazol-2-yI)acetamide
Figure imgf000090_0001
Following the same procedure of Step A in Example 4 using 2-te7-t-butyl-l-
(cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (40 mg, 0.134 mmol), 2- acetamido-4-methyl-5-thiazolesulfonyl chloride (44 mg, 0.174 mmol) in 3 mL of DCM containing a catalytic amount of DMAP. The solvent was evaporated and the product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 51 mg (60%). Η NMR (400 MHz, METHANOL-D4): δ 1.21 (m, 6 H), 1.59 (m, 2 H), 1.65 (m, 11 H), 2.08 (m, 4 H), 2.16 (s, 3 H), 3.32 (s, 3 H), 4.44 (d, J=7.81 Hz, 2 H), 7.41 (dd, J=9.08, 2.05 Hz, 1 H), 7.66 (d, J=1.76 Hz, 1 H), 7.86 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 518.0; Anal. Calcd for C25H35N5θ3S2 + 1.6 TFA + 0.4 H20: C, 47.88; H, 5.33; N, 9.90. Found: C, 47.88; H, 5.28; N, 10.02.
Example 48
N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methylpyridine-3- sulfonamide
Figure imgf000090_0002
Following the same procedure of Step A in Example 4 using 2-tert-butyl-l- (cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (65 mg, 0.217 mmol), 3- pyridinesulfonyl chloride hydrochloride (70 mg, 0.325 mmol) in 3 mL of DCM containing a catalytic amount of DMAP. The solvent was evaporated and the product was purified by reversed-phase HPLC using 20-80% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 81 mg (67%). Η NMR (400 MHz, METHANOL-D4): δ 1.23 (m, 5 H), 1.62 (m, 2 H), 1.66 (s, 9 H), 1.69 (m, 1 H), 1.76 (m, 2 H), 2.09 (m, 1 H), 3.31 (s, 3 H), 4.45 (d, J=7.62 Hz, 2 H), 7.32 (dd, J=8.98, 2.15 Hz, 1 H), 7.58 (d, J=1.56 Hz, 1 H), 7.61 (dd, J=8.01, 4.88 Hz, 1 H), 7.87 (d, J=8.98 Hz, 1 H), 8.02 (dt, J=8.15, 1.88 Hz, 1 H), 8.59 (s, 1 H), 8.81 (s, 1 H); MS (ESI) (M+H)+441.0; Anal. Calcd for C24H32N402S + 2.0 TFA + 0.5 H20: C, 49.63; H, 5.21; N, 8.27. Found: C, 49.69; H, 5.20; N, 8.29.
Example 49
N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N,l,2-trimethyl-lH- imidazole-5-sulfonamide
Figure imgf000091_0001
Following the same procedure of Step A in Example 4 using 2-te7-t-butyl-l-
(cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (40 mg, 0.134 mmol), 1,2- dimethylimidazole-5-sulphonyI chloride (39 mg, 0.201 mmol) in 3 mL of DCM containing a catalytic amount of DMAP. The solvent was evaporated and the product was purified by reversed-phase ΗPLC using 20-80% CΗ3CΝ/Η2O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 65 mg (85%). Η NMR (400 MHz, METHANOL-D4): δ 1.25 ( , 5 H), 1.64 (m, 2 H), 1.69 (s, 10 H), 1.78 ( , 2 H), 2.11 (m, 1 H), 2.59 (s, 3 H), 3.40 (s, 3 H), 3.49 (s, 3 H), 4.48 (d, J=7.62 Hz, 2 H), 7.53 (dd, J=8.98, 1.95 Hz, 1 H), 7.78 (d, J=1.95 Hz, 1 H), 7.92 (s, 1 H), 7.95 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 458.3; Anal. Calcd for C24H35N50 S + 3.0 TFA + 0.9 H20: C, 44.16; H, 4.92; N, 8.58. Found: C, 44.24; H, 5.00; N, 8.43. Example 50
N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazoI-5-yl]-
N,l,2-trimethyl-lH-imidazole-5-sulfonamide
Figure imgf000092_0001
Step A: N-[2-te7-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]-N,l,2-trimethyl-lH-imidazole-5-sulfonamide
Figure imgf000092_0002
2-tert-Butyl-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine (see following Steps B, C, D and E for preparation) (42 mg, 0.139 mmol) and 1,2- dimethylimidazole-5-sulphonyl chloride (33 mg, 0.167 mmol) were stirred in 3 mL of DCM containing a catalytic amount of DMAP overnight at rt. The solvent was evaporated and the product was purified by reversed-phase HPLC using 10-70% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 64 mg (80%). Η NMR (400 MHz, METHANOL-D4): δ 1.50 - 1.56 (m, 2 H), 1.57 - 1.64 (m, 2 H), 1.68 (s, 9 H), 2.32 - 2.41 (m, 1 H), 2.58 (s, 3 H), 3.33 (dt, J= 1 1.42, 2.34 Hz, 2 H), 3.38 (s, 3 H), 3.49 (s, 3 H), 3.90 - 3.93 (m, 1 H), 3.95 (d, J=2.54 Hz, 1 H), 4.54 (d, J=7.62 Hz, 2 H), 7.52 (dd, J=8.98, 2.15 Hz, 1 H), 7.76 (d, J=1.56 Hz, 1 H), 7.89 (s, 1 H), 7.96 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 460.0; Anal. Calcd for C23H33N503S + 2.1 TFA + 2.3 H20: C, 44.12; H, 5.40; N, 9.72. Found: C, 43.89; H, 5.02; N, 10.12.
Step B: Methyl {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}carbamate
Figure imgf000093_0001
Methyl (4-fluoro-3-nitrophenyl)carbamate (2.0g, 9.32 mmol) and 4-aminomethyl tetrahydropyran (1.28g, 1 1.2 mmol) were stirred in 50 mL of EtOH containing TEA (2.0 mL, 14.0 mmol) at 75°C for 48h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous 5% KHSO4, saturated aqueous
NaHCOs solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using 1:1 / hexanes : EtOAc as eluent. Yield: 2.53g (88%). Η NMR (400 MHz, CHLOROFORM-D): δ 1.42 (ddd, J=25.24, 12.06, 4.49 Hz, 2 H), 1.73 (d, J= 1.76 Hz, 1 H), 1.76 (d, J= 1.95 Hz, 1 H), 1.88 - 2.01 (m, 1 H), 3.22 (dd, J=6.74, 5.57 Hz, 2 H), 3.42 (td, J=l 1.86, 2.05 Hz, 2 H), 3.78 (s, 3 H), 4.01 (d, J=4.30 Hz, 1 H), 4.04 (d, J=3.51 Hz, 1 H), 6.48 (br.s, 1 H), 6.85 (d, J=9.37 Hz, 1 H), 7.65 (br.s, 1 H), 8.03 - 8.09 (m, 2 H).
Step C: Methyl {3-amino-4-[(tetrahydro-2H-pyran-4- ylmethyI)amino]phenyl}carbamate
Figure imgf000093_0002
Methyl { 3 -nitro-4- [(tetrahydro-2H-pyran-4-y lmethy l)am ino]pheny 1 } carbamate (2.53 g, 8.18 mmol) was dissolved in 50 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under H2 atmosphere (40 psi) using a Parr hydrogenation apparatus overnight at rt. The solution was filtered through celite and the solvent was evaporated. Yield: 2.29 g (99%). Η NMR (400 MHz, CHLOROFORM-D): δ 1.40 (ddd, J=25.09, 12.01, 4.49 Hz, 2 H), 1.70 - 1.74 (m, 1 H), 1.74 - 1.77 (m, 1 H), 1.81 - 1.92 (m, 1 H), 2.99 (d, J=6.64 Hz, 2 H), 3.34 (br.s, 2 H), 3.41 (dt, J=11.81, 2.15 Hz, 2 H), 3.74 (s, 3 H), 3.99 (d, J=3.51 Hz, 1 H), 4.02 (d, J=3.51 Hz, 1 H), 6.38 (br.s, 1 H), 6.55 - 6.60 (m, 1 H), 6.62 - 6.68 (m, 1 H), 6.95 (br.s, 1 H).
Step D: Methyl [2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazoI-5-yl]carbamate
Figure imgf000094_0001
Methyl {3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}carbamate (2.29 g, 8.20 mmol) and DMAP (0.20 g, 1.64 mmol) were dissolved in 75 mL of DCM. Trimethylacetyl chloride (1.10 mL, 9.02 mmol) was added dropwise and the solution was stirred at rt for 2h. The solution was washed with aqueous NaΗCθ3 solution, brine and dried over anhydrous MgS04. The residue was dissolved in 25 mL of AcOH and was heated at 125°C for lh using a Personal Chemistry microwaves apparatus. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHC03 solution, brine and dried over anhydrous MgSθ4. The crude product was purified by silica gel flash chromatography using 4:3 / hexanes : acetone as eluent. Yield: 1.81 g (64%). Η NMR (400 MHz, CHLOROFORM-D): δ 1.48 - 1.54 (m, 4 H) 1.56 (s, 9 H) 2.23 - 2.35 (m, 1 H) 3.27 - 3.35 (m, 2 H) 3.78 (s, 3 H) 3.96 (t, J=2.93 Hz, 1 H) 3.99 (t, J=3.03 Hz, 1 H) 4.18 (d, J=7.42 Hz, 2 H) 6.63 (br.s, 1 H) 7.24 - 7.28 (m, 1 H) 7.41 (br.s, 1 H) 7.61 (d, J=1.95 Hz, 1 H).
Step E: 2-tert-Butyl-N-methyI-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-amine
Figure imgf000094_0002
Methyl [2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yljcarbamate (1.80 g, 5.21 mmol) was dissolved in 75 mL of THF at 0°C. IM HCI/ether (7.3 mL, 7.29 mmol) was added dropwise and the solution was stirred at 0°C for 15 min. LiAlHU (988 mg, 26.1 mmol) was added slowly and the solution was stirred at rt overnight. The reaction was quenched at 0°C by the addition of MeOH (5 mL) followed by water (10 mL) and the solution was left to stir at rt for 30 min. Anhydrous Na2S04 (10 g) was added and the solution was stirred at rt for another 30 min. The solution was filtered and the solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHCθ3 solution, brine and dried over anhydrous MgS04. The solvent was evaporated. Yield: 1.54 g (98%). Η NMR (400 MHz, CHLOROFORM-D): δ 1.49 - 1.53 (m, 4 H), 1.53 - 1.57 (m, 9 H), 2.22 - 2.32 (m, 1 H), 2.87 (s, 3 H), 3.26 - 3.35 (m, 2 H), 3.95 (t, J=3.03 Hz, 1 H), 3.97 - 4.00 (m, 1 H), 4.13 (d, J=7.42 Hz, 2 H), 6.61 (dd, J=8.59, 2.15 Hz, 1 H), 6.99 (d, J=1.95 Hz, 1 H), 7.11 (d, J=8.59 Hz, 1 H).
Example 51
Ethyl 4-{[[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5- yI](methyl)amino]sulfonyl}-3,5-dimethyl-lH-pyrrole-2-carboxylate
Figure imgf000095_0001
Following the same procedure as in Step A of Example 4 using 2-tert-butyl-N-methyl- l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazol-5-amine (42 mg, 0.139 mmol), ethyl 4-(chlorosulfonyl)-3,5-dimethyl-lH-pyrrole-2-carboxylate (44 mg, 0.167 mmol) in 3 mL of DCM containing a catalytic amount of DMAP. The product was purified by reversed-phase HPLC using 10-70% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 61 mg (68%). Η NMR (400 MHz, METHANOL-D4): δ 1.33 (t, J=7.13 Hz, 3 H), 1.45 - 1.53 (m, 2 H), 1.53 - 1.65 (m, 2 H), 1.68 (s, 9 H), 2.04 (s, 3 H), 2.16 (s, 3 H), 2.32 - 2.41 (m, 1 H), 3.24 (s, 3 H), 3.35 (td, J=l 1.77, 2.05 Hz, 2 H), 3.93 (d, J=3.51 Hz, 1 H), 3.96 (d, J=3.51 Hz, 1 H), 4.28 (q, J=7.09 Hz, 2 H), 4.54 (d, J=7.62 Hz, 2 H), 7.42 (dd, J=9.08, 2.05 Hz, 1 H), 7.65 (d, J 1.56 Hz, 1 H), 7.91 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 531.2; Anal. Calcd for C27H38N405S + 1.4 TFA + 0.6 H20: C, 51.05; H, 5.84; N, 7.99. Found: C, 51.07; H, 5.91; N, 7.88.
Example 52
N-[2-te;Y-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-4-
(hydroxymethyl)-N-methylbenzenesulfonamide
Figure imgf000096_0001
2-tert-Butyl-Ν-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine
(35 mg, 0.1 16 mmol) and 4-formylbenzenesulfonyl chloride (29 mg, 0.139 mmol) were stirred in 3 mL of DCM containing a catalytic amount of DMAP at rt for 2h.
The solution was washed with aqueous NaHCθ3 solution, brine and dried over anhydrous MgS04. The solvent was evaporated. The residue was dissolved in MeOH (5 mL) and NaCNBH3 (20 mg, 0.298 mmol) was added. The solution was stirred overnight at rt. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHCθ3 solution, brine and dried over anhydrous MgS04. The solvent was evaporated. The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Yield: 55 mg (78%). Η NMR (400 MHz, METHANOL-D4) (TFA salt): δ 1.50 - 1.56 (m, 2 H), 1.57 - 1.65 (m, 2 H), 1.68 (s, 9 H), 2.31 - 2.41 (m, 1 H), 3.26 (s, 3 H), 3.35 (td, J=l 1.57, 2.64 Hz, 2 H), 3.93 (d, J=3.32 Hz, 1 H), 3.96 (d, J=3.71 Hz, 1 H), 4.52 (d, J=7.42 Hz, 2 H), 4.68 (s, 2 H), 7.30 (dd, J=8.98, 2.15 Hz, 1 H), 7.50 (s, 4 H), 7.54 (d, J=1.56 Hz, 1 H), 7.87 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 472.0; Anal. Calcd for C25H33N3θ4S + 1.5 TFA + 0.3 H20: C, 51.89; H, 5.46; N, 6.48. Found: C, 51.94; H, 5.48; N, 6.31. Example 53
N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5-yl]-N- methyl-4-(lH-l,2,3-triazol-l-ylmethyI)benzenesulfonamide
Figure imgf000097_0001
N-[2-te7't-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-4- (hydroxymethyl)-N-methylbenzenesulfonamide (55mg, 0.117 mmol) and TEA (0.025 mL, 0.176 mmol) were dissolved in 5 mL of DCM at 0°C. Methanesulfonyl chloride (0.011 mL, 0.140 mmol) was added dropwise and the solution was stirred at rt for 3h. The solution was washed with aqueous ΝaΗCθ3 solution, brine and dried over anhydrous MgS04. The solvent was evaporated. The residue was dissolved in 2 mL of DMF and KI (19 mg, 0.117 mmol) followed by lH-l,2,3-triazole (0.135 mL, 2.34 mmol) were added. The solution was stirred at 80°C for lh. The solvent was evaporated. The product was purified by reversed-phase HPLC using 10-70% CH3CN/H2O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 35 mg (47%). Η NMR (400 MHz, METHANOL-D4): 0 1.50 - 1.56 (m, 2 H), 1.56 - 1.65 (m, 2 H), 1.68 (s, 9 H), 2.32 - 2.40 (m, 1 H), 3.26 (s, 3 H), 3.35 (td, J=l 1.57, 2.64 Hz, 2 H), 3.93 (d, J=3.32 Hz, 1 H), 3.96 (d, J=3.51 Hz, 1 H), 4.52 (d, J=7.42 Hz, 2 H), 5.74 (s, 2 H), 7.31 (dd, J=8.98, 1.95 Hz, 1 H), 7.41 (d, J=8.59 Hz, 2 H), 7.54 (s, 1 H), 7.55 - 7.57 (m, 2 H), 7.79 (s, 1 H), 7.88 (d, J=8.98 Hz, 1 H), 8.09 (s, 1 H); MS (ESI) (M+H)+ 523.0; Anal. Calcd for C27H34Nb03S + 2.4 TFA: C, 47.96; H, 4.61; N, 10.55. Found: C, 48.02; H, 4.72; N, 10.22.
Example 54 N-[2-tert-ButyI-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5-yl]-4- {[(2-hydroxyethyI)amino]methyl}-N-methyIbenzenesuIfonamide
Figure imgf000098_0001
2-tert-Butyl-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine (58 mg, 0.192 mmol) and 4-formylbenzenesulfonyl chloride (47 mg, 0.230 mmol) were stirred in 5 mL of DCM containing a catalytic amount of DMAP at rt for 3h. The solution was washed with aqueous NaHC03 solution, brine and dried over anhydrous MgSθ4. The solvent was evaporated. The residue was dissolved in MeOH (5 mL) containing a few drops of AcOH and 3 A molecular sieves. Ethanolamine (0.057 mL, 0.960 mmol) was added and the solution was stirred at rt for 30 min. NaCNBH3 (36 mg, 0.576 mmol) was added and the solution was stirred at rt for 3h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHC03 solution, brine and dried over anhydrous MgS04. The product was purified by reversed-phase HPLC using 10-60% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 48 mg (40%). Η NMR (400 MHz, METHANOL-D4): δ 1.49 - 1.55 (m, 2 H), 1.55 - 1.61 (m, 2 H), 1.67 (s, 9 H), 2.32 - 2.39 (m, 1 H), 3.15 - 3.18 (m, 2 H), 3.27 (s, 3 H), 3.34 (dt, J=l 1.47, 2.64 Hz, 2 H), 3.81 (dd, J=5.96, 4.39 Hz, 2 H), 3.92 (d, J=3.12 Hz, 1 H), 3.95 (d, J=3.71 Hz, 1 H), 4.33 (s, 2 H), 4.51 (d, J=7.62 Hz, 2 H), 7.28 (dd, J=9.08, 2.05 Hz, 1 H), 7.56 (d, J=1.95 Hz, 1 H), 7.61 - 7.68 (m, 4 H), 7.85 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 515.2; Anal. Calcd for C27H38N40 S + 2.7 TFA + 0.9 H20: C, 46.40; H, 5.11; N, 6.68. Found: C, 46.41 ; H, 5.05; N, 6.75.
Example 55
N-[2-tert-Butyl-l-(cyclopentylmethyl)-lH-benzimidazol-5-yI]-N- methylbenzenesulfonamide
Figure imgf000099_0001
Step A: N-[2-tert-Butyl-l-(cycIopentyImethyI)-lH-benzimidazol-5-yI]-N- methylbenzenesulfonamide
Figure imgf000099_0002
N-{3-Amino-4-[(cyclopentylmethyl)amino]phenyl}-N-methylbenzenesulfonamide (see following Steps B and C for preparation) (50 mg, 0.139 mmol) and trimethylacetyl chloride (0.019 mL, 0.153 mmol) were stirred in 2 mL of DCM containing a catalytic amount of DMAP at rt for lh. The solvent was evaporated. The product was dissolved in 2 mL of AcOH and was stirred at 150°C for 40 min using a Personal Chemistry microwaves instrument. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous ΝaHCθ3 solution, brine and dried over anhydrous MgS0 . The product was purified by reversed-phase HPLC using 20-80% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 26 mg (35%). Η NMR (400 MHz, METHANOL- D4): δ 1.47 (m,-2 H), 1.62 (m, 2 H), 1.68 (s, 9 H), 1.78 (m, 4 H), 2.51 (m, 1 H), 3.28 (s, 3 H), 4.61 (d, J=7.42 Hz, 2 H), 7.30 (dd, J=9.08, 2.05 Hz, 1 H), 7.54 (m, 5 H), 7.68 (m, 1 H), 7.87 (d, J=9.18 Hz, 1 H); MS (ESI) (M+H)+ 426.2; Anal. Calcd for C24H3,N302S + 1.5 TFA + 0.9 H20: C, 52.92; H, 5.64; N, 6.96. Found: C, 52.80; H, 5.51 ; N, 7.35.
Step B: N-{4-[(CyclopentyImethyl)amino]-3-nitrophenyl}-N- methylbenzenesulfonamide
Figure imgf000100_0001
N-(4-Fluoro-3-nitrophenyl)-N-methylbenzenesulfonamide (for preparation see Example 3, Steps B and C) (50 mg, 0.161 mmol) and cyclopentylmethylamine (0.062 L of a lg / 3 mL solution, 0.209 mmol) were stirred in 2 mL of EtOH containing TEA (0.025 mL, 0.241 mmol) at 75°C for 5h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% aqueous KHS04 solution, aqueous ΝaHCθ3 solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using 3:1 / hexanes:EtOAc as eluent. Yield: 57 mg (91%). Η NMR (400 MHz, CHLOROFORM-D): δ 1.31 (m, 3 H), 1.66 (m, 4 H), 1.91 (m, 2 H), 2.28 (m, 1 H), 3.13 (s, 3 H), 3.24 (dd, J=7.23, 5.08 Hz, 2 H), 6.84 (d, J=9.37 Hz, 1 H), 7.45 (dd, J=9.28, 2.64 Hz, 1 H), 7.50 (m, 2 H), 7.60 (m, 3 H), 8.17 (m, 1 H).
Step C: N-{3-Amino-4-[(cyclopentylmethyl)amino]phenyl}-N- methylbenzenesulfonamide
Figure imgf000100_0002
N-{4-[(Cyclopentylmethyl)amino]-3-nitrophenyl}-N-methylbenzenesulfonamide (55 mg, 0.141 mmol) was dissolved in 15 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under H2 atmosphere (40 psi) at rt for 3h. The solution was filtered through celite and the solvent was evaporated. Yield: 51 mg (99%). MS (ESI) (M+H)+ 360.26.
Example 56
N-[2-tert-Butyl-l-(cyclobutylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
Figure imgf000101_0001
Step A: N-[2-tert-Butyl-l-(cyclobutylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
Figure imgf000101_0002
Following the same procedure used as in Step A in Example 3 using N-{3-amino-4- [(cyclobutylmethyl)aminojphenyl} -N-methylbenzenesulfonamide (for preparation see following Steps B and C) (53 mg, 0.153 mmol) and trimethylacetyl chloride (0.021 mL, 0.168 mmol) in 2 mL of DCM containing a catalytic amount of DMAP. The product was purified by reversed-phase HPLC using 20-80% CHsCΝ/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 43 mg (53%). Η NMR (400 MHz, METHANOL-D4): δ 1.66 (s, 9 H), 1.92 (m, 2 H), 2.10 (m, 4 H), 2.87 (m, 1 H), 3.27 (s, 3 H), 4.65 (d, J=6.44 Hz, 2 H), 7.30 (dd, J=8.98, 1.95 Hz, 1 H), 7.53 (m, 5 H), 7.68 (m, 1 H), 7.81 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 412.3; Anal. Calcd for C23H29N302S + 1.4 TFA + 0.8 H20: C, 52.92; H, 5.51; N, 7.18. Found: C, 52.91; H, 5.46; N, 7.1 1.
Step B: N-{4-[(Cyclobutylmethyl)amino]-3-nitrophenyl}-N- methylbenzenesulfonamide
Figure imgf000101_0003
Following the same procedure used as in Example 3, Step D using N-(4-fluoro-3- nitrophenyl)-N-methylbenzenesulfonamide (for preparation see Example 3, Steps B and C) (50 mg, 0.161 mmol), cyclobutylmethylamine (0.040 mL of a 5.3M solution/MeOH, 0.209 mmol) in 2 mL of EtOH containing TEA (0.025 mL, 0.242 mmol). The crude product was purified by silica gel flash chromatography using 3:1 / hexanes:EtOAc as eluent. Yield: 61 g (99%). Η NMR (400 MHz, CHLOROFORM-D): 5 1.56 (s, 2 H), 1.81 (m, 2 H), 1.95 (m, 1 H), 2.19 ( , 2 H), 3.13 (s, 3 H), 3.33 (dd, J=7.23, 5.08 Hz, 2 H), 6.83 (d, J=9.18 Hz, 1 H), 7.45 (dd, J=9.18, 2.54 Hz, 1 H), 7.51 (m, 2 H), 7.61 (m, 3 H), 8.04 (m, 1 H).
Step C: N-{3-Amino-4-[(cyclobutylmethyl)amino]phenyl}-N- methylbenzenesulfonamide
Figure imgf000102_0001
Following the same procedure used as in Example 3 Step E using N-{4- [(cyclobutylmethyl)amino]-3-nitrophenyl}-N-methylbenzenesulfonamide (58 mg, 0.154 mmol) in 15 mL of EtOAC containing a catalytic amount of 10% Pd/C. Yield: 53 mg (99%). MS (ESI) (M+H)+ 346.20.
Example 57
N-[2-te/t-Butyl-l-(2-cycIohexylethyl)-liT-benzimidazol-5-yl]-N- methylbenzenesulfonamide
Figure imgf000102_0002
Step A: N-[2-te/T-Butyl-l-(2-cycIohexylethyl)-lH-benzimidazol-5-yI]-N- methylbenzenesulfonamide
Figure imgf000103_0001
Following the same procedure used as in Step A of Example 3 using N-{3-amino-4- [(2-cyclohexylethyl)amino]phenyl} -N-methylbenzenesulfonamide (for preparation see following Steps B and C) (56 mg, 0.145 mmol) and trimethylacetyl chloride (0.020 mL, 0.160 mmol) in 2 mL of DCM containing a catalytic amount of DMAP. The product was purified by reversed-phase HPLC using 20-80% CH3CΝ/Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 37 mg (45%). Η NMR (400 MHz, METHANOL-D4): 5 1.11 (ddd, J=23.92, 12.11, 2.83 Hz, 2 H), 1.34 (m, 3 H), 1.60 (m, 1 H), 1.66 (s, 9 H), 1.72 (m, 1 H), 1.77 (m, 1 H), 1.81 (m, 2 H), 1.85 (m, 2 H), 1.90 (m, 1 H), 3.27 (s, 3 H), 4.60 (m, 2 H), 7.33 (dd, J=8.98, 1.95 Hz, 1 H), 7.54 (m, 5 H), 7.68 (m, 1 H), 7.74 (d, J=8.9S Hz, 1 H); MS (ESI) (M+H)+ 454.2; Anal. Calcd for C26H35N302S + 1.4 TFA: C, 56.40; H, 5.98; N, 6.85. Found: C, 56.48; H, 5.98; N, 6.99.
Step B: N-{4-[(2-CyclohexylethyI)amino]-3-nitrophenyl}-N- methylbenzenesulfona ide
Figure imgf000103_0002
Following the same procedure used as in Example 3 Step D using N-(4-fluoro-3- nitrophenyl)-N-methylbenzenesulfonamide (for preparation see Example 3, Steps B and C) (50 mg, 0.161 mmol), (2-cyclohexylethyl)amine hydrochloride (32 mg, 0.193 mmol) in 2 mL of EtOH containing TEA (0.060 mL, 0.402 mmol). The crude product was purified by silica gel flash chromatography using 4:1 / hexanes:EtOAc as eluent. Yield: 65 mg (97%). Η NMR (400 MHz, CHLOROFORM-D): δ 0.99 (m, 2 H), 1.25 (m, 4 H), 1.43 ( , 1 H), 1.64 (m, 3 H), 1.72 (m, 1 H), 1.75 (m, 2 H), 1.78 (m, 1 H), 3.13 (s, 3 H), 3.33 (m, 2 H), 6.83 (d, J=9.37 Hz, 1 H), 7.46 (m, 1 H), 7.51 ( , 2 H), 7.58 (m, 2 H), 7.61 (m, 1 H), 8.08 (m, 1 H).
Step C: N-{3-Amino-4-[(2-cycIohexylethyl)amino]phenyl}-N- methylbenzenesulfonamide
Figure imgf000104_0001
Following the same procedure used as in Example 3 Step E using N-{4-[(2- cyclohexylethyl)amino]-3-nitrophenyl}-N-methylbenzenesulfonamide (60 mg, 0.144 mmol) in 15 mL of EtOAc containing a catalytic amount of 10% Pd/C. Yield: 56 mg (99%). MS (ESI) (M+H)+ 388.26.
Example 58 N-[l-(l-Benzylpyrrolidin-3-yI)-2-te/t-butyI-lH-benzimidazoI-5-yl]-N- methylbenzenesulfonamide
Figure imgf000104_0002
Step A: N-[l-(l-Benzylpyrrolidin-3-yl)-2-tert-butyl-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
Figure imgf000105_0001
Following the same procedure used as in Step A in Example 3 using N-{3-amino-4- [(l-benzylpyrrolidin-3-yl)amino]phenyl}-N-methylbenzenesulfonamide (for preparation see following Steps B and C) (75 mg, 0.172 mmol) and trimethylacetyl chloride (0.025 mL, 0.189 mmol) in 5 mL of DCM containing a catalytic amount of DMAP. The product was purified by reversed-phase HPLC using 10-60% CH3CΝ/Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 48 mg (45%). 'H NMR (400 MHz, METHANOL- D4): δ 1.59 (s, 9 H), 2.61 (m, 1 H), 2.72 (m, 1 H), 3.23 (m, 3 H), 3.44 (m, 1 H), 3.66 (m, 1 H), 3.75 (m, 1 H), 3.81 (m, 1 H), 4.44 (m, 2 H), 5.85 (m, 1 H), 7.23 (dd, J=8.89, 2.05 Hz, 1 H), 7.43 (m, 4 H), 7.51 (m, 6 H), 7.65 (m, 1 H), 7.94 (d, J=7.81 Hz, 1 H); MS (ESI) (M+H)+ 503.2; Anal. Calcd for C29H34N402S + 2.3 TFA + 0.3 H20: C, 52.39; H, 4.83; N, 7.27. Found: C, 52.44; H, 4.87; N, 7.28.
Step B: N-{4-[(l-Benzylpyrrolidin-3-yl)amino]-3-nitrophenyl}-N- methylbenzenesulfonamide
Figure imgf000105_0002
Following the same procedure used as in Example 3 Step D using N-(4-fluoro-3- nitrophenyl)-N-methylbenzenesulfonamide (for preparation see Example 3, Steps B and C) (70 mg, 0.226 mmol), l-benzylpyrrolidin-3-amine (50 mg, 0.271 mmol) in 3 mL of EtOH containing TEA (0.050 mL, 0.339 mmol). The crude product was purified by silica gel flash chromatography using 50 to 80% EtOAc in hexanes as eluent. Yield: 95 mg (90%). MS (ESI) (M+H)+ 466.99. Step C: N-{3-Amino-4-[(l-benzylpyrrolidin-3-yl)amino]phenyl}-N- methylbenzenesulfonamide
Figure imgf000106_0001
Following the same procedure used as in Example 3 Step E using N-{4-[(l- benzylpyrrolidin-3-yl)amino]-3-nitrophenyl}-N-methylbenzenesulfonamide (95 mg, 0.204 mmol) in 15 mL of EtOAc containing a catalytic amount of 10% Pd C. Yield: 76 mg (85%). MS (ESI) (M+H)+ 437.02.
Example 59
N-{2-tert-Butyl-l-[(4,4-difluorocyclohexyl)methyl]-li -benzimidazoI-5-yl}-N- methylbenzenesulfonamide
Figure imgf000106_0002
Step A: N-{2-tert-Butyl-l-[(4,4-difluorocyclohexyl)methyl]-lH-benzimidazol-5- yl}-N-methylbenzenesulfonamide
Figure imgf000106_0003
Following the same procedure used as in Step A of Example 3 using N-(3-amino-4- {[(4,4-difluorocyclohexyl)methyl]amino}phenyl)-N-methylbenzenesulfonamide (for preparation see following Steps B, C, D and E) (61 mg, 0.149 mmol) and trimethylacetyl chloride (0.020 mL, 0.160 mmol) in 5 mL of DCM containing a catalytic amount of DMAP. The product was purified by reversed-phase HPLC using 20-80% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 25 mg (28%). Η NMR (400 MHz, METHANOL- D4): δ 1.57 (s, 2 H), 1.67 (s, 9 H), 1.72 (s, 2 H), 1.76 (m, 1 H), 1.80 (m, 1 H), 2.07 (m, 2 H), 2.24 (m, 1 H), 3.27 (s, 3 H), 4.54 (d, J=7.62 Hz, 2 H), 7.31 (dd, J=8.98, 1.95 Hz, 1 H), 7.54 (m, 5 H), 7.68 (m, 1 H), 7.86 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+ 476.0; Anal. Calcd for C25H3]N302SF2 + 1.6 TFA: C, 51.47; H, 4.99; N, 6.39. Found: C, 51.46; H, 5.00; N, 6.53.
Step B: tert-Butyl [(4,4-difluorocyclohexyl)methyl]carbamate
Figure imgf000107_0001
4-N-Boc-aminomethyl cyclohexanone (1.00 g, 4.4 mmol) was dissolved in 30 mL of DCM at 0°C. DAST (1.45 mL, 11.0 mmol) was added dropwise and the solution was stirred at rt overnight. The solution was washed with aqueous 5% KHSO4 solution, saturated aqueous NaHCOs solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using 3:1 / hexanes : EtOAc as eluent. Yield: 508mg (46%). Η NMR (400 MHz, CHLOROFORM-D): δ 1.19 - 1.36 (m, 2 H), 1.44 (s, 9 H), 1.51 - 1.56 (m, 1 H), 1.59 - 1.75 (m, 2 H), 1.75 - 1.84 (m, 2 H), 2.01 - 2.16 (m, 2 H), 3.03 (t, J=6.54 Hz, 2 H), 4.62 (br.s, 1 H).
Step C: [(4,4-DifluorocycIohexyl)methyl] amine hydrochloride
Figure imgf000107_0002
te7-t-Butyl [(4,4-difluorocyclohexyl)methyl]carbamate (505 mg, 2.03 mmol) was stirred in 5 mL of IM HCl/AcOH at rt for 2h. The solvent was evaporated. The residue was washed with ether, filtered and dried. Yield: 330 mg (88%). Η NMR (400 MHz, METHANOL-D4): δ 1.28 - 1.40 (m, 2 H), 1.71 - 1.82 (m, 2 H), 1.84 (d, J=3.12 Hz, 2 H), 1.86 - 1.89 ( , 1 H), 2.03 - 2.15 (m, 2 H), 2.85 (d, J=7.03 Hz, 2 H).
Step D: N-(4-{[(4,4-Difluorocyclohexyl)methyl]amino}-3-nitrophenyl)-N- methylbenzenesulfonamide
Figure imgf000108_0001
Following the same procedure used as in Example 3 Step D using N-(4-fluoro-3- nitrophenyl)-N-methylbenzenesulfonamide (for preparation see Example 3, Steps B and C) (50 mg, 0.161 mmol), [(4,4-difluorocyclohexyl)methyl]amine hydrochloride (35 mg, 0.193 mmol) in 3 mL of EtOH containing TEA (0.056 mL, 0.403 mmol).
The crude product was purified by silica gel flash chromatography using 40% EtOAc in hexanes as eluent. Yield: 71 mg (99%). Η ΝMR (400 MHz, CHLOROFORM- D): δ 1.42 (m, 2 H), 1.71 (m, 1 H), 1.80 (m, 2 H), 1.92 (m, 1 H), 1.96 (m, 1 H), 1.96 (m, 1 H), 2.17 (m, 2 H), 3.13 (s, 3 H), 3.24 (dd, J=6.64, 5.66 Hz, 2 H), 6.82 (d, J=9.18 Hz, 1 H), 7.48 (m, 2 H), 7.51 (m ,2 H), 7.61 (m, 3 H), 8.20 (t, J=5.27 Hz, 1 H).
Step E: N-(3-Amino-4-{[(4,4-difluorocyclohexyl)methyl]amino}phenyI)-N- methylbenzenesulfonamide
Figure imgf000108_0002
Following the same procedure used as in Example 3 Step E using N-(4-{[(4,4- difluorocyclohexyl)methyl]amino)-3-nitrophenyl)-N-methylbenzenesulfonamide (65 mg, 0.148 mmol) in 20 mL of EtOAC containing a catalytic amount of 10% Pd/C.
Yield: 61mg (99%). MS (ESI) (M+H)+ 410.24. Example 60
N-[2-tert-Butyl-l-(pyridin-4-ylmethyl)-lH-benzimidazoI-5-yl]-N- methylbenzenesulfonamide
Figure imgf000109_0001
Step A: N-[2-te/-t-Butyl-l-(pyridin-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
Figure imgf000109_0002
Following the same procedure used as in Step A of Example 3 using N-{3-amino-4- [(pyridin-4-ylmethyl)amino]phenyl}-N-methylbenzenesulfonamide (for preparation see following Steps B and C) (63 mg, 0.171 mmol) and trimethylacetyl chloride
(0.025 mL, 0.188 mmol) in 5 mL of DCM containing a catalytic amount of DMAP. The product was purified by reversed-phase HPLC using 10-60% CH3CΝ/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 48 mg (51%). Η NMR (400 MHz, METHANOL-D4): δ 1.57 (s, 9 H), 3.22 (s, 3 H), 6.08 (s, 2 H), 7.13 (dd, J=8.88, 2.05 Hz, 1 H), 7.29 (d, J=8.40 Hz, 1 H), 7.38 (d, ,T=4.88 Hz, 2 H), 7.49 (m, 4 H), 7.53 (m, 1 H), 7.63 (m, 1 H), 8.62 (m, 2 H); MS (ESI) (M+H)+ 435.0; Anal. Calcd for C24H26N402S + 2.3 TFA + 0.1 H20: C, 49.17; H, 4.11; N, 8.02. Found: C, 49.15; H, 4.10; N, 8.08.
Step B: N-Methyl-N-{3-nitro-4-[(pyridin-4- yImethyl)amino]phenyl}benzenesuIfonamide
Figure imgf000110_0001
N-(4-Fluoro-3-nitrophenyl)-N-methylbenzenesulfonamide (for preparation see Example 3, Steps B and C) (105 mg, 0.338 mmol) and 4-(aminomethyl)pyridine (0.070 mL, 0.676 mmol) were stirred in 3 mL of CH3CΝ at rt for 24h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHC0 solution, brine and dried over anhydrous MgS0 . The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Yield: 102 mg (76%). Η NMR (400 MHz, CHLOROFORM-D): o 3.13 (s, 3 H), 4.61 (d, J=5.0S Hz, 2 H), 6.65 (dd, J=9.08, 1.07 Hz, 1 H), 7.25 - 7.29 (m, 2 H), 7.37 (dd, J=9.18, 2.73 Hz, 1 H), 7.47 - 7.53 ( , 2 H), 7.56 - 7.59 (m, 2 H), 7.60 - 7.65 (m, 1 H), 7.70 (d, J=2.54 Hz, 1 H), 8.50 - 8.54 (m, 1 H), 8.62 (d, J=5.47 Hz, 2 H).
Step C: N-{3-Amino-4-[(pyridin-4-ylmethyl)amino]phenyl}-N- methylbenzenesulfonamide
O
Figure imgf000110_0002
Following the same procedure used as in Example 3 Step E using N-methyl-N-{3- nitro-4-[(pyridin-4-ylmethyl)amino]phenyl) benzenesulfonamide (96 mg, 0.241 mmol) in 15 mL of EtOAC containing a catalytic amount of 10% Pd/C. Yield: 63 mg (71%). MS (ESI) (M+H)+ 368.94.
Example 61
N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]benzenesulfonamide
Figure imgf000111_0001
A solution of N-{3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-N- methylbenzenesulfonamide (61.2 mg, 0.163 mmol) (for preparation, see the following steps B and C in Example 41) in trifluoroacetic acid (3 mL) was heated for 20 h at reflux. Upon evaporation, the residue was purified by reversed-phase HPLC using 20- 70% CH3CΝ/H20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 38.3 mg (52%). 'HNMR (400 MHz, CD3OD): δ 1.40 - 1.50 (m, 4 H), 2.16 - 2.33 (m, 1 H), 3.25 (s, 3 H), 3.31 - 3.41 (m, 2 H), 3.86 - 4.00 (m, 2 H), 4.32 (d, J=7.62 Hz, 2 H), 7.32 (dd, J=8.88, 2.05 Hz, 1 H), 7.38 (d, J=l .76 Hz, 1 H), 7.48 - 7.58 (m, 4 H), 7.62 - 7.69 (m, 1 H), 7.72 (d, J=8.79 Hz, 1 H). MS (ESI) (M+H)+ = 454.0. Anal. Calcd for C2ιH22F3N3θ3S+ 0.20 TFA (476.29): C, 53.97; H, 4.70; N, 8.82; Found: C, 54.01 ; H, 4.73; N, 9.00.
Example 62 N-[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol- 5-yl]-N-methylbenzenesulfonamide
Figure imgf000111_0002
Diisopropylethylamine (56.9 mg, 0.44 mmol) was added into a solution of N-{3- amino-4-[(tetrahydro-2H-py ran-4-ylmethy l)amino]phenyl } -N- methylbenzenesulfonamide (75.3 mg, 0.20 mmol) (for preparation, see the steps B and C in Example 41) and 2,2-difluoropropionic acid (23.1 g, 0.21 mmol) in DMF (5 mL) at 0 °C. Stirring for 20 min, HATU (91.3 mg, 0.24 mmol) was added. The reaction mixture was stirred overnight at room temperature. After evaporation of the solvent, the residue was dissolved in acetic acid (10 mL) and heated for 12 h at 90 °C. Upon evaporation of the solvent, the residue was diluted with EtOAc (100 mL), washed with 2 NNaOH(10 mL), saturated NaCl (2x10 mL) and dried over anhydrous sodium sulphate. After filtration and concentration, the crude product was purified by MPLC using Hex/EtOAc (1 :1) on silica gel to give 71.4 mg (79%) of a white solid as the title compound. 'HNMR (400 MHz, CD3OD): δ 1.28 - 1.45 (m, 4 H), 2.08 - 2.15 (m, 1 H), 2.21 (t, J=19.53 Hz, 3 H), 3.13 - 3.19 (m, 2 H), 3.19 (s, 3 H), 3.80 (m, 2 H), 4.28 (d, J=7.42 Hz, 2 H), 7.13 (dd, J=8.79, 1.95 Hz, 1 H), 7.36 (d, J=1.95 Hz, 1 H), 7.47 - 7.52 (m, 2 H) ,7.53 - 7.63 (m, 2 H) ,7.67 - 7.73 (m, 1 H), 7.75 (d, J=8.79 Hz, 1 H). MS (ESI) (M+H)+ = 450.0. Anal. Calcd for C22H25F2N303S (449.52): C, 58.78; H, 5.61; N, 9.35; Found: C, 58.94; H, 5.51 ; N, 8.94.
Example 63
N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(2,2,2-trifluoroethyI)-lH- benzimidazoI-5-yl]benzenesulfonamide
Figure imgf000112_0001
Following the procedure for Example 42, using N- {3-Amino-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl)-N-methylbenzenesulfonamide (150.6 mg, 0.40 mmol) (for preparation, see the steps B and C in Example 41), diisopropylethylamine (1 13.8 mg, 0.88 mmol) and 3,3,3-trifluoropropionic acid (56.3 mg, 0.44 mmol) and ΗATU (182.6 mg, 0.48 mmol) in DMF (10 mL) and then in acetic acid (5 mL), the crude product was purified by MPLC using EtOAc on silica gel to give 46.4 mg (32%) of a light yellow solid as the title compound. 'ΗΝMR (400 MHz, CD3OD): δ 1.39 - 1.56 (m, 4 H), 2.12 - 2.30 (m, 1 H), 3.25 (s, 3 H), 3.32 - 3.38 (m, 2 H), 3.88 - 3.96 (m, 2 H), 4.22 (q, J=9.96 Hz, 2 H), 4.31 (d, J=7.62 Hz, 2 H), 7.22 (dd, J=8.89, 2.05 Hz, 1 H), 7.39 (d, J=1.56 Hz, 1 H), 7.49 - 7.59 (m, 4 H) ,7.63 - 7.68 (m, 1 H), 7.70 (d, J=8.98 Hz, 1 H). MS (ESI) (M+H)+ = 468.0. Anal. Calcd for C22H24F3Ν3θ3S+ 1.10 TFA+0.20 H20 +0.20 CH3OH (602.95): C, 48.61; H, 4.40; N, 6.97; Found: C, 48.59; H, 4.31; N, 6.85.
- Ill - Example 64
N-[l-(cyclohexylmethyI)-2-(l-ethylpropyl)-lH-benzimidazol-5- yl]benzenesulfonamide
Figure imgf000113_0001
Following the procedure for Step A in Example 7, using N-{3-amino-4- [(cyclohexylmethyl)amino]phenyl}benzene sulfonamide (184.0mg, 0.51 mmol), DMAP (15.0 mg, 0.12 mmol) and 2-ethylbutyryl chloride (74.0 mg, 0.55 mmol) in CH2C12 (15 mL) and then in acetic acid (15 mL), the crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel. Yield: 164.4 mg (73%). 'HΝMR (400 MHz, CD3OD): δ 0.92 (t, J=7.42 Hz, 6 H), 1.18 (m, 5 H), 1.57 (m, 2 H), 1.73 (m, 3 H), 1.83 (m, 2 H), 1.94 (m, 3 H), 3.33 (m, 1 H), 4.26 (d, J=7.62 Hz, 2 H), 7.25 (m, 1 H), 7.48 (m, 2 H) ,7.57 (m, 2 H), 7.73 (d, J=8.98 Hz, 1 H), 7.81 (m, 2 H). MS (ESI) (M+H)+ = 440.0. Anal. Calcd for C25H33Ν3O2S+1.10 TFA+0.10 H20 (566.85): C, 57.63; H, 6.10; N, 7.41; Found: C, 57.56; H, 6.11; N, 7.45.
Example 65
N-[l-(cyclohexylmethyl)-2-(l-ethylpropyl)-lH-benzimidazoI-5-yl]-N- methylbenzenesulfonamide
Figure imgf000113_0002
Following the procedure for Example 14, using N-[l-(cyclohexylmethyl)-2-(l- ethylpropyl)-lH-benzimidazol-5-yl]benzenesulfonamide (85.4 mg, 0.194 mmol) (for preparation, see Example 7), sodium hydride (23.3 mg, 60%, 0.583 mmol) and iodomethane (82.6 mg, 0.582 mmol) in THF(10 mL). Yield: 69.9 mg (79%); white solid for TFA salt. 'HNMR (400 MHz, CD3OD): δ 0.95 (t, J=7.42 Hz, 6 H), 1.21 (m, 5 H), 1.61 (m, 2 H), 1.71 (m, 1 H,) 1.76 (m, 2 H), 1.86 (m, 2 H), 1.99 (m, 3 H), 3.27 (s, 3 H), 3.38 (m, 1 H), 4.33 (d, J=7.81 Hz, 2 H), 7.29 (m, 1 H), 7.53 (m, 2 H), 7.57 (m, 3 H), 7.68 (m, 1 H), 7.83 (d, J=8.98 Hz, 1 H). MS (ESI) (M+H)+ = 454.2. Anal. Calcd for C26H35N3O2S+1.00 TFA+0.20 H20 (571.28): C, 58.87; H, 6.42; N, 7.36; Found: C, 58.85; H, 6.54; N, 7.24.
Example 66
N-[2-tert-butyl-l-(cycIohexylmethyl)-lH-benzimidazol-5-yI]-N- ethylbenzenesulfonamide
Figure imgf000114_0001
Following the procedure for Example 14, using N-[2-tert-butyl-l-(cyclohexylmethyl)- lH-benzimidazol-5-yl]benzene sulfonamide (52.0 mg, 0.122 mmol) (for preparation, see Example 7), sodium hydride (20.3 mg, 60%, 0.508 mmol) and iodoethane (57.2 mg, 0.367 mmol) in TΗF (8 mL). Yield: 43.8 mg (79%), white solid for TFA salt. 1HΝMR (400 MHz, CD3OD): δ 1.08 (t, J=7.13 Hz, 3 H), 1.25 (m, 5 H), 1.62 (m, 2 H), 1.67 (s, 9 H), 1.71 (m, 1 H,) 1.78 (m, 2 H), 2.10 (m, 1 H), 3.74 (q, J=7.03 Hz, 2 H), 4.45 (d, J=7.62 Hz, 2 H), 7.22 (dd, J=8.98, 1.95 Hz, 1 H), 7.49 (d, J=1.56 Hz, 1 H), 7.54 (m, 2 H), 7.60 (m, 2 H), 7.66 (m, 1 H), 7.85 (d, J=8.98 Hz, 1 H). MS (ESI) (M+H)+ = 454.0. Anal. Calcd for
Figure imgf000114_0002
.lO TFA+0.20 H20 (582.68): C, 58.13; H, 6.31; N, 7.21; Found: C, 58.15; H, 6.41; N, 6.99.
Example 67
N-methyI-N-[2-(l-methyI-l-pyridin-2-yIethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000115_0001
Step A. N-methyl-N-[2-(l-methyl-l-pyridin-2-ylethyl)-l-(tetrahydro-2H-pyran- 4-ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000115_0002
N-methyl-2-(l -methyl- l-pyridin-2-ylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-amine hydrochloride (85.0 mg, 0.13 mmol) (for preparation, see the following steps B, C, D, E, F, and G), DMAP (64.0 mg, 0.53 mmol) and benzenesulfonyl chloride (46.0 mg, 0.26 mmol) in MeCΝ (5 mL) were stirred for 8 h at room temperature. The reaction mixture was quenched with Η 0 (3 mL). Upon evaporation, the residue was purified by reversed-phase HPLC using 15-75%
CH3CΝ/H20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 55.0 mg (68%). 'HNMR (400 MHz, CD3OD): δ 1.02 - 1.22 (m, 5 H), 2.01 (s, 6 H), 2.96 - 3.10 (m, 2 H), 3.28 (s, 3 H), 3.70 - 3.81 (m, 2 H), 3.93 (d, J=6.83 Hz, 2 H), 7.25 (dd, J=8.98, 2.15 Hz, 1 H), 7.39 - 7.47 (m, 1 H), 7.50 - 7.60 (m, 5 H), 7.64 - 7.76 (m, 4 H), 7.91 - 7.99 (m, 1 H). MS (ESI) (M+H)+ = 505.0. Anal. Calcd for C28H32N4O3S+ 1.0 TFA+0.2 H2O+0.4 CH3OH (635.10): C, 57.49; H, 5.55; N, 8.82; Found: C, 57.52; H, 5.46; N, 8.72.
Step B. N-(4-fluoro-3-nitrophenyl)-N-methylacetamide
Sodium hydride (2t.40g, 60%, 60 mmo —l) was added in p Vortionst to ax solurtion of N-(4- fluoro-3-nitrophenyl)acetamide(7.93 g, 40 mmol) in THF (120 mL) at 0 °C. Stirring for 20 min, iodomethane (17.0 g, 120 mmol) was added. The reaction mixture was stirred at room temperature for 2 h, quenched with saturaed NaHCθ3 (30 mL) and extracted with EtOAc (3x100 mL). The combined organic phases were washed with saturated NaCl (2x30 mL). After filtration and concentration, 8.73 g (100%) of the title compound was obtained as a brown solid. Η NMR (400 MHz, CDC13): δ 1.92 (s, 3 H), 3.30 (s, 3 H), 7.38 (s, 1 H), 7.52 (s, 1 H), 7.95 (s, 1 H).
Step C. N-methyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}acetamide
Figure imgf000116_0001
4-Aminomethylpyran (2.50 g, 21.7 mmol ) was added to a mixture of N-(4-fluoro-3- nitrophenyl)-N-methylacetamide (4.61 g, 21.27 mmol) and sodium carbonate (5.10 g, 47.7 mmol) in EtOH (120 mL) at room temperature. The reaction mixture was heated for 3 days at 60 °C. Upon evaporation of ethanol, the residue was dissolved in EtOAc (400 mL), washed with H20 (3x50 mL), saturated ΝaCl (3x50 mL), and dried over Νa2Sθ4. After filtation and concentration, 6.62 g (100%) of the title compound was obtained as an orange-red solid. Η NMR (400 MHz, CDC13) δ 1.38 - 1.52 (m, 2 H), 1.72 - 1.81 (m, 2 H), 1.90 (s, 3 H), 1.93 - 2.02 (m, 1 H), 3.23 (s, 3 H), 3.23 - 3.27 (m, 2 H), 3.36 - 3.49 (m, 2 H), 4.01 - 4.07 (m, 2 H), 6.91 (d, J=9.18 Hz, 1 H), 7.29 (dd, J=9.08, 2.64 Hz, 1 H), 8.05 (d, J=2.34 Hz, 1 H), 8.22 (t, J=5.37 Hz, 1 H). MS (ESI) (M+H)+ = 309.12.
Step D. N-{3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyI)amino]phenyl}-N- methylacetamide
Figure imgf000117_0001
N-methyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}acetamide (5.39 g, 16.7 mmol) was hydrogenated in ethyl acetate (200 mL) catalyzed by 10% Pd/C (0.2 g) at 30-40 psi Η2 in Parr shaker for 18 h at room temperature. After filtration through celite and concentration, 6.0 g (100%) of a purple solid was obtained as HCl salt, which was used in the next step without purification. Η ΝMR (400 MHz, CD3OD): δ 1.32 - 1.46 (m, 2 H), 1.78 - 1.84 (m, 2 H), 1.85 (s, 3 H), 1.91 - 2.06 (m, 1 H), 3.16 (d, J=6.83 Hz, 2 H), 3.20 (s, 3 H), 3.39 - 3.51 (m, 2 H), 3.94 - 4.03 (m, 2 H), 7.01 (d, J=8.59 Hz, 1 H), 7.12 (d, J=2.15 Hz, 1 H), 7.17 (dd, J=8.49, 4.39 Hz, 1 H), MS (ESI) (M+H)+: 278.7
Step E. N-methyl-N-[2-(pyridin-2-ylmethyl)-l-(tetrahydro-2H-pyran-4- ylmethyI)-lH-benzimidazol-5-yI]acetamide
Figure imgf000117_0002
Following the procedure for Example 10, using N-{3-amino-4-[(tetrahydro-2H-pyran- 4-ylmethyl)amino]phenyl}-N-methylacetamide hydrochoride (416.1 mg, 1.33 mmol), 2-pyridylacetic acid hydrochloride (286.4 mg, 1.65 mmol), diisopropylethylamine (970 mg, 7.5 mmol) and ΗATU (680.0 mg, 1.80 mmol) in DMF (15 mL) and then in acetic acid (10 mL), the crude product was purified by MPLC using EtOAc/MeOΗ (20:1) on silica gel to give 308.1 mg (61%) of a yellow solid as the title compound. MS (ESI) (M+Η)+ = 379.0.
Step F. N-methyl-N-[2-(l-methyl-l-pyridin-2-ylethyl)-l-(tetrahydro-2H-pyran- 4-ylmethyI)-lH-benzimidazoI-5-yI]acetamide
Figure imgf000118_0001
KHMDS (1.6 mL, 0.5 M, 0.8 mmol) was added to a solution of N-methyl-N-[2- (pyridin-2-ylmethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yljacetamide (248.4 mg, 0.656 mmol) in TΗF (25 mL) at -78 °C. Stirring for 10 min, iodomethane (113.6 mg, 50 uL, 0.80 mmol) was added. The mixture was stirred for 30 min at -78 °C and 30 min at room temperature, then cooled down to -78 °C again. Another 1.2 equivalent KΗMDS and iodomethane were added. The resulting mixture was stirred for 30 min at -78 °C and 45 min at room temperature, quenched with saturated ΝaΗCθ3 (5 mL), and extracted with EtOAc (3x20 mL). The combined organic phases were washed with saturated NaHCθ3 (20 mL), saturated NaCl (20 mL) and dried over Na2Sθ4. After filtration and concentration, the residue was purified by MPLC using EtOAc/MeOH (20:1) on silica gel to give 218.1 mg (90%) of the title compound as a white solid. Η NMR (400 MHz, CDC13): δ 1.02 - 1.12 (m, 2 H), 1.13 - 1.19 (m, 2 H), 1.19 - 1.27 ( , 1 H), 1.90 (s, 3 H), 1.97 (s, 6 H), 2.90 - 3.11 (m, 2 H), 3.31 (s, 3 H), 3.68 (d, J=7.22 Hz, 2 H), 3.81 (m, 2 H), 7.04 (dd, J=8.49, 2.05 Hz, 1 H), 7.18 - 7.32 (m, 3 H), 7.57 - 7.70 (m, 2 H), 8.53 - 8.70 (m, 1 H). MS (ESI) (M+H)+ = 407.03.
Step G. N-methyI-2-(l-methyl-l-pyridin-2-ylethyI)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-amine
Figure imgf000118_0002
N-methyl-N-[2-(l -methyl-1 -pyridin-2-ylethyl)-l -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]acetamide (214.0 mg, 0.526 mmol) was dissolved in 5 L of EtOH-2NHCl (3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for lh. After concentration and dried in vacuo, 331 mg (100%) of a grey white solid was obtained as the title product. Η ΝMR (400 MHz, DMSO-D6): δ 0.86 - 1.08 (m, 4 H), 1.94 (s, 6 H), 1.96 - 2.03 (m, 1 H), 2.71 - 2.92 (m, 5 H), 3.55 - 3.70 (m, 2 H), 3.86 (d, J=5.47 Hz, 2 H), 7.31 - 7.48 (m, 2 H), 7.69 (d, J=7.42 Hz, 1 H), 7.74 - 7.84 (m, 1 H), 7.93 (t, J=8.30 Hz, 1 H), 8.48 (d, J=4.10 Hz, 2 H). MS (ESI) (M+H)+ = 365.04.
Example 68 N-[2-(l-cyano-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazoI-5-yl]-N-methylbenzenesulfonamide
Figure imgf000119_0001
Following the procedure for Example 10, using N-{3-amino-4-[(tetrahydro-2H-pyran- 4-ylmethyl)amino]phenyl}-N-methylbenzenesulfonamide (1.0 g, 2.66 mmol) (for preparation, see the steps B and C in Example 41), 2-cyano-2-methylpropanoic acid (0.33 g, 2.93 mmol), diisopropylethylamine (0.76 g, 5.85 mmol) and ΗATU (1.21 g, 3.19 mmol) in DMF (30 mL) and then in acetic acid (50 mL), the crude product was purified by MPLC using Ηex/EtOAc (1:1) on silica gel to give 0.41 g (34%) of a white solid as the title compound. 'ΗΝMR (400 MHz, CD3OD): δ 1.43 - 1.53 (m, 2 H), 1.54 - 1.67 (m, 2 H), 1.93 (s, 6 H), 2.38 - 2.55 (m, 1 H), 3.24 (s, 3 H), 3.32 - 3.40 (m, 2 H), 3.93 (m, 2 H), 4.44 (d, J=7.62 Hz, 2 H), 7.13 (dd, J=8.79, 2.15 Hz, 1 H), 7.32 (d, j=l .56 Hz, 1 H), 7.47 - 7.57 (m, 4 H), 7.62 (d, J=8.98 Hz, 1 H), 7.64 - 7.69 (m, 1 H). MS (ESI) (M+H)+ = 453.0. Anal. Calcd for C24H28Ν403S+ 0.8 TFA+0.2 H20 (547.40): C, 56.17; H, 5.38; N, 10.24; Found: C, 56.05; H, 5.29; N, 10.44.
Example 69
N-methyl-N-[2-propyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yljbenzenesulfonamide
Figure imgf000120_0001
Following the procedure for Example 10, using N-{3-amino-4-[(tetrahydro-2H-pyran- 4-ylmethyl)amino]phenyl}-N-methylbenzenesulfonamide (75.3 mg, 0.20 mmol) (for preparation, see the steps B and C in Example 41), butyric acid (18.5 mg, 0.21 mmol), diisopropylethylamine (56.9 mg, 0.44 mmol) and ΗATU (91.3 mg, 0.24 mmol) in DMF (5 mL) and then in acetic acid (5 mL), the crude product was purified by reversed-phase ΗPLC using 20-50% CΗ3CΝ/Η2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 60.5 mg (71%). 'HNMR (400 MHz, CD3OD): δ 1.14 (t, J=7.42 Hz, 3 H), 1.43 - 1.65 (m, 4 H), 1.88 - 2.04 (m, 2 H), 2.15 - 2.35 ( , 1 H), 3.16 - 3.24 ( , 2 H), 3.27 (s, 3 H), 3.31 - 3.42 (m, 2 H), 3.88 - 3.99 (m, 2 H), 4.36 (d, J=7.62 Hz, 2 H), 7.31 (dd, J=8.98, 1.95 Hz, 1 H), 7.47 - 7.59 (m, 5 H,) 7.63 - 7.73 (m, 1 H), 7.86 (d, J=8.98 Hz, 1 H). MS (ESI) (M+H)+ = 428.0. Anal. Calcd for C23H29N303S+ 1.80 TFA+2.3 H20 +0.60 CH3CN (698.88): C, 47.78; H, 5.37; N, 7.21 ; Found: C, 47.76 ; H, 5.38; N, 7.20.
Example 70
N-[2-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-LH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
Figure imgf000120_0002
Following the procedure for Example 10, using N-{3-amino-4-[(tetrahydro-2H-pyran- 4-ylmethyl)amino]phenyl}-N-methylbenzenesulfonamide (75.3 mg, 0.20 mmol) (for preparation, see the steps B and C in Example 41), pentanoic acid (21.5 mg, 0.21 mmol), diisopropylethylamine (56.9 mg, 0.44 mmol) and HATU (91.3 mg, 0.24 mmol) in DMF (5 mL) and then in acetic acid (5 mL), the crude product was purified by MPLC using Hex EtOAc (1 :1) on silica gel to give 56.4 mg (64%) of a white solid as the title compound. 'HNMR (400 MHz, CD3OD): δ 1.05 (t, J=7.32 Hz, 3 H), 1.45 - 1.63 (m, 6 H), 1.85 - 1.99 (m, 2 H), 2.15 - 2.32 (m, 1 H,) 3.20 - 3.26 (m, 2 H), 3.27 (s, 3 H), 3.31 - 3.41 (m, 2 H), 3.85 - 4.05 (m, 2 H), 4.37 (d, J=7.62 Hz, 2 H), 7.32 (dd, J=8.98, 1.95 Hz, 1 H), 7.47 - 7.60 (m, 5 H), 7.63 - 7.73 (m, 1 H), 7.87 (d, J=8.79 Hz, 1 H). MS (ESI) (M+H)+ = 442.0. Anal. Calcd for C24H31N3O3S+ 1.00 HCl+1.00 H20 (496.07): C, 58.11; H, 6.91; N, 8.47; Found: C, 58.14 ; H, 6.92; N, 8.30.
Example 71
N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5-yI]-N- ethylbenzenesulfonamide
Figure imgf000121_0001
Step A. N-[2-tert-butyl-l- ■(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5 yl]-N-ethyIbenzenesulfonamide
Figure imgf000121_0002
2-tert-butyl-N-ethyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (52.8 mg, 0.15 mmol) (for preparation, see the following steps B, C, D, E and F), DMAP (73.3 mg, 0.60 mmol) and benzenesulfonyl chloride (53.0 mg, 0.30 mmol) in MeCΝ (5 mL) were stirred overnight at room temperature. The reaction mixture was diluted with EtOAc (100 mL), washed with saturated ΝaΗC03 (10 mL) and saturated NaCl (10 mL) and dried overNa2S04. Upon evaporation, the residue was purified by MPLC using Hex EtOAc (1 :1) on silica gel to give 53.0 mg (77%) of a white solid as the title compound. 'HNMR (400 MHz, CD3OD): δ 0.95 (t, J=7.03 Hz, 3 H), 1.36 - 1.50 (m, 4 H), 1.53 (s, 9 H), 2.08 - 2.29 (m, 1 H), 3.12 - 3.27 (m, 2 H), 3.65 (q, J=7.09 Hz, 2 H), 3.76 - 3.88 (m, 2 H), 4.37 (d, J=7.03 Hz, 2 H), 7.03 (d, J=8.79 Hz, 1 H), 7.32 (s, 1 H), 7.51 - 7.63 (m, 4 H), 7.64 - 7.76 (m, 1 H), 7.83 (d, J=8.59 Hz, 1 H). MS (ESI) (M+H)+ = 456.0 . Anal. Calcd for C25H33N3θ3S+ 1.20 TFA+0.3 CH3CN (604.77): C, 55.61; H, 5.85; N, 7.64; Found: C, 55.57; H, 5.79; N, 7.61.
Step B. N-ethyl-N-(4-fluoro-3-nitrophenyI)acetamide
Figure imgf000122_0001
Sodium hydr V XΎX ide (1t .20g, 60%, 30 mmol) was added in portions to a solution of N-(4- fluoro-3-nitrophenyl)acetamide(3.96 g, 20 mmol) (for preparation see the step B in Example 47) in THF (100 mL) at 0 °C. Stirring for 20 min, iodoethane (9.32 g, 60 mmol) was added. The reaction mixture was stirred overnight at room temperature, quenched with saturated ΝaHC03 (30 mL) and extracted with EtOAc (3x100 mL). The combined organic phases were washed with saturated NaCl (2x30 mL). After filtration and concentration, the residue was purified by MPLC using Hex EtOAc (1 :1) on silica gel to give 2.36 g (52%) of a yellow solid as the title compound. Η NMR (400 MHz, CDC13): δ 1.14 (t, J=6.93 Hz, 3 H), 1.88 (s, 3 H), 3.70 - 3.84 (q, J=7.0 Hz, 2 H), 7.34 - 7.43 (m, 1 H), 7.48 (s, 1 H), 7.87 - 7.98 (m, 1 H).
Step C. N-ethyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyI)amino]phenyl}acetamide
Figure imgf000122_0002
4-Aminomethylpyran (1.32 g, 11.4 mmol ) was added to a mixture ofN-ethyl-N-(4- fluoro-3-nitrophenyl)acetamide (2.36 g, 10.4 mmol) and sodium carbonate (2.43 g, 22.9 mmol) in EtOH (70 mL) at room temperature. The reaction mixture was heated for a weekend at 60 °C. Upon evaporation of ethanol, the residue was diluted with H20 (50 mL), and extracted with EtOAc (3x100 mL). The combined organic phases weer washed saturated NaCl (2x50 mL) and dried over Na2S04. After filtation and concentration, the residue was purified by MPLC using Hex/EtOAc (1 :1) on silica gel to give 2.83 g (85%) of an orange-red solid as the title compound. Η NMR (400 MHz, CDCl3): δ 1.1 1 (t, J=7.13 Hz, 3 H), 1.38 - 1.52 (m, 2 H), 1.78 (m, 2 H), 1.86 (s, 3 H), 1.92 - 2.04 (m, 1 H), 3.20 - 3.29 (m, 2 H), 3.39 - 3.49 (m, 2 H), 3.71 (q, J=7.09 Hz, 2 H), 4.00 - 4.08 (m, 2 H), 6.91 (d, J=8.98 Hz, 1 H), 7.24 (d, J=2.54 Hz, 1 H), 8.01 (d, J=2.54 Hz, 1 H), 8.22 (t, J=4.98 Hz, 1 H).
Step D. N-{3-amino-4-[(tetrahydro-2H-pyran-4-yImethyI)arnino]phenyI}-N- ethylacetamide
Figure imgf000123_0001
N-ethyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}acetamide (2.83 g, 8.79 mmol) was hydrogenated in ethyl acetate (200 mL) catalyzed by 10% Pd/C (0.2 g) at 30-40 psi Η2 in Parr shaker for 16 h at room temperature. After filtration through celite and concentration, 2.45 g (95%) of a light yellow solid was obtained, which was used in the next step without purification. MS (ESI) (M+H)+ = 292.3
Step E. N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]-N-ethylacetamide
Figure imgf000123_0002
Following the procedure for Step A in Example 7, using N-{3-amino-4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}-N-ethylacetamide (803.1 mg, 2.75 mmol), DMAP (671.9 mg, 5.50 mmol) and trimethylacetyl chloride (380.9 mg, 3.16 mmol) in CΗ2C12 (60 mL) and then in DCE (30 mL), the crude product was purified by MPLC using EtOAc MeOH (20:1) on silica gel. Yield: 694.1 mg (71%). Η ΝMR (400 MHz, CDC13): δ 1.12 (t, J=7.13 Hz, 3 H), 1.51 - 1.57 (m, 4 H), 1.58 (s, 9 H), 1.83 (s, 3 H), 2.21 - 2.40 (m, 1 H), 3.26 - 3.43 (m, 2 H), 3.78 (q, J=7.23 Hz, 2 H), 3.94 - 4.07 (m, 2 H), 4.22 (d, J=7.42 Hz, 2 H), 7.02 (dd, J=8.59, 1.95 Hz, 1 H), 7.34 (d, J=8.59 Hz, 1 H), 7.54 (d, J=0.98 Hz, 1 H). MS (ESI) (M+H)+ = 358.07.
Step F. 2-te/"t-butyl-N-ethyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH- benzimidazol-5-amine
Figure imgf000124_0001
N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- ethylacetamide (648.3 mg, 2.06 mmol) was dissolved in 15 mL of EtOΗ-2NΗCl
(3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for 3h. After concentration and dried in vacuo, 754.71 mg (100%) of a grey white solid was obtained as the title product. MS (ESI) (M+H)+ = 316.3.
Example 72
Λ7-ethyl-N-[2-(l-methoxy-l-methylethyI)-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazoI-5-yl]benzenesulfonamide
Figure imgf000124_0002
Step A N-ethyl-N-[2-(l-methoxy-l-methyIethyl)-l-(tetrahydro-2H-pyran-4- ylmethyI)-lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000125_0001
Following the procedure for the step A in Example 71, using N-ethyl-2-( 1 -methoxy- 1- methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (50.0 mg, 0.136 mmol) (for preparation, see the following steps B, C and D), DMAP (64.5 mg, 0.50 mmol) and benzenesulfonyl chloride (45.9.0 mg, 0.26 mmol) in MeCΝ (5 mL), the crude product was purified by reversed-phase ΗPLC using 20-50% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 12.1 mg (19%). 'HNMR (400 MHz, CD3OD): δ 1.07 (t, J=7.13 Hz, 3 H), 1.48 - 1.58 (m, 4 H), 1.78 (s, 6 H), 2.27 - 2.51 (m, 1 H), 3.32 (s, 3 H), 3.33 - 3.40 (m, 2 H), 3.72 (q, J=7.23 Hz, 2 H), 3.88 - 4.00 (m, 2 H), 4.51 (d, J=7.42 Hz, 2 H), 7.15 (dd, J=8.88, 1.86 Hz, 1 H), 7.40 (d, J=1.76 Hz, 1 H), 7.49 - 7.58 (m, 2 H), 7.59 - 7.64 (m, 2 H), 7.63 - 7.70 (m, 1 H), 7.76 (d, J=8.98 Hz, 1 H). MS (ESI) (M+H)+ = 472.0. Anal. Calcd for C25H33N3θ4S+ 0.90 TFA+0.20 H 0 +0.40 CH3OH (590.66): C, 55.31 ; H, 6.13; N, 7.1 1 ; Found: C, 55.29; H, 6.06; N, 7.10.
Step B. N-ethyI-N-[2-(l-hydroxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl] acetamide
Figure imgf000125_0002
Following the procedure for Example 10, using N-{3-amino-4-[(tetrahydro-2H-pyran- 4-ylmethyl)amino]phenyl}-N-ethylacetamide (0.841 g, 2.88 mmol) (for preparation, see the steps B, C and D in Example 71), 2-hydroxy-2-methylpropanoic acid (0.330 g, 3.17 mmol), diisopropylethylamine (0.558 g, 4.32 mmol) and HATU (1.31 g, 3.46 mmol) in DMF (40 mL) and then in acetic acid (50 mL), the crude product (1.78 g, purity >43%) was used directly for next step without purification. MS (ESI) (M+H)+ = 360.04.
Step C. N-ethyl-N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyI)-lH-benzimidazol-5-yl]acetamide
Figure imgf000126_0001
Sodium hydride (0.35 g, 60%, 8.64 mmol) was added in portions to a solution of N- ethyl-N-[2-( 1 -hydroxy- 1 -methylethyl)- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H- benzimidazol-5-yl]acetamide (1.78 g of the above crude product, 2.88 mmol) in TΗF (100 L) at 0 °C. Stirring for 20 min, iodoethane (1.23 g, 8.64 mmol) was added. The reaction mixture was stirred overnight at room temperature, quenched with saturated ΝΗ4C1 (20 L) and diluted with EtOAc (100 mL), washed with saturated NaCl (2x20 mL). After filtration and concentration, the residue was purified by MPLC using EtOAc/MeOH (20:1) on silica gel to give 0.423 g (39%) of a grey white solid as the title compound. MS (ESI) (M+H)+ = 374.03.
Step D. N-ethyl-2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-amine
Figure imgf000126_0002
N-ethyl-N-[2-(l -methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl]acetamide (422.5 mg, 1.13 mmol) was dissolved in 15 mL of EtOH-2NHCl (3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for 3.5 h. After concentration and dried in vacuo, 441.9 mg (100%) of a light brown solid was obtained as the title product. MS (ESI) (M+H)+ = 332.04.
Example 73
5-Bromo-N-[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazoI-5-yl]-6-chloro-
N-methylpyridine-3-sulfonamide
2-tert-Butyl-l-(cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (for preparation, see Example 1) (80 mg, 0.267 mmol) and 3-bromo-2-chloro pyridine-5- sulphonyl chloride (95 mg, 0.320 mmol) were stirred in 3 mL of DCM containing a catalytic amount of DMAP at rt overnight. The solution was washed with saturated aqueous ΝaΗC03 solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using 2:1 / hexanes:EtOAc as eluent. Yield: 127 mg (86%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.09 (m, 1 H), 1.1 1 (m, 1 H), 1.15 (m, 1 H), 1.18 (m, 1 H), 1.20 (m, 1 H), 1.54 (s, 9 H), 1.64 (m, 1 H), 1.67 (m, 1 H), 1.70 (m, 1 H), 1.75 (m, 2 H), 2.02 (m, 1 H), 3.29 (s, 3 H), 4.13 (d, J=7.42 Hz, 2 H), 7.12 (dd, J=8.79, 1.56 Hz, 1 H), 7.31 (m, 2 H), 8.06 (d, J=2.15 Hz, 1 H), 8.41 (d, J=2.15 Hz, 1 H); MS (ESI) (M+H)+: 553.0; Anal. Calcd for
C24H3oN402SClBr + 0.1 H20: C, 51.87; H, 5.48; N, 10.08. Found: C, 52.01; H, 5.54; N, 9.83.
Example 74 5-Bromo-N-[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yI]-6-[(2- hydroxyethyl)amino]-N-methylpyridine-3-sulfonamide
Figure imgf000128_0001
5-Bromo-N-[2-te/-t-butyl-l -(cyclohexylmethyl)- lH-benzimidazol-5-yl]-6-chloro-N- methylpyridine-3-sulfonamide (50 mg, 0.0903 mmol) and ethanolamine (0.025 L, 0.451 mmol) were dissolved in 2 mL of DMF. The solution was heated at 120°C for 30 min using a Personal Chemistry microwaves instrument. The solvent was evaporated. The product was directly purified by reversed-phase ΗPLC using 10- 60% CΗ3CΝ/Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 45 mg (72%); Η NMR (400 MHz, METHANOL-D4): δ 1.25 (m, 5 H), 1.65 (m, 2 H), 1.68 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.11 (m, 1 H), 3.27 (s, 3 H), 3.61 (t, J=5.37 Hz, 2 H), 3.70 (t, J=5.47 Hz, 2 H), 4.47 (d, J=7.62 Hz, 2 H), 7.38 (dd, J=9.08, 2.05 Hz, 1 H), 7.61 (d, J=2.15 Hz, 1 H), 7.63 (d, J=1.56 Hz, 1 H), 7.89 (d, J=8.98 Hz, 1 H), 8.09 (d, J=2.15 Hz, 1 H); MS (ESI) (M+H)+ 578.3; Anal. Calcd for C26H38N5θ3SBr + 1.9 TFA + 0.2 H20: C, 44.69; H, 5.07; N, 8.74. Found: C, 44.71; H, 5.13; N, 8.74.
Example 75
N-[2-tert-Butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5-yl]-6-[(2- hydroxyethyl)amino]-N-methylpyridine-3-sulfonamide
Figure imgf000128_0002
5-Bromo-N-[2-terf-butyl-l -(cyclohexylmethyl)- lH-benzimidazol-5-yl]-6-[(2- hydroxyethyl)amino]-N-methylpyridine-3-sulfonamide (55 mg, 0.0794 mmol) was dissolved in 15 mL of EtOΗ containing a catalytic amount of 10% Pd/C. The solution was shaken under Η2 atmosphere (45 psi) using a Parr hydrogenation apparatus at rt for 5h. The solution was filtered through celite and the solvent was evaporated. The product was purified by reversed-phase HPLC using 10-60% CH3CN H2O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 31 mg (64%); Η NMR (400 MHz, METHANOL-D4): δ 1.24 (m, 5 H), 1.64 (m, 2 H), 1.68 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.12 (m, 1 H), 3.27 (s, 3 H), 3.49 (t, J=5.57 Hz, 2 H), 3.70 (t, J=5.57 Hz, 2 H), 4.47 (d, J=7.62 Hz, 2 H), 6.63 (d, J=9.18 Hz, 1 H), 7.41 (dd, J=8.98, 1.95 Hz, 1 H), 7.47 (d, J=7.42 Hz, 1 H), 7.61 (d, J=1.95 Hz, 1 H), 7.88 (d, J=8.98 Hz, 1 H), 8.01 (d, J=2.34 Hz, 1 H); MS (ESI) (M+H)+: 500.3; Anal. Calcd for C26H37N503S + 2.5 TFA + 1.7 H20: C, 45.67; H, 5.30; N, 8.59. Found: C, 45.69; H, 5.32; N, 8.43.
Example 76
N-(5-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide
Figure imgf000129_0001
Step A. N-(5-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lif-benzimidazol-5- yI](methyI)amino]suIfonyl}pyridin-2-yl)acetamide
Figure imgf000129_0002
Following the same procedure as in Example 74 using N-(3-bromo-5-{[[2-tert-butyl- l-(cyclohexylmethyl)-lH-benzimidazol-5-yl](methyl)amino]sulfonyl)pyridin-2- yl)acetamide (see Step B for preparation) (16 mg, 0.0278 mmol). The product was purified by reversed-phase ΗPLC using 10-60% CΗ3CΝ/Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 13 mg (76%); Η NMR (400 MHz, METHANOL-D4): δ 1.24 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.70 (m, 1 H), 1.78 (m, 2 H), 2.11 (m, 1 H), 2.19 (s, 3 H), 3.30 (m, 3 H), 4.46 (d, J=7.62 Hz, 2 H), 7.36 (dd, J=8.98, 2.15 Hz, 1 H), 7.58 (d, J=1.95 Hz, 1 H), 7.81 (dd, J=8.89, 2.25 Hz, 1 H), 7.87 (d, J=8.98 Hz, 1 H), 8.25 (d, J=8.98 Hz, 1 H), 8.40 (s, 1 H); MS (ESI) (M+H)+: 498.2; Anal. Calcd for C26H 5N503S + 2.0 TFA + 1.0 H20: C, 48.45; H, 5.29; N, 9.42. Found: C, 48.37; H, 5.16; N, 9.64.
Step B. N-(3-Bromo-5-{[[2-tert-butyl-l-(cyclohexyImethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide
Figure imgf000130_0001
5-Bromo-N-[2-tert-butyl-l -(cyclohexylmethyl)- lH-benzimidazol-5-yl]-6-chloro-N- methylpyridine-3-sulfonamide (87 mg, 0.157 mmol) was dissolved in 2 mL of DMF containing ammonia (28% w/v in water) (1 mL). The solution was heated at 120°C for 30 min using a Personal Chemistry microwaves instrument. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous ΝaΗC03 solution, brine and dried over anhydrous MgS04. The solvent was evaporated. The product was dissolved in 2 mL of DCE containing a catalytic amount of DMAP. Acetyl chloride (0.055 L, 0.785 mmol) was added and the solution was heated at 120°C for 30 min using a Personal Chemistry microwaves instrument. The solution was washed with saturated aqueous NaHC03 solution, brine and dried over anhydrous MgS0 . The crude product was purified by silica gel flash chromatography using 1 :1 / hexanes:EtOAc as eluent. Yield: 16 mg (18%); MS (ESI) (M+H)+: 578.28.
Example 77
N-(3-{[[2-te/*t-ButyI-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000131_0001
Step A. N-(3-{[[2-tert-Butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000131_0002
3-Amino-N-[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide (see Step B and C for preparation) (40 mg, 0.0880 mmol) and acetyl chloride (0.008 mL, 0.106 mmol) were stirred in 2 mL of DCM containing a catalytic amount of DMAP at rt for lh. The solvent was evaporated. The product was purified by reversed-phase ΗPLC using 10-60% CΗsCΝ/ΗbO and lyophilized affording the title compound as the corresponding TFA salt. Yield: 38 mg (71%); Η ΝMR (400 MHz, METHAΝOL-D4): δ 1.24 (m, 5 H), 1.65 (m, 2 H), 1.68 (s, 9 H), 1.71 (m, 1 H), 1.77 ( , 2 H), 2.07 (s, 3 H), 2.1 1 (m, 1 H), 3.28 (s, 3 H), 4.46 (d, J=7.42 Hz, 2 H), 7.32 (m, 2 H), 7.47 (t, J=8.01 Hz, 1 H), 7.59 (m, 2 H), 7.84 (d, J=8.98 Hz, 1 H), 7.93 (t, J=1.86 Hz, 1 H); MS (ESI) (M+H)+: 497.2; Anal. Calcd for C27H36N403S + 1.7 TFA + 0.5 H20: C, 52.20; H, 5.58; N, 8.01. Found: C, 52.14; H, 5.48; N, 8.08.
Step B. N-[2-tert-Butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5-yl]-N-methyl-3- nitrobenzenesulfonamide
Figure imgf000131_0003
2-te7-t-Butyl-l-(cyclohexylmethyl)-N-methyl-lH-benzimidazol-5-amine (50 mg, 0.167 mmol) and 3-nitrophenylsulphonyl chloride (44 mg, 0.200 mmol) were stirred in 3 mL of DCM containing a catalytic amount of DMAP at rt overnight. The solution was washed with saturated aqueous ΝaΗCU3 solution, brine and dried over anhydrous MgS0 . The crude product was purified by silica gel flash chromatography using 1 :1 / hexanes:EtOAc as eluent. Yield: 75 mg (94%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.09 (m, 1 H), 1.1 1 (m, 1 H), 1.15 ( , 1 H), 1.18 (m, 1 H), 1.21 (m, 1 H), 1.53 (s, 9 H), 1.64 (m, 1 H), 1.67 ( , 1 H), 1.72 (m, 1 H), 1.76 (m, 1 H), 2.03 (m, 1 H), 3.29 (s, 3 H), 4.12 (d, J=7.62 Hz, 2 H), 7.18 (m, 2 H), 7.31 (d, J=8.40 Hz, 1 H), 7.67 (t, J=8.01 Hz, 1 H), 7.91 (m, 1 H), 8.39 (t, J=1.76 Hz, 1 H), 8.43 (ddd, J=8.10, 2.25, 0.98 Hz, 1 H).
Step C. 3-Amino-N-[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide
Figure imgf000132_0001
N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methyl-3- nitrobenzenesulfonamide (72 mg, 0.149 mmol) was dissolved in 15 mL of EtOΗ containing a catalytic amount of 10% Pd/C. The solution was shaken under Η2 atmosphere (45 psi) using a Parr hydrogenation apparatus at rt for 6h. The solution was filtered through celite and the solvent was evaporated. The crude product was purified by silica gel flash chromatography using 1:1 / hexanes:EtOAc as eluent. Yield: 43 mg (63%); Η ΝMR (400 MHz, CHLOROFORM-D): δ 1.08 (m, 1 H), 1.1 1 (m, 1 H), 1.15 (m, 1 H), 1.18 (m, 1 H), 1.20 (m, 1 H), 1.54 (s, 9 H), 1.65 (m. 1 H), 1.68 (m, 1 H), 1.71 (m, 1 H), 1.75 (m, 2 H), 2.03 (m, 1 H), 3.22 (s, 3 H), 3.82 (m, 2 H), 4.11 (d, J=7.42 Hz, 2 H), 6.83 (ddd, J=8.01, 2.44, 0.88 Hz, 1 H), 6.90 (t, J=1.95 Hz, 1 H), 6.97 (m, 1 H), 7.22 (m, 2 H), 7.28 (m, 1 H), 7.33 (m, 1 H). Example 78
N1-(4-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyI)amino]sulfonyl}phenyl)-N2-(2-hydroxyethyl)glycinamide
Figure imgf000133_0001
2-Bromo-N-(4- { [[2-te/-t-butyl- 1 -(cyclohexylmethyl)- 1 H-benzim idazol-5 - yl](methyI)amino]sulfonyl}phenyl)acetamide (for preparation, see Example 33, Step B) (56 mg, 0.0973 mmol) and ethanolamine (0.030 mL, 0.487 mmol) were heated in 1 mL of DMF at 125°C for 15 min using a Personal Chemistry microwaves instrument. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous ΝaΗC03 solution, brine and dried over anhydrous MgS0 . The solvent was evaporated. The product was purified by reversed-phase HPLC using 10- 70% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 20 mg (31 %); Η NMR (400 MHz, METHANOL-D4): δ 1.24 ( , 5 H), 1.63 (m, 2 H), 1.67 (s, 9 H), 1.70 (m, 1 H), 1.78 (m, 2 H), 2.11 (m, 1 H), 3.24 (m, 2 H), 3.27 (s, 3 H), 3.85 (m, 2 H), 4.07 (s, 2 H), 4.45 (d, J=7.62 Hz, 2 H), 7.31 (dd, J=9.08, 2.05 Hz, 1 H), 7.53 (d, J=8.98 Hz, 2 H), 7.59 (d, J=l .76 Hz, 1 H), 7.77 (d, J=8.98 Hz, 2 H), 7.84 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 556.3.
Example 79
4-{(Aminocarbonyl)amino]-N-[2-te;-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]-N-methylbenzenesulfonamide
Figure imgf000133_0002
2-tert-But}'l-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine (see Example 50 for preparation) (30 mg, 0.0995 mmol) and 4-ureido- benzenesulfonyl chloride (28 mg, 0.119 mmol) were stirred in 3 mL of DMF containing a catalytic amount of DMAP at rt for 4h. The solvent was evaporated. The product was purified by reversed-phase HPLC using 10-70% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 24 mg (39%); Η NMR (400 MHz, METHANOL-D4): δ 1.50 - 1.55 (m, 2 H), 1.56 - 1.63 (m, 2 H), 1.67 (s, 9 H), 2.32 - 2.40 (m, 1 H), 3.23 (s, 3 H), 3.34 (dt, J=l 1.42, 2.34 Hz, 2 H), 3.92 (d, J=3.12 Hz, 1 H), 3.95 (d, J=3.12 Hz, 1 H), 4.51 (d, J=7.42 Hz, 2 H), 7.32 (ddd, J=9.03, 2.00, 0.88 Hz, 1 H), 7.38 (d, J=8.20 Hz, 2 H), 7.49 - 7.54 (m, 3 H), 7.88 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 500.0; Anal. Calcd for C25H33N504S + 1.7 TFA + 0.6 H20: C, 48.43; H, 5.14; N, 9.94. Found: C, 48.44; H, 5.04; N, 10.04.
Example 80
N-(4-{[[2-te/-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000134_0001
2-tert-ButyI-Ν-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine (200 mg, 0.663 mmol) and N-acetylsulfanilyl chloride (186 mg, 0.796 mmol) were stirred in 10 mL of DCM containing DMAP (16 mg, 0.133 mmol) at rt for 48h. The solution was washed with saturated aqueous NaHCθ3 solution, brine and dried over anhydrous MgS04. The solvent was evaporated. The product was purified by reversed-phase HPLC using 10-60% CH3CN/H2O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 353 mg (87%); 'H NMR (400 MHz, METHANOL-D4): δ 1.51 - 1.57 (m, 2 H), 1.56 - 1.65 (m, 2 H), 1.68 (s, 9 H), 2.14 (s, 3 H), 2.32 - 2.41 (m, 1 H), 3.25 (s, 3 H), 3.35 (td, J=l 1.47, 2.64 Hz, 2 H), 3.93 (d, J=2.93 Hz, 1 H), 3.96 (d, J=3.71 Hz, 1 H), 4.52 (d, J=7.62 Hz, 2 H), 7.32 (dd, J=8.98, 2.15 Hz, 1 H), 7.45 (d, J=8.98 Hz, 2 H), 7.54 (d, 7=1.56 Hz, 1 H), 7.71 (d, J=8.98 Hz, 2 H), 7.88 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 499.0.
Example 81
N-(4-{[[2-te;*t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5- yI](methyl)amino]sulfonyl}phenyl)-N-methylacetamide
Figure imgf000135_0001
2-tert-Butyl-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine (37 mg, 0.123 mmol) and N-acetylsulfanilyl chloride (37 mg, 0.160 mmol) were stirred in 5 L of DCM containing DMAP (catalytic) at rt overnight. The solution was washed with saturated aqueous NaHCθ3 solution, brine and dried over anhydrous MgS04. The product was passed through a plug of silica gel using EtOAc as eluent and the solvent was evaporated. The product was dissolved in 5 mL of DMF at 0°C and NaH (60% dispersion in oil) (7 mg, 0.185 mmol) was added followed by iodomethane (0.012 mL, 0.185 mmol). The solution was stirred at rt for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHC03 solution, brine and dried over anhydrous MgS04. The solvent was evaporated. The product was purified by reversed-phase HPLC using 10- 60% CH3CN/H O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 28 mg (36%); 'H NMR (400 MHz, METHANOL-D4): δ 1.51 - 1.57 (m, 2 H), 1.57 - 1.64 (m, 2 H), 1.69 (s, 9 H), 2.00 (br.s, 3 H), 2.32 - 2.41 (m, 1 H), 3.29 - 3.30 (m, 6 H), 3.32 - 3.39 ( , 2 H), 3.93 (d, j=2.93 Hz, 1 H), 3.96 (d, J=3.51 Hz, 1 H), 4.53 (d, J=7.42 Hz, 2 H), 7.34 (dd, J=8.98, 1.95 Hz, 1 H), 7.48 (d, J=8.79 Hz, 2 H), 7.59 - 7.65 (m, 3 H), 7.90 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 513.0; Anal. Calcd for C27H36N404S + 2.3 TFA + 0.2 H20: C, 48.75; H, 5.01; N, 7.20. Found: C, 48.69; H, 4.97; N, 7.39. Example 82
N-(4-{[l2-tert-Butyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH-benzimidazol-5- yll(methyl)aminolsulfonyl}phenyl)-2,2-dimethylpropanamide
Figure imgf000136_0001
Step A. N-(4-{[[2-te/t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide
Figure imgf000136_0002
4-Amino-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]- N-methylbenzenesulfonamide (see following Steps B and C for preparation) (375 mg, 0.821 mmol) and trimethylacetyl chloride (0.120 mL, 0.985 mmol) were stirred in 20 mL of DCM containing a catalytic amount of DMAP at rt for 3h. The solution was washed with saturated aqueous ΝaΗCθ3 solution, brine and dried over anhydrous MgS04. The product was purified by reversed-phase HPLC using 10-75% CH3CN/H 0 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 445 mg (83%); Η NMR (400 MHz, METHANOL-D4): δ 1.29 (s, 9 H), 1.50 - 1.56 (m, 2 H), 1.57 - 1.65 (m, 2 H), 1.67 (s, 9 H), 2.32 - 2.40 ( , 1 H), 3.26 (s, 3 H), 3.35 (td, J=l 1.47, 2.64 Hz, 2 H), 3.93 (d, J=2.93 Hz, 1 H), 3.96 (d, J=3.32 Hz, 1 H), 4.51 (d, J=7.42 Hz, 2 H), 7.30 (dd, J=9.08, 2.05 Hz, 1 H), 7.45 (d, J=8\98 Hz, 2 H), 7.51 (d, J=l .95 Hz, 1 H), 7.75 (d, J=2.34 Hz, 1 H), 7.77 (d, J=2.34 Hz, 1 H),' 7.86 (d, J=8.98 Hz, 1 H), 9.39 (s, 1 H); MS (ESI) (M+H)+: 541.0.
Step B. N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH-benzimidazoI-5- yl]-N-methyl-4-nitrobenzenesulfonamide
Figure imgf000137_0001
2-tert-Butyl-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine (280 mg, 0.929 mmol) and 4-nitrobenzenesulfonyl chloride (247 mg, 1.11 mmol) were stirred in 10 mL of DCM containing a catalytic amount of DMAP at rt overnight. The solution was washed with saturated aqueous NaHCθ3 solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using 1:1 / hexanes : EtOAc as eluent. Yield: 404 mg (89%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.51 - 1.57 (m, 13 H), 2.24 - 2.34 (m, 1 H), 3.27 (s, 3 H), 3.30 - 3.38 (m, 2 H), 3.99 (t, J=2.93 Hz, 1 H), 4.02 (t, J=3.03 Hz, 1 H), 4.20 (d, J=7.42 Hz, 2 H), 7.19 - 7.23 (m, 2 H), 7.29 - 7.33 (m, 1 H), 7.77 (d, J=8.98 Hz, 2 H), 8.30 (d, J=8.79 Hz, 2 H).
Step C. 4-Amino-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl]-N-methylbenzenesulfonamide
Figure imgf000137_0002
N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methyl-4-nitrobenzenesulfonamide (400 mg, 0.822 mmol) was dissolved in 30 mL of 1:1 / EtOAc:EtOΗ containing a catalytic amount of 10% Pd/C. The solution was shaken under H2 atmosphere (40 psi) using a Parr hydrogenation apparatus overnight at rt. The solution was filtered through celite and the solvent was evaporated. Yield: 375 mg (99%); MS (ESI) (M+H)+: 457.32. Example 83
N-(4-{[[2-te;-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide
Figure imgf000138_0001
Step A. N-(4-{[[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yI](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide
Figure imgf000138_0002
2-[(4- { [[2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyI)- 1 H-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate (see following Step B for preparation) (45 mg, 0.0808 mmol) was dissolved in 3 mL of MeOΗ at 0°C. 25% ΝaOMe/MeOΗ (pΗ adjusted to 9.0) was added and solution was stirred at 0°C for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous 5% KΗS04 solution. The aqueous phase was basified with saturated aqueous ΝaHCθ3 solution and extracted with EtOAc (2X). The organic phase was washed with brine and dried over anhydrous MgS0 . The product was purified by reversed- phase HPLC using 10-60% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 35 mg (69%); 'H NMR (400 MHz, METHANOL-D4): δ 1.51 - 1.57 (m, 2 H), 1.57 - 1.65 (m, 2 H), 1.68 (s, 9 H), 2.32 - 2.41 (m, 1 H), 3.26 (s, 3 H), 3.35 (dt, J=l 1.47, 2.64 Hz, 2 H), 3.93 (d, J=2.93 Hz, 1 H), 3.96 (d, J=3.71 Hz, 1 H), 4.13 (s, 2 H), 4.53 (d, J=7.62 Hz, 2 H), 7.33 (dd, J=9.08, 2.05 Hz, 1 H), 7.48 (d, J=8.98 Hz, 2 H), 7.54 (d, J=1.56 Hz, 1 H), 7.81 (d, J=8.98 Hz, 2 H), 7.89 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 515.0; Anal. Calcd for C26H34N405S + 2.2 TFA + 1.6 H20: C, 42.84; H, 4.48; N, 6.25. Found: C, 42.77; H, 4.28; N, 6.65. Step B. 2-[(4-{[[2-te/t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyl}ρhenyl)amino]-2-oxoethyl acetate
Figure imgf000139_0001
4-Amino-N-[2-tβrt-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]- N-methylbenzenesulfonamide (45 mg, 0.0986 mmol) and acetoxyacetyl chloride (0.013 mL, 0.118 mmol) were stirred in 2 mL of DCM containing a catalytic amount of DMAP at rt for 3h. The solution was washed with saturated aqueous ΝaΗCθ3 solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Yield: 45 mg (82%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.50 - 1.55 (m, 13 H), 2.23 (s, 3 H), 2.25 - 2.33 (m, 1 H), 3.18 (s, 3 H), 3.29 - 3.37 (m, 2 H), 3.97 (t, J=2.83 Hz, 1 H), 4.00 (t, J=2.64 Hz, 1 H), 4.18 (d, J=7.23 Hz, 2 H) 4.67 - 4.71 (m, 2 H), 7.18 - 7.24 (m, 2 H), 7.24 - 7.29 (m, 1 H), 7.51 (d, J=8.79 Hz, 2 H), 7.62 (d, J=8.79 Hz, 2 H), 8.31 (s, 1 H).
Example 84
N1-(4-{[[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-N"^ -dimethylglycinamide
Figure imgf000139_0002
Step A. N,-(4-{[[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]suIfonyl}phenyI)-N2^/V2-dimethylglycinamide
Figure imgf000140_0001
2-Bromo-N-(4- { [[2-tert-butyl-l -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazoI- 5-yl](methyl)amino]sulfonyl}phenyl)acetamide (see following Step B for preparation) (36 mg, 0.0625 mmol) and dimethylamine hydrochloride (25 mg, 0.311 mmol) were stirred in 2 mL of -DMF containing DIPEA (0.054 mL, 0.311 mmol) at 125°C for 15 min using a Personal Chemistry microwaves instrument. The solvent was evaporated. The product was purified by reversed-phase ΗPLC using 10-60% CΗ3CN/Η2O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 34 mg (83%); Η NMR (400 MHz, METHANOL-D4): δ 1.50 - 1.55 (m, 2 H), 1.56 - 1.64 (m, 2 H), 1.66 (s, 9 H), 2.31 - 2.40 (m, 1 H), 2.99 (s, 6 H), 3.26 (s, 3 H), 3.35 (dt, J=11.47, 2.64 Hz, 2 H), 3.93 (d, J=2.93 Hz, 1 H), 3.96 (d, J=3.71 Hz, 1 H), 4.18 (s, 2 H), 4.49 (d, J=7.62 Hz, 2 H), 7.26 (dd, J=8.98, 2.15 Hz, 1 H), 7.52 (d, J=8.98 Hz, 2 H), 7.55 (d, J=1.95 Hz, 1 H), 7.76 (d, J=8.98 Hz, 2 H), 7.81 (d, J=8.79 Hz, 1 H); MS (ESI) (M+H)+: 542.3; Anal. Calcd for C28H39N5O4S + 2.3 TFA + 1.0 H20: C, 47.64; H, 5.31; N, 8.52. Found: C, 47.68; H, 5.27; N, 8.55.
Step B. 2-Bromo-N-(4-{[[2-tert-butyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH- benzimidazol-5-yl](methyl)amino)sulfonyl}phenyI)acetamide
Figure imgf000140_0002
4-Amino-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]- N-methylbenzenesulfonamide (160 mg, 0.350 mmol) and bromoacetyl chloride (0.035 mL, 0.420 mmol) were stirred in 5 mL of DCM containing a catalytic amount of DMAP at rt for 3h. The solution was washed with saturated aqueous ΝaΗC03 solution, brine and dried over anhydrous MgS0 . The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Yield: 127 mg (63%); H NMR (400 MHz, CHLOROFORM-D): δ 1.50 - 1.58 (m, 11 H), 1.59 - 1.67 (m, 2 H), 2.25 - 2.36 (m, 1 H), 3.21 (s, 3 H), 3.30 - 3.39 (m, 2 H), 3.99 (br.s, 1 H), 4.01 (br.s, 1 H), 4.05 (s, 1 H), 4.20 (d, J=7.42 Hz, 2 H) 4.23 (s, 1 H), 7.22 (s, 1 H), 7.24 - 7.30 (m, 2 H), 7.53 - 7.59 (m, 2 H), 7.63 - 7.70 (m, 2 H), 8.43 (d, J=14.84 Hz, 1 H).
Example 85 N1-(4-{[[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lJfiT-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)glycinamide
Figure imgf000141_0001
Same procedure as in Step A in Example 84 using 2-bromo-N-(4-{[[2-tert-butyl-l- (tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide (50 mg, 0.0866 mmol) and 28% (w/v) ammonia in water (0.5 mL) in 2 mL of DMF. The product was purified by reversed- phase ΗPLC using 10-60% CΗ3CΝ/Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 41 mg (75%); Η NMR (400 MHz, METHANOL-D4): δ 1.50 - 1.56 (m, 2 H), 1.56 - 1.64 (m, 2 H), 1.67 (s, 9 H), 2.32 - 2.40 (m, 1 H), 3.26 (s, 3 H), 3.35 (dt, J=l 1.47, 2.64 Hz, 2 H), 3.89 (s, 2 H), 3.94 (d, J=2.93 Hz, 1 H), 3.96 (d, J=3.32 Hz, 1 H), 4.50 (d, J=7.42 Hz, 2 H), 7.27 (dd, J=9.08, 2.05 Hz, 1 H), 7.51 (d, J=8.98 Hz, 2 H), 7.56 (d, J=1.76 Hz, 1 H), 7.75 (d, J=9.18 Hz, 2 H), 7.83 (d, J=8.79 Hz, 1 H); MS (ESI) (M+H)+: 514.0.
Example 86
N1-(4-{[[2-tert-ButyI-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyI)amino]sulfonyl}phenyI)-N*-methylgIycinamide
Figure imgf000142_0001
Same procedure as in Step A in Example 84 using 2-bromo-N-(4-{[[2-tert-butyl-l- (tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide (30 mg, 0.0519 mmol), DIPEA (0.045 mL, 0.260 mmol) and methylamine hydrochloride (18 mg, 0.260 mmol) in 2 mL of DMF. The product was purified by reversed-phase ΗPLC using 10-60% CΗ3CΝ Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 20 mg (60%); Η NMR (400 MHz, METHANOL-D4): δ 1.49 - 1.57 (m, 2 H), 1.55 - 1.63 (m, 2 H), 1.66 (s, 9 H), 2.32 - 2.39 (m, 1 H), 2.78 (s, 3 H), 3.26 (s, 3 H), 3.35 (dt, J=l 1.42, 2.54 Hz, 2 H), 3.93 (d, J=2.93 Hz, 1 H), 3.96 (d, J=3.12 Hz, 1 H), 4.00 (s, 2 H), 4.48 (d, J=7.62 Hz, 2 H), 7.25 (dd, J=8.98, 1.95 Hz, 1 H), 7.52 (d, J=8.79 Hz, 2 H), 7.54 (d, J=1.95 Hz, 1 H), 7.75 (d, J=8.98 Hz, 2 H), 7.80 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 528.0.
Example 87
N-[2-tert-ButyI-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazoI-5-yI]-6-
[(2-hydroxyethyl)amino]-N-methylpyridine-3-sulfonamide
Figure imgf000142_0002
Step A. N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5- yl]-6-[(2-hydroxyethyl)amino]-N-methyIpyridine-3-sulfonamide
Figure imgf000143_0001
5-Bromo-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]- 6-chloro-N-methylpyridine-3-sulfonamide (see following Step B for preparation) (270 mg, 0.484 mmol) and ethanolamine (0.145 mL, 2.42 mmol) were stirred in 5 mL of DMF at 120°C for 3h. The solvent was concentrated. The product precipitated and was rinsed with ether. The product was dissolved in a 5:1 / EtOΗ:AcOΗ mixture (40 mL) containing a catalytic amount of 10% Pd/C and was shaken under H2 atmosphere (50 psi) using a Parr hydrogenation apparatus at rt for 24h. The solution was filtered through celite and the solvent was evaporated. The product was purified by reversed- phase HPLC using 10-60% CH3CΝ/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 240 mg (81%); 1H NMR (400 MHz, METHANOL-D4): δ 1.52 - 1.57 (m, 2 H), 1.58 - 1.65 (m, 2 H), 1.69 (s, 9 H), 2.33 - 2.41 (m, 1 H), 3.26 (s, 3 H), 3.36 (td, J=11.47, 2.64 Hz, 2 H), 3.48 (t, J=5.66 Hz, 2 H), 3.70 (t, J=5.57 Hz, 2 H), 3.93 (d, J=2.93 Hz, 1 H), 3.96 (d, J=3.71 Hz, 1 H), 4.53 (d, J=7.42 Hz, 2 H), 6.61 (d, J=8.98 Hz, 1 H), 7.41 (dd, J=9.08, 2.05 Hz, 1 H), 7.47 (dd, J=8.98, 1.95 Hz, 1 H), 7.61 (d, J=1.56 Hz, 1 H), 7.92 (d, J=9.18 Hz, 1 H), 7.99 (dd, J=2.44, 0.68 Hz, 1 H); MS (ESI) (M+H)+: 502.0; Anal. Calcd for 5H35N5O4S + 2.7 TFA: C, 45.11; H, 4.69; N, 8.65. Found: C, 45.18; H, 4.73; N, 8.43.
Step B. 5-Bromo-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-yImethyI)-lH- benzimidazol-5-yl]-6-chloro-N-methylpyridine-3-sulfonamide
Figure imgf000143_0002
2-tert-Butyl-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine (180 mg, 0.597 mmol) and 3-bromo, 2-chloro-pyridine-5-sulphonyl chloride (225 mg, 0.776 mmol) were stirred in 5 mL of DCM containing a catalytic amount of DMAP at rt for 4h. The solution was washed with saturated aqueous NaHCOs solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using 1 :1 / hexanes:EtOAc as eluent. Yield: 275 mg (83%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.51 - 1.60 (m, 13 H), 2.24 - 2.34 (m, 1 H), 3.30 (s, 3 H), 3.30 - 3.38 (m, 2 H), 3.99 (t, J=2.93 Hz, 1 H), 4.02 (t, J=2.93 Hz, 1 H), 4.20 (d, J=7.42 Hz, 2 H), 7.15 (dd, J=S.79, 1.76 Hz, 1 H), 7.29 - 7.33 (m, 2 H), 8.08 (d, J=2.15 Hz, 1 H), 8.39 (d, J=2.15 Hz, 1 H).
Example 88
N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-6-
[(2-methoxyethyl)amino]-N-methylpyridine-3-sulfonamide
Figure imgf000144_0001
Following the same procedure as in Step A in Example 87 using 5-bromo-N-[2-te/-t- butyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazol-5-yI]-6-chloro-N- methylpyridine-3-sulfonamide (70 mg, 0.126 mmol) and 2-methoxyethylamine (0.055 mL, 0.630 mmol) in 2 ml of DMF. The product was purified by reversed-phase ΗPLC using 10-60% CΗ3CΝ/Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 36 mg (45%); Η NMR (400 MHz, METHANOL- D4): δ 1.52 - 1.57 (m, 2 H), 1.57 - 1.66 (m, 2 H), 1.69 (s, 9 H), 2.33 - 2.42 (m, 1 H), 3.26 (s, 3 H), 3.32 - 3.39 (m, 5 H), 3.52 - 3.56 (m, 4 H), 3.93 (d, J=3.32 Hz, 1 H), 3.96 (d, j=3.91 Hz, 1 H), 4.53 (d, J=7.42 Hz, 2 H), 6.59 (d, J=9.18 Hz, 1 H), 7.41 (dd, J=9.08, 2.05 Hz, 1 H), 7.45 (dd, j=9.18, 1.95 Hz, 1 H), 7.61 (d, J=1.76 Hz, 1 H), 7.92 (d, j=8.98 Hz, 1 H), 8.00 (d, J=1.95 Hz, 1 H); MS (ESI) (M+H)+: 516.0. Example 89
N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-6-
(formylamino)-N-methyIpyridine-3-sulfonamide
Figure imgf000145_0001
Step A. N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]-6-(formylamino)-N-methylpyridine-3-sulfonamide
Figure imgf000145_0002
N-(3-Bromo-5-([[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol- 5-yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide (see following Step B for preparation) (56 mg, 0.0992 mmol) was dissolved in 20 mL of EtOΗ containing a catalytic amount of 10% Pd/C. The solution was shaken under Η2 atmosphere (40 psi) using a Parr hydrogenation apparatus at rt overnight. The solution was filtered through celite and the solvent was evaporated. The product was purified by reversed- phase HPLC using 10-60% CH3CΝ/H2O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 36 mg (45%); Η NMR (400 MHz,
METHANOL-D4): δ 1.52 - 1.57 (m, 2 H), 1.57 - 1.66 (m, 2 H), 1.69 (s, 9 H), 2.33 - 2.42 (m, 1 H), 3.25 (s, 3 H), 3.35 (td, J=l 1.47, 2.83 Hz, 2 H), 3.93 (d, J=3.12 Hz, 1 H), 3.96 (d, J=3.71 Hz, 1 H), 4.54 (d, J=7.42 Hz, 2 H), 6.70 (d, J=9.18 Hz, 1 H), 7.40 (dd, J=8.98, 2.15 Hz, 1 H), 7.58 (dd, J=9.37, 2.54 Hz, 1 H), 7.60 (d, J=l.76 Hz, 1 H), 7.92 (d, J=8.98 Hz, 1 H), 8.05 (dd, J=2.54, 0.39 Hz, 1 H); MS (ESI) (M+H)+: 486.0.
Step B. 5-Bromo-N-[2-te;-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH- benzimidazol-5-yl]-6-(formylamino)-N-methylpyridine-3-sulfonamide
Figure imgf000146_0001
5-Bromo-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]- 6-chloro-N-methylpyridine-3-sulfonamide (81 mg, 0.146 mmol) and 28% (w/v) ammonia in water (0.5 mL) were stirred in 3 mL of DMF at 120°C using a Personal Chemistry microwaves instrument for 30 min. The solvent was evaporated. The product was dissolved in EtOAc and washed with saturated aqueous ΝaΗCθ3 solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Yield: 56 mg (68%). MS (ESI) (M+H)+: 564.21.
Example 90
N-(5-{[[2-te;-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl)(methyl)amino]sulfonyl}pyridin-2-yl)acetamide
Figure imgf000146_0002
5-Bromo-N-[2-te7-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]- 6-chIoro-Λ/-methylpyridine-3-sulfonamide (275 mg, 0.495 mmol) and 28% (w/v) ammonia in water (1 mL) were dissolved in 4 mL of dioxane. The solution was stirred at 125°C using a Personal Chemistry microwaves instrument for lh. The solvent was evaporated. The product was dissolved in EtOAc and washed with saturated aqueous ΝaΗCOs solution, brine and dried over anhydrous MgS04. The product was dissolved in 25 mL of EtOΗ containing a catalytic amount of 10% Pd/C. The solution was shaken under Η atmosphere (40 psi) using a Parr hydrogenation apparatus at rt overnight. The solution was filtered through celite and the solvent was evaporated. The residue was dissolved in 10 mL of 1:1 / DCE:pyridine and acetyl chloride (0.070 mL, 0.990 mmol) was added dropwise. The solution was stirred at rt for 3h. The solvent was evaporated. The product was dissolved in EtOAc and washed with saturated aqueous NaHCθ3 solution, brine and dried over anhydrous MgS0 . The product was purified by reversed-phase HPLC using 10-60% CH3CN/H20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 170 mg (56%); Η NMR (400 MHz, METHANOL-D4): δ 1.51 - 1.56 (m, 2 H), 1.57 - 1.64 (m, 2 H), 1.68 (s, 9 H), 2.18 (s, 3 H), 2.32 - 2.41 (m, 1 H), 3.29 - 3.31 (m, 3 H), 3.35 (td, J=l 1.52, 2.54 Hz, 2 H), 3.93 (d, J=3.12 Hz, 1 H), 3.96 (d, J=2.93 Hz, 1 H), 4.52 (d, J=7.42 Hz, 2 H), 7.35 (dd, J=9.08, 2.05 Hz, 1 H), 7.57 (d, J=1.95 Hz, 1 H), 7.80 (dd, J=8.88, 2.44 Hz, 1 H), 7.90 (d, J=8.98 Hz, 1 H), 8.24 (d, J=8.79 Hz, 1 H), 8.39 (d, J=2.15 Hz, 1 H); MS (ESI) (M+H)+:500.0; Anal. Calcd for C25H33N5O4S + 1.4 TFA + 0.3 H20: C, 50.24; H, 5.31 ; N, 10.54. Found: C, 50.25; H, 5.30; N, 10.44.
Example 91
N-[4-({[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yI]amino}sulfonyl)phenyI)acetamide
Figure imgf000147_0001
Step A. N-[4-({[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH- benzimidazoI-5-yl]amino}sulfonyI)phenyl]acetamide
Figure imgf000147_0002
2-tert-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-amine (for preparation see following Steps B, C, D, and E) (30 mg, 0.104 mmol) and 4- acetamidophenyl sulphonyl chloride (29 mg, 0.125 mmol) were stirred in 2 mL of DMF containing a catalytic amount of DMAP at rt for 4h. The solvent was evaporated and the product was purified by reversed-phase ΗPLC using 10-60% CΗ3CN/Η O and lyophilized affording the title compound as the corresponding TFA salt. Yield: 23 mg (37%); 'H NMR (400 MHz, METHANOL-D4): δ 1.45 - 1.51 (m, 2 H), 1.52 - 1.60 (m, 2 H), 1.63 (s, 9 H), 2.09 (s, 3 H), 2.26 - 2.36 (m, 1 H), 3.32 (dt, J= 11.42, 2.34 Hz, 2 H), 3.89 (d, J=2.93 Hz, 1 H), 3.92 (d, J=3.12 Hz, 1 H), 4.44 (d, J=7.62 Hz, 2 H), 7.24 (dd, J=8.98, 2.15 Hz, 1 H), 7.60 - 7.66 (m, 3 H), 7.62 - 7.73 (m, 2 H), 7.78 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 485.0; Anal. Calcd for C25H32N4O4S + 1.8 TFA + 0.5 H20: C, 49.15; H, 5.02; N, 8.02. Found: C, 49.09; H, 5.00; N, 8.21.
Step B . N-{3-Nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}acetamide
Figure imgf000148_0001
N-(4-Fluoro-3-nitrophenyl)acetamide (500 mg, 2.52 mmol) and 4-aminomethyl tetrahydropyran (350 mg, 3.02 mmol) were stirred in 20 mL of EtOH containing TEA (0.525 mL, 3.78 mmol) at 75°C overnight. The solvent was concentrated. The residue was dissolved in EtOAc and washed with aqueous 5% KΗSO4, saturated aqueous ΝaHCOs solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Yield: 61 1 mg (83%); Η ΝMR (400 MHz, CHLOROFORM-D): δ 1.42 (ddd, J=25.19, 12.11, 4.49 Hz, 2 H), 1.74 (dd, J=12.89, 1.95 Hz, 2 H), 1.89 - 2.00 ( , IH), 2.18 (s, 3 H), 3.22 (dd, J=6.44, 5.66 Hz, 2 H), 3.42 (dt, J=l 1.86, 2.05 Hz, 2 H), 4.02 (dd, J=10.94, 3.71 Hz, 2 H), 6.84 (d, J=9.37 Hz, 1 H), 7.20 (br.s, 1 H), 7.81 (dd, J=9.37, 2.54 Hz, 1 H), 8.09 (d, J=2.54 Hz, 1 H), 8.10 - 8.12 (m, 1 H). Step C . N-{3-Amino-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}acetamide
Figure imgf000149_0001
N-{3-Νitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} acetamide (605mg, 2.06 mmol) was dissolved in 50 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under Η2 atmosphere (40 psi) using a Parr hydrogenation apparatus overnight at rt. The solution was filtered through celite and the solvent was evaporated. Yield: 315mg (58%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.40 (ddd, J=25.14, 12.06, 4.39 Hz, 2 H), 1.74 (dd, J=12.89, 1.95 Hz, 2 H), 1.82 - 1.91 (m, IH), 2.13 (s, 3 H), 2.99 (d, J=6.64, 2 H), 3.42 (dt, J=11.86, 2.05 Hz, 2 H), 4.02 (dd, J=10.94, 3.71 Hz, 2 H), 6.84 (d, J=9.37 Hz, 1 H), 7.20 (br.s, 1 H), 7.81 (dd, J=9.37, 2.54 Hz, 1 H), 8.09 (d, J=2.54 Hz, 1 H), 8.10 - 8.12 (m, 1 H).
Step D . N-[2-tβrt-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol- 5-yl] acetamide
Figure imgf000149_0002
N-{3-Amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}acetamide (315 mg, 1.20 mmol) and DMAP (30 mg, 0.240 mmol) were dissolved in 20 mL of DCM.
Trimethylacetyl chloride (0.160 mL, 1.32 mmol) was added dropwise and the solution was stirred at rt for 2h. The solution was washed with aqueous ΝaΗCU3 solution, brine and dried over anhydrous MgS04. The residue was dissolved in 3 L of AcOH and was heated at 125°C for lh using a Personal Chemistry microwave apparatus. The solvent was evaporated. The residue was dissolved in EtOAc and washed with aqueous NaHCθ3 solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using 1 :1 / hexanes : acetone as eluent. Yield: 135 mg (34%); 1H NMR (400 MHz, CHLOROFORM-D): δ 1.48 - 1.54 (m, 4 H), 1.56 (s, 9 H), 2.20 (s, 3 H), 2.24 - 2.35 (m, 1 H), 3.28 - 3.35 ( , 2 H), 3.96 (t, J= 2.83 Hz, 1 H), 3.99 (t, J= 3.03 Hz, 1 H), 4.19 (d, J=7.42 Hz, 2 H), 7.27 (d, J=8.59 Hz, 1 H), 7.34 (br.s, 1 H), 7.57 (dd, J=8.79, 1.95 Hz, 1 H), 7.67 (d, J=1.95 Hz, I H).
Step E . 2-tej-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- amine
Figure imgf000150_0001
N-[2-te/-t-Butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]acetamide (135 mg, 0.409 mmol) was dissolved in 4 mL of 1 :1 / EtOΗ:2M HCl. The solution was heated at 120°C for 30 min using a Personal Chemistry microwave apparatus. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 2M ΝaOH solution, brine and dried over anhydrous MgS0 . The solvent was evaporated. Yield: 117 mg (99%); Η ΝMR (400 MHz, CHLOROFORM-D): δ 1.47 - 1.52 (m, 4 H), 1.54 (s, 9 H), 2.23 - 2.31 (m, 1 H), 3.28 - 3.36 (m, 2 H), 3.96 (t, J= 3.12 Hz, 1 H), 3.97 - 4.00 (m, 1 H), 4.13 (d, J=7.62 Hz, 2 H), 6.66 (dd, J=8.40, 2.15 Hz, 1 H), 7.06 (d, J=2.15 Hz, 1 H), 7.10 (d, J=8.40 Hz, 1 H).
Example 92
N-[4-({[2-tert-Buryl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl]amino}sulfonyl)phenyl]acetamide
Figure imgf000151_0001
Step A. N-[4-({[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzin idazol-5- yl]amino}sulfonyl)phenyI]acetamide
Figure imgf000151_0002
2-te?-t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-amine (for preparation see following Steps, B, C, D, and E) (50 mg, 0.175 mmol) and 4-acetamidophenyl sulphonyl chloride (49 mg, 0.210 mmol) were stirred in 3 mL of DCM containing a catalytic amount of DMAP at rt for 4h. The solvent was evaporated and the product was purified by reversed-phase ΗPLC using 10-70% CΗ3CN/Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 80 mg (77%); Η NMR (400 MHz, METHANOL-D4): δ 1.21 (m, 5 H), 1.59 ( , 1 H), 1.61 ( , 1 H), 1.63 (s, 9 H), 1.68 (m, 1 H), 1.75 (m, 2 H), 2.06 (m, 1 H), 2.10 (s, 3 H), 4.38 (d, J=7.62 Hz. 2 H), 7.25 (dd, J=9.08, 2.05 Hz, 1 H), 7.61 (d, J=1.56 Hz, 1 H), 7.66 (m, J=8.98 Hz, 2 H), 7.72 (m, 2 H), 7.76 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 483.3; Anal. Calcd for C26H34N403S + 1.4 TFA + 0.5 H20: C, 53.11; H, 5.63; N, 8.60. Found: C, 53.03; H, 5.64; N, 8.72.
Step B. N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl}acetamide
Figure imgf000151_0003
N-(4-Fluoro-3-nitrophenyl)acetamide (500 mg, 2.52 mmol) and cyclohexanemethylamine (0.400 mL, 3.02 mmol) were stirred in 15 mL of EtOH containing TEA (0.525 mL, 3.78 mmol) at 75°C overnight. The solvent was concentrated. The residue was dissolved in EtOAc and washed with aqueous 5% KHSO4, saturated aqueous ΝaHCθ3 solution, brine and dried over anhydrous MgSθ4. The solvent was evaporated. Yield: 735 mg (99%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.03 (m, 2 H), 1.25 (m, 3 H), 1.62 (m, 1 H), 1.69 (m, 1 H), 1.76 (m, 1 H), 1.79 (m, 1 H), 1.82 (m, 1 H), 1.86 (m, 1 H), 2.17 (s, 3 H), 3.14 (dd, J=6.25, 4.30 Hz, 2 H), 6.83 (d, J=9.37 Hz, 1 H), 7.20 (m, 1 H), 7.78 (dd, J=9.28, 2.64 Hz, 1 H), 8.07 (d, J=2.54 Hz, 1 H), 8.12 (m, 1 H).
Step C. N-{3-Amino-4-[(cyclohexylmethyl)amino]phenyI}acetamide
Figure imgf000152_0001
N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl}acetamide (730 mg, 2.51 mmol) was dissolved in 40 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken under H2 atmosphere (45 psi) using a Parr hydrogenation apparatus overnight at rt. The solution was filtered through celite and the solvent was evaporated. Yield: 629 mg (96%); Η ΝMR (400 MHz, CHLOROFORM-D): δ 1.00 (m, 2 H), 1.25 (m, 4 H), 1.60 ( , 1 H), 1.69 ( , 1 H), 1.73 (m, 1 H), 1.76 (m, 1 H), 1.83 (m, 1 H), 1.86 (m, 1 H), 2.13 (s, 3 H), 2.91 (d, J=6.64, 2 H), 3.38 (m, 2 H), 6.56 (d, J=8.40 Hz, 1 H), 6.69 (dd, J=8.40, 2.15 Hz, 1 H), 7.01 (m, 1 H), 7.1 l(d, J=2.34 Hz, 1 H).
Step D. N-[2-tert-Butyl-l-(cyclohexyImethyl)-lH-benzimidazol-5-yl]acetamide
Figure imgf000153_0001
N-{3-Amino-4-[(cyclohexylmethyl)amino]phenyl}acetamide (367 mg, 1.40 mmol) and DMAP (34 mg, 0.280 mmol) were dissolved in 10 mL of DCM. Trimethylacetyl chloride (0.190 L, 1.54 mmol) was added dropwise and the solution was stirred at rt for lh. The solvent was evaporated. The product was dissolved in 4 mL of AcOH and was stirred at 150°C for 45 min. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous ΝaHC03 solution, brine and dried over anhydrous MgS04. The crude product was purified by silica gel flash chromatography using 2:1 / hexanes : acetone as eluent. Yield: 268 mg (58%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.09 (m, 2 H), 1.17 (m, 3 H), 1.55 (s, 9 H), 1.62 (m, 1 H), 1.65 (m, 1 H), 1.69 (m, 1 H), 1.73 (m, 2 H), 2.03 (m, 1 H), 2.19 (s, 3 H), 4.11 (d, J=7.42, 2 H), 4.11 (d, J=7.42 Hz, 2 H), 7.27 (m, 1 H), 7.37 (m, 1 H), 7.55 (dd, J=8.69, 2.05 Hz, 1 H), 7.65(d, J=1.95 Hz, 1 H).
Step E. 2-tert-Butjrl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- amine
Figure imgf000153_0002
N-[2-terf-Butyl-l -(cyclohexylmethyl)-lH-benzimidazol-5-yl]acetamide (260 mg, 0.794 mmol) was dissolved in 4 mL of 1:1 / EtOΗ:2M HCl mixture. The solution was stirred at 170°C using a Personal Chemistry microwaves instrument for 30 min. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous ΝaHC03 solution, brine and dried over anhydrous MgSU4. The solvent was evaporated. Yield: 205 mg (90%); 'H NMR (400 MHz, CHLOROFORM-D): δ 1.08 (m, 2 H), 1.17 (m, 3 H), 1.53 (s, 9 H), 1.63 (m, 1 H), 1.67 (m, 1 H), 1.72 ( , 1 H), 2.01 (m, 1 H), 3.58 (m, 1 H), 4.05 (d, J=7.42, 2 H), 6.64 (dd, J=8.59, 2.15 Hz, 2 H), 7.06 (d, J=1.95 Hz, 1 H), 7.1 l(d, J=8.40 Hz, 1 H).
Example 93 N-(4-{[[2-tert-Butyl-l-(2-piperidin-l-ylethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000154_0001
Step A. N-(4-{[[2-tert-Butyl-l-(2-piperidin-l-ylethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000154_0002
Same procedure used as in Step A of Example 92 using 2-tert-butyl-N-methyl-l-(2- piperidin-l-ylethyI)-lH-benzimidazol-5-amine (for preparation see following Steps B,
C, D and E) (22 mg, 0.070 mmol) and 4-acetamidophenyl sulphonyl chloride (20 mg,
0.084 mmol) in 5 mL of DCM. The solvent was evaporated and the product was purified by reversed-phase ΗPLC using 10-50% CΗ3CΝ/Η20 and lyophilized affording the title compound as the corresponding TFA salt. Yield: 30 mg (68%); Η NMR (400 MHz, METHANOL-D4): δ 1.64 (s, 9 H), 1.94 (m, 6 H), 2.15 (s, 3 H), 3.18 (m, 2 H), 3.25 (s, 3 H), 3.57 (m, 2 H), 4.98 (m, 2 H), 7.33 (dd, J=8.88, 2.05 Hz, 1 H), 7.44 (d, J=1.95 Hz, 1 H), 7.46 (d, J=8.98 Hz, 2 H), 7.72 (m, 3 H); MS (ESI) (M+H)+: 512.3; Anal. Calcd for C27H37N5θ3S + 3.0 TFA + 0.8 H20: C, 45.66; H, 4.83; N, 8.07. Found: C, 45.67; H, 4.81; N, 8.02. Step B. Methyl {3-nitro-4-[(2-piperidin-l-ylethyl)amino]phenyl}carbamate
Figure imgf000155_0001
Same procedure used as in Step B of Example 92 using methyl (4-fluoro-3- nitrophenyOcarbamate (75 mg, 0.350 mmol), TEA (0.075 mL, 0.525 mmol) and 1- aminoethylpiperidine (0.060 mL, 0.420 mmol). The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Yield: 81 mg (72%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.46 (m, 2 H), 1.62 (m, 4 H), 2.45 (m, 4 H), 2.66 (t, J=6.35 Hz, 2 H), 3.36 (m, 2 H), 3.78 (s, 3 H), 6.46 (s, 1 H), 6.83 (d, J=9.37 Hz, 1 H), 7.64 (s, 1 H), 8.05 (d, J=2.73 Hz, 1 H), 8.41 (m, 1 H).
Step C. Methyl {3-amino-4-[(2-piperidin-l-ylethyI)amino]phenyl}carbamate
Figure imgf000155_0002
Same procedure used as in Step C of Example 92 using methyl {3-nitro-4-[(2- piperidin-l-ylethyl)amino]phenyl}carbamate (78 mg, 0.242 mmol) and a catalytic amount of 10% Pd/C in 15 mL of EtOAc. Yield: 56 mg (79%). MS (ESI) (M+H)+ 293.22.
Step D. Methyl [2-tert-butyl-l-(2-piperidin-l-ylethyl)-lH-benzimidazol-5- yl]carbamate
Figure imgf000156_0001
Methyl {3-amino-4-[(2-piperidin-l-ylethyl)amino]phenyl)carbamate (55 mg, 0.188 mmol) and trimethylacetyl chloride (0.025 mL, 0.207 mmol) were stirred in 5 L of DCM containing a catalytic amount of DMAP at rt for lh. The solution was washed with saturated aqueous NaHCθ3 solution, brine and dried over anhydrous MgSθ4. The solvent was evaporated. The residue was dissolved in 2 mL of AcOH and stirred at 150°C in a Personal Chemistry microwaves instrument for 40 min. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHC03 solution, brine and dried over anhydrous MgS0 . The product was purified by reversed-phase HPLC using 10-50% CH3CN H2O. The fractions were concentrated. The residue was dissolved in EtOAc and washed with aqueous 2M NaOH solution, brine and dried over anhydrous MgS04. Yield: 27 mg (40%); H NMR (400 MHz, CHLOROFORM-D): δ 1.49 (m, 2 H), 1.55 (m, 9 H), 1.65 (m, 6 H), 2.55 (m, 2 H), 2.73 (m, 2 H), 3.78 (s, 3 H), 4.45 (m, 2 H), 4.45 (m, 2 H), 6.62 (m, 1 H), 7.26 (m, 1 H), 7.40 (m, 1 H), 7.61 (d, J=1.95 Hz, 1 H).
Step E. 2-tert-Butyl-N-methyl-l-(2-piperidin-l-ylethyl)-lH-benzimidazol-5- amine
Figure imgf000156_0002
Methyl [2-tert-butyl-l -(2-piperidin-l -ylethyl)-lH-benzimidazol-5-yl]carbamate (27 mg, 0.0753 mmol) was dissolved in 5 mL of TΗF at 0°C. IM ΗCl/ether (0.115 mL, 0.113 mmol) was added and the solution was stirred at 0°C for 15 min. LiAlFL (15 mg, 0.377 mmol) was added and the solution was stirred at rt for 24h. The reaction was quenched at 0°C by the addition of MeOH (0.5 mL) and water (0.5 mL). Solid Na2S04 (lg) was added and the solution was stirred at rt for lh. The solution was filtered and rinsed with THF. The solvent λvas evaporated. Yield: 22 mg (93%); MS (ESI) (M+H)+: 315.03.
Example 94
N-(4-{[[2-tert-Butyl-l-(l,4-dioxan-2-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]suIfonyl}phenyl)acetamide
Figure imgf000157_0001
Step A. N-(4-{[[2-te;T-Butyl-l-(l,4-dioxan-2-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000157_0002
Methyl [2-tert-butyl-l-(l,4-dioxan-2-ylmethyl)-lH-benzimidazol-5-yl]carbamate (for preparation see following Steps B, C and D) (45 mg, 0.130 mmol) was dissolved in 5 mL of TΗF at 0°C. IM ΗCI/ether (0.195 mL, 0.195 mmol) was added and the solution was stirred at 0°C for 15min. LiAlΗ4 (25 mg, 0.650 mmol) was added and the solution was stirred at rt for 24h. The reaction was quenched at 0°C by the addition of MeOH (0.5 mL) and water (0.5 mL). Solid Νa2S04 (lg) was added and the solution was stirred at rt for lh. The solution was filtered and rinsed with THF. The solvent was evaporated. The residue was dissolved in 3 mL of 1 :1 / DCM:DMF solution containing a catalytic amount of DMAP. 4-AcetamidophenyIsulfonyI chloride (35 mg, 0.156 mmol) was added and the solution was stirred at rt for 2h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous NaHCOs solution, brine and dried over anhydrous MgS0 . The product was purified by reversed-phase HPLC using 10-50% CH3CN/H2O affording the title compound as its corresponding TFA salt. Yield: 26 mg (33%); Η NMR (400 MHz, METHANOL-D4): δ 1.65 (s, 9 H), 2.13 (s, 3 H), 3.25 (s, 3 H), 3.50 (m, 2 H), 3.61 (dt, J=11.2S, 2.44 Hz, 1 H), 3.67 (m, 1 H), 3.70 (m, 1 H), 4.00 (dd, J=l 1.52, 2.54 Hz, 1 H), 4.10 (m, 1 H), 4.63 (m, 2 H), 5.47 (s, 2 H), 7.28 (dd, J=9.08, 2.05 Hz, 1 H), 7.50 (d, J=1.76 Hz, 1 H), 7.70 (d, J=8.98 Hz, 2 H), 7.86 (d, J=8.79 Hz, 1 H); MS (ESI) (M+H)+: 501.0; Anal. Calcd for C 5H32N405S + 1.5 TFA + 0.9 H20: C, 48.89; H, 5.17; N, 8.14. Found: C, 48.82; H, 5.12; N, 8.16.
Step B. Methyl {4-[(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}carbamate
Figure imgf000158_0001
Same procedure used as in Step B of Example 92 using methyl (4-fluoro-3- nitrophenyl)carbamate (125 mg, 0.583 mmol), TEA (0.120 mL, 0.875 mmol) and C- [l,4]dioxane-2-yl-methylamine (82 mg, 0.700 mmol). The crude product was purified by silica gel flash chromatography using 50 to 75% EtOAc/hexanes as eluent. Yield: 94 mg (52%); Η NMR (400 MHz, CHLOROFORM-D): δ 3.31 (m, 2 H), 3.46 (dd, J=l 1.42, 9.S6 Hz, 1 H), 3.64 (dd, J=3.03, 0.88 Hz, 1 H), 3.66 (d, J=3.12 Hz, 1 H), 3.73 (m, 1 H), 3.76 (m, 4 H), 3.81 (dd, J=4.20, 2.64 Hz, 1 H), 3.84 (m, 1 H), 3.87 (m, 1 H), 6.46 (m, 1 H), 6.81 (d, J=9.18 Hz, 1 H), 7.63 (m, 1 H), 8.06 (d, J=2.54 Hz, 1 H).
Step C. Methyl {3-amino-4-[(l,4-dioxan-2-yImethyl)amino]phenyl}carbamate
Figure imgf000159_0001
Same procedure used as in Step C of Example 92 using methyl {4-[(l ,4-dioxan-2- ylmethyl)amino]-3-nitrophenyl}carbamate (90 mg, 0.289 mmol) and a catalytic amount of 10% Pd/C in 15 mL of EtOAc. Yield: 81 mg (99%); MS (ESI) (M+H)+ 281.88.
Step D. Methyl [2-tert-butyI-l-(l,4-dioxan-2-ylmethyl)-lH-benzimidazol-5- yl]carbamate
Figure imgf000159_0002
Same procedure as in Step D of Example 93 using methyl {3-amino-4-[(l,4-dioxan-2- ylmethyI)amino]phenyl) carbamate (81 mg, 0.288 mmol) and trimethylacetyl chloride (0.039 mL, 0.317 mmol). The crude product was purified by silica gel flash chromatography using EtOAc as eluent. Yield: 45 mg (45%).
Example 95
N-(4-{[{2-tert-Butyl-l-[(l-methylpiperidin-2-yl)methyl]-lH-benzimidazoI-5- yl}(methyl)amino]suIfonyl}phenyl)acetamide
Figure imgf000160_0001
Step A. N-(4-{[{2-te/T-ButyI-l-[(l-methyIpiperidin-2-yI)methyl]-lH- benzimidazol-5-yl}(methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000160_0002
Same procedure as in Step A of Example 94 using methyl {2-tert-butyl-l-[(l- methylpiperidin-2-yl)methyl]-lH-benzimidazoI-5-yl}carbamate (for preparation see following Steps B, C, D, and E) (38 mg, 0.106 mmol), IM ΗCl/ether (0.150 mL, 0.159 mmol), LiAlΗ, (20 mg, 0.530 mmol) in 5 mL of TΗF and 4- acetamidophenylsulfonyl chloride (30 mg, 0.127 mmol) in 5 mL of DCM. The product was purified by reversed-phase ΗPLC using 10-50% CΗ3CΝ/Η 0 affording the title compound as its coiTesponding TFA salt. Yield: 43 mg (65%); Η NMR (400 MHz, METHANOL-D4): δ 1.39 ( , 2 H), 1.66 (s, 9 H), 1.84 (m, 2 H), 1.91 (m, 1 H), 2.15 (s, 3 H), 3.16 (s, 3 H), 3.25 (s, 3 H), 3.63 (m, 1 H), 4.02 (m, 1 H), 4.88 (m, 1 H), 5.19 (m, 1 H), 7.29 (dd, J=8.98, 2.15 Hz, 1 H), 7.46 (d, J=8.98 Hz, 2 H), 7.49 (d, J=1.76 Hz, 1 H), 7.71 (d, J=8.98 Hz, 2 H), 7.84 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 512.3; Anal. Calcd for
Figure imgf000160_0003
+ 2.7 TFA + 1.0 H20: C, 46.46; H, 5.02; N, 8.36. Found: C, 46.46; H, 4.92; N, 8.59.
Step B. tert-Butyl 2-[({4-[(methoxycarbonyl)amino]-2- nitrophenyl}amino)methyl]piperidine-l-carboxyIate
Figure imgf000161_0001
Same procedure used as in Step B of Example 92 using methyl (4-fluoro-3- nitrophenyl)carbamate (100 mg, 0.467 mmol), TEA (0.100 mL, 0.700 mmol) and 2- (aminomethyl)-l-N-Boc-piperidine (120 mg. 0.560 mmol). The crude product was purified by silica gel flash chromatography using 35 to 55% EtOAc/hexanes as eluent. Yield: 121 mg (63%); Η NMR (400 MHz, CHLOROFORM-D) D ppm 1.46 (s, 9 H), 1.53 (m, 1 H), 1.65 (m, 1 H), 1.69 (m, 2 H), 1.72 (m, 2 H), 2.79 (m, 1 H), 3.33 (m, 1 H), 3.57 ( , 1 H), 3.78 (s, 3 H), 4.07 (m, 1 H), 6.47 (m, 1 H), 6.97 (d, J=9.57 Hz, 1 H), 7.66 (m, 1 H), 8.04 (m, 1 H), 8.07 (d, J=2.54 Hz, 1 H).
Step C. Methyl (4-{[(l-methylpiperidin-2-yl)methyl]amino}-3- nitrophenyl)carbamate
Figure imgf000161_0002
tert-Butyl 2-[({4-[(methoxycarbonyl)amino]-2-nitrophenyl}amino)methyl]piperidine- 1-carboxylate (118 mg, 0.289 mmol) was stirred in 3 mL of IM HCl/AcOH at rt for lh. The solvent was evaporated. The residue was dissolved in 5 mL of MeOH and 37% HCHO/water (1 mL) was added, followed by NaBH(OAc)3 (120 mg, 0.578 mmol). The solution was stirred at rt for lh. The solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated aqueous N HCθ3 solution, brine and dried over anhydrous MgS04. The solvent was evaporated. Yield: 87 mg (93%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.29 ( , 2 H), 1.61 (m, 5 H), 1.67 (m, 1 H), 1.78 (m, 1 H), 2.15 ( , 1 H), 2.22 (m, 1 H), 2.29 (s, 3 H), 2.93 (m, 1 H), 3.26 (m, 1 H), 3.43 (m, 1 H), 6,46 (m, 1 H), 6.79 (d, J=9.37 Hz, 1 H), 7.64 (m, 1 H), 8.05 (d, J=2.54 Hz, 1 H), 8.34 (m, 1 H).
Step D. Methyl (3-amino-4-{[(l-methylpiperidin-2- yl)methyl]amino}phenyl)carbamate
Figure imgf000162_0001
Same procedure used as in Step C of Example 92 using methyl (4-{[(l- methylpiperidin-2-yl)methyl]amino}-3-nitrophenyl)carbamate (83 mg, 0.257 mmol) and a catalytic amount of 10% Pd/C in 20 mL of EtOAc. Yield: 75 mg (99%): MS (ESI) (M+H)+: 293.26.
Step E. Methyl {2-tert-butyl-l-[(l-methylpiperidin-2-yl)methyl]-lH- benzimidazol-5-yl}carbamate
Figure imgf000162_0002
Same procedure as in Step D of Example 93 using methyl (3-amino-4-{[(l- methylpiperidin-2-yl)methyI]amino}phenyl)carbamate (72 mg, 0.246 mmol) and trimethylacetyl chloride (0.033 mL, 0.271 mmol). The product was purified by reversed-phase HPLC using 10-50% CH3CN/H20. The fractions were concentrated. The residue was dissolved in EtOAc and washed with aqueous 2M NaOH solution, brine and dried over anhydrous MgS04. Yield: 38 mg (43%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.07 ( , 2 H), 1.25 (m, 1 H), 1.56 (m, 9 H), 1.59 (m, 1 H), 1.63 (m, 1 H), 1.75 (m, 1 H), 2.20 (m, 1 H), 2.47 (s, 3 H), 2.68 (m, 1 H), 2.93 (d, J=l 1.52 Hz, 1 H), 3.78 (s, 3 H), 4.24 (dd, J=14.25, 10.15 Hz, 1 H), 4.66 (dd, J=14.35, 5.17 Hz, 1 H), 6.66 (m, 1 H), 7.31 (d, J=8.59 Hz, 1 H), 7.39 (m, 1 H), 7.60 (s, 1 H).
Example 96
N-(4-{[(2-tert-Butyl-l-{[(2Λ)-l-methylpiperidin-2-yl]methyl}-lH-benzimidazol-5- yl)(methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000163_0001
Step A. N-(4-{[(2-tert-Butyl-l-{[(2i?)-l-methylpiperidin-2-yl]methyI}-lH- benzimidazol-5-yl)(methyI)amino]sulfonyl}phenyI)acetamide
Figure imgf000163_0002
Same procedure as in Step A of Example 94 using methyl (2-tert-butyl-l-{[(2i?)-l- methylpiperidin-2-yl]methyl}-lH-benzimidazol-5-yl)carbamate (for preparation see following Steps B, C, D, and E) (51 mg, 0.142 mmol), IM ΗCl/ether (0.215 mL, 0.213 mmol), LiAlΗ4 (27 mg, 0.710 mmol) in 5 mL of THF and 4- acetamidophenylsulfonyl chloride (40 mg, 0.170 mmol) in 5 mL of DCM. The product was purified by reversed-phase HPLC using 10-50% CH3CN/H2O affording the title compound as its corresponding TFA salt. Yield: 59 mg (66%); Η NMR (400 MHz, METHANOL-D4): δ 1.41 (m, 2 H), 1.65 (s, 9 H), 1.82 (m, 2 H), 1.89 (m, 2 H), 2.13 (s, 3 H), 3.15 (s, 3 H), 3.24 (s, 3 H), 3.62 (m, 1 H), 4.00 (m, 1 H), 4.86 (m, 1 H), 5.17 (m, 1 H), 7.29 (dd, J=8.98, 1.95 Hz, 1 H), 7.45 (d, J=8.79 Hz, 2 H), 7.49 (d, J=1.95 Hz, 1 H), 7.70 (d, J=8.79 Hz, 2 H), 7.83 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 512.3; Anal. Calcd for C27H37N5θ3S + 2.9 TFA + 1.2 H20: C, 45.60; H, 4.93; N, 8.11. Found: C, 45.64; H, 4.95; N, 8.05.
Step B. tert-Butyl (2i?)-2-[({4-[(methoxycarbonyl)amino]-2- nitrophenyl}amino)methyl]piperidine-l-carboxylate
Figure imgf000164_0001
Same procedure used as in Step B of Example 92 using methyl (4-fluoro-3- nitrophenyl)carbamate (300 mg, 1.40 mmol), TEA (0.300 mL, 2.10 mmol) and 2-R- (aminomethyl)-l-N-Boc-piperidine (360 mg, 1.68 mmol). The crude product was purified by silica gel flash chromatography using 30 to 50% EtOAc/hexanes as eluent. Yield: 285 mg (50%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.46 (s, 9 H), 1.53 (m, 1 H), 1.65 (m, 1 H), 1.69 (m, 2 H), 1.72 (m, 2 H), 2.79 (m, 1 H), 3.33 (m, 1 H), 3.57 (m, 1 H), 3.78 (s, 3 H), 4.07 (m, 1 H), 6.47 (m, 1 H), 6.97 (d, J=9.57 Hz, 1 H), 7.66 (m, 1 H), 8.04 (m, 1 H), 8.07 (d, J=2.54 Hz, 1 H).
Step C. Methyl [4-({[(2i?)-l-methylpiperidin-2-yl]methyI}amino)-3- nitrophenyl]carbamate
Figure imgf000164_0002
Same procedure used as in Step C of Example 95 using tert-butyl (2i?)-2-[({4- [(methoxycarbonyl)amino]-2 -nitrophenyl amino)methyl]piperidine-l -carboxylate (280 mg, 0.686 mmol), IM HCl/AcOH (3 mL), 37% HCHO/water (1 mL) and NaBH(OAc)3 (290 mg, 1.37 mmol) in 5 mL of THF. Yield: 187 mg (85%); MS (ESI) (M+H)+: 323.27.
Step D. Methyl [3-amino-4-({[(2Λ)-l-methylpiperidin-2- yl]methyl}amino)phenyl]carbamate
Figure imgf000165_0001
Same procedure used as in Step C of Example 92 using methyl [4-({[(27?)-l- methylpiperidin-2-yl]methyl}amino)-3-nitrophenyl]carbamate (187 mg, 0.580 mmol) and a catalytic amount of 10% Pd/C in 25 mL of EtOAc. Yield: 164 mg (97%); MS (ESI) (M+H)+: 293.24.
Step E. Methyl (2-tert-butyl-l-{[(2R)-l-methylpiperidin-2-yl]methyl}-lH- benzimidazol-5-yl)carbamate
Figure imgf000165_0002
Same procedure as in Step D of Example 93 using methyl [3-amino-4-({[(2i?)-l - methylpiperidin-2-yl]methyl}aιτιino)phenyl]carbamate (160 mg, 0.547 mmol) and trimethylacetyl chloride (0.075 mL, 0.602 mmol). The product was purified by reversed-phase HPLC using 10-50% CH3CN/H20. The fractions were concentrated. The residue was dissolved in EtOAc and washed with aqueous 2M NaOH solution, brine and dried over anhydrous MgS04. Yield: 55 mg (28%); Η NMR (400 MHz, CHLOROFORM-D): δ 1.08 (m, 2 H), 1.29 (m, 1 H), 1.57 (s, 9 H), 1.61 (m, 3 H), 2.22 (m, 1 H), 2.49 (s, 3 H), 2.72 (m, 1 H), 2.96 ( , 1 H), 3.78 (s, 3 H), 4.26 (dd, J=14.35, 4.98 Hz, 1 H), 6.62 (s, 1 H), 7.32 (d, J=8.59 Hz, 1 H), 7.39 (m, 1 H), 7.61 (s, I H).
Example 97
N-[4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lJH- benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide
Figure imgf000166_0001
Step A. N-[4-({methyl[l-(tetrahydro-2H-pyran-4-yImethyl)-2-(trifluoromethyl)- lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide
Figure imgf000166_0002
N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH-benzimidazol- 5-amine hydrochloride (76.1 mg, 0.2 mmol) (for preparation, see the following steps B, C, D, and E), DMAP (97.7 mg, 0.8 mmol) and 4-(acetylamino)benzenesulfonyl chloride (93.5 mg, 0.4 mmol) in MeCΝ (5 mL) were stirred overnight at room temperature. The reaction mixture was quenched with Η2O (6 mL). Upon evaporation, the crude product was purified by reversed-phase HPLC using 20-70% CH3CΝ/H20 and then lyophilized affording the title compound as the coiTesponding TFA salt. Yield: 49.1 mg (48%); 'HNMR (400 MHz, CD3OD): 1.39 - 1.56 (m, 4 H), 2.14 (s, 3 H), 2.19 - 2.32 ( , 1 H), 3.24 (s, 3 H), 3.31 - 3.39 (m, 2 H), 3.85 - 4.01 ( , 2 H), 4.32 (d, J=7.42 Hz, 2 H), 7.32 (dd, J=8.88, 2.05 Hz, 1 H). 7.40 (d, J=1.95 Hz, 1 H), 7.43 - 7.49 (m, 2 H), 7.67 - 7.75 (m, 3 H); MS (ESI) (M+H)+: 511.0; Anal. Calcd for C23H25F3N4O4S+ 0.4 TFA+0.2 H20 (559.75): C, 51.07, H, 4.65, N, 10.01 ; Found: C, 51.16; H, 4.74; N, 9.65.
StepB . N-methyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}acetamide
Figure imgf000167_0001
4-Aminomethylpyran (2.50 g, 21.7 mmol ) was added to a mixture of N-(4-fluoro-3- nitrophenyl)-N-methylacetamide (4.61 g, 21.27 mmol) and sodium carbonate (5.10 g, 47.7 mmol) in EtOH (120 mL) at room temperature. The reaction mixture was heated for 3 days at 60 °C. Upon evaporation of ethanol, the residue was dissolved in EtOAc (400 mL), washed with H20 (3x50 mL), saturated ΝaCl (3x50 mL), and dried over Νa2S04. After filtation and concentration, 6.62 g (100%) of the title compound was obtained as an orange-red solid. Η NMR (400 MHz, CDC13) δ 1.38 - 1.52 ( , 2 H), 1.72 - 1.81 (m, 2 H), 1.90 (s, 3 H), 1.93 - 2.02 (m, 1 H), 3.23 (s, 3 H), 3.23 - 3.27 (m, 2 H), 3.36 - 3.49 (m, 2 H), 4.01 - 4.07 (m, 2 H), 6.91 (d, J=9.18 Hz, 1 H), 7.29 (dd, J=9.08, 2.64 Hz, 1 H), 8.05 (d, J=2.34 Hz, 1 H), 8.22 (t, J=5.37 Hz, 1 H); MS (ESI) (M+H)+: 309.12.
Step C . N-{3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl]-N- methylacetamide
Figure imgf000167_0002
N-methyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} acetamide (5.39 g, 16.7 mmol) was hydrogenated in ethyl acetate (200 mL) catalyzed by 10% Pd/C (0.2 g) at 30-40 psi H2 in Parr shaker for 18 h at room temperature. After filtration through celite and concentration, 6.0 g (100%) of a purple solid was obtained as HCl salt, which was used in the next step without further purification. Η NMR (400 MHz, CD3OD): δ 1.32 - 1.46 (m, 2 H), 1.78 - 1.84 (m, 2 H), 1.85 (s, 3 H), 1.91 - 2.06 (m, 1 H), 3.16 (d, J=6.83 Hz, 2 H), 3.20 (s, 3 H), 3.39 - 3.51 (m, 2 H), 3.94 - 4.03 (m, 2 H), 7.01 (d, J=8.59 Hz, 1 H), 7.12 (d, J=2.15 Hz, 1 H), 7.17 (dd, J=8.49, 4.39 Hz, 1 H); MS (ESI) (M+H)+: 278.7.
Step D . N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- lH-benzimidazoI-5-yl]acetamide
V
Figure imgf000168_0001
A solution of N-{3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl -N- methylacetamide hydrochoride (395.1 mg, 1.42 mmol) in trifluoroacetic acid (10 mL) was heated to reflux for 20 h. After evaporation of the solvent, the crude product was used directly for next step without further purification. MS (ESI) (M+Η)+: 356.02.
Step E . N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-amine
Figure imgf000168_0002
The crude N-methyl-N-[l -(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]acetamide (-500 mg, 1.42 mmol) was dissolved in 10 mL of EtOΗ-2NΗCl (3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for 4 h. After concentration and dried in vacuo, 539 mg (100%) of a grey white solid was obtained as the title product, which was used directly for Step A. MS (ESI) (M+H)+: 314.20.
Example 98 4-Bromo-N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]- N-methyl-benzenesulfonamide
Figure imgf000169_0001
N-l-(Cyclohexylmethyl)-2-(l,l-dimethylethyl)-N-methyl-lH-benzimidazol-5-amine hydrochloride (532.2 mg, 1.39 mmol) (for preparation, see Example 39), DMAP
(679.3 mg, 5.56 mmol) and 4-bromobenzenesulfonyl chloride (426.7 mg, 1.67 mmol) in MeCΝ (50 mL) were stirred overnight at room temperature. The reaction mixture was quenched with saturated ΝaΗC03 (10 mL), evaporated td small volume and extracted with EtOAc (3x50 mL). The combined organic phases were washed with brine and dried over Na2S04. After evaporation of the solvent, the product was purified by MPLC using Hexanes/EtOAc (1 :1) on silica gel to give 529.6 mg (74%) of a white solid as the title product. A small amount of the title product was converted to the corresponding TFA salt. Η NMR (400 MHz, CD3OD): δ 1.26 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.1 1 (m, 1 H), 3.29 (s, 3 H), 4.45 (d, J=7.62 Hz, 2 H), 7.3 l(m, 1 H), 7.45 (m, 2 H), 7.53 (d, J=l .56 Hz, 1 H), 7.72 (m, 2 H), 7.85 (d, .1=8.98 Hz, 1 H); MS (ESI) (M+H)+: 518.2; Anal. Calcd for C25H32BrN3θ2S+1.00 TFA+1.40 H20 (639.75): C, 50.69; H, 5.33; N, 6.57; Found: C, 50.75; H, 5.40; N, 6.47.
Example 99
N-[2-tert-butyl-l-(cy ohexylmethyl)-lH-benzimidazoI-5-yI]-4-[(2- hydroxyethyl)amino]-N-methylbenzenesulfonamide
Figure imgf000170_0001
4-Bromo-N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]-N- methyl-benzenesulfonamide (21.0 mg, 0.0405 mmol) (for preparation, see Example 40) and ethanolamine (1.0 mL) were placed in a sealed tube. The mixture was heated at 220°C in a Personal Chemistry SmithSynthesizer microwave instrument for 1.5 h, and purified by reversed-phase ΗPLC using 15-60% CΗ3CΝ Η2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 20.8 mg (84%); Η NMR (400 MHz, CD3OD): δ 1.24 (m, 5 H), 1.63 (m, 2 H), 1.66 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.11 (m, 1 H), 3.20 (s, 3 H), 3.26 (t, J=5.76 Hz, 2 H), 3.70 (t, J=5.86 Hz, 2 H), 4.44 (d, J=7.62 Hz, 2 H), 6.61 ( , 2 H), 7.23 (m, 2 H), 7.32 (dd, J=8.98, 2.15 Hz, 1 H), 7.51 (d, J=1.95 Hz, 1 H), 7.81 (d, J=9.18 Hz, 1 H); MS (ESI) (M+H)+: 499.2; Anal. Calcd for C27H38N4O3S+1.60 TFA+2.30 H20 +0.3 MeCN (734.88): C, 50.34; H, 6.19; N; 8.20; Found: C, 50.40; H, 6.17; N, 8.18.
Example 100
N-[2-te/T-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-4-(dimethyIamino)- N-methylbenzenesulfonamide
Figure imgf000170_0002
Following the procedure for Example 99, using 4-Bromo-N-[l-(cyclohexylmethyl)-2- (l,l-dimethylethyl)-lH-benzimidazol-5-yl]-N-methyl-benzenesulfonamide (31.6 mg, 0.0609 mmol) (for preparation, see Example 98) and ethanolamine (0.5 mL) in DMF (1.0 mL), the crude product was purified by reversed-phase ΗPLC using 15-60% CΗ3CΝ/Η2O and then lyophilized affording 20.4 mg (56%) of the title compound and 12.8 mg (34%) of the title compound in Example 41 as the corresponding TFA salt. 'H NMR (400 MHz, CD3OD): δ 1.25 ( , 5 H), 1.63 (m, 2 H), 1.67 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.1 1 (m, 1 H), 3.03 (s, 6 H), 3.21 (s, 3 H), 4.44 (d, J=7.62 Hz, 2 H), 6.70 (m, 2 H), 7.31 (m, 3 H), 7.52 (d, J=1.95 Hz, 1 H), 7.82 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 483.3; Anal. Calcd for C27H38N4O2S+1.50 TFA+1.10 H20 (673.55): C, 53.50; H, 6.24; N, 8.32, Found: C, 53.42; H, 6.20; N, 8.42.
Example 101
4-[bis(2-hydroxyethyl)amino]-N-[2-tert-butyl-l-(cyclohexylmethyl)-lH- benzimidazol-5-yI]-N-methyIbenzenesulfonamide
Figure imgf000171_0001
Following the procedure for Example 99, using 4-Bromo-N-[l-(cyclohexylmethyl)-2-
(l,l-dimethylethyl)-lH-benzimidazol-5-yl]-N-methyl-benzenesulfonamide (31.2 mg,
0.0602 mmol) (for preparation, see Example 40) and 2,2'-iminodiethanol (1.0 mL), the crude product was purified by reversed-phase HPLC using 15-60% CH3CΝ/H2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 25.3 mg (64%); Η NMR (400 MHz, CD3OD): 1.25 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 2.10 ( , 1 H), 3.22 (s, 3 H), 3.60 (t, J=5.86 Hz, 4 H), 3.72 (t, J=5.86 Hz, 4 H), 4.45 (d, J=7.62 Hz, 2 H), 6.77 (m, 2 H), 7.30 (m, 2 H), 7.33 (m, 1 H), 7.54 (d, J=1.95 Hz, 1 H), 7.83 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 543.2; Anal. Calcd for C29H42N4θ4S+l .60 TFA+0.4 H20 (732.39): C, 52.81 ; H, 6.11 ; N, 7.65, Found: C, 52.85; H, 6.06; N, 7.69.
Example 102
N-[2-tert-butyl-l-(cyclohexylmethyI)-lH-benzimidazoI-5-yl]-N,4-dimethyl-3,4- dihydro-2H-l,4-benzoxazine-7-sulfonamide
Figure imgf000172_0001
Following the procedure as in Example 98, using N-l-(Cyclohexylmethyl)-2-(l,l- dimethylethyl)-N-methyl-lH-benzimidazol-5-amine hydrochloride (33.0 mg, 0.0886 mmol) (for preparation, see the step F in Example 40), DMAP (43.3 mg, 0.354 mmol) and 4-methyl-3,4-dihydro-2H-l,4-benzoxazine-7-sulfonyl chloride (28.5 mg, 0.115 mmol) in MeCΝ (5 mL), the crude product was purified by by reversed-phase ΗPLC using 20-70% CΗ3CΝ/Η2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 43.3 mg (78%); Η NMR (400 MHz, CD3OD): δ 1.25 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.70 (m, 1 H), 1.78 (m, 2 H), 2.1 1 (m, 1 H), 2.72 (s, 3 H), 3.24 (s, 3 H) , 3.28 (m, 2 H), 4.31 (m, 2 H) , 4.46 (d, J=7.42 Hz, 2 H), 6.66 (s, 1 H), 6.77 (m, 2 H), 7.32 (m, 1 H), 7.57 (d, J=1.37 Hz, 1 H), 7.85 (d, J=7.62 Hz, 1 H);. MS (ESI) (M+H)+: 511.2; Anal. Calcd for C28H38N4O3S+1.40 TFA+0.40 H20 (677.54): C, 54.60; H, 5.98; N, 8.27, Found: C, 54.48; H, 5.89; N, 8.52.
Example 103
N-[4-({methyl[2-(l-methyl-l-pyridin-2-ylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide
Figure imgf000172_0002
Step A. N-[4-({methyl[2-(l-methyl-l-pyridin-2-ylethyl)-l-(tetrahydro-2H-pyran- 4-ylmethyl)-lH-benzimidazol-5-yl]amino}sulfonyI)phenyl]acetamide
Figure imgf000173_0001
N-methyl-2-(l -methyl- l-pyridin-2-yIethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-amine hydrochloride (85.0 mg, 0.13 mmol) (for preparation, see the following steps B, C, D, E and F), DMAP (64.0 mg, 0.53 mmol) and 4- (acetylamino)benzenesulfonyl chloride (60.7 mg, 0.26 mmol) in MeCΝ (5 L) were stirred for 8 h at room temperature. The reaction mixture was quenched with Η20 (3 mL). Upon evaporation, the residue was purified by reversed-phase HPLC using 10- 50% CH3CΝ/H2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 45.8 mg (63%);. ' HNMR (400 MHz, CD3OD): δ 1.07 - 1.13 (m, 4 H), 1.14 - 1.21 (m, 1 H). 2.02 (s, 6 H), 2.14 (s, 3 H), 2.92 - 3.09 (m, 2 H), 3.27 (s, 3 H), 3.71 - 3.80 (m, 2 H), 3.95 (d, J=6.64 Hz, 2 H), 7.28 (dd, J=8.98, 1.95 Hz, 1 H), 7.41 - 7.46 (m, 1 H), 7.46 - 7.51 (m, 2 H), 7.57 (d, J=1.76 Hz, 1 H), 7.67 - 7.80 (m, 4 H), 7.91 - 8.02 (m, 1 H), 8.43 - 8.55 (m, 1 H); MS (ESI) (M+H)+: 562.0; Anal. Calcd for C3oH35N504S+ 1.20TFA+0.40H2O +0.50 CH3OH (721.61): C, 54.75; H, 5.45; N, 9.70; Found: C, 54.76 ; H, 5.46; N, 9.76.
Step B. N-methyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyI)amino]phenyl}acetamide
Figure imgf000173_0002
4-Aminomethylpyran (2.50 g, 21.7 mmol ) was added to a mixture ofN-(4-fluoro-3- nitrophenyl)-N-methylacetamide (4.61 g, 21.27 mmol) (for preparation, see Example 97, Step B) and sodium carbonate (5.10 g, 47.7mmol) in EtOH (120 mL) at room temperature. The reaction mixture was heated for 3 days at 60 °C. Upon evaporation of ethanol, the residue was dissolved in EtOAc (400 mL), washed with H20 (3x50 mL), saturated NaCl (3x50 mL), and dried over Na2S04. After fϊltation and concentration, 6.62 g (100%) of the title compound was obtained as an orange-red solid. Η NMR (400 MHz, CDC13) δ 1.38 - 1.52 ( , 2 H), 1.72 - 1.81 (m, 2 H), 1.90 (s, 3 H), 1.93 - 2.02 (m, 1 H), 3.23 (s, 3 H), 3.23 - 3.27 (m, 2 H), 3.36 - 3.49 (m, 2 H), 4.01 - 4.07 (m, 2 H), 6.91 (d, J=9.18 Hz, 1 H), 7.29 (dd, J=9.08, 2.64 Hz, 1 H), 8.05 (d, J=2.34 Hz, 1 H), 8.22 (t, J=5.37 Hz, 1 H); MS (ESI) (M+H)+: 309.12.
Step C. N-{3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyI)amino]phenyl}-N- methylacetamide
Figure imgf000174_0001
N-methyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) acetamide (5.39 g, 16.7 mmol) was hydrogenated in ethyl acetate (200 mL) catalyzed by 10% Pd/C (0.2 g) at 30-40 psi Η> in Parr shaker for 18 h at room temperature. After filtration through celite and concentration, 6.0 g (100%) of a purple solid was obtained as HCl salt, which was used in the next step without purification. Η ΝMR (400 MHz, CD3OD): δ 1.32 - 1.46 (m, 2 H), 1.78 - 1.84 (m, 2 H), 1.85 (s, 3 H), 1.91 - 2.06 (m, 1 H), 3.16 (d, J=6.83 Hz, 2 H), 3.20 (s, 3 H), 3.39 - 3.51 (m, 2 H), 3.94 - 4.03 (m, 2 H), 7.01 (d,J=8.59 Hz, 1 H), 7.12 (d, J=2.15 Hz, 1 H), 7.17 (dd, J=8.49, 4.39 Hz, 1 H); MS (ESI) (M+H)+: 278.7
Step D. N-methyl-N-[2-(pyridin-2-ylmethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl]acetamide
Figure imgf000174_0002
Diisopropylethylamine (0.970 g, 7.50 mmol) was added into a solution of N-{3- amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-N-methylacetamide hydrochoride (0.416 g, 1.33 mmol) and 2-pyridylacetic acid hydrochloride (0.286 g, 1.65 mmol) in DMF (15 mL) at 0 °C. Stirring for 20 min ΗATU (0.680 g, 1.80 mmol) was added. The reaction mixture was stirred for 4 h at room temperature, quenched with water (5 mL), concentrated to small volume, dissolved EtOAc (150 mL), washed with saturated ΝaCl (10 mL) and dried with anhydrous Νa2S04. After filtration and concentration, the residue was dissolved in acetic acid (20 mL) and heated for 18 h at 80 °C. Upon evaporation of the solvent, the residue was diluted with EtOAc (150 L), washed with 2 NNaOΗ(10 mL) and satturated NaCl (2x10 mL), and dried over Na2S04. After filtration and evaporation, the crude product was purified by MPLC using CH CL/MeOH (10:1) on silica gel to give 0.3 lg (61%) of a yellow solid as the title compound. MS (ESI) (M+H)+: 379.0.
Step E. N-methyl-N-[2-(l-methyl-l-pyridin-2-ylethyI)-l-(tetrahydro-2H-pyran- 4-ylmethyl)-lH-benzimidazoI-5-yI]acetamide XrN
Figure imgf000175_0002
Figure imgf000175_0001
KHMDS (1.6 mL, 0.5 M, 0.8 mmol) was added to a solution of N-methyl-N-[2- (pyridin-2-ylmethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yljacetamide (248.4 mg, 0.656 mmol) in TΗF (25 mL) at -78 °C. Stirring for 10 min, iodomethane (113.6 mg, 50 uL, 0.80 mmol) was added. The mixture was stirred for 30 min at -78 °C and 30 min at room temperature, then cooled down to -78 °C again. Another 1.2 equivalent KΗMDS and iodomethane were added. The resulting mixture was stirred for 30 min at -78 °C and 45 min at room temperature, quenched with saturated ΝaΗC03 (5 mL), and extracted with EtOAc (3x20 mL). The combined organic phases were washed with saturated NaHC03 (20 mL), brine (20 mL) and dried over Na2S04. After filtration and concentration, the residue was purified by MPLC using EtOAc/MeOH (20:1 ) on silica gel to give 218.1 mg (90%) of the title compound as a white solid. ]HNMR (400 MHz, CDC13): δ 1.02 - 1.12 (m, 2 H), 1.13 - 1.19 (m, 2 H), 1.19 - 1.27 (m, 1 H), 1.90 (s, 3 H), 1.97 (s, 6 H), 2.90 - 3.11 (m, 2 H), 3.31 (s, 3 H), 3.68 (d, J=7.22 Hz, 2 H), 3.81 (m, 2 H), 7.04 (dd, J=8.49, 2.05 Hz, 1 H), 7.18 - 7.32 (m, 3 H), 7.57 - 7.70 (m, 2 H), 8.53 - 8.70 (m, 1 H); MS (ESI) (M+H)+: 407.03.
Step F. N-methyl-2-(l-methyl-l-pyridin-2-ylethyI)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-amine
Figure imgf000176_0001
N-methyl-N-[2-( 1 -methyl- 1 -pyridin-2-ylethyl)- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]acetamide (214. Omg, 0.526 mmol) was dissolved in 5 mL of EtOΗ-2NΗCl (3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for lh. After concentration and dried in vacuo, 331 mg (100%) of a grey white solid was obtained as the title product. Η ΝMR (400 MHz, DMSO-D6): δ 0.86 - 1.08 (m, 4 H), 1.94 (s, 6 H), 1.96 - 2.03 (m, 1 H), 2.71 - 2.92 (m, 5 H), 3.55 - 3.70 (m, 2 H), 3.86 (d, J=5.47 Hz, 2 H), 7.31 - 7.48 (m, 2 H), 7.69 (d, J=7.42 Hz, 1 H), 7.74 - 7.84 (m, 1 H), 7.93 (t, J=8.30 Hz, 1 H), 8.48 (d, J=4.10 Hz, 2 H); MS (ESI) (M+H)+: 365.04.
Example 104
N-(4-{[[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](ethyl)amino]sulfonyl}phenyI)acetamide
Figure imgf000177_0001
2-te7-t-butyl-N-ethyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazol-5-amine hydrochloride (52.8 mg, 0.15 mmol) (for preparation, see Example 71), DMAP (73.3 mg, 0.60 mmol) and 4-(acetylamino)benzenesulfonyl chloride (70.1 mg, 0.30 mmol) in MeCΝ (5 mL) were stirred overnight at room temperature. The reaction mixture was diluted with EtOAc (100 mL), washed with saturated ΝaΗC03 (10 mL) and saturated NaCl (10 mL), and dried overNa2S04. Upon evaporation, the residue was purified by MPLC using EtOAc/MeOH (20:1) on silica gel to give 60.3 mg (78%) of a white solid as the title compound. ' HNMR (400 MHz, CD3OD): δ 1.07 (t, J=7.13 Hz, 3 H), 1.51 - 1.64 (m, 4 H), 1.68 (s, 9 H), 2.15 (s, 3 H), 2.29 - 2.47 (m, 1 H), 3.32 - 3.42 (m, 2 H), 3.72 (q, J=7.22 Hz, 2 H), 3.90 - 4.01 (m, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.25 (dd, J=8.98, 1.95 Hz, 1 H), 7.47 - 7.55 (m, 3 H), 7.66 - 7.78 (m, 2 H), 7.90 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 513.0; Anal. Calcd for C27H36N404S+ 1.30 TFA+0.30 CH3OH (670.52): C, 53.56; H, 5.79; N, 8.36; Found: C, 53.66 ; H, 5.75; N, 8.10..
Example 105 4-[(aminocarbonyl)amino]-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyI)- lH-benzimidazol-5-yl]-N-ethyIbenzenesulfonamide
Figure imgf000177_0002
Following the procedure as in Example 104, using 2-tert-butyl-N-ethyl-l-(tetrahydro- 2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (52.8 mg, 0.15 mmol), DMAP (73.3 mg, 0.60 mmol) and 4-[(aminocarbonyl)amino3benzenesulfonyl chloride (70.3 mg, 0.30 mmol) in MeCΝ (5 mL), the crude product was purified by MPLC using EtOAc/MeOΗ (20:1) on silica gel to give 59.9 mg (78%) of a white solid as the title compound. 'ΗΝMR (400 MHz, CD3OD): δ 1.06 (t, J=7.13 Hz, 3 H), 1.51 - 1.64 (m, 4 H), 1.68 (s, 9 H), 2.29 - 2.48 ( , 1 H), 3.31 - 3.43 (m, 2 H), 3.71 (q, J=7.03 Hz, 2 H), 3.86 - 4.01 (m, 2 H), 4.52 (d, J=7.62 Hz, 2 H), 7.26 (dd, J=8.88, 1.85 Hz, 1 H), 7.41 - 7.49 (m, 3 H), 7.51 - 7.59 ( , 2 H), 7.90 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 514.0; Anal. Calcd for C26H35Ν5O4S+ 1.30 TFA+0.40 CH3OH (674.71): C, 51.63; H, 5.66; N, 10.38; Found: C, 51.65; H, 5.63; N,10.38.
Example 106
N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5-yl]-N- ethyI-4-{[(methylamino)carbonyl]amino}benzenesulfonamide
Figure imgf000178_0001
Following the procedure as in Example 104, using 2-tert-butyl-N-ethyl-l-(tetrahydro- 2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (52.8 mg, 0.15 mmol). DMAP (73.3 mg, 0.60 mmol) and 4-
{[(methylamino)carbonyl]amino) benzenesulfonyl chloride (74.6 mg, 0.30 mmol) in MeCΝ (5 mL), the crude product was purified by MPLC using EtOAc/MeOΗ (20:1) on silica gel to give 63.2 mg (80%) of a white solid as the title compound. 'ΗΝMR (400 MHz, CD3OD): δ 1.06 (t, J=7.13 Hz, 3 H), 1.50 - 1.64 ( , 4 H), 1.68 (s, 9 H), 2.29 - 2.46 (m, 1 H), 2.77 (s, 3 H), 3.31 - 3.41 (m, 2 H), 3.71 (q, J=7.16 Hz, 2 H), 3.91 - 4.00 (m, 2 H), 4.52 (d, J=7.42 Hz, 2 H), 7.26 (dd, J=8.88, 2.05 Hz, 1 H), 7.40 - 7.46 (m, 2 H) ,7.48 (d, J=l .76 Hz, 1 H) ,7.50 - 7.55 (m, 2 H), 7.89 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 528.0; Anal. Calcd for C27H37N504S+ 1.40 TFA+0.50 H20 (696.33): C, 51.40; H, 5.70; N, 10.06; Found: C, 51.38 ; H, 5.69; N, 10.09.
Example 107 4-amino-N-[2-te/-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl)-N-ethylbenzenesulfonamide
Figure imgf000179_0001
Step A. 4-amino-N-[2-tert-butyI-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH- benzimidazol-5-yl]-N-ethylbenzenesulfonamide
Figure imgf000179_0002
N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5-yl]-N-ethyl- 4-nitrobenzenesulfonamide (399.6 mg, 0.798 mmol) (for preparation, see the following step B) was hydrogenated in ethyl acetate (50 mL) catalyzed by 10% Pd/C (100 mg) at 30-40 psi Η2 in Parr shaker for 6 h at room temperature. After filtration through celite and concentration, 457.9 mg (100?/o) of a white solid was obtained. Small amounts of the crude product was purified by reversed-phase HPLC using 20- 50% CH3CΝ/H2O and then lyophilized affording the title compound as the corresponding TFA salt. 1HNMR (400 MHz, CD3OD): δ 1.04 (t, J=7.13 Hz, 3 H), 1.49 - 1.65 (m, 4 H), 1.68 (s, 9 H), 2.25 - 2.55 ( , 1 H,) 3.32 - 3.43 ( , 2 H), 3.66 (q, J=7.03 Hz, 2 H), 3.88 - 4.04 (m, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 6.50 - 6.69 (m, 2 H), 7.19 - 7.26 (m, 2 H), 7.28 (dd, J=8.98, 1.95 Hz, 1 H), 7.50 (d, J=1.76 Hz, 1 H), 7.90 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 471.0; Anal. Calcd for C25H34N403S+ 1.80 TFA+0.30 H20 (681.29): C, 50.42; H, 5.39; N, 8.22; Found: C, 50.38 ; H, 5.21 ; N, 8.44.
Step B. N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazol-5- yl]-N-ethyl-4-nitrobenzenesulfonamide
Figure imgf000180_0001
Following the procedure as in Example 104, using 2-tert-butyl-N-ethyl-l-(tetrahydro- 2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (354.1 mg, 1.01 mmol DMAP (491.7 mg, 4.03 mmol) and 4-nitrobenzenesulfonyl chloride (445.9 mg, 2.01 mmol) in MeCN (20 mL), the crude product was purified by MPLC using
Ηex/EtOAc (1 :1) on silica gel to give 399.6 mg (80%) of a yellow solid as the title compound. MS (ESI) (M+Η)+: 501.0.
Example 108 N-(4-{[[2-te;*t-butyI-l-(tetrahydro-2H-pyran-4-yImethyl)-lH-benzimidazol-5- yl](ethyl)amino]sulfonyl}phenyl)-2,2-dirnethylpropanamide
Figure imgf000180_0002
4-amino-N-[2-ter/-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yI]- N-ethylbenzenesulfonamide (56.7 mg, 0.10 mmol) (for preparation, see the step A in Example 107), DMAP (48.9 mg, 0.40 mmol) and trimethylacetyl chloride (24.6 mg, 0.20 mmol) in MeCN (5 mL) were stirred for 4 h at room temperature. The reaction mixture was diluted with EtOAc (100 mL), washed with saturated NaHCθ3 (10 mL) and saturated NaCl (10 mL), and dried over Na2S04. Upon evaporation, the residue was purified by reversed-phase HPLC using 20-70% CH3CN/H20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 41.3 mg (74%); 'HNMR (400 MHz, CD3OD): δ 1.07 (t, J=7.13 Hz, 3 H), 1.29 (s, 9 H), 1.52 - 1.63 (m, 4 H), 1.67 (s, 9 H), 2.31 - 2.44 (m, 1 H), 3.31 - 3.41 (m, 2 H), 3.72 (q, J=7.03 Hz, 2 H), 3.95 ( , 2 H), 4.51 (d, J=7.62 Hz, 2 H), 7.24 (dd, J=8.98, 1.95 Hz, 1 H), 7.47 (d, J=1.95 Hz, 1 H), 7.48 - 7.56 (m, 2 H), 7.73 - 7.82 (m, 2 H), 7.88 (d, J=8.98 Hz, 1 H), 9.39 (s, 1 H); MS (ESD (M+H)+: 555.0; Anal. Calcd for
C30H43N3 O4S+ 1.80 TFA+0.30 H20 (765.40): C, 52.73; H, 5.85; N, 7.32; Found: C, 52.67; H, 5.75; N, 7.45.
Example 109 2-[(4-{[[2-tert-butji-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazoI-5- yl](ethyl)amino]sulfonyl}phenyI)amino]-2-oxoethyI acetate
Figure imgf000181_0001
Following the procedure for Example 108, using 4-amino-N-[2-tert-butyl-l - (tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- ethylbenzenesulfonamide (113.4 mg, 0.20 mmol) (for preparation, see the step A in Example 107), DMAP (97.7 mg, 0.80 mmol) and 2-chloro-2-oxoethyl acetate (54.6 mg, 0.40 mmol) in MeCΝ (10 mL), the crude product was purified by MPLC using EtOAc on silica gel to give 102.6 mg (90%) of a white solid as the title compound. ' ΗΝMR (400 MHz, CD3OD): δ 1.07 (t, J=7.13 Hz, 3 H), 1.51 - 1.64 (m, 4 H), 1.67 (s, 9 H), 2.16 (s, 3 H), 2.30 - 2.45 ( , 1 H), 3.32 - 3.44 (m, 2 H), 3.73 (q, J=7.23 Hz, 2 H), 3.84 - 4.04 (m, 2 H), 4.51 (d, J=7.42 Hz, 2 H), 4.69 (s, 2 H), 7.24 (dd, J=8.98, 1.95 Hz, 1 H), 7.47 (d, J=1.76 Hz, 1 H), 7.50 - 7.57 (m, 2 H), 7.68 - 7.79 (m, 2 H), 7.89 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 571.0; Anal. Calcd for C29H38N406S+ 0.90 TFA (673.33): C, 54.94; H, 5.82; N, 8.32; Found: C, 54.95; H, 5.79; N, 8.13.
Example 110
N-(4-{[[2-te/Y-butyI-l-(tetrahydro-2H-pyran-4-ylmethyl)-li?-benzimidazol-5- yl](ethyI)amino]sulfonyl}phenyl)-2-hydroxyacetamide
Figure imgf000182_0001
2-[(4-{[[2-te/-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](ethyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate (70.3 mg, 0.123 mmol) (for preparation, see the Example 109) and a drop of sodium methoxide (25% in MeOΗ) in MeOΗ (5 mL) was stirred overnight at room temperature. After evaporation, the crude product was purified by reversed-phase ΗPLC using 10-50% CΗ3CΝ/Η2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 58.5 mg (90%); 'HNMR (400 MHz, CD3OD): δ 1.07 (t, J=7.13 Hz, 3 H), 1.51 - 1.64 (m, 4 H), 1.68 (s, 9 H), 2.25 - 2.48 (m, 1 H), 3.31 - 3.41 (m, 2 H), 3.73 (q, J=7.16 Hz, 2 H), 3.95 (m, 2 H), 4.13 (s, 2 H), 4.52 (d, J=7.42 Hz, 2 H), 7.25 (dd, J=8.98, 1.95 Hz, 1 H), 7.49 (d, J=1.76 Hz, 1 H), 7.50 - 7.58 (m, 2 H), 7.78 - 7.85 (m, 2 H), 7.89 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 529.0; Anal. Calcd for
C27H36N405S+ 1.50 TFA+0.20 H20 +0.30 CH3CN (715.63): C, 51.36; H, 5.47; N, 8.42; Found: C, 51.35; H, 5.47; N, 8.35.
Example 111 N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH-benzimidazol-5-yl]-N- ethyl-4-{[(isopropylamino)carbonyl]amino}benzenesulfonamide
Figure imgf000183_0001
4-Amino-N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]- N-ethylbenzenesulfonamide (56.7 mg, 0.1 mmol) (for preparation, see the step A in Example 107) and 2-isocyanatopropane (0.1 mL) in DCE (5 L) was heated overnight at 80 °C. After evaporation, the crude product was purified by reversed- phase ΗPLC using 20-50% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 39.5 mg (71%); 'HNMR (400 MHz, CD3OD): δ 1.06 (t, J=7.13 Hz, 3 H), 1.18 (d, J=6.64 Hz, 6 H), 1.51 - 1.63 (m, 4 H), 1.68 (s, 9 H), 2.27 - 2.42 (m, 1 H), 3.32 - 3.42 (m, 2 H), 3.70 (q, J=7.03 Hz, 2 H), 3.83 - 3.92 (m, 1 H), 3.92 - 3.99 (m, 2 H), 4.52 (d, J=7.42 Hz, 2 H), 7.25 (dd, J=8.8S, 2.05 Hz, 1 H), 7.40 - 7.46 (m, 2 H), 7.47 (d, J=1.95 Hz, 1 H), 7.48 - 7.54 (m, 2 H), 7.89 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 556.0; Anal. Calcd for C29H4ιN504S+ 1.80 TFA+0.20 H20 +0.50 CH3CN (785.12): C, 51.40; H, 5.74; N, 9.81 ; Found: C, 51.40; H, 5.72; N, 9.79.
Example 112
N-[4-({ethyl[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyI)- lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide
Figure imgf000183_0002
Step A. N-[4-({ethyl[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- yImethyI)-lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide
Figure imgf000184_0001
Following the procedure as in Example 104, using N-ethyl-2-( 1 -methoxy- 1- methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (50.0 mg, 0.136 mmol) (for preparation, see the following steps B, C and D), DMAP (64.5 mg, 0.50 mmol) and 4-(acetylamino)benzenesulfonyl chloride (61.2 mg, 0.26 mmol) in MeCΝ (5 L), the crude product was purified by reversed- phase HPLC using 10-50% CH3CΝ/H20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 42.0 mg (58%); ΗNMR (400 MHz, CD3OD): δ 1.06 (t, J=7.03 Hz, 3 H), 1.42 - 1.61 (m, 4 H), 1.80 (s, 6 H), 2.15 (s, 3 H), 2.31 - 2.46 (m, 1 H), 3.34 (s, 3 H), 3.35 - 3.43 (m, 2 H), 3.71 (q, J=7.23 Hz, 2 H), 3.89 - 4.02 (m, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.20 (dd, J=8.88, 1.85 Hz, 1 H), 7.43 (d, J=l .76 Hz, 1 H), 7.48 - 7.57 (m, 2 H), 7.68 - 7.76 (m, 2 H), 7.81 (d, J=8.79 Hz, 1 H); MS (ESI) (M+H)+: 529.0; Anal. Calcd for C27H36N405S+ 1.20 TFA+0.20 H20 (669.11): C, 52.78; H, 5.66; N, 8.37; Found: C, 52.80; H, 5.59; N, 8.51.
Step B. N-ethyl-N-[2-(l-hydroxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl]acetamide
Figure imgf000184_0002
Diisopropylethylamine (0.558 g, 4.32 mmol) was added into a solution of N-{3- amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-N-ethylacetamide (0.841 g, 2.88 mmol) and 2-hydroxy-2-methylpropanoic acid (0.330 g, 3.17 mmol) in DMF (40 mL) at 0 °C. Stirring for 30 min, ΗATU (1.31 g, 3.46 mmol) was added. The reaction mixture was stirred for overnight at room temperature and quenched with water (5 L). After concentration, the residue was dissolved in acetic acid (50 mL) in sealed tubes. The solutions were heated at 140°C using a Personal Chemistry Smith Synthesizer microwave instrument for 35 min. Upon evaporation of the solvent, the residue was diluted with EtOAc (100 mL), washed with 2 NNaOH(10 mL) and satturated NaCl (2x10 mL), and dried over Na2S04. After filtration and evaporation, 1.78 g (purity >43%) of the crude product was obtained, which was used directly for next step without purification. MS (ESI) (M+H)+: 360.04.
Step C. N-ethyl-N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazoI-5-yl] acetamide
Figure imgf000185_0001
Sodium hydride (0.35 g, 60%, 8.64 mmol) was added in portions to a solution of N- ethyl-N-[2-( 1 -hydroxy- 1 -methylethyl)- 1 -(tetrahydro-2H-pyran-4-y lmethyl)- 1H- benzimidazol-5-yl]acetamide (1.78 g of the above crude product, 2.88 mmol) in TΗF (100 mL) at 0 °C. Stirring for 20 min, iodomethane (1.23 g, 8.64 mmol) was added. The reaction mixture was stirred overnight at room temperature, quenched with saturated ΝΗtCl (20 mL) and diluted with EtOAc (100 mL), washed with saturated ΝaCl (2x20 mL) and dried overΝa2S0 . After filtration and concentration, the residue was purified by MPLC using EtOAc/MeOΗ (20:1) on silica gel to give 0.423 g (39%) of a grey white solid as the title compound. MS (ESI) (M+Η)+: 374.03.
Step D. N-ethyl-2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-amine
Figure imgf000185_0002
N-ethyl-N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl]acetamide (422.5 mg, 1.13 mmol) was dissolved in 15 mL of EtOΗ-2N ΗCl (3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for 3.5 h. After concentration and dried in vacuo, 441.9 mg (100%) of a light brown solid was obtained as the title product. MS (ESI) (M+H)+: 332.04.
Example 113
4-[(aminocarbonyl)amino]-N-ethyl-N-[2-(l-methoxy-l-methylethyl)-l- (tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide H2
Figure imgf000186_0001
Following the procedure for the step A in Example 105, using N-ethyl-2-(l-methoxy- l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (50.0 mg, 0.136 mmol) (for preparation, see the steps B, C and D in example 15), DMAP (64.5 mg, 0.50 mmol) and 4-
[(aminocarbonyl)amino]benzenesulfonyl chloride (64.5 mg, 0.26 mmol) in MeCΝ (5 mL), the crude product was purified by reversed-phase FIPLC using 10-45% CΗ3CΝ/Η2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 31.1 mg (43%); ' HNMR (400 MHz, CD3OD): δ 1.06 (t, J=7.13 Hz, 3 H), 1.50 - 1.58 (m, 4 H), 1.81 (s, 6 H), 2.29 - 2.48 (m, 1 H), 3.35 (s, 3 H), 3.36 - 3.43 ( , 2 H), 3.70 (q, J=7.03 Hz, 2 H), 3.89 - 4.02 (m, 2 H), 4.54 (d, J=7.22 Hz, 2 H), 7.22 (dd, J=8.98, 1.95 Hz, 1 H), 7.40 - 7.49 (m, 3 H), 7.51 - 7.58 (m, 2 H), 7.77 - 7.90 (m, 1 H); MS (ESI) (M+H)+: 530.0; Anal. Calcd for C26H35N505S+ 1.20 TFA+1.10 H20 +0.10 CH3OH (689.51): C, 49.65; H, 5.67; N, 10.16: Found: C, 49.67; H, 5.67; N, 10.19. Example 114
N-ethyl-N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2Jfi/r-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]-4-{[(methylamino)carbonyl]amino}benzenesulfonamide
Figure imgf000187_0001
Following the procedure for the step A in Example 105, using N-ethyl-2-(l -methoxy - l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (50.0 mg, 0.136 mmol) (for preparation, see the steps B, C and D in example 112), DMAP (64.5 mg, 0.50 mmol) and 4- {[(methylamino)carbonyl]amino}benzenesulfonyl chloride (62.0 mg, 0.26 mmol) in MeCΝ (5 mL), the crude product was purified by reversed-phase ΗPLC using 10- 45% CΗ3CΝ/Η2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 36.9 mg (50%); 'HNMR (400 MHz, CD3OD): δ 1.06 (t, J=7.13 Hz, 3 H), 1.51 - 1.59 (m, 4 H), 1.81 (s, 6 H), 2.31 - 2.47 ( , 1 H), 2.77 (s, 3 H), 3.35 (s, 3 H) ,3.36 - 3.41 (m, 2 H), 3.70 (q, J=7.16 Hz, 2 H), 3.91 - 3.99 (m, 2 H), 4.54 (d, J=7.42 Hz, 2 H), 7.20 - 7.25 (m, 1 H), 7.44 (d, J=2.15 Hz, 1 H), 7.44 - 7.48 (m, 2 H), 7.50 - 7.56 (m, 2 H), 7.85 (d, J=9.18 Hz, 1 H); MS (ESI) (M+H)+: 544.0; Anal. Calcd for C27H37N5O5S+ 0.80 TFA+0.50 H20 (643.92): C, 53.35; H, 6.07; N, 10.88; Found: C, 53.25; H, 6.05; N, 10.99.
Example 115
4-amino-N-ethyI-N-[2-(l-methoxy-l-methylethyI)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000188_0001
Step A. 4-amino-N-ethyl-N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H- pyran-4-ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000188_0002
Following the procedure for the step A in Example 107, using N-ethyl-N-[2-(l- methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]- 4-nitrobenzenesulfonamide (276.0 mg, 0.798 mmol) (for preparation, see the following step B) and 10% Pd/C (50 mg) in ethyl acetate (50 mL), 287.7 mg (100%) of a white solid was obtained. Small amounts of the crude product was purified by reversed-phase ΗPLC using 10-50% CΗ3CΝ/Η2O and then lyophilized affording the title compound as the corresponding TFA salt. 'HNMR (400 MHz, CD3OD): δ 1.03 (t, J=7.13 Hz, 3 H), 1.50 - 1.58 (m, 4 H), 1.81 (s, 6 H), 2.31 - 2.48 (m, 1 H), 3.35 (s, 3 H), 3.36 - 3.42 (m, 2 H), 3.65 (q, J=7.03 Hz, 2 H), 3.90 - 3.99 (m, 2 H), 4.54 (d,
J=7.42 Hz, 2 H), 6.60 - 6.66 (m, 2 H), 7.21 - 7.27 (m, 3 H), 7.44 (d, J=1.95 Hz, 1 H), 7.82 (d, J=8.79 Hz, 1 H); MS (ESI) (M+H)+: 487.0; Anal. Calcd for C25H34N404S+ 1.50 TFA (657.67): C, 51.14; H, 5.44; N, 8.52; Found: C, 51.31 ; H, 5.44: N, 8.40.
Step B. Λ'-ethyI-N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl]-4-nitrobenzenesulfonamide
Figure imgf000189_0001
Following the procedure as in Example 104, using N-ethyl-2-( 1 -methoxy- 1 - methylethyl)- l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (248.2 mg, 0.675 mmol) (for preparation, see the steps B, C and D in example 112), DMAP (329.9 mg, 2.70 mmol) and 4-nitrobenzenesulfonyl chloride (299.0 mg, 1.35 mmol) in MeCΝ (15 mL), the crude product was purified by MPLC using Ηex EtOAc (1 :1) on silica gel to give 276.0 mg (79%) of a yellow solid as the title compound. MS (ESI) (M+Η)+: 517.00.
Example 116
N-[4-({ethyl[2-(l-methoxy-l-methylethyI)-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]amino}sulfonyl)phenyI]-2,2-dimethylpropanamide
Figure imgf000189_0002
Following the procedure for Example 108, using 4-amino-N-ethyl-N-[2-(l -methoxy- l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]benzenesulfonamide (51.5 mg, 0.095 mmol) (for preparation, see the step A in Example 1 15), DMAP (50.0 mg, 0.409 mmol) and trimethylacetyl chloride (24.6 mg, 0.20 mmol) in MeCΝ (5 mL), the crude product was purified by reversed-phase ΗPLC using 20-60% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 45.8 mg (85%); 'HNMR (400 MHz, CD3OD): δ 1.06 (t, J=7.13 Hz, 3 H), 1.30 (s, 9 H), 1.49 - 1.60 (m, 4 H), 1.80 (s, 6 H), 2.32 - 2.46 (m, 1 H), 3.34 (s, 3 H), 3.35 - 3.42 (m, 2 H), 3.71 (q, J=7.03 Hz, 2 H), 3.90 - 4.00 (m, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.20 (dd, J=8.98, 1.95 Hz, 1 H), 7.42 (d, J=1.76 Hz, 1 H), 7.48 - 7.55 (m, 2 H), 7.75 - 7.81 (m, 2 H), 7.82 (s, 1 H); MS (ESI) (M+H)+: 571.0 0; Anal. Calcd for C30H42N4O5S+ 1.20 TFA+0.80 H20 (722.00): C, 53.90; H, 6.25; N, 7.76; Found: C, 53.93; H, 6.25; N, 7.67.
Example 117
2-{[4-({ethyl[2-(l-methoxy-l-methylethyI)-l-(tetrahydro-2H-pyran-4-yImethyl)- lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]amino}-2-oxoethyl acetate
Figure imgf000190_0001
Following the procedure for Example 108, using 4-amino-N-ethyl-N-[2-(l-methoxy- l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yljbenzenesulfonamide (100.0 mg, 0.185 mmol) (for preparation, see the step A in Example 115), DMAP (97.7 mg, 0.80 mmol) and 2-chloro-2-oxoethyI acetate (54.6 mg, 0.40 mmol) in MeCΝ (10 mL), the crude product was purified by MPLC using Ηex/EtOAc on silica gel to give 68.7 mg (63%) of a light yellow solid as the title compound. 'ΗΝMR (400 MHz, CD3OD): δ 1.06 (t, J=7.13 Hz, 3 H), 1.48 - 1.56 (m, 4 H), 1.76 (s, 6 H), 2.17 (s, 3 H), 2.30 - 2.46 ( , 1 H), 3.28 (s, 3 H), 3.32 - 3.42 (m, 2 H), 3.70 (q, J=7.23 Hz, 2 H), 3.85 - 4.04 (m, 2 H), 4.47 (d, J=7.62 Hz, 2 H), 4.70 (s, 2 H), 7.11 (dd, J=8.79, 1.95 Hz, 1 H), 7.33 (d, J=1.95 Hz, 1 H), 7.50 - 7.58 (m, 2 H), 7.68 (d, J=8.79 Hz, 1 H), 7.72 - 7.79 (m, 2 H); MS (ESI) (M+H)+: 587.0; Anal. Calcd for C29H38Ν 07S+ 0.70 TFA+3.10 H20 +0.90 CH3CN (759.32): C, 50.93; H, 6.32; N, 9.04; Found: C, 50.90 ; H, 6.26; N, 9.05. Example 118
N-[4-({ethyl[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-yImethyl)- lH-benzimidazoI-5-yl]amino}sulfonyI)phenyl]-2-hydroxyacetamide
Figure imgf000191_0001
Following the procedure for Example 110, using 2- {[4-({ ethyl [2-(l -methoxy- 1 - methylethyl)- l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]amino}sulfonyl)phenyl]amino}-2-oxoethyl acetate (46.3 mg, 0.0789 mmol) (for preparation, see the Example 116) and a drop of sodium methoxide (25% in MeOΗ) in MeOΗ (5 mL), the crude product was purified by reversed-phase ΗPLC using 10- 45% CΗ3CN/Η2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 27.4 mg (64%); ]HNMR (400 MHz, CD3OD): δ 1.07 (t, J=7.13 Hz, 3 H), 1.50 - 1.56 (m, 4 H), 1.80 (s, 6 H), 2.32 - 2.46 (m, 1 H), 3.34 (s, 3 H), 3.35 - 3.41 (m, 2 H), 3.72 (q, J=7.03 Hz, 2 H), 3.91 - 3.99 (m, 2 H), 4.13 (s, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.20 (dd, J=8.98, 1.95 Hz, 1 H), 7.44 (d, J=1.76 Hz, 1 H), 7.51 - 7.58 (m, 2 H), 7.79 - 7.85 (m, 3 H); MS (ESI) (M+H)+: 545.0; Anal. Calcd for C27H36N4θ6S+ 1.30 TFA+0.50 H20 (701.91): C, 50.65; H, 5.50; N, 7.98; Found: C, 50.61; H, 5.50; N, 8.12.
Example 119
N-ethyl-4-{[(isopropylamino)carbonyl]amino}-N-[2-(l-methoxy-l-methylethyl)- l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000192_0001
Following the procedure for Example 111, using 4-amino-N-ethyl-N-[2-(l-methoxy- 1 -methylethyl)- l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]benzenesulfonamide (45.7 mg, 0.0845 mmol) (for preparation, see the step A in Example 114) and 2-isocyanatopropane (0.2 mL) in DCE (5 mL), the crude product was purified by reversed-phase ΗPLC using 20-50% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 17.1 mg (35%); 'HNMR (400 MHz, CD3OD): δ 1.05 (t, J=7.13 Hz, 3 H), 1.18 (d, J=6.44 Hz, 6 H), 1.50 - 1.57 (m, 4 H), 1.79 (s, 6 H), 2.31 - 2.46 (m, 1 H), 3.33 (s, 3 H), 3.35 - 3.43 (m, 2 H), 3.69 (q, J=7.03 Hz, 2 H), 3.84 - 3.92 ( , 1 H), 3.92 - 3.99 (m, 2 H), 4.52 (dd, J=7.42 Hz, 2 H), 7.18 (dd, J=8.98, 1.95 Hz, 1 H), 7.41 (d, J=1.76 Hz, 1 H), 7.42 - 7.48 (m, 2 H), 7.48 - 7.56 (m, 2 H), 7.79 (d, J=8.79 Hz, 1 H); MS (ESI) (M+H)+: 572.0; Anal. Calcd for C29H41N5O5S+ 1.60 TFA+0.40 H20 (761.39): C, 50.80; H, 5.75; N, 9.20; Found: C, 50.83; H, 5.77; N, 9.01.
Example 120
N-(4-{[[2-(l-methoxy-l-methylethyI)-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH- benzimidazol-5-yl](methyl)amino]suIfonyl}phenyl)acetamide
Figure imgf000192_0002
Step A. N-(4-{[[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazoI-5-yI](methyl)aminoJsulfonyI}phenyI)acetamide
Figure imgf000193_0001
Following the procedure as in Example 104, using 2-( 1 -methoxy- 1 -methylethyl)-N- methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (77.8 mg, 0.15 mmol) (for preparation, see the following steps B, C and D), DMAP (73.3 mg, 0.60 mmol) and 4-(acetylamino)benzenesulfonyl chloride (68.9 mg, 0.30 mmol) in MeCΝ (10 mL), the crude product was purified by MPLC using EtOAc/MeOΗ (20:1) on silica gel to give 55.7 mg (72%) of a white solid as the title compound. 'ΗΝMR (400 MHz, CD3OD): δ 1.49 - 1.62 (m, 4 H), 1.83 (s, 6 H), 2.14 (s, 3 H), 2.32 - 2.46 (m, 1 H), 3.26 (s, 3 H), 3.32 - 3.37 (m, 2 H), 3.38 (s, 3 H), 3.90 - 4.00 (m, 2 H), 4.57 (d, J=7.42 Hz, 2 H), 7.33 (dd, J=8.98, 1.95 Hz, 1 H), 7.43 - 7.50 (m, 2 H), 7.54 (d, J=1.76 Hz, 1 H), 7.68 - 7.76 (m, 2 H), 7.89 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 515.0; Anal. Calcd for C26H34Ν4θ5S+ 1.3 HCl +0.4 CH3OH (574.86): C, 55.16, H, 6.47, N, 9.75; Found: C, 55.25; H, 6.38; N, 9.58.
Step B. N-[2-(l-hydroxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]-N-methylacetamide
Figure imgf000193_0002
Following the procedure for the step B in Example 112, using N-{3-amino-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl] -N-methylacetamide (1.14 g, 4.1 1 mmol) (for preparation, see the steps B, C and D in Example 103), 2-hydroxy-2- methylpropanoic acid (0.470 g, 4.52 mmol), diisopropylethylamine (0.800 g, 6.17 mmol) and ΗATU (1.88 g, 4.93 mmol) in DMF (40 mL) and then in acetic acid (50 L), the crude product was purified by MPLC using EtOAc/MeOΗ (20: 1) on silica gel to give 0.475 g (33%) of a brown solid as the title compound. MS (ESI) (M+H)+: 346.03.
Step C. N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]-N-methylacetamide
Figure imgf000194_0001
Following the procedure for the step C in Example 112, using N-[2-( 1 -hydroxy- 1- methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylacetamide (103.1, 0.299 mmol), iodomethane (93.6 mg, 0.66 mmol) and sodium hydride (26.4 mg, 60%, 0.66 mmol) in TΗF (10 mL, 110 mg 100%) of the title compound was obtained as a colorless syrup. MS (ESI) (M+Η)+: 360.05.
Step D. 2-(l-methoxy-l-methylethyl)-N-methyl-l-(tetrahydro-2H-pyran-4- yImethyI)-lH-benziπτidazol-5-arnine
Figure imgf000194_0002
Following the procedure for the step D in Example 1 12, using N-[2-(l -methoxy- 1- methylethyl)- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]-N- methylacetamide (110 mg, 0.299 mmol) in 5 mL of EtOΗ-2NΗCl (3:2), 121.6 mg (100%) of a grey white solid was obtained as the title product. MS (ESI) (M+H)+: 318.57.
Example 121
4-[(aminocarbonyl)amino]-N-[2-(l-methoxy-l-methylethyI)-l-(tetrahydro-2H- pyran-4-ylmethyl)-lH-benzimidazol-5-yI]-N-methylbenzenesulfonamide
Figure imgf000195_0001
Following the procedure for the step A in Example 120, using 2-( 1 -methoxy- 1 - methylethyl)-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazol-5- amine hydrochloride (48.6 mg, 0.120 mmol) (for preparation, see the steps B, C and D in example 120), DMAP (58.6 mg, 0.48 mmol) and 4-
[(aminocarbonyl)amino]benzenesulfonyl chloride (42.1 mg, 0.178 mmol) in MeCΝ (5 mL), the crude product was purified by reversed-phase ΗPLC using 10-45% CΗ3CΝ/Η7O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 34.7 mg (56%); ' HNMR (400 MHz, CD3OD): δ 1.47 - 1.59 (m, 4 H), 1.80 (s, 6 H), 2.31 - 2.46 (m, 1 H), 3.24 (s, 3 H), 3.34 (s, 3 H), 3.35 - 3.41 (m, 2 H), 3.87 - 4.04 (m, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.28 (dd, J=8.79, 1.95 Hz, 1 Η), 7.37 - 7.44 (m, 2 H), 7.47 (d, J=1.56 Hz, 1 H), 7.50 - 7.58 (m, 2 H), 7.81 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 516.0; Anal. Calcd for C25H33N505S+ 1.3TFA(663.87): C, 49.94, H, 5.21, N, 10.55; Found: C, 50.07; H, 5.16; N, 10.44.
Example 122
2-Hydroxy-N-(4-{[[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000195_0002
Step A. 2-Hydroxy-N-(4-{[[2-(l-methoxy-l-methyIethyI)-l-(tetrahydro-2H- pyran-4-yImethyl)-lH-benzimidazoI-5- yl](methyI)amino]sulfonyl}phenyI)acetamide
Figure imgf000196_0001
Following the procedure for Example 110, using 2-[(4- ([[2-(l -methoxy- 1 - methylethyl)- l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate (100 mg, crude, 0.097 mmol) (for preparation, see the following steps B, C and D) and a drop of sodium methoxide (25% in MeOΗ) in MeOΗ (10 mL), the crude product was purified by reversed-phase ΗPLC using 10-50% CΗ3CN/Η2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 16.7 mg (32%); 'HNMR (400 MHz, CD3OD): δ 1.47 - 1.60 ( , 4 H), 1.80 (s, 6 H), 2.29 - 2.46 (m, 1 H), 3.25 (s, 3 H), 3.34 (s, 3 H), 3.35 - 3.40 (m, 2 H), 3.90 - 4.01 (m, 2 H), 4.13 (s, 2 H), 4.53 (d, J=7.42 Hz, 2 H), 7.27 (dd, J=8.Sδ, 2.05 Hz, 1 H), 7.47 (d, J=2.15 Hz, 1 H), 7.48 - 7.53 (m, 2 H), 7.79 (s, 1 H), 7.79 - 7.84 (m, 2 H); MS (ESI) (M+H)+: 531.0; Anal. Calcd for C25H34N406S+ 1.40 TFA+0.2 H20 (693.88): C, 49.85, H, 5.20, N, 8.07; Found: C, 49.78; H, 5.18; N, 8.20.
Step B. N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-yImethyI)- lH-benzimidazol-5-yl]-N-methyI-4-nitrobenzenesulfonamide
Figure imgf000196_0002
Following the procedure as in Example 104, using 2-( 1 -methoxy- 1 -methylethyl)-N- methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (72.9 mg, 0.179 mmol) (for preparation, see the steps B, C and D in example 62), DMAP (87.5 mg, 0.716 mmol) and 4-nitrobenzenesulfonyl chloride (59.8 mg, 0.269 mmol) in MeCN (6 mL), the crude product was purified by MPLC using Hex/EtOAc (1:1) on silica gel to give 49.8 mg (55%) of a yellow solid as the title compound. MS (ESI) (M+H)+: 502.98.
Step C. 4-Amino-N-[2-(l-methoxy-l-methyIethyl)-l-(tetrahydro-2H-pyran-4- yImethyl)-lH-benzimidazoI-5-yI]-N-methylbenzenesulfonamide
Figure imgf000197_0001
Following the procedure for the step A in Example 107, using N-[2-(l -methoxy- 1- methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N-methyl- 4-nitrobenzenesulfonamide (48.9 mg, 0.097 mmol) and 10% Pd C (20 mg) in ethyl acetate (20 mL), 70.1 mg (100%) of a grey solid was obtained. MS (ESI) (M+Η)+: 474.06.
Step D. 2-[(4-{[[2-(l-methoxy-l-methyIethyl)-l-(tetrahydro-2i -pyran-4- ylmethyl)-lH-benzimidazoI-5-yI](methyl)amino]sulfonyl}phenyl)amino]-2- oxoethyl acetate
Figure imgf000197_0002
Following the procedure for Example 108, using 4-amino-N-[2-(l -methoxy- 1- methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide (70.1 mg, 0.097 mmol), DMAP (35.6 mg, 0.291 mmol) and 2-chloro-2-oxoethyl acetate (26.5 mg, 0.194mmol) in MeCN (6 mL), 100 mg of the crude title product was obtained, which was used directly for next step.
Example 123 N-(4-{[[2-(l-ethoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl)(methyI)amino]sulfonyl}phenyl)acetamide
Figure imgf000198_0001
Step A. N-(4-{[[2- l-ethoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazoI-5-yl](methyI)amino]sulfonyl}phenyl)acetamide
Figure imgf000198_0002
Following the procedure as in Example 104, using 2-(l-ethoxy-l-methylethyl)-N- methyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-amine hydrochloride (96.2 mg, 0.15 mmol) (for preparation, see the following steps B and C), DMAP (73.3 mg, 0.60 mmol) and 4-(acetylamino)benzenesulfonyI chloride (70.0 mg, 0.30 mmol) in MeCΝ (10 mL), the crude product was purified MPLC using EtOAc/MeOΗ (20:1) on silica gel to give 46.2 mg (55%) of a white solid as the title compound. 'ΗΝMR (400 MHz, CD3OD): δ 1.25 - 1.33 (m, 3 H), 1.43 - 1.64 (m, 4 H). 1.84 (s, 6 H), 2.14 (s, 3 H), 2.35 - 2.51 (m, 1 H,) 3.25 (s, 3 H), 3.31 - 3.41 (m, 2 H), 3.60 (q, J=6.90 Hz, 2 H), 3.95 (m, 2 H), 4.62 (d, J=7.62 Hz, 2 H), 7.31 (dd, J=8.98, 2.15 Hz, 1 H), 7.43 - 7.50 (m, 2 H), 7.52 (d, J=1.76 Hz, 1 H), 7.67 - 7.76 (m, 2 H), 7.87 (d, J=8.79 Hz, 1 H); MS (ESI) (M+H)+: 529.0; Anal. Calcd for C27H36Ν4O5S+ 0.7 HCl ++0.7 H2O+0.6 CH3OH (586.03): C, 56.57, H, 6.97, N, 9.56; Found: C, 56.60; H, 6.96; N, 9.59.
Step B. N-[2-(l-ethoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzinιidazol-5-yl]-N-methylacetamide
Figure imgf000199_0001
Following the procedure for step C in Example 120, using of N-[2-(l -hydroxy- 1 - methylethyl)- l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylacetamide (51.8 mg, 0.15 mmol) (for preparation see the step B in Example 62), sodium hydride (13.5 mg, 60%, 0.33 mmol) and iodoethane (51.5 mg, 0.33 mmol) in TΗF (5 mL), 73.5 mg (100%) of the title compound was obtained as a colorless syrup. MS (ESI) (M+Η)+: 374.04.
Step C. 2-(l-ethoxy-l-methylethyI)-N-methyl-l-(tetrahydro-2H-pyran-4- yImethyl)-lH-benzimidazol-5-amine
Figure imgf000199_0002
Following the procedure for step D in Example 120, using N-[2-( 1 -ethoxy- 1 - methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazol-5-yl]-N- methylacetamide of (73.5 mg, 0.15 mmol) in 5 mL of EtOΗ-2NΗCl (3:2), 96.32 mg (100%) of a grey solid was obtained as the title product. MS (ESI) (M+H)+: 332.02.
Example 124
N-[4-({[l-(2-azetidin-l-ylethyl)-2-tert-butyl-lH-benzimidazol-5- yl]amino}suIfonyl)phenyI]acetamide
Figure imgf000200_0001
Step A. N-[4-({[l-(2-azetidin-l-ylethyI)-2-tert-butyl-lH-benzimidazol-5- yl]amino}sulfonyl)phenyl]acetamide
Figure imgf000200_0002
2-[5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-tert-butyl-lH-benzimidazol-l- yljethyl methanesulfonate (0.10 g, 0.196 mmol), azetidine (0.20 g, 3.93 mmol) and KI (0.65 g, 0.393 mmol) were mixed together and heated to 80°C in DMF (3 L). The solvent was concentrated. The crude product was purified by preparative reverse- phase ΗPLC using 10-90% CΗ3CΝ/Η20 as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 30 mg (26%); MS (ESI) (M+H)+: 470.0.
Step B. N-(4-{[(4-fluoro-3-nitrophenyl)amino]sulfonyl}phenyl)acetamide
Υ r F
Figure imgf000200_0003
4-Fluoro-3-nitroaniline (6.22 g, 39.8 mmol) and 4-(acetylamino)benzenesulfonyl chloride (10.2 g, 43.8 mmol) were heated to 50°C for 20hrs. in pyridine (70 L). The solvent was concentrated. The crude product was recovered in DCM and washed with water, 2N HCl, saturated NaHC03 solution, water and brine. The organic layer was dried over anhydrous MgS04. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 10 g (70%); MS (ESI) (M+H)+: 354.0. Step C. N-{4-[({4-[(2-hydroxyethyl)amino]-3- nitrophenyl}amino)sulfonyl]phenyl}acetamide
Figure imgf000201_0001
N-(4-{[(4-fluoro-3-nitrophenyl)amino]sulfonyl}phenyl)acetamide (2.91 g, 8.23 mmol), 2-aminoethanol (3.00 mL, 49.4 mmol) and pyridine (1.33 L, 16.4 mmol) in DMSO (30 mL) were heated at 90°C for 40 min. Cooled down to room temperature, the reaction mixture was poured into water (250 L) at 0°C. The dark-purple mixture was acidified with concentrated HCl until red color appears. The compound was extracted with EtOAc (3X). The combined organic layers were washed with brine and dried over anhydrous MgS04. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 3.25 g (99%); MS (ESI) (M+H)+: 395.2.
Step D. N-{4-[({4-l(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)aminoJ-3- nitrophenyl}amino)sulfonyl]phenyI}acetamide
Figure imgf000201_0002
A solution of TBDMSCl (1.36g, 9.05 mmol) in EtOAc (100 L) was slowly added to a solution of N-{4-[({4-[(2-hydroxyethyl)amino]-3- nitrophenyl)amino)sulfonyl]phenyl}acetamide (3.25 g, 8.23 mmol) and imidazole (0.67 g, 9.88 mmol) in EtOAc (250 mL) at room temperature. The reaction mixture was stirred overnight. The reaction was quenched with water and washed with saturated NH CI solution, water and brine. The organic layer was dried over anhydrous MgS04. The solvent was concentrated. The crude product was purified by flash chromatography on silica gel using EtOAc/Hex (3:1) as eluent to give the title compound. Yield: 3.39 g (81%); MS (ESI) (M+H)+: 509.1.
Step E. N-{4-[({3-amino-4-[(2-{[tert- butyI(dimethyl)siIyl]oxy}ethyl)amino]phenyl}amino)sulfonyl]phenyl}acetamide
Figure imgf000202_0001
N-{4-[({4-[(2-{[/ert-butyl(dimethyl)silyl]oxy}ethyl)amino]-3- nitrophenyl}amino)sulfonyl]phenyl}acetamide (3.27 g, 6.42 mmol) was hydrogenated in EtOAc (200 mL) catalyzed by 10% Pd/C at 50 psi H2 in Parr shaker overnight at room temperature. The mixture was filtered through a celite pad. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 3.05 g (99%); MS (ESI) (M+H)+: 479.1.
Step F. N-{5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-[(2-{[tert- butyl(dimethyl)silyl]oxy}ethyI)amino]phenyI}-2,2-dimethylpropanamide
Figure imgf000202_0002
A solution of tBuCOCl (0.85 mL, 7.20 mmol) in DCM (50 mL) was added dropwise to a solution of N-(4-[({3-amino-4-[(2-{[tert- butyl(dimethyl)silyl]oxy)ethyl)amino]phenyl}amino)sulfonyl]phenyl}acetamide (3.05 g, 6.37 mmol) and Et3N (1.20 mL, 8.60 mmol) in DCM (250 mL) at 0°C. The reaction mixture was stirred for 1.5 hours and washed with water (3X), saturated NaHC03 solution, water and brine. The organic layer was dried over anhydrous MgS04. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 3.59 g (99%); MS (ESI) (M+H)+: 563.0.
Step G. 2-[5-({[4-(acetyIamino)phenyl]sulfonyl}amino)-2-tert-butyI-lH- benzimidazol-l-yl]ethyl acetate
Figure imgf000203_0001
N-{5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-[(2-{[tert-butyl(dimethyl)silyl] oxy]ethyl)amino]phenyl}-2,2-dimethylpropanamide (2.87g, 5.10 mmol) was dissolved in glacial acetic acid (40 L) heated to 170°C in a microwave oven for 15 min. The solvent was concentrated. The crude compound was purified on silica gel by flash chromatography using EtOAc as eluent. The fractions containing the desired material were purified by preparative reverse-phase HPLC using 10-90% CH3CΝ/H2O as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 260 mg (8%); Η NMR (400 MHz, CD3OD): δ 1.64 (s, 9 H), 1.83 (s, 3 H), 2.10 (s, 3 H), 4.53 (t, J=5.66 Hz, 2 H), 4.83 - 4.90 (m, 2 H), 7.27 (dd, J=9.08, 2.05 Hz, 1 H), 7.60 (d, J=l .95 Hz, 1 H), 7.62 - 7.73 (m, 4 H), 7.79 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 473.0; Anal. Calcd. for C23H28N405S + 1.30 TFA: C, 49.53; H, 4.76; N, 9.02. Found: C, 49.51; H, 4.43; N, 9.10.
Step H. N-[4-({[2-tert-butyI-l-(2-hydroxyethyl)-lH-benzimidazoI-5- yl]amino}sulfonyl)phenyI]acetamide
Figure imgf000204_0001
To 2-[5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-tert-butyl-lH-benzimidazol-l- yljethyl acetate (0.20 g, 0.423 mmol) in water (50 mL) was added 2N NaOH (5 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 2hrs. The reaction mixture was neutralized with concentrated HCl at 0°C until precipitation occurs. The product was extracted with EtOAc (3X). The combined organic layers were dried over anhydrous Na2S04 and filtered. The solvent was concentrated giving the pure title compound. Yield: 184 mg (99%), MS (ESI) (M+H)+: 431.0.
Step I. 2-[5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-tert-butyl-lH- benzimidazol-l-yl]ethyl methanesulfonate
Figure imgf000204_0002
Methane sulfonyl chloride (0.36 mL, 0.47 mmol) was added to a solution of N-[4- ({ [2-tert-butyl- 1 -(2-hydroxyethyl)- lH-benzimidazol-5- yl]amino}sulfonyl)phenyl]acetamide (0.18 g, 0.42 mmol) and Et^Ν (0.90 mL, 0.64 mmol) in a 1 :3 mixture of EtOAc:DCM (120 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 3hrs. The solvent was concentrated and the crude product was recovered in EtOAc (150 mL). The organic phase was washed with water, saturated ΝaΗC03 solution, water and brine. The solution was dried over anhydrous MgS04 and filtered. The solvent was concentrated giving the pure title compound. Yield: 205 mg (94%); MS (ESI) (M+H)+: 509.1. Example 125
3-[5-({[4-(acetylamino)phenyI]sulfonyI}amino)-2-tert-butyl-lH-benzimidazoI-l- yl]propyl acetate
Figure imgf000205_0001
Step A. 3-[5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-/ert-butyl-lH- benzimidazol-l-yI]propyl acetate
Figure imgf000205_0002
N-{5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-[(3-{[tert-butyl(dimethyl)silyl] oxy}propyl)amino]phenyl}-2,2-dimethylpropanamide (2.56 g, 4.44 mmol) (for preparation, see Example 124, Steps B to F) was dissolved in acetic acid (150 mL) and heated to 80°C overnight. The solvent was concentrated. The residue was recovered in EtOAc and washed with saturated ΝaHCθ3 solution, water and brine. The organic layer was dried with anhydrous MgSθ4, filtered and concentrated. The crude compound was purified on silica gel by flash chromatography using MeOH 1% to 5% in EtOAc as eluent. The fractions containing the desired material were purified by preparative reverse-phase HPLC using 10-90% CH3CN/H2O as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 60 mg (2%); Η NMR (400 MHz, CD3OD): δ 1.63 (s, 9 H), 2.04 (s, 3 H), 2.10 (s, 3 H), 2.20 - 2.31 (m, 2 H), 4.25 (t, J=5.86 Hz, 2 H), 4.59 - 4.69 (m, 2 H), 7.28 (dd, J=8.88, 2.05 Hz, 1 H), 7.58 - 7.67 (m, 3 H), 7.67 - 7.75 (m, 3 H); MS (ESI) (M+H)+: 487.0; Anal. Calcd. for C24H30N4θ5S + 1.30 TFA: C, 50.33; H, 4.97; N, 8.83. Found: C, 50.42; H, 5.10; N, 8.66. Step B. N-{4-[({4-[(3-hydroxypropyl)amino]-3- nitrophenyl}amino)suIfonyl]phenyl}acetamide
Figure imgf000206_0001
N-(4-{[(4-fluoro-3-nitrophenyl)amino]sulfonyl}phenyl)acetamide (4.00 g, 11.3 mmol) (for preparation, see Example 124, Step B , 3-aminopropanol (4.25 g, 56.6 mmol) and pyridine (1.83 mL, 22.6 mmol) in DMSO (50 mL) were heated to 80°C overnight. The room temperature cooled down reaction mixture was poured in water
(400 mL) at 0°C. The dark-purple mixture was acidified with concentrated HCl until red color appears. The compound was extracted with EtOAc (3X). The combined organic layers were washed with brine and dried over anliydrous MgSU4. The solvent was concentrated. The crude product was purified by flash chromatography on silica gel, using EtOAc as eluent, giving the title compound. Yield: 1.67 g (36%); MS (ESI)
(M+H)+: 409.4.
Step C. N-{4-[({4-[(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)amino]-3- nitrophenyl}amino)suIfonyl]phenyl}acetamide
Figure imgf000206_0002
A solution of TBDMSCl (0.74 g, 4.90 mmol) in EtOAc (50 mL) was slowly added to a solution of N-{4-[({4-[(3-hydroxypropyl)amino]-3- nitrophenyl}amino)sulfonyI]phenyl) acetamide (1.67 g, 4.08 mmol) and imidazole (0.36 g, 5.31 mmol) in EtOAc (200 mL) at room temperature. The reaction mixture was stirred overnight. The reaction was quenched with water and washed with ΝHjCl saturated solution, water and brine. The organic layer was dried over anhydrous MgS04. The solvent was concentrated. The crude product was purified by flash cliromatography on silica gel, using EtOAc Hex (3:1) as eluent, giving the title compound. Yield: 2.06 g (99%); MS (ESI) (M+H)+: 523.8.
Step E. N-{4-[({3-amino-4-[(3-{[tert- but3'l(dimethyl)silyl]oxy}propyl)amino]phenyl}amino)sulfonyl]phenyl}acetamide
Figure imgf000207_0001
N-{4-[({4-[(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)amino]-3- nitrophenyl}amino)sulfonyl]phenyl}acetamide (2.06 g, 3.94 mmol) was hydrogenated in EtOAc (200 mL) catalyzed by 10% Pd/C at 50 psi H2 in Parr shaker overnight at room temperature. The mixture was filtered over a celite pad. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 1.78 g (91%); MS (ESI) (M+H)+: 493.6.
Step F. N-{5-({[4-(acetylamino)phenyllsuIfonyl}amino)-2-[(3-{[tert- butyl(dimethyl)silyl]oxy}propyl)amino]phenyl}-2,2-dimethylpropanamide
Figure imgf000207_0002
tBuCOCl (0.44 mL, 3.61 mmol) was added to a solution of N-{4-[({3-amino-4-[(3- {[tert-butyl(dimethyl)silyl]oxy}propyl)amino]phenylJ amino)sulfonyl]pheny]} acetamide (1.78 g, 3.61 mmol) and Ets in DCM at 0°C. The reaction mixture was stirred for 3hrs. at 0°C. The reaction was quenched with saturated ΝaHCθ3 solution. The organic layer was washed with water, brine and dried over anhydrous MgS04. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 2.06 g (98%); MS (ESI) (M+H)+: 577.9.
Example 126
N-{4-[({l-[(l^,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]-2-tert-butyl-li7- benzimidazol-5-yl}amino)sulfonyl]phenyl}acetamide
Figure imgf000208_0001
StepA. N-{4-[({l-[(15,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]-2-tert-butyl-lH- benzimidazol-5-yl}amino)sulfonyl]phenyl}acetamide
Figure imgf000208_0002
N-[5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-amino phenyl]-2,2-dimethyl propanamide (200 mg, 0.494 mmol) (for preparation, see the following steps B to D) and (IS, 4S)-bicyclo[2.2.1]hept-5-ene-2-carbaldehyde (60 mg, 0.494 mmol) were mixed together in acetic acid (15 mL). The reaction mixture was heated to 50°C and stirred for 1 hr. Νa(BH3)CΝ (31 mg, 0.494 mmol) was added to the warm solution and stirred for one extra hour (50°C). The reaction mixture was heated to 100°C for 3 days (typically overnight). The solvent was concentrated. The crude product was purified by preparative reverse-phase HPLC using 10-90% CH3CN H2O as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 30 mg (10%); Η NMR (400 MHz, CD3OD): δ 0.80 - 0.90 (m, 1 H), 1.26 - 1.36 (m, 1 H), 1.37 - 1.45 (m, 1 H), 1.45 - 1.53 (m, 1 H), 1.63 (d, J=6.83 Hz, 9 H), 1.79 - 1.90 (m, 1 H), 2.10 (s, 3 H), 2.1 1 - 2.20 (m, 1 H), 2.57 (s, 1 H), 2.85 (s, 1 H), 2.93 (s, 1 H), 4.13 - 4.44 (m, 1 H), 4.45 - 4.73 (m, 1 H), 5.91 - 6.15 (m, 1 H), 6.24 - 6.46 (m, , 1 H), 7.26 (td, J=8.98, 2.15 Hz, 1 H), 7.62 (dd, J=4.78, 2.05 Hz, 1 H), 7.63 - 7.76 (m, 5 H); MS (ESI) (M+H)+: 493.0; Anal. Calcd. for C27H32N4θ3S + 1.70 TFA + 1.00 H20 + 0.50 MeCN: C, 52.02; H, 5.17; N, 8.69. Found: C, 52.01 ; H, 5.13; N, 8.66.
Step B. N-(2-amino-5-nitrophenyl)-2,2-dimethylpropanamide
Figure imgf000209_0001
tBuCOCl (10.9 mL, 88.5 mmol) was added to a mixture of 2-amino-4-nitroaniline (13.5 g, S8.5 mmol) and pyridine (7.50 mL, 92.9 mmol) in DCM (600 mL) at 0°C. The reaction mixture was slowly allowed to warm to room temperature and stirred for 4hrs. The reaction mixture was washed with water, 0.1 N HCl, brine and dried over anhydrous MgS04. The volume of the organic layer was reduced to 200 L. The resulting precipitate was filtered off and washed with small amount of cold DCM. The operation was repeated 3 times, giving the title compound as a pale-yellow solid. Yield: 9.35 g (44%); MS (ESI) (M+H)+: 238.2.
Step C. N-(2,5-diaminophenyl)-2,2-dimethylpropanamide
Figure imgf000209_0002
N-(2-amino-5-nitrophenyl)-2,2-dimethyIpropanamide (9.35 g, 39.4 mmol) was hydrogenated in EtOAc (400 mL) catalyzed by 10% Pd/C at 40 psi H2 in Parr shaker overnight at room temperature. The mixture was filtered through a celite pad. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 8.12 g (99%); MS (ESI) (M+H)+: 208.2. Step . N-[5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-arninophenyl]-2,2- dimethylpropanamide
Figure imgf000210_0001
4-(Acetylamino)benzenesulfonyl chloride (4.89 g, 20.9 mmol) was added by portion (over 3hrs) to a solution of N-(2,5-diaminophenyi)-2,2-dimethylpropanamide (4.34 g, 20.9 mmol) and pyridine (20 mL) in MeCΝ (600 mL). During the addition, the reaction temperature was maintained between -30 and -40°C. The reaction mixture was allowed to warm to room temperature and stirred for lhr. The solvent was concentrated. The residue was triturated in Et20 and filtered. The resulting solid was stirred in water (200 mL), filtered and air-dried giving the title compound that was used for the next step without further purification. Yield: 6.2 g (73%); MS (ESI) (M+H)+: 405.1.
Example 127
N-[4-({[2-ter/-butyl-l-(tetrahydro-2H-pyran-3-ylmethyl)-lH-benzimidazol-5- yI]amino}sulfonyl)phenyl]acetamide
Figure imgf000210_0002
N-[5-({[4-(acetylamino) phenyl] sulfonyl} amino) -2 -amino phenyl] -2,2- dimethyl propanamide (73 mg, 0.18 mmol) (for preparation, see Example 126, Steps B to D) and tetrahydro-2H-pyran-3-carbaldehyde (31 mg, 0.27 mmol) were stirred together at room temperature for lhr. in a 2:1 mixture of DCE and acetic acid (3 mL). Borane- pyridine complex (45 μL, 0.36 mmol) and concentrated ΗCi (5 drops) were added to the reaction mixture. The reaction mixture was heated to 95°C overnight. The solvent was concentrated. The crude product was purified by preparative reverse-phase HPLC using 10-90% CH3CN/H2O as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 25 mg (23%); Η NMR (400 MHz, CD3OD): δ 1.26 - 1.31 (m, 1 H), 1.50 - 1.61 (m, 1 H), 1.63 (s, 9 H), 1.67 - 1.77 (m, 2 H), 1.77 - 1.87 (m, 1 H), 2.10 (s, 3 H), 2.24 - 2.34 (m, 1 H), 3.39 (dd, J=l 1.62, 7.71 Hz, 1 H), 3.55 - 3.62 (m, 1 H), 3.66 (dd, J=l 1.52, 2.93 Hz, 1 H), 3.71 - 3.80 (m, 1 H), 4.38 (dd, J=15.04, 6.05 Hz, 1 H), 4.59 (dd, J=15.04, 8.98 Hz, 1 H), 7.24 (dd, J=8.98, 1.95 Hz, 1 H) ,7.61 (d, J=2.15 Hz, 1 H), 7.63 - 7.68 (m, 2 H), 7.69 - 7.74 (m, 2 H), 7.76 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 485.0; Anal. Calcd. for C25H32N4O4S + 1.50 TFA: C, 51.29; H, 5.15; N, 8.55. Found: C, 51.43; H, 5.22; N, 8.11.
Example 128
N-[4-({[2-tert-butyl-l-(tetrahydrofuran-3-yImethyl)-lH-benzimidazol-5- yl]amino}sulfonyI)phenyI]acetamide
Figure imgf000211_0001
N-[5-({[4-(acetylamino) phenyl] sulfonyl) amino) -2-amino phenyl] -2,2- dimethyl propanamide (113 mg, 0.27 mmol) (for preparation, see Example 126, Steps B to D), 50% tetrahydrofuran-3-carbaldehyde aqueous solution (60 mg, 0.27 mmol) and concentrated HCl (4 drops) were stirred together at room temperature in a 1 : 1 mixture of water and MeCΝ (15 mL). Borane-pyridine complex (69 μL, 0.55 mmol) was added and the reaction mixture was heated to 95°C overnight. The solvent was concentrated. The crude product was purified by preparative reverse-phase HPLC using 10-90% CH3CΝ/H20 as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 25 mg (15%); Η NMR (400 MHz, CD3OD): δ 1.63 (s, 9 H), 1.74 - 1.85 (m, 1 H), 2.04 - 2.16 (m, 4 H), 2.98 (dd, J=7.91, 5.37 Hz, 1 H), 3.60 (d, J=5.47 Hz, 2 H), 3.68 - 3.78 (m, 1 H), 3.95 - 4.04 (m, 1 H), 4.53 (d, J=7.81 Hz, 2 H), 7.25 (dd, J=8.98, 2.15 Hz, 1 H), 7.59 - 7.68 (m, 3 H), 7.68 - 7.73 (m, 2 H), 7.76 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 471.0; Anal. Calcd. for 4H30N4O4S + 1.40 TFA + 0.10 H20 + 0.10 MeCN: C, 50.98; H, 5.05; N, 9.03. Found: C, 51.01; H, 4.79; N, 9.01.
Example 129
N-{4-[({2-te;t-butyl-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-benzimidazoI-5- y!}amino)sulfonyl]phenyl}acetamide
Figure imgf000212_0001
Step A. N-{4-I({2-tert-butyl-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH- benzimidazoI-5-yl}amino)sulfonyl]phenyl}acetamide
Figure imgf000212_0002
N-(5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-{[2-(tetrahydro-2H-pyran-4- yl)ethyl]amino}phenyl)-2,2-dimethylpropanamide (95 mg, 0.183 mmol) (for preparation, see the following step B) in acetic acid was heated to 100°C (10 mL) overnight. The solvent was concentrated. The crude product was purified by preparative reverse-phase ΗPLC using 10-90% CΗ3CΝ/Η 0 as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 50 mg (44%); 1H NMR (400 MHz, CD3OD): δ 1.32 - 1.48 (m, 1 H), 1.62 (s, 9 H), 1.75 (d, J=12.89 Hz, 2 H), 1.79 - 1.89 (m, 2 H), 2.10 (s, 3 H), 3.40 - 3.51 (m, 4 H), 3.95 (dd, J=l 1.81 , 4.00 Hz, 2 H), 4.52 - 4.60 (m, 2 H), 7.28 (dd, J=8.98, 2.15 Hz, 1 H), 7.60 - 7.65 (m, 2 H), 7.65 - 7.68 (m, 2 H),7.68 - 7.74 (m, 2 H); MS (ESI) (M+H)+: 499.0; Anal. Calcd. for C26H34N4O4S + 1.60 TFA + 0.20 H20: C, 51.22; H, 5.30; N, 8.18. Found: C, 51.29; H, 5.26; N, 8.13.
Step B. N-(5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-{[2-(tetrahydro-2H- pyran-4-yl)ethyl]amino}phenyl)-2,2-dimethylpropanamide
Figure imgf000213_0001
N-[5-({[4-(acetylamino) phenyl] sulfonyl) amino) -2-amino phenyl] -2,2- dimethyl propanamide (90 mg, 0.22 mmol) (for preparation, see Example 126, steps B to D) and tetrahydro-2H-pyran-4-ylacetaldehyde (85 mg, 0.66 mmol) were stirred together in acetic acid (8 mL) at 70°C for lhr. The reaction mixture was cooled to room temperature and Νa(BΗ>3CΝ (30 mg, 0.44 mmol) was added. The reaction was stirred overnight at room temperature. The solvent was concentrated. The crude product was purified by preparative reverse-phase HPLC using 10-90% CH3CN/H2O as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 95 mg (69%); MS (ESI) (M+H)+: 517.6.
Example 130
N-(4-{[[2-tert-butyI-l-(cycIobutylmethyI)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000213_0002
Step A. N-(4-{[[2-tert-butyl-l-(cyclobutylmethyI)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyI)acetamide
Figure imgf000214_0001
4-(acetylamino)benzenesu]fonyl chloride (55 mg, 0.2 mmol) was added to a solution of 2-tert-butyl-l-(cyclobutylmethyl)-N-methyl-lH-benzimidazol-5-amine (53 mg, 0.19 mmol) (for preparation, see Steps B to E ) and DMAP (48 mg, 0.39 mmol) in MeCΝ (5 mL) at 70°C. The reaction mixture was stirred for 1 hr. and allowed to cool to room temperature. The solvent was concentrated. The crude product was purified by preparative reverse-phase HPLC using 10-90% CH3CΝ/H2O as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 82 mg (71%); Η NMR (400 MHz, CD3OD): δ 1.65 (s, 9 H), 1.83 - 1.97 (m, 3 H), 2.04 - 2.13 (m, 3 H), 2.14 (s, 3 H), 2.79 - 2.93 (m, 1 H), 3.25 (s, 3 H), 4.64 (d, J=6.64 Hz, 2 H), 7.31 (dd, J=9.08, 2.05 Hz, 1 H), 7.41 - 7.49 ( , 2 H), 7.52 (d, J=1.95 Hz, 1 H), 7.71 (d, J=8.79 Hz, 2 H), 7.80 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 469.0.
Step B . N-{4-[(cyclobutylmethyl)amino]-3-nitrophenyl}-N-methylacetamide
Figure imgf000214_0002
A solution of (cylobutylmethyl)amine in Et20 (excess) was added to a solution of N- (4-fluoro-3-nitrophenyl)-N-methylacetamide (1.00 g, 4.71 mmol) and DIPEA (1.00 L, 5.65 mmol) in DMF (50 L) at 0°C The reaction mixture was allowed to warm to room temperature and stirred overnight. The solvent was concentrated. The crude product was purified by flash chromatography on silica gel, using EtOAc/Hep (30 to 90%) as eluent, giving the title compound. Yield: 1.01 g (77%); MS (ESI) (M+H)+: 278.3.
Step C. N-{3-amino-4-[(cyclobutylmethyl)amino]phenyl}-N-methylacetamide
Figure imgf000215_0001
N-{4-[(cyclobutylmethyl)amino]-3-nitrophenyl}-N-methylacetamide (1.01 g, 3.64 mmol) was hydrogenated in EtOAc (150 mL) catalyzed by 10% Pd/C at 50 psi H2 in Parr shaker overnight at room temperature. The mixture was filtered through a celite pad. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 833 mg (92%); MS (ESI) (M+H)+: 248.3.
Step D. N-[2-tert-butyl-l-(cyclobutylmethyI)-lH-benzimidazol-5-yl]-N- methylacetamide
Figure imgf000215_0002
tBuCOCl (0.41 mL, 3.36 mmol) was added to a solutin of N-{3-amino-4- [(cyclobutylmethyl)amino]phenyl}-Λ-methylacetamide (0.83 mg, 3.36 mmol) and Et3Ν (0.50 mL, 3.53 mmol) in DCM (125 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 3 hrs. The solvent was concentrated and the crude compound was recovered in acetic acid (100 mL). The solution was heated to 100°C overnight. The solvent was concentrated. The crude product was purified by flash chromatography on silica gel, using EtOAc/Hep (30 to 90%) as eluent, giving the title compound. Yield: 529 mg (50%); MS (ESI) (M+H)+: 314.4.
Step E. 2-te/-t-butyl-l-(cyclobutylmethyl)-N-methyl-lH-benzimidazol-5-amine
Figure imgf000216_0001
N-[2-tert-butyl-l-(cyclobutylmethyl)-lH-benzimidazol-5-yl]-N-methylacetamide (0.53 g, 1.68 mmol) was heated to 80°C overnight in concentrated ΗC1 (10 mL). The room temperature cooled down reaction mixture was poured in water (100 mL). The resulting mixture was brought to slightly basic pΗ using ΝaOΗ solution at 0°C. The compound was extracted with EtOAc (3X) and the combined organic layers were washed with brine, dried over anhydrous Νa2S04 and filtered. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 343 mg (75%); MS (ESI) (M+Η)+: 272.4.
Example 131
4-[(aminocarbonyI)amino]-N-[2-tert-butyl-l-(cycIobutylmethyl)-lH- benzimidazol-5-yl]-N-methylbenzenesulfonamide
Figure imgf000216_0002
Following the procedure for Step A in Example 130, , using the 4-[(aminocarbonyl) amino] benzenesulfonyl chloride (57 mg, 0.24 mmol) and 2 -tert-butyl- 1- (cyclobutylmethyl)-N-methyl-lH-benzimidazol-5-amine (55 mg, 0.20 mmol), the title compound was obtained as the corresponding TFA salt. Yield: 60 mg (50%); Η ΝMR (400 MHz, CD3OD): δ 1.65 (s, 9 H), 1.81 - 1.99 (m, 3 H), 2.04 - 2.15 (m, 3 H), 2.80 - 2.92 (m, 1 H), 3.23 (s, 3 H), 4.64 (d, J=6.44 Hz, 2 H), 7.33 (dd, J=9.08, 2.05 Hz, 1 H), 7.36 - 7.42 (m, 2 H), 7.50 (d, J=1.95 Hz, 1 H), 7.51 - 7.56 (m, 2 H), 7.81 (d, J=9.18 Hz, 1 H); MS (ESI) (M+H)+: 470.0. Example 132
N-(4-{[[2-tert-butyl-l-(cyclobutyImethyI)-lH-benzimidazol-5- yl](methyl)amino]suIfonyl}phenyl)-2,2-dimethylpropanamide
Figure imgf000217_0001
2,2-DimethylpropanoyI chloride (31 mg, 0.25 mol) was added to a solution of 4-amino-N-[2-tert-butyl-l-(cyclobutylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide (100 mg, 0.23 mmol) and Et3Ν (40 μL, 0.28 mmol) in DCM (15 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 4 hours. The solvent was concentrated. The crude product was purified by preparative reverse-phase ΗPLC using 10-90% CΗ3C /Η20 as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 95 mg (64%); IH NMR (400 MHz, CD3OD): δ 1.29 (s, 9 H), 1.65 (s, 9 H), 1.80 - 1.98 (m, 2 H), 2.04 - 2.15 (m, 4 H), 2.80 - 2.93 (m, 1 H), 3.25 (s, 3 H), 4.64 (d, .1=6.44 Hz, 2 H), 7.31 (dd, J=8.98, 2.15 Hz, 1 H), 7.41 - 7.48 ( , 2 H), 7.51 (d, J=1.56 Hz, 1 H), 7.73 - 7.79 (m, 2 H), 7.81 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)+: 511.0.
Example 133
N-(4-{[[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-yImethyl)-lH- benzimidazoI-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide
Figure imgf000217_0002
Step A. N-(4-{[[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yI](methyI)amino]sulfonyl}phenyl)-2-hydroxyacetamide
Figure imgf000218_0001
4NNaOH (10 drops) was added to a solution of 2-[(4-{[[2-(l,l-difluoroethyl)-l-
(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate (74 mg, 0.13 mmol)(for preparation, see Steps B to G) in MeOΗ (5 mL). The reaction mixture was stin-ed for lhr. at room temperature and poured in water (100 mL). The mixture was acidified with concentrated ΗC1 and the compound was extracted with EtOAc (3X). The combined organic layers were dried over anhydrous Na2S04. The solvent was concentrated. The crude product was purified by preparative reverse-phase ΗPLC using 10-90% CΗ3CN/Η2O as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 48 mg (57%); Η NMR (400 MHz, CDC13): δ 1.44 - 1.58 (m, 4 H), 2.25 (t, J=19.23 Hz, 4 H), 3.21 (s, 3 H), 3.29 - 3.44 m, 2 H), 4.01 (d, J=l 1.33 Hz, 2 H), 4.24 (s, 2 H), 4.28 (d, J=7.42 Hz, 2 H), 7.30 (s, 1 H), 7.36 - 7.52 (m, 4 H), 7.66 (d, J=8.79 Hz, 2 H), 8.75 (s, 1 H); MS (ESI) (M+H)+: 523.0; Anal. Calcd. for C24H2sF2N4OsS + 0.90 TFA + 0.40 H20 + 0.10 MeCN: C, 49.06; H, 4.75; N, 9.02. Found: C, 49.07; H, 4.76; N, 9.04.
Step B. N-{5-[acetyl(methyl)amino]-2-[(tetrahydro-2H-pyran-4- yImethyl)amino]phenyl}-2,2-difluoropropanamide
Figure imgf000218_0002
HATU (1.44 g, 3.78 mmol) and N-{3-amino-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}-N-methylacetamide (1.00 g, 3.60 mmol) (for preparation, see Example 67) were added to a solution of 2,2-difluoropropanoic acid (0.40 g, 3.60 mmol) and DIPEA (0.75 mL, 4.32 mmol) in DMF (100 mL) at room temperature. The reaction mixture was stirred overnight. The solvent was concentrated and the crude product was recovered in EtOAc. The organic was washed with water, saturated NaHC03 solution and brine. The organic layer was dried over anhydrous Na2S04 and filtered. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 1.00 g (75%); MS (ESI) (M+H)+: 370.2.
Step C. N-[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl]-N-methylacetamide
Figure imgf000219_0001
N-{5-[acetyl(methyl)amino]-2-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-2,2- difluoropropanamide (1.00 g, 2.70 mmol) was heated to 90°C overnight in acetic acid (20 mL). The solvent was concentrated. The crude product was purified by flash chromatography on silica gel, using MeOΗ 3.5% and acetone 8% in DCM as eluent, giving the title compound. Yield: 0.48 g (50%); MS (ESI) (M+Η)+: 352.0.
Step D. 2-(l,l-difluoroethyI)-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-amine I I
Figure imgf000219_0002
N-[2-( 1 , 1 -difluoroethyl)- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzimidazoI-5-yl]- N-methylacetamide (0.48 g, 1.37 mmol) was heated to 80°C overnight in concentrated ΗC1 (80 mL). The reaction mixture was cool to 0°C and brought to slightly basic pΗ using ΝaOΗ solution. The compound was extracted with EtOAc (3X) and the combined organic layers were washed with brine, dried over anhydrous Νa2Sθ4 and filtered. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 0.42 g (98%); MS (ESI) (M+H)+: 310.2.
Step E. N-[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl]-N-methyl-4-nitrobenzenesulfonamide
Figure imgf000220_0001
4-Νitrobenzenesulfonyl chloride (0.28 g, 1.27 mmol) was added to a solution of 2-(l,l-difluoroethyl)-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-amine (0.26 g, 0.84 mmol) and DMAP (0.21 g, 1.69 mmol) in DCE (50 mL). The reaction mixture was heated to 70°C for 1 hr. The solvent was concentrated. The crude product was purified by preparative reverse-phase ΗPLC using 10-90% CΗ3CΝ/Η2O as eluent and then lyophilized to give the title compound. Yield: 415 mg (99%); MS (ESI) (M+H)+: 495.3.
Step F. 4-amino-N-[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-yImethyl)- lH-benzimidazoI-5-yl]-N-methylbenzenesulfonamide
Figure imgf000220_0002
N-[2-(l ,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]- N-methyl-4-nitrobenzenesulfonamide (415 mg, 0.84 mmol) was hydrogenated in
EtOAc (100 mL) catalyzed by 10% Pd/C at 40 psi Η2 in Parr shaker overnight at room temperature. The mixture was filtered over a celite pad. The solvent was concentrated giving the title compound that was used for the next step without further purification. Yield: 386 g (99%); MS (ESI) (M+H)+: 465.5. Step G. 2-[(4-{[[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate
Figure imgf000221_0001
2-Chloro-2-oxoethyl acetate (36 mg, 0.26 mmol) was added to a solution of 4-amino-N-[2-( 1 , 1 -difluoroethyl)- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1H- benzimidazol-5-yl]-N-methylbenzenesulfonamide (100 mg, 0.21 mmol) and Et3Ν (44 μL, 0.32 mmol) in DCM (20 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 4 hrs. The solvent was concentrated. The crude product was purified by preparative reverse-phase ΗPLC using 10-90% CΗ3CN/Η2O as eluent and then lyophilized to give the title compound. Yield: 74 mg (62%); MS (ESI) (M+H)+: 565.6.
Example 134
N-(4-{[[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazoI-5-yl](methyl)amino]sulfonyl}phenyl)acetamide
Figure imgf000221_0002
4-(Acetylamino)benzenesulfonyl chloride (45 mg, 0.19 mmol) was added to a solution of 2-(l,l-difluoroethyl)-N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-amine (50 mg, 0.16 mmol) (for preparation, see Example 133, Steps B to D) and DMAP (39 mg, 0.32 mmol) in MeCΝ (5 mL) at 70°C. The reaction mixture was stirred for 1 hr. and allowed to cool to room temperature. The solvent was concentrated. The crude product was purified by preparative reverse-phase ΗPLC using 10-90% CΗ3CΝ/Η20 as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 87 mg (86%); Η NMR (400 MHz, CD3OD): δ 1.39 - 1.55 ( , 5 H), 2.14 (s, 3 H), 2.21 (t, J=19.33 Hz, 3 H), 3.24 (s, 3 H) 3.32 - 3.38 (m, 2 H), 3.88 - 3.97 (m, 2 H), 4.34 (d, J=7.62 Hz, 2 H), 7.23 (dd, J=8.88, 2.05 Hz, I H), 7.35 (d, J=1.9S Hz, 1 H), 7.43 - 7.48 ( , 2 H), 7.64 (d, J=8.79 Hz, 1 H), 7.67 - 7.73 (m, 2 H); MS (ESI) (M+H)+: 507.0; Anal. Calcd. for C24H28F2N404S + 1.20 TFA + 0.20 H20 + 0.10 MeCN: C, 49.07; H, 4.63; N, 8.82. Found: C, 49.04; H, 4.59; N, 8.84.
Example 135
N-(4-{[[2-(l,l-difluoroethyI)-l-(tetrahydro-2iy-pyran-4-ylmethyl)-lJfiT- benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-3-methylbutanamide
Figure imgf000222_0001
3-Methylbutanoyl chloride (15 mg, 0.12 mmol) was added to a solution of
4-amino-N-[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl]-N-methylbenzenesulfonamide (50 mg, 0.10 mmol) (for preparation, see Example 133, Steps B to F) and Et3Ν (22 μL, 0.16 mmol) in DCM (10 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred overnight. The solvent was concentrated. The crude product was purified by preparative reverse-phase ΗPLC using 10-90% CΗ3CN/Η20 as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 25 mg (35%); H NMR (400 MHz, CDC13): δ 1.03 (d, J=6.44 Hz, 6 H), 1.43 - 1.56 (m, 4 H), 2.16 - 2.35 ( , 6 H), 3.13 (s, 1 H), 3.21 (s, 3 H), 3.29 - 3.41 (m, 2 H), 3.94 - 4.05 (m, 2 H), 4.27 (d, J=7.42 Hz, 2 H), 7.33 (s, 1 H), 7.37 - 7.43 (m, 2 H), 7.45 - 7.53 ( , 3 H), 7.63 (d, J=8.79 Hz, 2 H); MS (ESI) (M+H)+: 549.0; Anal. Calcd. for C27H34F2N4O4S + 1.40 TFA + 0.30 MeCN: C, 50.67; H, 5.08; N, 8.36. Found: C, 50.68; H, 5.07; N, 8.32.
Example 136
N-(4-{[[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyI}phenyl)-2,2-dimethyIpropanamide
Figure imgf000223_0001
2,2-Dimethylpropanoyl chloride (15 mg, 0.12 mmol) was added to a solution of 4-amino-Λ-[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazoI-5-yl]-N-methyIbenzenesulfonamide (50 mg, 0.10 mmol) (for preparation, see Example 133, Steps B to F) and Et3Ν (22 μL, 0.16 mmol) in DCM (10 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred overnight. The solvent was concentrated. The crude product was purified by preparative reverse-phase ΗPLC using 10-90% CΗ3CN/Η20 as eluent and then lyophilized to give the title compound. Yield: 31 mg (43%); !H NMR (400 MHz, CDC13): δ 1.34 (s, 9 H), 1.46 - 1.56 (m, 3 H), 1.69 (s, 2 H), 2.17 (s, 3 H), 2.26 (t, J=19.23 Hz, 3 H), 3.29 - 3.40 (m, 2 H), 3.98 (dt, J=l 1.23, 2.98 Hz, 2 H), 4.26 (d, J=7.42 Hz, 2 H), 5.30 (s, 1 H), 7.31 (s, 1 H), 7.32 - 7.42 (m, 2 H), 7.47 - 7.53 (m, 1 H), 7.59 (s, 1 H), 7.62 - 7.69 (m, 2 H); MS (ESI) (M+H)+: 549.0; Anal. Calcd. for C27H34F2N404S: C, 59.11; H, 6.25; N, 10.21. Found: C, 59.54; H, 6.16; N, 10.05.
Example 137
N-[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazol-
5-yl]-4-{{(isopropylamino)carbonyl]amino}-N-methylbenzenesulfonaraide
Figure imgf000223_0002
2-Isocyanatopropane (excess) was added to a solution of 4-amino-N-[2-(l,l- difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide (50 mg, 0.10 mmol) (for preparation, see Example 133, Steps B to F) in DCE (5 mL). The reaction mixture was stirred at 90°C overnight. The solvent was concentrated. The crude product was purified by preparative reverse- phase HPLC using 10-90% CH3CN/H20 as eluent and then lyophilized to give the title compound as the corresponding TFA salt. Yield: 12 mg (16%); Η NMR (400 MHz, CDC13): δ 1.20 (d, J=6.44 Hz, 6 H), 1.23 (d, J=6.64 Hz, 1 H), 1.44 - 1.57 (m, 4 H), 1.80 (s, 1 H), 2.26 (t, J=19.14 Hz, 3 H), 3.19 (s, 3 H), 3.28 - 3.41 (m, 2 H), 3.91 - 4.05 (m, 3 H), 4.27 (d, J=7.42 Hz, 2 H), 7.22 (s, 1 H), 7.31 - 7.48 (m, 6 H); MS (ESI) (M+H)+: 550.0.
Example 138 4-{Bis[(isopropylamino)carbonyl]amino}-N-[2-(l,l-difluoroethyl)-l-(tetrahydro- 2H-pyran-4-ylmethyI)-lH-benzimidazol-5-yl]-N-methylbenzenesuIfonamide
Figure imgf000224_0001
The title compound was obtained as a by-product in Example 137. The material was purified by preparative reverse-phase HPLC using 10-90% CH3CN/H 0 as eluent and then lyophilized to give the corresponding TFA salt. Yield: 18 mg (22%); Η NMR (400 MHz, CDCI3): δ 1.15 (d, J=6.64 Hz, 12 H), 1.44 - 1.55 (m, 4 H), 1.82 (s, 2 H), 2.27 (t, J=19.23 Hz, 3 H), 3.28 (s, 3 H), 3.29 - 3.39 (m, 2 H), 3.88 - 4.03 ( , 3 H), 4.25 (d, J=7.42 Hz, 2 H), 6.55 (s, 1 H), 7.24 (dd, J=8.79, 1.95 Hz, 1 H), 7.39 (d, J=8.59 Hz, 2 H), 7.53 (d, J=l .76 Hz, 1 H), 7.73 (d, J=8.59 Hz, 2 H); MS (ESI) (M+H)+: 635.0.
Example 139
N-[4-({methyI[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide
Figure imgf000225_0001
Step A. N-[4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyI)- lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide
Figure imgf000225_0002
N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH-benzimidazol- 5-amine hydrochloride (76.1 mg, 0.2 mmol) (for preparation, see following Steps B and C), DMAP (97.7 mg, 0.8 mmol) and 4-(acetylamino)benzenesulfonyl chloride (93.5 mg, 0.4 mmol) in MeCΝ (5 mL) were stirred overnight at room temperature. The reaction mixture was quenched with Η20 (6 mL). Upon evaporation, the crude product was purified by reversed-phase HPLC using 20-70% CH3CΝ/H2O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 49.1 mg (48%). 'HNMR (400 MHz, CD3OD): 1.39 - 1.56 (m, 4 H), 2.14 (s, 3 H), 2.19 - 2.32 (m, 1 H), 3.24 (s, 3 H), 3.31 - 3.39 (m, 2 H), 3.85 - 4.01 (m, 2 H), 4.32 (d, J=7.42 Hz, 2 H), 7.32 (dd, J=8.88, 2.05 Hz, 1 H), 7.40 (d, J=1.95 Hz, 1 H), 7.43 - 7.49 (m, 2 H), 7.67 - 7.75 (m, 3 H). MS (ESI) (M+H)+ = 511.0. Anal. Calcd for
C23H25F3N4O4S+ 0.4 TFA+0.2 H20 (559.75): C, 51.07, H, 4.65, N, 10.01 ; Found: C, 51.16; H, 4.74; N, 9.65.
Step B. N-methyI-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyI)- lH-benzimidazol-5-yI]acetamide
124 -
Figure imgf000226_0001
A solution ofN-{3-amino-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyI}-N- methylacetamide hydrochoride (395.1 mg, 1.42 mmol) (for preparation see Example 67) in trifluoroacetic acid (10 mL) was heated to reflux for 20 h. After evaporation of the solvent, the crude product was used directly for next step without purification. MS (ESI) (M+Η)+: 356.02.
Step C. N-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-amine
Figure imgf000226_0002
The crude N-methyl-N-[ 1 -(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- 1H- benzimidazol-5-yl]acetamide (~500 mg, 1.42 mmol) was dissolved in 10 mL of EtOH-2NHCl (3:2), and then heated at 120°C in a Personal Chemistry SmithSynthesizer microwave instrument for 4 h. After concentration and dried in vacuo, 539 mg (100%) of a grey white solid was obtained as the title product, which was used directly for Step A. MS (ESI) (M+H)+ = 314.20.
Example 140
4-[(aminocarbonyl)amino]-N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2- (trifluoromethyl)-lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000227_0001
Following the procedure for Step A in Example 139, using N-methyl-l-(tetrahydro- 2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH-benzimidazol-5-amine hydrochloride (76.1 mg, 0.2 mmol) (for preparation, see the steps B and C in Example 139), DMAP (97.7 mg, 0.8 mmol) and 4-[(aminocarbonyl)amino]benzenesulfonyl chloride (94.0 mg, 0.4 mmol) in MeCΝ (6 mL), the crude product was purified by reversed-phase ΗPLC using 20-50% CΗ3CΝ/Η20 and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 42.9 mg (42%). !HNMR (400 MHz, CD3OD): δ 1.40 - 1.52 (m, 4 H), 2.15 - 2.34 (m, 1 H), 3.23 (s, 3 H), 3.31 - 3.40 (m, 2 H), 3.87 - 3.98 (m, 2 H), 4.32 (d, J=7.81 Hz, 2 H), 7.32 (dd, J=8.88, 2.05 Hz, 1 H), 7.37 - 7.43 (m, 3 H), 7.48 - 7.56 (m, 2 H), 7.72 (d, J=8.79 Hz, 1 H). MS (ESI) (M+H)+ = 512.0. Anal. Calcd for C22H24F3N504S+ 0.3 TFA (545.73): C, 49.74, H, 4.49, N, 12.83; Found: C, 49.84; H, 4.55; N, 12.78.
Example 141
N-methyl-4-nitro-N-[l-(tetrahydro-2H-pyran-4-ylmethyI)-2-(trifluoromethyl)- lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000227_0002
Following the procedure for Step A in Example 139, using N-methyl-l-(tetrahydro- 2H-pyran-4-ylmethyl)-2-(trifluoromethyI)-lH-benzimidazol-5-amine hydrochloride (387.0 mg, 1.0 mmol) (for preparation, see the steps B and C in Example 139), DMAP (488.7 mg, 4.0 mmol) and 4-nitrobenzenesulfonyl chloride (443.2 mg, 2.0 mmol) in MeCΝ (10 mL), the crude product was purified by MPLC using Hex/EtOAc (1 :1) on silica gel to give 295.0 mg (59%) of a yellow solid as the title compound. 1HNMR (400 MHz, CD3OD): δ 1.39 - 1.54 (m, 4 H), 2.14 - 2.34 (m, 1 H), 3.32 (s, 3 H), 3.33 - 3.40 (m, 2 H), 3.86 - 4.01 (m, 2 H), 4.32 (d, J=7.42 Hz, 2 H), 7.31 (dd, J=8.88, 2.05 Hz, 1 H), 7.45 (d, J=2.15 Hz, 1 H), 7.74 (d, J=8.98 Hz, 1 H), 7.76 - 7.82 (m, 2 H), 8.27 - 8.42 (m, 2 H). MS (ESI) (M+H)+ = 499.0. Anal. Calcd for C2iH2iF3N405S+ 0.50 TFA+0.20 H20 (559.10): C, 47.26; H, 3.95; N, 10.02; Found: C, 47.24; H, 3.80; N, 10.20.
Example 142 4-amino-N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyI)-2-(trifluoromethyI)- lH-benzimidazoI-5-yI]benzenesuIfonamide
Figure imgf000228_0001
N-methyl-4-nitro-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]benzenesuIfonamide (235.6 mg, 0.47 mmol) (for preparation, see the Example 141) was hydrogenated in ethyl acetate (20 mL) catalyzed by 10% Pd/C (90 mg) at 30-40 psi Η2 in Parr shaker for 5 h at room temperature. After filtration through celite and concentration, 229.8 mg (100%) of a white solid was obtained. Small amounts of the crude product was purified by reversed-phase HPLC using 20- 70% CH3CΝ/H2O and then lyophilized affording the title compound as the corresponding TFA salt. 'HNMR (400 MHz, CD3OD): δ 1.38 - 1.55 (m, 4 H), 2.15 - 2.35 (m, 1 H), 3.18 (s, 3 H), 3.33 - 3.40 (m, 2 H), 3.82 - 4.02 (m, 2 H), 4.32 (d, J=7.62 Hz, 2 H), 6.58 - 6.69 (m, 2 H), 7.15 - 7.23 (m, 2 H), 7.35 (dd, J=8.98, 1.95 Hz, 1 H), 7.40 (d, J=1.56 Hz, 1 H), 7.71 (d, J=8.79 Hz, 1 H). MS (ESI) (M+H)+ = 469.0. Anal. Calcd for C2iH23F3N403S+ 0.40 TFA (514.1 1): C, 50.93; H, 4.59; N, 10.90; Found: C, 51.00; H, 4.72; N, 10.54.
Example 143 2,2-dimethyl-N-[4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2- (trifluoromethyI)-lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]propanamide
Figure imgf000229_0001
4-Amino-N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]benzenesulfonamide (50.3 mg, 0.107 mmol) (for preparation, see the Example 142), DMAP (59.0 mg, 0.483 mmol) and trimethylacetyl chloride (14.7 mg, 0.122 mmol) in MeCΝ (5 L) were stirred for 6 h at room temperature. The reaction mixture was diluted with EtOAc (100 L), washed with saturated ΝaΗC03 (10 mL) and saturated NaCl (10 mL), and dried over Na2S04. Upon evaporation, the residue was purified by by MPLC using Hex EtOAc (1:1) on silica gel to give 30.5 mg (52%) of a white solid as the title compound. ' HNMR (400 MHz, CD3OD): δ 1.29 (s, 9 H), 1.39 - 1.58 (m, 4 H), 2.15 - 2.37 (m, 1 H), 3.24 (s, 3 H), 3.31 - 3.40 (m, 2 H), 3.87 - 3.99 (m, 2 H), 4.32 (d, J=7.62 Hz, 2 H), 7.32 (dd, J=8.88, 2.05 Hz, 1 H), 7.40 (d, J=1.95 Hz, 1 H), 7.42 - 7.49 (m, 2 H), 7.72 (d, J=8.98 Hz, 1 H), 7.74 - 7.79 (m, 2 H), 9.35 (s, 1 H). MS (ESI) (M+H)+ = 553.0. Anal. Calcd for C26H3iF3N4θ4S+ 0.1 TFA+0.50 H20 (573.03): C, 54.92; H, 5.65; N, 9.78; Found: C, 54.77; H, 5.54; N, 10.09.
Example 144 2-{l4-({methyl[l-(tetrahydro-2H-pyran-4-yImethyl)-2-(trifIuoromethyI)-lH- benzimidazoI-5-yI]amino}suIfonyI)phenyl]amino}-2-oxoethyI acetate
Figure imgf000230_0001
Following the procedure for Example 143, using 4-Amino-N-methyl-N-[l- (tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH-benzimidazol-5- yl]benzenesulfonamide (113.0 mg, 0.241 mmol) (for preparation, see the Example 142), DMAP (109.0 mg, 0.892 mmol) and 2-chloro-2-oxoethyl acetate chloride (38.1 mg, 0.279 mmol) in MeCΝ (10 mL), the crude product was purified by MPLC using Ηex/EtOAc (1:1) on silica gel to give 90.0 mg (66%) of a white solid as the title compound. ' ΗΝMR (400 MHz, CD3OD): δ 1.41 - 1.54 (m, 4 H), 2.16 (s, 3 H), 2.20 - 2.33 (m, 1 H), 3.25 (s, 3 H), 3.31 - 3.40 (m, 2 H), 3.87 - 3.98 (m, 2 H), 4.32 (d, J=7.62 Hz, 2 H), 4.69 (s, 2 H), 7.32 (dd, J=8.88, 2.05 Hz, 1 H), 7.41 (d, J=1.56 Hz, 1 H), 7.44 - 7.50 (m, 2 H), 7.69 - 7.76 (m, 3 H), 10.24 (s, 1 H). MS (ESI) (M+H)+ = 569.1. Anal. Calcd for C25H27F3Ν406S+ 0.1 TFA+0.40 H20 (587.18): C, 51.55; H, 4.79; N, 9.54; Found: C, 51.60; H, 4.74; N, 9.56.
Example 145
4-{[(isopropylamino)carbonyI]anιino}-N-methyl-N-[l-(tetrahydro-2H-pyran-4- ylmethyl)-2-(trifluoromethyl)-lH-benzimidazol-5-yl]benzenesulfonamide
Figure imgf000230_0002
4-Amino-A^-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]benzenesulfonamide (31.3 mg, 0.067 mmol) (for preparation, see the Example 142) and 2-isocyanatopropane (0.5 mL) in DCE (5 mL) was heated overnight at 80 °C. After evaporation, the crude product was purified by MPLC using Hex/EtOAc (1 :1) on silica gel to give 17.2 mg (46%) of a white solid as the title compound. 'HNMR (400 MHz, CD3OD): δ 1.17 (d, J=6.44 Hz, 6 H), 1.41 - 1.53 (m, 4 H), 2.18 - 2.33 (m, 1 H), 3.23 (s, 3 H), 3.31 - 3.39 (m, 2 H), 3.83 - 3.90 (m, 1 H), 3.90 - 3.96 (m, 2 H), 4.32 (d, J=7.42 Hz, 2 H), 7.32 (dd, J=8.88, 2.05 Hz, 1 H), 7.36 - 7.40 (m, 2 H), 7.40 (d, J=1.56 Hz, 1 H), 7.46 - 7.52 (m, 2 H), 7.72 (d, J=8.59 Hz, 1 H). MS (ESI) (M+H)+ = 554.0. Anal. Calcd for C25H30F3N5O4S+ 0.70 TFA+0.20 H20 +O.5CH3OH (653.06): C, 49.48; H, 5.11; N, 10.72; Found: C, 49.50; H, 5.16; N, 10.71.
Example 146
2-Hydroxy-N-[4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-
(trifluoromethyl)-lH-benzimidazol-5-yI]amino}suIfonyl)phenyl]acetamide
Figure imgf000231_0001
2-{[4-({Methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]amino}sulfonyl)phenyl]amino) -2-oxoethyl acetate (56.3 mg, 0.107 mmol) (for preparation, see the Example 144 ) and a drop of sodium methoxide (25% in MeOΗ) in MeOΗ (10 mL) was stirred overnight at room temperature. After evaporation, the crude product was purified by reversed-phase ΗPLC using 15-65% CΗ3CΝ/Η7O and then lyophilized affording the title compound as the corresponding TFA salt. Yield: 36.6 mg (65%). 'HNMR (400 MHz, CD3OD): δ 1.39 - 1.56 (m, 4 H), 2.15 - 2.35 (m, 1 H), 3.25 (s, 3 H), 3.32 - 3.41 (m, 2 H), 3.86 - 4.00 (m, 2 H), 4.13 (s, 2 H), 4.32 (d, J=7.62 Hz, 2 H), 7.33 (dd, J=8.88, 2.05 Hz, 1 H), 7.41 (d, J=1.56 Hz, 1 H), 7.45 - 7.53 (m, 2 H), 7.72 (d, J=8.40 Hz, 1 H), 7.76 - 7.85 (m, 2 H). MS (ESI) (M+H)+ = 527.0. Anal. Calcd for C23H25F3N4O5S+0.80 H20 (540.95): C, 51.07; H, 4.96; N, 10.36; Found: C, 51.22; H, 5.11 ; N, 10.14.
231

Claims

What is claimed is:
1. A compound of Formula I or a pharmaceutically acceptable salt thereof:
Figure imgf000233_0001
wherein R1 is selected from Ci.ioalkyl, C2-ι0alkenyl, C .ioalkynyl, R5-C(=0)-0-
Cι.6alkyl, R5R6N-C,.6alkyl, R5O-Cw alkyl, R5C(=0)N(-R6)-d.6alkyl, R5R6NS(=0)2-
C,.6alkyl, R5CS(=0)2N(-R6)-Cι.6alkyl; R5R6NC(=0)N(-R7)-C,.6alkyl,
Figure imgf000233_0002
C3. ιocycloalkyl-Cι.6alkyl, C .8cycloalkenyl-Cι-6alkyl, C3-6heterocyclyl-Cι.6alkyl, C . όheterocyclyl-C(=0)-Cι.6alkyl, C Ohydrocarbylamino, RSR6N-, R50-, R5C(=0)N(-
R6)-, R5RόNS(=0)2-, R5CS(=0)2N(-R6)-, R5R°NC(=0)N(-R7)-, R5R6NS(=0)2N(R7)-,
Cg-ioaryl, C6-ι0aryl-C(=O)-, C3.ιocycloalkyl, C4-8cycloalkenyl, C3-6heterocyclyI and C3- 6heterocyclyl-C(=0)-; wherein said C).,oalkyl, C .ι0alkenyl, C2.ι0alkynyl, Cό-ioaryl-
Ci-ealkyl, C6.ιoaryl-C(=0)-Cι.6alkyl, C3.ιocycloalkyl-Cι.6alkyl, C4.8cycloalkenyl-
Cι.6alkyl, C3.6heterocyclyl-Cι.6alkyl, C3.6heterocyclyl-C(=0)-Cι.6alkyl, C\. lohydrocarbylamino, C6.ioaryl, C6-ιoaryl-C(=0)-, C3.ιocycloalkyl, C4_8cycloalkenyl, C3. όheterocyclyl or C3.6heterocyclyl-C(=0)- used in defining R1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and -NR5R6; R" is selected from Ci.ioalkyl, C2.ιoalkenyl, C2-ιoalkynyl, C3-ιocycloalkyl, C3. ιocycloalkyl-Cι.6alkyl, C4-8cycloalkenyl-Cι-6alkyl, C3.6heterocycloalkyl-Cι.6alkyl, C4. scycloalkenyl, R5R6N-, Cs-sheteroaryl, Cό-ioaryl and C3-6heterocycloalkyl, wherein said Ci.ioalkyl, C2.]0alkenyl, C2-ι0alkynyl, C3-8cycloalkyl, C3.8cycloalkyl-C].6alkyl,
C4.scycloalkenyl-Cι-6alkyl, C3-6heterocycIoalkyl-Cu6alkyl, C4.8cycloalkenyl, C3.
5heteroaryl, Cβ-ioaryl or C .6heterocycloalkyl used in defining R" is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR5R6; wherein R5, R6 and R7 are independently selected from -H, C).6alkyl, C .6alkenyl, C2.6alkynyl, and a divalent Cι.6group that together with another divalent R5, R6 or R7 forms a portion of a ring; Ar is selected from Cό-ioaryl and C3-8heteroaryl; n is selected from 0, 1, 2 and 3; each of R3 is independently selected from -H, nitro, halogen, Ci.ioalkyl C2. loalkenyl, C2-ι0aIkynyl, C3.ι0cycloalkyl, C3.ιocycloalkyl-Cι-6alkyl, C4.8cycloalkenyl- Cι.6alkyl, C3.6heterocycloalkyl-Cι-όalkyl, C3.6heterocycloalkyl and
R80^- R9^
Figure imgf000234_0001
RS R|9 °Λ - RS O-RI9; ° Λ and «s o optionally subsitituted with one or more groups selected from Cι.6alkyl, hydroxy, halogen, amino and Cι.6alkoxy,
Figure imgf000235_0001
each of R8 and R9 is independently selected from -H, Ci.ioalkyl, C2-ι0alkenyl, C2-ιoalkynyl, C3.ι0cycloalkyl, C3.iocycloalkyl-C].6alkyl, C3-oheterocyclyl, Cό-ι0aryl, C3.6heterocylcyl-Cι.όalkyl, C6-ιoaryl-Cι.6alkyl, and a divalent Cι.6group that together with another divalent group selected from R8 and R9 forms a portion of a ring, wherein said Ci.ioalkyl, C2.ι0alkenyl, C2.ιoalkynyl, C3.ι0cycloalkyl, C3.ιocycloalkyl- Cι.6alkyl, Cs-όheterocyclyl, Cg.ioaryl, C3-6heterocylcyl-Cι-6alkyl, Cg.]0aryl-Cι.6alkyl, or divalent Cι.6group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR5R6; and R4 is selected from -H, Ci.ioalkyl, C .ι0alkenyl, C2.ι0alkynyl, C3-ι0cycloalkyl,
C3-ιocycloalkyl-Cι-6alkyl, and C4.8cycloalkenyl-Cι-6alkyl.
2. A compound as claimed in claim 1, wherein R' is selected from C1-6alkyl, C].6alkyl-C(=0)-0-C alkyl, C2.6alkenyl, C2. 6alkynyl, phenyl-C|.4alkyl, C3.ι0cycloalkyl-Cι.4alkyl, C4.6cycloaIkenyl-Cι-4alkyl, C3. 6heterocyclyl-Cι.4alkyl, C6.ι0aryl, C3.6heterocyclyl, C3.]0cycloalkyl, and C4.
6cycloalkenyl, wherein said Cι.6alkyl,
Figure imgf000235_0002
C2.6alkenyl, C2. 6alkynyl, phenyl-Cι.4alkyl, C .ι0cycloalkyl-C alkyl, C4.6cycloalkenyl-Cι. alkyl, C6. loaryl, Cs-όheterocyclyl-C alkyl, C3.6heterocyclyl, C3.)0cycloalkyl, and C4. 6cycloaIkenyl used in defining R1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and -NR5R6; R2 is selected from Cι.6alkyl, C2.6alkenyl, C3.6cycloalkyl, C3.6cycloalkyl- C alkyl, C .6cycloalkenyl-Cι.4alkyl, C3-6heterocycloalkyl-C alkyl, C4. 6cycloalkenyl, C3.5heteroaryl, R5R6N-, and phenyl, wherein said Cι.6alkyl, C2- 6alkenyl, C3_6cycloalkyl, C3.6cycloalkyl-Cι. alkyI, C4.6cycloalkenyl-Cι.4alkyl, C3-όheterocycloalkyl-C alkyl, C4.6cycloalkenyl, C3.5heteroaryl, R5R6N-, and phenyl used in defining R~ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; wherein R5 and R6 are independently selected from -H, Cι.6alkyl, C2.6alkenyl, and a divalent C^alkylene that together with another divalent R5 or R° and optionally a heteroatom forms a portion of a ring; Ar is selected from phenyl and C3_5heteroaryl; n is selected from 0, 1 and 2; each of R3 is independently selected from -H, nitro, halogen, Cι-6alkyl C2. 6alkenyl, C3.6cycloalkyl, C3.6heterocycloalkyl-CMalkyl,
Figure imgf000236_0001
and, C3.6heterocycloalkyl optionally subsitituted with one or more groups selected from Ci-galkyl, hydroxy, halogen and
Figure imgf000237_0001
each of R and R .9 is independently selected from -H, Cι.6alkyl, C2.6alkenyl, C3.6cycloalkyl, C3.6cycloalkyl-Cι-6alkyl, C3-6heterocyclyl and C3.όheterocylcyl-Cι. 6alkyl, wherein said Cι.6alkyl, C2.6alkenyl, C3.6cycloalkyl, C3.6cycloalkyl-Cι.6alkyl, C3.6heterocyclyl and C3.6heterocylcyl-Cι-6alkyl are optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR'°R" ; and R4, R10 and R1' are independently selected from -H and Cι.3alkyl.
3. A compound as claimed claim 1, wherein R1 is selected from Cι.6alkyl, Cι-3alkyl-C(=0)-0-Cι.3alkyl, C2-6alkenyl, phenyl-C alkyl, C3.ι0cycloalkyl-Cι-4alkyl, C4.6cycloalkenyl-C].4alkyl, Cs-δheterocylcoalkyl-CMalkyl, C6-ιoaryl, C3-ι0cycloalkyl, and C4-6cycloalkenyl, wherein said Cι-6alkyl, C2.6alkenyl, phenyl-Cι.4alkyl, C3.ι0cycloalkyl-Cι. alkyl, C4.6cycloalkenyl-Cι. alkyl, C3.6heterocylcoalkyl-CMalkyl, C6-ιoaryl, C3.ι0cycloalkyl, and C4.6cycloalkenyl used in defining R1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and amino; R2 is selected from Cι.6alkyl, C2.6alkenyl, C3.6cycloalkyl and C3-6cycloalkyl- C alkyl, wherein said Cι.6alkyl, C .6alkenyl, C3.6cycloalkyl and C3.6cycloalkyl-
Cι.4alkyl used in defining R" is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; Ar is selected from phenyl and C3.sheteroaryl and n is selected from 0, 1 and 2; each of R is independently selected from -H, halogen, nitro, Chalky 1, C3.
όheterocycloalkyl
Figure imgf000238_0001
optionally subsitituted with one or
more Cι.6alkyl or hydroxy,
Figure imgf000238_0002
; wherein said C3.6heterocycloalkyl contain at least one nitrogen ring atom and the radical of C3-6heterocycloalkyl is located on the at least one nitrogen ring atom, and wherein each of R8 and R9 is independently selected from -H, Cuβalkyl, moφholinyl- Cι_3alkyl,
Figure imgf000238_0003
and piperidinyl-Ci alkyl, wherein said
Cι.6alkyl, moφholinyl-
Figure imgf000238_0004
and piperidinyl-Cι.3alkyl are optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR5R6; and R4, R5 and R6 are independently selected from -H and C].3alkyl.
4. A compound as claimed in claim 1, wherein R1 is selected from cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl,cyclohexylethyl, cyclopentylethyl, bicyclo[2.2.1]hept-5-en-2- ylmethyl, 4,4-difluorocyclohexylmethyl, tetrahydropyranylmethyl, tetrahydropyranylethyl, tetrahydrofuranylmethyl, 1-piperidinylethyl, and N-methyl-2- piperidinylmethyl ; R2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2- propyl, 2-hydroxyl-propyl, trifluoromethyl, 1 ,1-difluoroethyl, 2,2,2-trifluoroethyl, 1- methyl-propyl, 1,1-dimethyl-propyl, l,l-dimethyl-3-buten-l-yl, ethyl, and 2-propyl; Ar is selected from phenyl, pyridyl, pyrimidyl, thiazolyl, thienyl, isoxazolyl, imidazolyl, and pyrazolyl; n is selected from 0, 1 and 2; each of R3 is independently selected from -H, Cι-3alkyl, 4-moφholinyl, 1-
piperidinyl, 1-piperazinyl,
Figure imgf000238_0005
; and wherein 4-moφholinyl, 1-piperidinyl, and 1 -piperazinyl are optionally substituted with one or more methyl; and wherein each of R and R is independently selected from -H, C]-3alkyI, morpholinylmethyl, pyrrolidinyl-methyl, and piperidinyl-methyl, wherein said moφholinylmethyl, pyrrolidinyl-methyl, and piperidinyl-methyl are optionally substituted by one or more groups selected from hydroxy, amino and dimethylamino.
5. A compound selected from: N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]thiophene-2- sulfonamide; N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methylthiophene- 2-sulfonamide; N-(l-Benzyl-2-tert-butyl-lH-benzimidazol-5-yl)-N-methylbenzenesulfonamide; N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N,3,5- trimethylisoxazole-4-sulfonamide; N-[2-te/'t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N,l,2-trimethyl-lH- imidazole-4-sulfonamide; N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N,l,3,5- tetramethyl-lH-pyrazole-4-sulfonamide; N-[2-tert-butyl-l -(cyclohexylmethyl)- lH-benzimidazol-5-yl]benzene sulphonamide; N-[l-(cyclohexylmethyl)-2-ethyl-lH-benzimidazol-5-yl]benzenesulfonamide; N-[l-(cyclohexylmethyl)-2-isopropyl-lH-benzimidazol-5-yl]benzene sulphonamide; N-[l-(cyclohexyImethyl)-2-(l-methylcyclopropyl)-lH-benzimidazoI-5- yl]benzenesulfonamide; N-[l-(cyclohexylmethyl)-2-(l,l-dimethylpropyI)-lH-benzimidazol-5-yl]- benzenesulfonamide; N-[l-(cyclohexylmethyl)-2-(l,l-dimethyl-3-butenyl)-lH-benzimidazol-5-yl]- benzenesulfonamide; N-[l-(cyclohexylmethyl)-2-(l-methyl-4-piperidinyl)-lH-benzimidazol-5-yl]- benzenesulfonamide; N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]-N-methyl- benzenesulfonamide;
N-[l-(cyclohexylmethyl)-2-ethyl-lH-benzimidazol-5-yl]-N-methyl-benzene sulphonamide; N-[l-(cycIohexyImethyl)-2-isopropyl-lH-benzimidazol-5-yl]-N-methyl-benzene sulphonamide;
N-[l-(cyclohexylmethyl)-2-(l-methyIcyclopropyl)-lH-benzimidazol-5-yl]-N- methyl-benzenesulfonamide;
N-[l-(cyclohexylmethyl)-2-(l-methyl-4-piperidinyl)-lH-benzimidazol-5-yl]-N- methyl- benzenesulfonamide;
4-[l-(cyclohexylmethyl)-5-[methyl(phenylsulfonyl)amino]-lH-benzimidazol-2- yl]- 1,1 -dimethyl- piperidinium;
N-[2-(l,l-dimethylethyl)-l-[(tetrahydro-2H-pyran-4-yl)methyl]-lH-benzimidazol-
5-yl]-benzenesulfonamide; N-[2-(l,l-dimethylethyl)-l-[(tetrahydro-2-furanyl)methyl]-lH-benzimidazol-5- yl]-benzenesulfonamide;
N-[l-(cyclobutylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]- benzenesulfonamide;
N-[l-(cyclopropylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]- benzenesulfonamide;
N-(4- { [[2-tert-butyl- 1 -(cyclohexylmethyl)- lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl) acetamide;
N-[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methyl-6- morpholin-4-ylpyridine-3-sulfonamide; N-[2-ter/-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N-methyl-4- nitrobenzenesulfonamide;
4-Amino-N-[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfona ide;
N-(4-{[[2-te7-t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)propanamide;
N-(4-([[2-/ert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2-methylpropanamide; N-(4- { [[2-tert-Buty 1- 1 -(cyclohexylmethyl)- lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;
N-[2-tert-Butyl-l -(cyclohexylmethyl)- lH-benzimidazol-5-yl]-4-(ethylamino)-N- methylbenzenesulfonamide; N-[2-te7-f-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-4-(formylamino)-N- methylbenzenesulfonamide;
2-Bromo-N-(4-{[[2-tert-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-(4-{[[2-te/-t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2-pyιτolidin-l-ylacetamide;
N'-(4-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl]phenyl)-N",N'-dimethylglycinamide;
N-(4-{[[2-te7-t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2-moφholin-4-ylacetamide; N'-(4-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyI)amino]sulfonyl}phenyl)glycinamide;
2-[(4-{[[2-te7-t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate;
N-(4-{[[2-tert-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;
N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazol-5-yl]-N-methyl-
4-(4-moφholinyl)-benzenesulfonamide;
N-[ 1 -(cyclohexylmethyl)-2-( 1 , 1 -dimethylethyl)- lH-benzimidazol-5-yl]-N-methyI-
4-(4-methyl- 1 -piperazinyl)-benzenesulfonamide; N-[2-te7"/-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide;
N-[2-te7-t-Butyl-l-(tetrahydro-2H-pyran-2-ylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide;
N-[l -(cyclohexylmethyl)-2-(l-hydroxy-l-methylethyl)-lH-benzimidazol-5-yl]- benzenesulfonamide;
N-[l-(cyclohexylmethyI)-2-(l-methoxy-l-methylethyl)-lH-benzimidazol-5-yl]-N- methyl-benzenesulfonamide; N-[l-(cyclohexylmethyl)-2- l-methoxy-l-methylethyl)-lH-benzimidazol-5-yl] — benzenesulfonamide;
N-[2-te7-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-
N,l,2-trimethyl-lH-imidazole-5-sulfonamide; Ethyl 4-{[[2-te7't-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}-3,5-dimethyl-lH-pyrrole-2-carboxylate;
N-[2-te7-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-4-
(hydroxy ethyl)-N-methylbenzenesulfonamide;
N-[2-te/-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- methyl-4-( IH- 1 ,2,3-triazol- 1 -ylmethy l)benzenesulfonamide;
N-[2-te7-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyI)-lH-benzimidazol-5-yl]-4-
{[(2-hydroxyethyl)amino]methyl}-N-methylbenzenesulfonamide;
N-[2-te7-t-Butyl-l-(cyclopentylmethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide; N-[2-terf-Butyl-l-(2-cyclohexylethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide;
N-[l-(l-Benzylpyrrolidin-3-yl)-2-tβ7-t-butyl-lH-benzimidazol-5-)'l]-N- methylbenzenesulfonamide;
N-{2-te/"t-Butyl-l-[(4,4-difluorocyclohexyl)methyl]-lH-benzimidazol-5-yl}-N- methylbenzenesulfonamide;
N-[2-te7-t-Butyl-l-(pyridin-4-yImethyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide;
N-methyl-N-[ 1 -(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- 1H- benzimidazol-5-yl]benzenesulfonamide; N-[2-(l ,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]-N-methylbenzenesulfonamide;
N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(2,2,2-trifIuoroethyl)-lH- benzimidazol-5-yl]benzenesulfonamide;
N-[l-(cyclohexylmethyl)-2-(l-ethylpropyl)-lH-benzimidazol-5- yl]benzenesulfonamide;
N-[l-(cyclohexylmethyl)-2-(l-ethylpropyl)-lH-benzimidazol-5-yl]-N- methylbenzenesulfonamide;N-[2-te/-t-butyl-l-(cycIohexylmethyI)-lH- benzimidazol-5-yl]-N-ethylbenzenesulfonamide; N-methyl-N-[2-(l-methyl-l-pyridin-2-ylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide;
N-[2-(l-cyano-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl]-N-methylbenzenesulfonamide; N-methyl-N-[2-propyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]benzenesulfonamide;
5-Bromo-N-[2-te7-t-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-6-chloro-
N-methylpyridine-3-sulfonamide;
5-Bromo-N-[2-te7-t-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-6-[(2- h}'droxyethyl)amino]-N-methylpyridine-3-sulfonamide;
N-[2-te7-t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-6-[(2- hydroxyethyl)amino]-N-methylpyridine-3-sulfonamide;
N-(5-{[[2-te/'t-ButyI-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide; N-(3- { [[2-te7-t-Butyl- 1 -(cyclohexylmethyl)- lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide;
N'-(4-{[[2-te7-t-Butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-N"-(2-hydroxyethyl)glycinamide;
4-[(Aminocarbonyl)amino]-N-[2-te7-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]-N-methylbenzenesulfonamide;
N-(4-{[[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-(4-{[[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl ) phenyl)-N-methylacetamide; N-(4-{[[2-te7-t-Butyl-l -(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;
N-(4-{[[2-te7-/-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;
N'-(4-{[[2-te7-t-Butyl-I-(tetrahydro-2H-pyran-4-yImethyl)-lH-benzimidazol-5- yl](methyI)amino]sulfonyl)phenyl)-N2,N2~dimethylglycinamide;
N'-(4-{[[2-tβ77-Butyl-l-(tetrahydro-2H-pyran-4-yImethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)glycinamide; N'-(4-{[[2-te/-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-N2-methylglycinamide;
N-[2-tert-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-6-
[(2-hydroxyethyl)amino]-N-methylpyridine-3-sulfonamide; N-[2-/e7-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-6-
[(2-methoxyethyl)amino]-N-methylpyridine-3-sulfonamide;
N-[2-fβ7-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-6-
(formylamino)-N-methylpyridine-3-sulfonamide;
N-(5-{[[2-te7-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide;
N-[4-({[2-te7-t-Butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]amino}sulfonyl)phenyl]acetamide;
N-[4-({[2-te7-t-ButyI-l-(cyclohexylmethyl)-lH-benzimidazol-5- yl]amino}sulfonyl)phenyl]acetamide; N-(4-{[[2-te7-t-Butyl-l-(2-piperidin-l-ylethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-(4- {[[2-te7"t-Butyl-l-(l,4-dioxan-2-ylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-(4-{[{2-tert-Butyl-l-[(l-methylpiperidin-2-yl)methyl]-lH-benzimidazol-5- yl) (methyl)amino]sulfonyl}phenyl)acetamide;
N-(4-{[(2-tert-Butyl-l-{[(2 ?)-l-methylpiperidin-2-yl]methyl}-lH-benzimidazol-
5-yl)(methyl)amino]sulfonyl}phenyl)acetamide;
N-[4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide; 4-Bromo-N-[l-(cyclohexylmethyl)-2-(l,l-dimethylethyl)-lH-benzimidazoI-5-yI]-
N-methyl-benzenesulfonamide;
N-[2-te7-t-butyl-l-(cyclohexylmethyI)-lH-benzimidazol-5-yl]-4-[(2- hydroxyethyl)amino]-N-methylbenzenesulfonamide;
N-[2-te7-t-butyI-l -(cyclohexylmethyl)- IH-benzimidazol-5-yl]-4-(dimethyIamino)- N-methylbenzenesulfonamide;
4-[bis(2-hydroxyethyl)amino]-N-[2-te7-t-butyl-l-(cyclohexylmethyl)-lH- benzimidazol-5-yl]-N-methylbenzenesulfonamide; N-[2-te/-t-butyl-l-(cyclohexylmethyl)-lH-benzimidazol-5-yl]-N,4-dimethyl-3,4- dihydro-2H-l,4-benzoxazine-7-sulfonamide;
N-[4-({methyl[2-(l-methyl-l-pyridin-2-ylethyl)-l-(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide; N-(4-{[[2-te7-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](ethyl)amino]sulfonyl]phenyl)acetamide;
4-[(aminocarbonyl)amino]-N-[2-te7-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]-N-ethylbenzenesulfonamide;
N-[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl N- ethyl-4-{[(methylamino)carbonyl]amino}benzenesulfonamide;
4-amino-N-[2-/e7-r-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5- yl]-N-ethylbenzenesulfonamide;
N-(4-{[[2-tert-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](ethyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide; 2-[(4- { [[2-te7-t-butyl- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzimidazol-5- yl](ethyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate;
N-(4-{[[2-te7-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl](ethyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;
N-[2-te7-t-butyl-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N- ethyl-4-{[(isopropylamino)carbonyl]amino}benzenesulfonamide;
N-[4-({ethyl[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]amino) sulfonyl)phenyl]acetamide;
4-[(aminocarbonyl)amino]-N-ethyl-N-[2-(l-methoxy-l-methylethyl)-l-
(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide; N-ethyl-N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]-4-{[(methylamino)carbonyl]amino}benzenesulfonamide;
4-amino-N-ethyl-N-[2-( 1 -methoxy- 1 -methylethyl)- 1 -(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide;
N-[4-({ethyl[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]amino} sulfonyl)phenyl]-2,2-dimethylpropanamide;
2- { [4-( {ethyl[2-( 1 -methoxy- 1 -methylethyl)- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]amino}-2-oxoethyl acetate; N-[4-({ethyl[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)- lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]-2-hydroxyacetamide;
N-ethyl-4-{[(isopropylamino)carbonyl]amino}-N-[2-(l-methoxy-l-methylethyl)- l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]benzenesulfonamide; N-(4- { [[2-( 1 -methoxy- 1 -methylethyl)- 1 -(tetrahy dro-2H-pyran-4-y lmethyl)- 1H- benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
4-[(aminocarbonyl)amino]-N-[2-(l-methoxy-l-methylethyl)-l-(tetrahydro-2H- pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N-methylbenzenesulfonamide;
2-Ηydroxy-N-(4-{[[2-(l -methoxy- 1 -methylethyl)- 1 -(tetrahydro-2H-pyran-4- ylmethyl)-lH-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-(4- { [[2-( 1 -ethoxy- 1 -methylethyl)- 1 -(tetrahydro-2H-pyran-4-y lmethyl)- 1 H- benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-[4-({[l-(2-azetidin-l-ylethyl)-2-te7-t-butyl-lH-benzimidazol-5- yl]amino}sulfonyl)phenyl]acetamide; 3-[5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-te/-t-butyl-lH-benzimidazol-l- yl]propyl acetate;
N-{4-[({l-[(lS,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]-2-tert-butyl-lH- benzimidazol-5-yl}amino)sulfonyl]phenyl} acetamide;
N-[4-({[2-te7-t-butyl-l-(tetrahydro-2H-pyran-3-ylmethyl)-lH-benzimidazol-5- yl]amino) sulfonyl)phenyl]acetamide;
N-{4-[({2-te7-/-butyl-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-benzimidazol-5- yl]amino)sulfonyl]phenyl}acetamide;
N-(4-{[[2-te7-t-butyl-l-(cyclobutylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl ) phenyl)acetamide; 4-[(aminocarbonyl)amino]-N-[2-te7-t-butyl-l-(cyclobutylmethyl)-lH- benzimidazol-5-yl]-N-methylbenzenesulfonamide;
N-(4-{[[2-te7-t-butyl-l-(cyclobutylmethyl)-lH-benzimidazol-5- yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;
N-(4-([[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;
N-(4-{[[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide; N-(4-{[[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-3-methylbutanamide; N-(4-{[[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH- benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide; N-[2-(l,l-difluoroethyl)-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-benzimidazol-5- yl]-4-{[(isopropylamino)carbonyl]amino}-N-methylbenzenesulfonamide; 4-{Bis[(isopropylamino)carbonyl]amino}-N-[2-(l,l-difluoroethyl)-l-(tetrahydro- 2H-pyran-4-ylmethyl)-lH-benzimidazol-5-yl]-N-methylbenzenesulfonamide; N-[4-({methyl[l-(tetrahydiO-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide; 4-[(aminocarbonyl)amino]-N-methyl-N-[l-(tetrahydro-2H-pyran-4.-ylmethyl)-2- (trifluoromethyl)-lH-benzimidazol-5-yl]benzenesulfonamide; N-methyl-4-nitro-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]benzenesulfonamide; 4-amino-N-methyl-N-[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)- lH-benzimidazol-5-yl]benzenesulfonamide; 2,2-dimethyl-N-[4-({ methyl [1 -(tetrahydro-2H-pyran-4-ylmethyl)-2- (trifluoromethyl)-lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]propanamide; 2-{[4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)-lH- benzimidazol-5-yl]amino}sulfonyl)phenyI]amino}-2-oxoethyl acetate; 4-{[(isopropylamino)carbonyl]amino}-N-methyl-N-[l-(tetrahydro-2H-pyran-4- ylmethyl)-2-(trifluoromethyl)-lH-benzimidazol-5-yl]benzenesulfonamide; 2-Ηydroxy-N-[4-({methyl[l-(tetrahydro-2H-pyran-4-ylmethyl)-2- (trifluoromethyl)-lH-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide and pharmaceutically acceptable salts thereof.
6. A compound according to any one of claims 1-5 for use as a medicament.
7. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the therapy of pain.
8. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of anxiety disorders.
9. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson's disease, cancer, Huntington's chorea, Alzheimer's disease, gastrointestinal disorders and cardiavascular disorders.
10. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.
11. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.
12. A method for preparing a compound of Formula I,
I comprising the step of reacting a compound of Formula II,
Figure imgf000248_0002
π with a compound of R2C(=0)X, in the presence of a base and optionally a coupling reagent, followed by treatment with an acid; wherein X is selected from Cl, Br, F and OH; R' is selected from Ci.ioalkyl, C2-ι0alkenyl, C2-ι0alkynyl, R5-C(=0)-0- Cι.6alkyl, R5R6N-C,.6alkyl, R50-C,.6 alkyl, R5C(=0)N(-R6)-Ci.6alkyl, R5R6NS(=0)2- C,.6alkyl, R5CS(=0)2N(-R6)-Ci.6alkyl, R5R6NC(=0)N(-R7)-Ci.6alkyl, R5R°NS(=0)2N(R7)-Ci.6alkyl, C6.!0aryl-Cι.6alkyl, Cb.ι0aryl-C(=O)-C,.6alkyl, C3. ιocycloalkyl-Cι.6alkyl, C .8cycloalkenyl-Cι-6alkyl, C3.6heterocyclyl-C].6alkyl, C3.
6heterocyclyl-C(=0)-C,.6alkyl, C ohydrocarbylamino, R5R6N-, R50-, R5C(=0)N(-
R6)-, RsR6NS(=0)2-, R5CS(=0)2N(-R6)-, R5R6NC(=0)N(-R7)-, R5R6NS(=0)2N(R7)-, C6-ι0aryl, C6-ι0aryl-C(=O)-, C3.]0cycloalkyl, C4-8cycloalkenyl, C3.6heterocyclyl and C3.
6heterocyclyl-C(=0)-; wherein said Ci.ioalkyl, C2.ι0alkenyl, C2-ι0alkynyl, C6.ιoaryl-
C|.6alkyl, C6-ι0aryl-C(=O)-Cι.6alkyl, C3.ι0cycloalkyl-C].όalkyl, C4.8cycloalkenyl-
Cι.6alkyl, C3.6heterocyclyl-Cι.6alkyl, C3-6heterocyclyl-C(=0)-Cι.6alkyl, Cj. lohydrocarbylamino, C6.ι0aryl, C6.ι0aryl-C(=O)-, C3.)0cycloalkyl, C4.8cycloalkenyl, C3. 6heterocyclyl or C3.6heterocyclyl-C(=0)- used in defining R1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and -NR5R6; R2 is selected from Ci.ioalkyl, C2-ι0alkenyl, C2-ι0alkynyl, C3-ιocycloalkyl, C3. locycloalkyl-Ci-όalkyl, C4.8cycloalkenyl-Cι.6alkyl, C3.6heterocycloalkyl-Cι.6alkyl, C4. scycloalkenyl, R5R°N-, C3_5heteroaryl, C6.ioaryl and C3.6heterocycloalkyl, wherein said Ci-ioalkyl, C2.ιoalkenyl, C -ι0alkynyl, C3.8cycloalkyl, C3.8cycloalkyl-Cι-6alkyl,
C .8cycloalkenyl-Cι.6alkyl, C3.6heterocycloalkyl-Cι.6alkyl, C4.8cycloalkenyl, C3. sheteroaryl, C6.ιoaryl or C3-6heterocycloalkyl used in defining R2 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR5R6; wherein R5, Rb and R7 are independently selected from -H, C|.6alkyl,
C2-6alkenyl, C2-6alkynyl, and a divalent Cι.6group that together with another divalent
R5, R6 or R7 forms a portion of a ring; Ar is selected from C6-ιoaryl and C3.8heteroaryl; n is selected from 0, 1, 2 and 3; each of R3 is independently selected from -H, nitro, halogen, Ci.ioalkyl ,C2. ι0alkenyl, C2-ι0alkynyl, C3-ι0cycloalkyl, C3.ιocycloalkyl-Cι.6alkyl, C4.8cycIoalkenyl-
Cusalkyl, C3.6heterocycloalkyl-Cι.6alkyl, C3.6heterocycloalkyl
Figure imgf000250_0001
R° •o R,Λ0A R NΛ0Λ RVNΛ0A R 0ΛO R9 ' ORa
Figure imgf000250_0002
optionally subsitituted with one or more groups selected from Cι.6alkyl, hydroxy, halogen, amino and Cι.6alkoxy,
Figure imgf000251_0001
each of R and R' is independently selected from -H, Ci.ioalkyl, C .]0alkenyl, C2.ιoalkynyl, C3.ιocycloalkyl, C3-ιocycloalkyl-Cι.6alkyl, C3.6heterocyclyl, Cβ-ioaryl, C3.6heterocylcyl-Cι.6alkyl, C6.ι0aryl-Cι.6alkyl, and a divalent C].6group that together with another divalent group selected from R8 and R9 forms a portion of a ring, wherein said Ci.ioalkyl, C2.ιoalkenyl, C2.ι0alkynyl, C3-ι0cycloalkyl, C3.ιocycloalkyl- Cι.6alkyl, C3.6heterocyclyl, Cό-ioaryl, C3.6heterocylcyl-C|.6alkyl,
Figure imgf000251_0002
or divalent Cι.6group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR5R6; and R4 is selected from -H, Ci.ioalkyl, C2_ιoalkenyl, C2-ι0alkynyl, C3.ι0cycloalkyl,
C3-ιocycloalkyl-Cι.6alkyl, and C4-scycloalkenyl-Cι.6alkyl.
PCT/GB2004/004112 2003-09-26 2004-09-24 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof WO2005030761A1 (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
US10/572,826 US20070072853A1 (en) 2003-09-26 2004-09-24 Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof
EP04768655A EP1673369A1 (en) 2003-09-26 2004-09-24 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP2006527485A JP2007506718A (en) 2003-09-26 2004-09-24 Benzimidazole derivatives, compositions containing them, methods for their preparation and uses
MX2007003121A MX2007003121A (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, preparations thereof and uses thereof ii.
CN200580032338.4A CN101027292A (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, preparation thereof and uses thereof
JP2007533435A JP2008514595A (en) 2004-09-24 2005-09-22 Compound, composition containing it, its production and its use II
KR1020077006690A KR20070057856A (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, preparations thereof and uses thereof
AU2005287429A AU2005287429A1 (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, preparations thereof and uses thereof II
PCT/SE2005/001405 WO2006033633A1 (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, preparations thereof and uses thereof ii
EP05784958A EP1797070A1 (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, preparations thereof and uses thereof ii
PCT/SE2005/001400 WO2006033628A1 (en) 2004-09-24 2005-09-22 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP2007533429A JP2008514589A (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, their preparation and their use IIII
JP2007533430A JP2008514590A (en) 2004-09-24 2005-09-22 Benzimidazole derivative, composition containing the same, method for producing the same, and use thereof
CN200580031827.8A CN101023075A (en) 2004-09-24 2005-09-22 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CA002582512A CA2582512A1 (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, preparations thereof and uses thereof ii
BRPI0515876-1A BRPI0515876A (en) 2004-09-24 2005-09-22 compound, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof, pharmaceutical composition, and methods for pain therapy in a warm-blooded animal and for preparing a compound
EP05784565A EP1797074A4 (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, preparation thereof and uses thereof iiii
PCT/SE2005/001401 WO2006033629A1 (en) 2004-09-24 2005-09-22 Benzimidazole derivatives and their use as cannabinoid receptor ligands
EP05786524A EP1794150A1 (en) 2004-09-24 2005-09-22 Benzimidazole derivatives and their use as cannabinoid receptor ligands I
PCT/SE2005/001399 WO2006033627A1 (en) 2004-09-24 2005-09-22 Compounds, compositions containing them, preparation thereof and uses thereof iiii
CN200580031826.3A CN101052637A (en) 2004-09-24 2005-09-22 Benzimidazole derivatives and their application as cannabinoid receptor ligand i
PCT/SE2005/001404 WO2006033632A1 (en) 2004-09-24 2005-09-22 Benzimidazole derivatives and their use as cannabinoid receptor ligands I
EP05786401A EP1797076A1 (en) 2004-09-24 2005-09-22 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP2007533434A JP2008514594A (en) 2004-09-24 2005-09-22 Benzimidazole derivatives and their use as cannabinoid receptor ligands I
JP2007533431A JP2008514591A (en) 2004-09-24 2005-09-22 Benzimidazole derivatives and their use as cannabinoid receptor ligands
EP05784659A EP1797075A1 (en) 2004-09-24 2005-09-22 Benzimidazole derivatives and their use as cannabinoid receptor ligands
CN200580032329.5A CN101027291A (en) 2004-09-24 2005-09-22 Benzimidazole derivatives and their use as cannabinoid receptor ligands
UY29135A UY29135A1 (en) 2004-09-24 2005-09-23 DERIVATIVES OF N-METHYLBENZENOSULFONAMIDE 4 AND N SUBSTITUTES, PREPARATION PROCEDURES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
UY29129A UY29129A1 (en) 2004-09-24 2005-09-23 SULFONAMIDS, CARBOXAMIDS AND ACETAMIDS 1- (TETRAHIDRO-2H-PIRAN4-IL-METIL-2-TER-BUTIL-1H-BENCIMIDAZOL-5-IL-REPLACED, PREPARATION PROCEDURE, COMPOSITIONS CONTAINING AND APPLICATIONS
UY29133A UY29133A1 (en) 2004-09-24 2005-09-23 AMIDAS CONTAINING (!! 2-TERT-BUTIL-1- (TETRAHIDRO-2H-PIRAN-4-ILMETIL) -1H-BENCIMIDAZOL-5- !!) (METHYL) AMINO! SULFONYL) AS SUBSTITUTE. PREPARATION PROCEDURE, COMPOSITIONS CONTAINING IT AND APPLICATIONS
TW094133189A TW200626583A (en) 2004-09-24 2005-09-23 Novel compounds
TW094133158A TW200614991A (en) 2004-09-24 2005-09-23 Novel compounds
UY29132A UY29132A1 (en) 2004-09-24 2005-09-23 DERIVATIVES OF N-! 2-TERT-BUTIL-1- (TETRAHIDRO-2H-PIRAN-4-ILMETIL) -1H-BENCIMIDAZOL-5-IL) -N-METHYL-BENZENE-SULPHONAMIDE, PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITIONS CONTAINING AND APPLICATIONS
TW094133156A TW200626582A (en) 2004-09-24 2005-09-23 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW094133160A TW200616970A (en) 2004-09-24 2005-09-23 Compounds, compositions containing them, preparation thereof and uses thereof
TW094133192A TW200626577A (en) 2004-09-24 2005-09-23 Compounds, compositions containing them, preparation thereof and uses thereof
ARP050104023A AR051448A1 (en) 2004-09-24 2005-09-26 DERIVATIVES OF BENCIMIDAZOL AS SELECTIVE AGONISTS OF THE CB1 RECEPTORS, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PAIN AND OTHER DISEASES.
ARP050104024A AR053096A1 (en) 2004-09-24 2005-09-26 BENCIMIDAZOL COMPOUNDS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION OF THE SAME AND USES FOR THE PREPARATION OF MEDICINES
ARP050104026A AR051449A1 (en) 2004-09-24 2005-09-26 COMPOUNDS DERIVED FROM 1-3 BENCIMIDAZOLS, COMPOSITIONS THAT CONTAIN IT, PREPARATION AND USES OF THE SAME
IL182021A IL182021A0 (en) 2004-09-24 2007-03-19 Compounds, compositions containing them, preparations thereof and uses thereof
NO20072090A NO20072090L (en) 2004-09-24 2007-04-23 Compounds, compositions containing them, their preparation and their use II

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302570A SE0302570D0 (en) 2003-09-26 2003-09-26 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570-7 2003-09-26

Publications (1)

Publication Number Publication Date
WO2005030761A1 true WO2005030761A1 (en) 2005-04-07

Family

ID=29246979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004112 WO2005030761A1 (en) 2003-09-26 2004-09-24 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Country Status (7)

Country Link
US (1) US20070072853A1 (en)
EP (1) EP1673369A1 (en)
JP (1) JP2007506718A (en)
AR (1) AR045822A1 (en)
SE (1) SE0302570D0 (en)
TW (1) TW200524594A (en)
WO (1) WO2005030761A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033632A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands I
WO2006033627A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iiii
WO2006033629A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands
WO2006033633A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparations thereof and uses thereof ii
WO2007120101A1 (en) * 2006-04-18 2007-10-25 Astrazeneca Ab Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands
WO2008029825A1 (en) * 2006-09-05 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
US7550495B2 (en) 2004-09-24 2009-06-23 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof I
US7566788B2 (en) 2006-03-23 2009-07-28 Astrazeneca Ab Crystalline forms
US7598393B2 (en) 2004-11-02 2009-10-06 Pfizer Inc. Sulfonyl benzimidazole derivatives
US8633235B2 (en) 2003-09-26 2014-01-21 Neomed Institute Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302572D0 (en) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (en) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
RU2008129821A (en) * 2005-12-21 2010-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) HETEROCYCLIC DERIVATIVES AS ION CHANNEL MODULATORS
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5354M (en) * 1965-09-10 1967-09-11
EP0597304A1 (en) * 1992-11-06 1994-05-18 Bayer Ag Use of substituted benzimidazoles
WO1994011350A1 (en) * 1992-11-06 1994-05-26 Bayer Aktiengesellschaft 2-fluoroalkyl-substituted benzimidazoles, their preparation and their use as pesticides
WO2001051473A1 (en) * 2000-01-14 2001-07-19 Schering Aktiengesellschaft 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
WO2002085866A1 (en) * 2001-04-20 2002-10-31 Astrazeneca Ab Novel compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE666351A (en) * 1964-07-02
DE4237557A1 (en) * 1992-11-06 1994-05-11 Bayer Ag Substituted benzimidazoles
US6114532A (en) * 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19945787A1 (en) * 1999-09-24 2001-03-29 Boehringer Ingelheim Pharma New 2-(amidino- or aminomethyl-phenethyl)-5-sulfonylamino-benzimidazoles, are tryptase inhibitors useful e.g. for treating inflammatory or allergic disease such as asthma, urticaria or arthritis
US7115645B2 (en) * 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
EP1556040A1 (en) * 2002-10-24 2005-07-27 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
SE0301701D0 (en) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (en) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (en) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (en) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5354M (en) * 1965-09-10 1967-09-11
EP0597304A1 (en) * 1992-11-06 1994-05-18 Bayer Ag Use of substituted benzimidazoles
WO1994011350A1 (en) * 1992-11-06 1994-05-26 Bayer Aktiengesellschaft 2-fluoroalkyl-substituted benzimidazoles, their preparation and their use as pesticides
WO2001051473A1 (en) * 2000-01-14 2001-07-19 Schering Aktiengesellschaft 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
WO2002085866A1 (en) * 2001-04-20 2002-10-31 Astrazeneca Ab Novel compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002307925 *
KOSHCHIENKO ETB AL., KHIM. GETEROTSIKL. SOEDIN., vol. 7, 1971, pages 1132 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633235B2 (en) 2003-09-26 2014-01-21 Neomed Institute Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2006033627A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iiii
WO2006033629A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands
WO2006033633A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparations thereof and uses thereof ii
US7550495B2 (en) 2004-09-24 2009-06-23 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof I
WO2006033632A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands I
US7598393B2 (en) 2004-11-02 2009-10-06 Pfizer Inc. Sulfonyl benzimidazole derivatives
US7566788B2 (en) 2006-03-23 2009-07-28 Astrazeneca Ab Crystalline forms
US7615642B2 (en) 2006-04-18 2009-11-10 Astrazeneca Ab Therapeutic compounds
WO2007120101A1 (en) * 2006-04-18 2007-10-25 Astrazeneca Ab Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands
JP2009534379A (en) * 2006-04-18 2009-09-24 アストラゼネカ・アクチエボラーグ Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (CB1) receptor ligands
JP2009203238A (en) * 2006-09-05 2009-09-10 Kyowa Hakko Kirin Co Ltd Imidazole derivative
US8273738B2 (en) 2006-09-05 2012-09-25 Kyowa Hakko Kirin Co., Ltd. Imidazole derivatives
AU2007292155B2 (en) * 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
WO2008029825A1 (en) * 2006-09-05 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
KR101404360B1 (en) 2006-09-05 2014-06-09 교와 핫꼬 기린 가부시키가이샤 Imidazole Derivative

Also Published As

Publication number Publication date
AR045822A1 (en) 2005-11-16
TW200524594A (en) 2005-08-01
EP1673369A1 (en) 2006-06-28
JP2007506718A (en) 2007-03-22
US20070072853A1 (en) 2007-03-29
SE0302570D0 (en) 2003-09-26

Similar Documents

Publication Publication Date Title
EP1814863A1 (en) Indazole sulphonamide derivatives
ZA200602446B (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ZA200502928B (en) Novel compounds.
WO2005030761A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP2010526A1 (en) Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands
US7501447B2 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1670790B1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2004108688A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1670770B1 (en) Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof
EP1797070A1 (en) Compounds, compositions containing them, preparations thereof and uses thereof ii
EP1797074A1 (en) Compounds, compositions containing them, preparation thereof and uses thereof iiii
WO2006052189A1 (en) Nitro indazole derivatives
EP1636194A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004768655

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006527485

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004768655

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007072853

Country of ref document: US

Ref document number: 10572826

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10572826

Country of ref document: US